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ABSTRACT 
DNA-dependent protein kinase (DNA-PK) and poly(ADP-ribose) 
polymerase-1 (PARP-1) participate in non-homologous end joining and base 
excision repair respectively, and are key determinants of radio-resistance. The 
interactive effects of PARP-1 and DNA-PK in the cellular responses to DNA damage 
were investigated using novel specific inhibitors of DNA-PK (NU7026) and PARP-1 
(AG14361) and cell lines proficient or deficient for DNA-PK or PARP-1. 
Enzyme deficient cell lines were 4-fold more sensitive to ionizing radiation 
(IR) alone, and showed reduced potentially lethal damage recovery (PLDR), 
compared to their proficient counterparts. NU7026 potentiated IR cytotoxicity in 
exponentially growing DNA-PK proficient, but not deficient cells. Similarly 
AG14361 potentiated IR in PARP-1 +/+ but not PARP-1-/- cells. When NU7026 and 
AG14361 were used in combination, their potentiating effects were additive. Both 
inhibitors reduced PLDR in the proficient cell lines. Furthermore, inhibitor 
combination completely abolished PLDR. Both inhibitors prevented IR-induced 
DNA double strand break repair, but only AG14361 prevented DNA single strand 
break repair 
The enzyme activities were investigated using purified enzymes and 
permeabilised cells. In cell-free assays, PARP- 1 activity was unaffected by the 
presence of DNA-PK, and vice versa, provided the enzyme substrates were present. 
DNA-PK inhibited PARP-1 when ATP was absent or NU7026 present. PARP-1 
inhibited DNA-PK when NAD+ was absent or AG14361 present. Furthermore, 
PARP-1 inhibition increased with increasing ratio of DNA-PK to PARP-1, and vice 
versa. Similar results were obtained using the inhibitors in permeabilised cells. 
PARP-1 was inactive in the absence of histones, but activity was restored by the 
addition of DNA-PK. DNA-PK was inactive in the absence of its p53 peptide 
substrate unless PARP-1 was included. 
These data suggest reciprocal regulation of PARP-1 and DNA-PK, and co-operation 
in DSB repair and survival. Thus, individually, or in combination, the DNA-PK and 
PARP-1 inhibitors act as potent radio-sensitisers. 
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CHAPTER 1 
INTRODUCTION 
1.1 Cancer 
Cancer is the most common cause of death in the UK and other developed 
countries, after heart disease, and it will affect around one in three people in the UK 
at some time in their lives. Alarmingly, one in four people will eventually die from 
cancer (Cancer Research Campaign, 1998). Cancer is a new growth that arises from 
abnormal and uncontrolled division of cells that may then go on to invade and 
destroy surrounding tissues (i. e. metastasise). More than 200 types of cancer have 
been identified (Fawcett and Drew, 1996). Cancers are classified according to the 
tissue and cell type from which they arise. For example, those arising from epithelial 
cells are defined as carcinomas whilst connective tissue or muscle tumours are 
termed sarcomas. Cancers which do not fall into either of these broad categories 
include leukaemias, which derive from hemopoietic cells and tumours of the nervous 
system. The likelihood of developing cancer varies with age and many cancers are a 
feature of the ageing process, resulting from an accumulation of mutations in 
genomic DNA. Accordingly, 65 % of all new cases of cancer are diagnosed in 
people over the age of 65. 
1.1.1 Carcinogenesis 
There is a strong genetic component in the development of cancer involving a 
multistage process of accumulation of genetic mutations in genes that control normal 
cellular growth and epigenetic alterations At least four to seven `hits' are thought to 
be required for cancer to develop. Colorectal cancers, for example, typically 
develop over decades and appear to acquire at least seven genetic events for 
completion (Kinzler and Voglestein, 1996). Successive mutation enables a clone of 
cells to expand and gain selective advantage over surrounding cells and this 
phenomenon is termed clonal evolution. 
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Carcinogenesis is conventionally considered to comprise of two phases, 
namely initiation and promotion: - 
" Initiation involves the irreversible mutation of cellular DNA, either spontaneous, 
ionising radiation (IR), virus or carcinogen induced, in such a way that the cell 
escapes the normal constraints of regulated growth. 
" Promotion is the increased proliferative state that enhances the possibility of 
further genetic change. For example, mutation or amplification of proto- 
oncogenes and/or deactivation of tumour-suppressor genes, which result in the 
development of a fully malignant tumour. 
Mutations in proto-oncogenes are known as `gain of function' mutations and are 
generally activating mutations of cellular genes which have a dominantly acting role 
in the control of cell proliferation. A raised level of the nuclear oncogene c-myc has 
been reported in 60-70 % of carcinomas (Finley et al., 1989). Mutations in tumour 
suppressor genes (TSGs) are, by contrast, `loss of function' mutations. These may 
be identified as mutations that reduce or abolish the activity of genes that negatively 
regulate critical cellular functions, so that a loss of activity leads, for example, to 
enhanced cellular proliferation, blocked differentiation, or the suppression of cell 
death pathways. An example of a TSG that regulates the cell death pathway, termed 
apoptosis is p53. p53 is a common target for genetic alterations in cancer, with 
around 50 % of tumours possessing mutations in the p53 gene (Lutz and Nowakoska- 
Swirka, 2002). 
1.2 Treatment 
The ultimate goal of anticancer treatment is to achieve a cure. The ability to 
achieve a cure depends on the type of tumour and how far it has spread and, 
consequently, survival rates and the chances of recurrence differ according to the 
organ or tissues affected. Many cancer treatments do not achieve 100 % cure and 
therefore the aim is to achieve long-term survival. This recognises that it is virtually 
impossible to eradicate every single cancer cell in the body and that eventually the 
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condition may recur. Treatment effectiveness is therefore often assessed in terms of 
5 or 10 year survival. 
The principle approaches to the treatment of cancer are surgery, radiotherapy 
and chemotherapy. Where a tumour is accessible, surgery is usually the first line of 
action. Surgery aims to excise as much tumour as possible and therefore a wide 
margin of tissue, including normal tissue and lymph nodes, is usually removed in 
order to limit the risk of relapse. Unfortunately, it is often impossible to excise all 
tumour tissue which may eventually invade surrounding tissues and often tumour 
cells may have already spread to other parts of the body by the time of surgery. 
Consequently, radiotherapy is often used as an adjunct to surgery with the aim of 
suppressing the rate of cell division in any tumour cells that remain following 
surgery at the site of excision. Where cancer is advanced, surgery may be used to 
reduce tumour bulk or relieve obstruction as a means of palliative care. 
Radiotherapy relies on the use of ionising radiation (IR) to directly damage 
the DNA of malignant cells (section 1.3.4.1). This form of treatment may be used 
either as the principle means of local control or as an adjunct to surgery as detailed 
above. It may be applied externally (beam therapy) or internally (brachy therapy) 
and the two approaches can be combined. 
Surgery and/or radiotherapy are only effective in locally confined tumours 
and less than a quarter of those diagnosed with cancer will be cured solely by these 
means. Most patients will receive systemic chemotherapy at some time during their 
illness. In a small fraction of cancer patients, representing selected neoplasms, 
chemotherapy will result in a cure or prolonged remission. In most cases, however, 
drug therapy will produce only a regression of the disease and complications or 
relapse may eventually lead to death. In addition, most currently available anti- 
cancer drugs do not specifically recognise neoplastic cells but rather affect all 
proliferating cells. Consequently, treatment often lacks specificity and results in side 
effects which include gastrointestinal damage, hair loss and myelosuppression. As a 
result, anti-cancer drugs tend to have a steep dose response curve for both toxic and 
therapeutic effects. 
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Other forms of treatment include hormone therapy, gene therapy, 
immunotherapy, bone marrow transplant and peripheral blood stem cell transplants 
in conjunction with high dose chemotherapy. One approach which has received 
much publicity is the `magic bullet' which employs toxin-linked monoclonal 
antibodies to target tumour cell antigens. In practice, however, monoclonal antibody 
therapy has been disappointing since the antibody is all too often recognised as 
foreign and destroyed by the actions of the immune system before any significant 
cell kill is achieved. 
1.3 DNA damage 
The number of ways that DNA can be damaged is extremely large since DNA is 
continuously subject to hydrolysis, oxidation and non-enzymic methylation damage, 
as well as environmentally and chemically induced lesions. The major causes of 
spontaneous DNA damage as well as that caused by IR and chemotherapeutic agents 
most commonly used in the treatment of cancer are reviewed below. 
1.3.1 Endogenous damage 
Base loss 
The N-glycosyl base sugar bond linking DNA bases with deoxyribose is 
labile under physiological conditions. Within a typical mammalian cell, several 
thousand DNA purines and several hundred DNA pyrimidines are spontaneously lost 
per cell per day due to hydrolytic cleavage of the glycosyl bond. Loss of a purine or 
pyrimidine base creates an apurinic or apyrimidinic (AP) site also known as an 
abasic site. 
Base modification 
Deamination The primary amino groups of nucleic acid bases are unstable and may 
be converted to keto groups in a process termed deamination. Cytosine in DNA is 
deaminated to uracil and it is estimated that between 100 and 500 cytosine 
deamination events take place per human cell per day. Other deamination reactions 
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include conversion of adenine to hypoxanthine, guanine to xanthine and 5-methyl 
cytosine to thymine (Lindahl, 1993). Deamination of cytosine and 5-methyl cytosine 
is potentially mutagenic because if the damage remains uncorrected the resultant 
thymine or uracil can pair with an adenine instead of guanine at replication. 
Similarly, the deamination of adenine is a potentially mutagenic lesion because 
hypoxanthine forms a more stable base pair with cytosine rather than thymine. 
Oxidation In the course of normal metabolism, cells are exposed to several types of 
reactive oxygen species (ROS) which include singlet oxygen, peroxide radicals, 
hydrogen peroxide and hydroxyl radicals (OH). ROS can modify DNA bases. A 
common product of thymine oxidation is a thymine glycol which has lost the 5,6 
double bond and are non-coding bases. Hydroxyl radicals react with guanine to 
generate 8-hydroxyguanine, a potentially mutagenic lesion that shows preference for 
base pairing with adenine rather than cytosine. This latter reaction is estimated to 
occur at approximately the same rate as cytosine deamination, i. e. 100-500 events per 
day. 
Methylation In addition to oxygen, living cells contain several other reactive 
molecules that have the potential to cause DNA damage. The most important of 
these is probably S-adenosylmethionine (SAM). SAM is a methyl group donor that is 
used as a co-factor in most cellular transmethylation reactions. SAM can react 
accidentally with DNA to produce alkylated bases which include 3-methyladenine 
and 7-methylguanine. The latter is relatively harmless as it does not alter the coding 
specificity of the base. However, 3-methyladenine blocks replication, and is 
therefore a cytotoxic DNA lesion. 
1.3.2 Environmental damage 
Ultraviolet light is absorbed by nucleic acid bases and the resulting deposition 
of energy can induce chemical changes. The most frequent photoproducts are the 
consequences of bond formation between adjacent pyrimidines within one strand, 
and, of these, the most frequent are cyclobutane pyrimidine dimers (CPDs). T-T 
CPDs are formed most readily, followed by T-C or C-T and C-C dimers are least 
abundant. CPDs cause extreme distortion of the DNA chain structure. The 
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mechanisms by which UV irradiation generates point mutations are only partially 
understood, however, the most frequently observed mutations are C to T transitions, 
with CC to TT double transitions also being commonly seen (Pfeifer, 1997). 
1.3.3 Replication errors 
Another major source of potential alterations in DNA is the generation of 
mismatches or small insertions or deletions during DNA replication, particularly in 
highly repetitive sequences. Although DNA polymerases are moderately accurate 
and most mistakes are immediately corrected by polymerise-associated 
`proofreading'exonucleases, nevertheless, the replication machinery is not perfect. 
1.3.4 Chemical damage 
Many environmental chemicals including those substances encountered in 
daily living can damage DNA and act as carcinogens by modifying DNA bases, 
frequently by addition of an alkyl group (alkylation). Examples include, polycyclic 
aromatic hydrocarbons such as benzo(a)pyrene occurring in tobacco smoke, pitch, tar 
fumes and soot; aromatic amines which are used principally in the chemical and 
rubber industries. 
The alkylating agents, dimethyl- and diethyl-nitrosamine, which require 
metabolic activation and are indirect acting, are found in trace amounts in many food 
products. In addition, nitrosamines are generated within the body by the action of 
nitrosating agents on ingested amines, or formed from diethylamine and methylnitrite 
in tobacco smoke (Beranek, 1990). 
Radio- and chemo-therapy are effective treatments for cancer, yet 
paradoxically, they are also known to cause cancer since they induce genetic 
changes. With the ultimate goal of producing a cure, radio-and chemo-therapy aim to 
cause a cytotoxic lesion that will arrest tumour progression without affecting normal 
tissue. Often, the cytotoxic lesion is a DNA strand break. Strand breaks may be 
introduced into DNA by a variety of mechanisms which include direct damage and 
indirect damage by repair mechanisms which introduce breaks as part of the repair 
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process. The major lethal effect of ionising radiation (IR) is the creation of double 
stranded breaks (DSBs). Chemotherapeutic agents which damage DNA, producing 
strand breaks as part of their mechanism include alkylating agents, topoisomerase 
poisons, including etoposide, and the radiomimetic drug, bleomycin. The latter two 
agents have been used in the studies described in this thesis and are therefore 
reviewed below. 
1.3.4.1 Radiotherapeutic agents 
Ionising radiation (IR), which includes X rays, y rays and high energy 
electrons, interacts with matter by transferring energy to the electrons in the 
irradiated sample. IR acts indiscriminately on all molecules in the irradiated area and 
DNA is the critical target of IR-induced cell death. The toxic effect of IR on cells is 
a result of a direct interaction of energy with DNA or indirectly through the 
formation of free radicals. These include the hydroxyl (OH) radical, the hydrated 
electron, the H atom, as well as secondary radicals that are produced as a 
consequence of reaction with small solute molecules within the cell. 
The proportions of reactive species formed is dependent on the oxygen status 
of the cell, where under oxygenated conditions, the OH radical predominates. This 
radical can diffuse to the DNA and efficiently react with the sugar of any nucleotide 
resulting in base damage or disruption of a phosphodiester bond or ribose ring (by H 
abstraction, for example), ultimately giving rise to DNA strand breaks in the 
individual strands of the double helix. In addition, alkali-labile bonds result in the 
formation of apyrimidinic sites, base damage (For example, ring saturated thymines, 
thymine glycol, 5-hydroxy-5-methylhydantoin, 5-hydroxycysteine, phosphoglycols) 
and adducts such as formate and COO' which cause protein cross links (Ward, 1988). 
Double strand breaks (DSBs) are the major cytotoxic lesion produced by IR 
and it is estimated that a single unrepaired DSB is sufficient to cause cell death. 
DSBs can result from direct interaction of energy with the DNA or as repair 
intermediates through the conversion of multiply damaged sites (MDS) (described in 
more detail in section 5.1). IR is thought to produce about 40 double strand breaks 
(DSBs), 1000 single strand breaks (SSBs), 2000 base damages, 1500 sugar damages, 
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30 DNA-DNA cross-links, 150 DNA-protein crosslinks and 300 alkali-labile sites 
per Gray (Ward, 1990). Due to the wide spectrum of lesions introduced into the 
DNA, IR-induced DNA damage is repaired by multiple DNA repair pathways (see 
section 1.5.2). 
Low LET radiation (gamma) predominantly causes indirect damage through 
OH radical intermediates. There are two main consequences of the reaction of 
hydroxyl radicals with the deoxyribose of DNA; Strand breaks leaving 5'- and 3'- 
phosphate termini; Strand break leaving 5'-phosphate and 3'-phosphoglycolate 
termini. 
1.3.4.2 Chemotherapeutic agents 
Alkylating agents 
The alkylating agents, which include the nitrogen mustards, were the first used 
chemotherapeutic agents and are still widely used today. Indeed, the use of nitrogen 
mustard as an anticancer agent dates from 1946 when it was shown to induce 
regression of lymphomas (Chabner and Collins, 1990). Nitrogen mustards exert their 
cytotoxic effects through covalent reaction of alkyl groups (one or more saturated 
carbons) with cellular molecules thus forming covalent adducts with bases in the 
DNA. Alkylating agents are electrophilic agents that react with nucleophilic centres 
on DNA. The most common mechanism of action is thought to be the alkylation of 
DNA most frequently at the nucleophilic positions, N7 and 06 of guanine. The 
principal mutagenic lesion is the 06 methylguanine which mispairs with thymine 
during replication. 
Monofunctional alkylating agents carry one reactive alkyl group that can lead to 
DNA SSBs during repair of such lesions. Bifunctional alkylating agents have two 
reactive alkyl groups and in addition to monofunctional lesions, can induce inter- or 
intra-strand DNA cross links with other bases. The cross-links are not easily repaired 
by DNA repair systems and are therefore readily cytotoxic. 
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Other agents such as the nitrosoureas and platinating agents (cisplatin, for 
example) have a similar mode of action to the nitrogen mustards, whereby reactive 
species from these agents (electrophilic) react with nucleophilic centres on DNA to 
form a variety of adducts (Chabner and Collins, 1990). 
Bleomycin 
Bleomycin is a radiomimetic drug because it produces similar DNA lesions in 
DNA compared to IR i. e. single and double strand breaks, through the generation of 
free radicals that cause scission of DNA through an oxidative process. The 
bleomycin molecule contains a metal binding region which forms a complex with Fe 
(II), thus allowing efficient oxygen binding and reduction and therefore giving rise to 
hydroxyl and superoxide radicals. Association of bleomycin with DNA occurs 
through a DNA binding domain directed to specific nucleotide sequences, 5'-GC-3' 
and 5'-GT-3', for example (Muraoka and Takita, 1988), and this enables the metal 
chelated portion of the molecule to generate free radicals in close proximity to DNA. 
The free radicals in turn produce DNA strand scission and base release. 
Topoisomerase poisons 
Topoisomerase I and II (topo I and II) are enzymes that regulate the strand 
breakage, rotation and rejoining of DNA to enable DNA transcription, replication, 
recombination and repair to occur. 
Both enzymes catalyse the unlinking and relaxation of DNA strands by forming 
transient DNA breaks through the formation of a `cleavable complex' thus allowing 
DNA to rotate around or traverse through these breaks. In the case of topoisomerase 
I, a SSB is formed that allows the DNA to unwind by one turn. Topoisomerase II 
forms a DSB, allowing relaxation of torsional strain by two turns. 
Topo I poisons act by stabilising the cleavable complex thus giving rise to strand 
breaks. Topo I poisons are associated with single strand breaks whilst topo II poisons 
give rise to the formation of DSBs. Cytotoxic lesions can also appear through the 
processing of cleavable complexes by repair pathways thus leading to the formation 
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of frank DNA strand breaks. Alternatively, cytotoxic strand breaks appear due to an 
interaction between drug stabilised cleavable complexes and replication forks. 
Indeed, topo I poisons are particularly cytotoxic during S phase of the cell cycle. In 
this way, reversible Topo I DNA cleavable complexes are converted to irreversible 
DSBs. 
1.4 Mechanisms of drug resistance 
Anti-cancer agents and IR present a lethal threat to the cell and in some cases are 
able to achieve a cure. However, treatment of many types of cancer fails to achieve a 
cure because tumour cells are chemo- or radio-resistant. Chemo- and radio- 
resistance, the phenomenon whereby a cell can survive doses of a chemical or IR that 
would normally be cytostatic or cytotoxic is the main obstacle to the clinical success 
of chemotherapeutic agents and IR. Resistance may be intrinsic, i. e. when, despite 
no prior therapy, a tumour cell is refractory to treatment from the outset, or acquired, 
i. e. when an initially sensitive tumour cell becomes resistant. Drug resistance can 
arise as a result of various biochemical mechanisms. These mechanisms are 
reviewed below and in Figure 1.1. It should be noted that resistance to a particular 
drug could be achieved by more than one mechanism and in some cases, particularly 
those involving changes in drug transportation or detoxification, protection against 
more than one chemical (cross-resistance) is observed. 
1.4.1 Drug delivery 
Drug resistance may be caused by reduced drug delivery. The concentration 
of drug in the blood is of critical importance in the delivery of drug to the target 
tissue. The vascularisation of tumours is highly variable and poorly vascularised 
tumours may not receive adequate drug exposure. Another feature influencing drug 
delivery are the pharmacokinetics of the drug in plasma, which are dependent on 
factors such as chemical stability, metabolism, biliary and renal elimination. 
Alternatively, a reduction in the active drug concentration may result from drug 
sequestration due to increased intracellular drug binding. 
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1.4.2 Drug uptake/efflux 
The defective cellular uptake of drugs constitutes a general mechanism of 
resistance. The contribution of decreased drug uptake to drug resistance varies 
according to the lipophilicity of the drug and on the physiochemical properties of the 
cell membrane and involves drugs that are absorbed passively or those requiring 
active transport. If the influx of the drug is by simple diffusion, the properties of the 
cell membrane may be altered. Carrier mediated transport is of importance in the 
uptake and resistance to several anticancer drugs, particularly those that are charged 
at physiological pH. Examples of carrier mediated transport of anticancer drugs 
include the uptake of nitrogen mustard via the choline transport system and 
methotrexate via the reduced folate carrier. Mutations affecting these transport 
systems have been implicated in resistance to anti-cancer drugs. 
Multidrug resistance (MDR) describes the situation where exposure to one 
drug induces cross-resistance to a variety of agents of different chemical classes, to 
which the cell has never been exposed (Hochhauser and Harris, 1991). MDR occurs 
in a wide range of cell types and involves alterations to drug transport systems. A 
common example of MDR is P-glycoprotein which is a 179 kDa trans-membrane, 
energy-dependent efflux pump (Ling, 1997). Overexpression of P-glycoprotein 
causes increased drug efflux thus removing many anti-cancer drugs from the cell. P- 
glycoprotein and other similar pumps, including the multi-drug resistance associated 
protein (MRP) family, for example, are overexpressed in many tumour cell types. 
1.4.3 Drug metabolism 
Drug metabolising enzymes can act either to potentiate or reduce the toxicity 
of chemicals. Changes in both activation and de-activation pathways are important 
variables that can lead to drug resistance. Resistance to antimetabolite drugs is often 
associated with decreased activation. In contrast, resistance to 1- 
arabinofuranoslcytosine (araC) has been attributed to the increased deactivation of 
the drug by metabolising enzymes that serve to inactivate the drug, in this case, 
specific deaminases. In addition, resistance to alkylating agents can involve 
overexpression of glutathione S-tranferases (Chabner and Collins, 1990). 
11 
1.4.4 Changes to target sites 
Alteration of the structure of the drug target may reduce the affinity of the 
drug for the target, or reduce the activity of the target. This type of resistance is 
usually associated with drugs whose target is well defined. For example, mutations 
in the dihydrofolate reductase gene can result in resistance to methotrexate and 
mutated or down regulation of topo I can result in resistance to camptothecin. 
Similarly, over-expression of the target protein due to gene amplification and/ or 
increased transcription, reduced degradation, posttranslational modification, could 
increase the concentration of target sites. In this mechanism the structure of the 
target site is unchanged and resistance is solely due to an increase in target 
abundance. An example of this mechanism of resistance is the increase in 
dihydrofolate reductase protein concentration resulting from gene amplification 
observed in methotrexate resistant cell lines. 
1.4.5 DNA repair as a resistance mechanism 
Increased rates of repair of cellular DNA damage represents an important 
mechanism of resistance to chemo- and radiotherapy. A number of repair pathways 
have been described (section 1.5). In the context of this thesis, modulation of repair 
by the use of specific inhibitors has been evaluated as an attractive mechanism by 
which to modulate resistance to a number of anticancer agents. 
1.5 DNA repair 
As described in section 1.3, cells are continuously under assault from a wide 
array of DNA-damaging agents. These include reactive oxygen species generated as 
a consequence of oxidative metabolism, UV light, IR and radio-mimetic chemicals. 
The forms of damage are many, and range from base modifications, inter- and intra- 
cross-links, DNA SSB and DSBs. 
The integrity of cellular DNA is of paramount importance for survival and 
therefore cells have evolved very efficient mechanisms for both DNA damage 
recognition and repair in order to ultimately maintain genomic stability and prevent 
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cancer. Following DNA damage, three main processes have been described; repair, 
excision and tolerance of the lesion (Friedberg, 1985). Those mechanisms 
responsible for the repair of DNA strand breaks include direct repair, excision repair 
and double strand break repair. 
Key players in DNA damage recognition and signalling are considered to be 
the tumour suppressor protein p53, ataxia telangiectasia mutated (ATM), DNA 
dependent protein kinase (DNA-PK) and poly(ADP-ribose) polymerase-1 (PARP-1) 
(Watters, 1999). The relative and joint roles of PARP-1 and DNA-PK in DNA 
damage repair and survival have been investigated in the studies described in this 
thesis. Evidence in the literature indicates that these enzymes are involved in base 
excision repair (BER) and double strand break repair (DSB repair), respectively, and 
therefore these mechanisms of repair are described in more detail below (sections 
1.5.1 and 1.5.2). 
Excision repair 
This may be considered to be the most important repair mechanism. Briefly, 
it involves the recognition of damaged DNA, its removal either as free bases or as 
nucleotides followed by the gap being filled by synthesis of new DNA using the 
complementary strand as a template. Excision repair may be subdivided into the 
three main classes of base excision repair (BER), nucleotide excision repair (NER) 
and mismatch repair (MMR). As PARP-1 has only been implicated in BER, only 
this pathway is described in more detail. 
1.5.1 Base excision repair 
The base excision repair (BER) pathway has evolved to protect cells against 
mutations induced by oxidative, alkylating and other DNA-damaging agents 
(McCullough et al., 1999). BER is therefore one of the major pathways to repair base 
lesions, AP sites and SSBs. This pathway is a multi-step process involving the 
sequential action of several proteins (Figure 1.2). The key enzymes involved in this 
pathway are the DNA glycosylases. The glycosylases provide the only lesion 
specificity in the BER pathway with specific glycosylases for a specific type of 
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lesion (Seeberg et al., 1995). For example, N-methylpurine-DNA glycosylase (MGP) 
removes N-methylpurines. 
BER is initiated by the excision of any damaged bases by a glycosylase that 
cleaves the glycosidic bond between the base and the deoxyribose-phosphate 
backbone of DNA. The modified base is released and this results in the generation 
of an apyrimidinic or apurinic (AP) site that is then converted to a SSB through 
incision upstream of the AP site creating a 3'OH terminus adjacent to the AP site by 
an AP endonuclease or by the AP lyase action of bifunctional glycosylases. The 
resulting single base gap is then filled by extension of the 3'OH terminus, by a DNA 
polymerase which also removes the 5'phosphate terminus to permit ligation. The 
DNA strand is then sealed by a DNA ligase and either short-patch or long-patch 
processes. 
Short-patch BER is responsible for the majority of repair and involves the 
removal of a damaged base by one of six DNA glycosylases that have been 
identified. The abasic site is recognised by APE-l, an endonuclease that incises 5' to 
the lesion leaving a normal 3'OH. One nucleotide is then added by DNA polymerase 
ß which also excises the deoxyribose phosphate moiety using its deoxyribose 
phosphatase (dRPase) activity. This is followed by the rejoining of the DNA ends by 
DNA ligase III in partnership with the scaffold protein XRCC1. However, if a 
glycosylase/lyase is involved in the removal of the damaged base, the resulting 3'- 
phosphodeoxyribose group must be removed and replaced to leave a 3'OH for 
polymerase activity. A function for the recently identified polynucleotide kinase 
(PNK) in this process has been proposed (Whitehouse et al., 2001). 
Long-patch BER, a minor repair process, involves the incorporation of two to 
six nucleotides into the repair gap. This pathway is orchestrated by enzymes 
normally involved in DNA replication, including DNA polymerase 0/8, proliferating 
cell nuclear antigen (PCNA), which serves as a cofactor for both polymerases, flap 
endonuclease (FEN1), which excises the flap-like structure that is produced by DNA 
polymerase strand displacement and ligase 1. 
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Figure 1.2 Model of Base Excision Repair 
Adapted from Wood, 1996 
1.5.2 Double strand break repair 
DSBs arise from IR, free radicals, chemotherapeutic drugs and during 
replication of a SSB. A single DNA double strand break (DSB) may be sufficient to 
cause cell death and therefore repair of these breaks is an important process if a cell 
is to survive. To maintain the integrity of the genome and overcome the cytotoxic 
and mutagenic properties of DSBs, at least three pathways exist in eukaryotic 
organisms: - 
(1) Non- homologous end joining (NHEJ), (2) homologous recombination 
(HR) and (3) single strand annealing (SSA). Although these three DSB repair 
mechanisms are evolutionarily conserved, their relative contributions differ between 
lower and higher eukaryotes. NHEJ is the predominant pathway for DSB repair in 
multicellular eukaryotes (Chu, 1997) since it requires little sequence homology and it 
has the advantage of being rapid. However, it is not necessarily error free. 
1.5.2.1 Non-homologous end-joining 
NHEJ is involved in repair and survival following exposure to IR, 
radiomimetic drugs and topoll poisons. This pathway occurs primarily in the G1 
phase of the cell cycle and rejoins ends in the absence of significant homology. 
There are three processes; The first involves the precise joining of short overhanging, 
complementary ends, such as, those produced by site-specific endonucleases. This is 
a highly efficient process where most ends are successfully rejoined. However, 
when the ends are not complementary or when the continued presence of an 
endonuclease precludes precise re-ligation, there are two additional, but much less 
efficient, NHEJ processes. The first is independent of microhomology and involves 
the misalignment of overhanging ends. This occurs through the pairing of as few as 
one base pair (bp), followed by filling-in by a DNA polymerase and results in the 
ligation of ends with the insertion of a few bp. Alternatively, annealing of 
microhomologies of one to a few bp and removal of single stranded tails leads to the 
formation of deletions ranging from a few bp to several kb. 
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Many of the proteins important for NHEJ have been identified. At present, 5 
proteins have been identified and these include the 3 components of the DNA-PK 
complex, DNA-PKcs, Ku70 and Ku80 (described in section 1.10.2). Repair is 
completed by DNA ligase IV and its associated protein XRCC4 (Lee et al., 2003). A 
model for the basic NHEJ pathway is shown in Figure 1.3A. Although there have 
been many advances in the analysis of NHEJ, knowledge of additional factors 
implicated in this process is limited. Nevertheless, a role has been described for the 
recently identified cofactor, Artemis which is described in more detail in section 5.1 
and reviewed in Jeggo and O'Neill, 2002. 
1.5.2.2 Homologous recombination 
The mechanism of DSB repair by homologous recombination (HR) is only 
partially understood, though many models have been proposed. What is known is 
that it takes advantage of a homologous sequence to repair the DNA DSB in order to 
ensure accurate rejoining. Whilst NHEJ is considered the major mechanism for DSB 
repair in mammals, HR has an important role in overcoming replication-specific 
breaks and as such occurs in the G2/M phases of the cell cycle. A model for the basic 
HR pathway is shown in Figure 1.3B. 
Key HR proteins include RAD51, RAD52, RAD54, RAD55, RAD57 and 
RAD59. The RAD51 protein is a key member of this group and has a central role in 
HR. It mediates ATP-dependent homologous pairing and sister chromatid exchange 
(SCE) (Sonoda et al., 1999). This strand exchange reaction is facilitated by RAD52 
and RAD54, a DNA-dependent ATPase (Van Dyck et al., 1999). Several other 
proteins have poorly defined roles in HR and these include the RAD51 related 
proteins (XRCC2 and XRCC3), products of the breast cancer genes (BRCA 1 and 
BRCA 2), replication protein A, p53, c-Abl and ATM (Bertrand, et al., 1997; Mekeel 
et al., 1997; Meyn et al., 1993; Iftode et al., 1999). In response to IR, distinct nuclear 
foci are formed in mammalian cells containing either RAD51or RAD50 but not both 
(Haaf et al., 1995; Zhong et al., 1999) and these foci are associated with BRCA1 and 
BRCA2. The formation of RAD51 foci is dependent on the presence of RAD54 and 
XRCC3 (Bishop et al., 1998). Despite an accumulation of evidence describing links 
between HR proteins and ATM, the involvement of ATM in DNA damage 
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recognition and repair remains unclear although ATM has been demonstrated to 
interact with H2AX through phosphorylation in some cell lines. 
Individuals carrying germline mutations in BRCA1 or BRCA2 are at 
increased risk of developing breast cancer. At the cellular level, mutations in ATM 
result in increased IR sensitivity and inherited mutations of the ATM gene cause 
increased susceptibility to leukaemias. Defective ATM may also predispose to 
sporadic colon cancer and epidemiologic studies also indicate an increased incidence 
of breast cancer in the relatives of individuals with ataxia telangiectasia. (Shen et al., 
2000). 
1.5.2.3 Single strand annealing (SSA) 
Single strand annealing (SSA) is a form of HR that is initiated when a DSB is 
formed between two repeated sequences orientated in the same direction (Gottlich et 
al., 1998). Briefly, single stranded regions are created adjacent to the breaks that 
extend to repeated sequences such that the complementary strands can anneal to each 
other. This is carried out through a series of steps; (1) generation of long single 
strands by helicase-mediated duplex unwinding (2) annealing of single strands at 
microhomology patches (3) removal of unpaired flap strands by endo-or exo- 
nucleases (4) DNA polymerase mediated fill in of gaps (5) sealing of remaining 
nicks by DNA ligase. A model for the basic SSA pathway is shown in Figure 1.3C. 
Like HR, SSA requires a number of gene products, including, RAD52 and 
RAD59, however, RAD51 is not required for this process. SSA differs from HR in 
that it does not require a homologous chromosome and therefore, like NHEJ, occurs 
in the G1 phase of the cell cycle. Furthermore, DNA synthesis is `conservative' i. e. 
within the newly synthesised stretch of DNA in the final repaired chromosome, both 
strands are newly synthesised and both template strands are restored to the template 
chromosome. 
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Figure 1.3 Schematic representation of eukaryotic DSB repair mechanisms 
A, Non-homologous end joining which is based on the religation of the two ends, 
frequently involves the deletion and/or insertion of oligonucleotides; B, Homologous 
recombination involves the invasion of a homologous undamaged donor sequence by 
a 3'single strand end. Repair synthesis results in restoration of the original sequence 
of the damaged DNA; C, Single strand annealing pathway which involves exposure 
of regions of homology and repair is completed by the removal of non-homologous 
ends and ligation. As a consequence, a deletion is introduced into the DNA. Adapted 
from Pastnik et al., 2001. 
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1.6 Poly(ADP-ribose) polymerase-1 (PARP-1) 
1.6.1 General Introduction 
The initial observation which led to the discovery of a nicotinamide adenine 
dinucleotide (NAD) consuming enzyme was by Roitt in 1956 who showed that 
following treatment of tumours with alkylating agents, a depletion of intracellular 
NAD+ occurred (Roitt, 1956). Following further studies by research groups, the 
enzyme responsible for this NAD+ depletion was discovered: - Chambon et al., 1963; 
Chambon et al., 1966. 
Chambon et al., 1963, observed that the incorporation of radioactivity from 
[14C]-ATP into acid insoluble material by a nuclear preparation of hen liver was 
decreased 1000-fold when nicotinamide mononucleotide (NMN) was removed. In 
1966, the group further demonstrated that a polymer of ADP-ribose was generated 
from ATP and NMN, with NAD+ as the intermediate precursor. A study by 
Nishizuka et al., 1967, then showed that the ADP-ribose moiety of NAD+ was 
incorporated into ADP-ribose polymer with the concomitant release of nicotinamide, 
and that the enzyme responsible was localised exclusively to the nucleus. Initially, 
this enzyme was named ADP-ribose synthetase (ADPRS) or ADP-ribose transferase 
(ADPRT) but was later renamed poly(ADP-ribose) polymerase-1 and it is by this 
name that the enzyme will be hereafter referred to in this thesis. 
Poly(ADP-ribose) polymerase-1 (PARP-1) [EC: 2.4.2.30] is a nuclear 
protein which is considered to have functions involved in numerous cellular 
processes including, differentiation, gene expression, recombination, transformation, 
chromatin structure formation and DNA repair (de Murcia et al., 1991). PARP-1 is 
found in all mammalian cells and some other eukaryotes, but is absent in prokaryotes 
and several terminally differentiated cells, such as mature granulocytes, epidermal 
cells, intestinal epithelial cells and mature erythrocytes (Chatterjee and Berger, 
1998). PARP-1 is ubiquitous, with approximately 1 enzyme per 10-20 nucleosomes 
per cell (Cleaver and Morgan, 1991) and it is estimated that there are approximately 
1x 106 molecules per cell in total (Chatterjee and Berger, 1998). 
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The catalytic activity of the enzyme has been shown to be dependent upon 
activation by DNA strand breaks (Benjamin and Gill, 1980). PARP-1 is continually 
present at high basal levels within the cell and therefore transcription of the enzyme 
remains unchanged in response to DNA damage (Bhatia et al., 1990). However, the 
presence of DNA strand breaks, increases the activity of the enzyme by up to 500- 
fold (Menissier-de Murcia et al., 1989). The enzyme catalyses the formation of 
ADP-ribose polymers from NAD+, by cleaving NAD+ at the N-glycosidic bond 
between the nicotinamide and ribose rings thus releasing nicotinamide as a by- 
product (Ueda and Hayaishi, 1985). Briefly, poly (ADP-ribose) (PAR) synthesis can 
be separated into 3 individual steps of initiation, elongation (the addition of 
successive ADP-ribose residues by ribose-ribose O-glycosidic linkages) and 
branching (characterised by ribose-ribose bonding between ADP-ribose units) 
(Alvarez-Gonzalez and Mendoza-Alvarez, 1995). 
Poly(ADP-ribose) polymers can be over 200 residues long, at which point 
they form a complex structure that resembles nucleic acids. Accordingly, PAR has 
often been referred to as the `third nucleic acid' within the literature. Once formed, 
the polymers are rapidly degraded by the enzyme poly(ADP-ribose) glycohydrolase 
(PARG), giving them a short half life of under one minute. 
PARP-1 synthesises polymer and transfers it to acceptor proteins by covalent 
modification of glycine residues. Acceptors of PAR are mostly DNA-binding 
proteins which include nuclear proteins (heteromodification) such as histones, DNA 
and RNA polymerases, topoisomerases, transcription factors (D'amours et al., 1999) 
and PARP-1 itself (automodification). Indeed, PARP-1 is the main acceptor in vivo 
and since both the polymer and DNA are strongly negatively charged, 
automodification of PARP-1 causes dissociation of the enzyme from DNA strands 
due to electrostatic repulsion (Ueda and Hayaishi, 1985). ADP-ribosylation results 
in altered functions of proteins (Althaus and Richter, 1987) although the precise 
role(s) of this post-translational modification remains unknown. 
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1.6.2 Structure 
The PARP-1 gene has been mapped to chromosome Ig41-42 in humans 
(Cherney et al., 1987). It is 43 Kb in length and contains 23 exons. PARP-1 is a 
protein of 1014 amino acids with a molecular weight of 113 kDa (Kurosaki et al., 
1987) (Table 1.1). Briefly, PARP-1 consists of three functional domains; an amino 
terminal DNA binding domain (DBD) containing two zinc finger motifs (Mazen et 
al., 1989) and a nuclear location signal (NLS) which is required for transport of the 
enzyme to the nucleus (Schreiber et al., 1992), a central automodification domain 
and a highly conserved catalytic domain at the carboxyl terminal Kameshita et al., 
1984; Lindahl et al., 1995). 
The elucidation of the PARP-1 structure into three functional domains was 
achieved by Kameshita et al., 1984, using limited proteolysis with a-chymotrypsin 
and papain. Briefly, proteolysis with a-chymotrypsin cleaved the enzyme into two 
fragments of 54 kDa and 66 kDa, respectively. The latter fragment was then further 
cleaved using papain into two fragments of 46 kDa and 22 kDa thus indicating that 
PARP-1 contains three separable domains. 
It was demonstrated by Zahradka et al., 1984, that PARP-1 was inhibited by 
various chelating agents and therefore it was suggested that PARP-1 is a 
metalloenzyme. Following atomic absorption spectroscopy, the enzyme was shown 
to contain zinc and it was proposed that the presence of this metal ion might be 
involved in the interaction of PARP-1 with DNA since a variety of other DNA- 
dependent reactions require zinc. In addition, this provided an explanation for the 
requirement of DNA for PARP-1 activation. Mazen et al., 1989, confirmed that 
each molecule of PARP-1 contains Zn(II) ions and demonstrated that PARP-1 binds 
DNA nicks in a zinc-dependent manner. Furthermore, the authors showed that the 
two metal binding sites correspond to two `zinc fingers'. The two zinc fingers (FI 
and FII) are differentially required for the recognition of strand breaks (Ikejima, et 
al., 1990). The second zinc finger (FII) detects predominantly single strand breaks 
(Gradwohl et al., 1990). The first zinc finger (FI), on the other hand, recognises both 
single and double strand breaks. In addition, FI possibly contributes to increased 
enzyme activity following nick binding by FII since enzyme activity is abolished in 
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FI mutants (de Murcia et al., 1994a). Thus both fingers are required for activation by 
single stranded nicks but only the first finger is required for activation by DSBs. 
Following the elucidation of the function of the zinc finger motifs, PARP-1 is 
sometimes referred to as a molecular nick sensor (de Murcia and Menissier de 
Murcia, 1994b). 
The DNA binding domain 
The N-terminal region of human PARP-1 is 42.5 kDa and contains a repeated 
amino acid sequence in which 35 amino acids are highly conserved (Chatterjee and 
Berger, 1998). The zinc finger motifs are contained within these sequences. In 
addition, this domain contains a caspase cleavage site. 
The automodification domain 
The automodification domain is 16 kDa and is located between amino acid 
residues 374 and 525. Since PARP-1 is the major acceptor of PAR, this domain 
contains 15 highly conserved amino acid residues thought to be the major 
autoribosylation sites (Uchida et al., 1993). This domain also contains a BRCA1 C- 
terminal domain (BRCT) motif that is found in a number of proteins involved in the 
response to DNA damage. This motif mediates interactions between several DNA 
repair and cell cycle checkpoint proteins. In PARP-1, this motif is important for 
interactions with XRCC1, PARP-2, histones, DNA polymerase ß and transcription 
factors (Bouchard et al., 2003). In addition, this domain is involved in PARP-1 
dimerization and other protein-protein interactions (Burkle et al., 2002). 
The catalytic domain 
This domain is the NAD+binding domain and is the most conserved region of 
the protein. It is located at the C-terminus and is 55.4 kDa, consisting of residues 
526-1014. Residues 859-908 are designated the `PARP signature' since this region 
contains a region of 50 amino acids that are conserved 100 % amongst invertebrates 
and 92 % across all species (de Murcia et al., 1994a). 
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1.6.3 Activation by strand breaks 
Benjamin and Gill, amongst others, were able to show that PARP-1 has an 
absolute requirement for double stranded DNA and that activation occurs as a result 
of nick binding (Benjamin and Gill, 1980). This work was supported by the findings 
of Kupper et al., 1990, who showed that over expression of the DNA binding domain 
markedly reduced the activity of the enzyme in a dominant negative fashion, by 
competing with holoPARP-1 for binding at DNA nicks. 
A study by de Murcia et al., in 1994 investigated what PARP-1 recognises in 
nicked DNA that ultimately leads to its activation. A study which employed a 39 bp 
DNA duplex containing a single stranded break in its centre, revealed that upon the 
introduction of a break to only one strand of the DNA duplex, flexibility was 
conferred at the site of the breaks, which under electron microscopy, appeared as a 
distinctive `V' conformation (de Murcia et al., 1994b). The authors observed that 
PARP-1 specifically bound to the centre of the `V' and from this it was inferred that 
this may be a specific structure required to stimulate PARP-1 activity. In addition, 
this research group found that PARP-1 protected symmetrically +/- 7 nucleotides 
either side of the nick and this is referred to as the PARP-1 `footprint'. Caution 
should be taken when considering this data, however, as isolated DNA in the absence 
of associated histones was used and this may be different to chromosomal DNA. 
PARP-1 exhibits a preference for various types of strand interruptions. In an 
elegant study, Benjamin and Gill, 1980, showed that closed circular DNA was 
ineffective in activating PARP-1, whilst greatest stimulation could be seen with 
double strand breaks with blunt ends followed by those with 3' overhangs, 
5'overhangs and lastly by single strand breaks (Benjamin and Gill, 1980; Hengartner 
et al., 1991). Contradictory evidence has recently been given by D'Silva et al., 1999, 
who found that whilst PARP-1 had greatest affinity for blunt ends, they were the 
weakest activators of PARP-1. The authors propose the possibility that the use of 
purified PARP-1 and an absence of magnesium in the assays performed by Benjamin 
and Gill in 1980 may explain the different results. 
23 
1.6.4 Functions for PARP-1 in DNA repair 
The high basal levels of PARP-1 suggest PARP-1 is involved in the 
immediate, emergency response to DNA damage. Furthermore, the rapid yet 
transient synthesis of ADP-ribose polymers in response to DNA damage, which 
imposes a high energy cost to the cell due to the resulting consumption of NAD+ and 
ATP, coupled with the fact that PARP-1 is well conserved across species suggests 
that PARP-1 may play a fundamental role in the DNA damage response network. 
Durkacz et al., 1980, presented the initial evidence to indicate the 
involvement of PARP-1 in the cellular recovery from DNA damage. This group 
demonstrated that inhibitors of PARP-1, such as 3-aminobenzamide (3-AB), were 
able to potentiate the cytotoxicity of alkylating agents and retard DNA strand break 
rejoining. Furthermore, intracellular levels of the PARP substrate, NAD+ have been 
shown to be acutely lowered by agents that generate DNA damage (Roitt, 1956; 
Satoh et al., 1993). Several functions for PARP-1 in DNA repair, and in maintaining 
the integrity of the genome have been proposed and these are described below. 
PARP-1 function may be mediated by the synthesis of the poly (ADP-ribose) 
polymers that confer a negative charge on modified proteins although the precise 
physiological role of polymerisation in response to DNA damage is unclear. The 
attachment of long negatively charged polymers causes electrostatic repulsion of the 
enzyme from the negatively charged DNA. In addition, covalent poly (ADP- 
ribosylation) of DNA binding enzymes will likely alter their physiological and 
biochemical properties by reducing their affinity for DNA and presumably increasing 
their affinity for positively charged cellular macromolecules. A proposed 
mechanism of action for PARP-1 is shown in Figure 1.4. 
1.6.4.1 Histone shuttling model 
The formation of poly(ADP-ribose) polymer at the sites of DNA damage may 
serve to loosen chromatin by temporarily extracting the histones in a process termed 
histone shuttling (Realini and Althaus, 1992; Althaus et al., 1993; Althaus et al., 
1994). In this model, positively charged histones associate with negatively charged 
ADP-ribose polymers, either by direct covalent modification of H1 by PARP-1 or by 
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attraction to the automodified PARP-1. This, in turn, causes repulsion from 
negatively charged DNA thus facilitating the displacement of histones from DNA 
and hence relaxation of chromatin. 
Local disruption of chromatin structure may be critical for repair in areas 
where chromatin is highly condensed, and secondly, by altering steric congestion 
imposed by chromatin, this gives rise to a more open chromatin structure rendering 
the damaged site more accessible to repair enzymes. Indeed, many repair factors are 
large complexes, DNA-PK being a good example, whose functions may be otherwise 
hindered by the presence of chromatin. 
Reassembly of chromatin structure occurs following degradation of the 
polymers by poly(ADP-ribose) glycohydrolase (PARG) and the subsequent 
reassociation of histones with DNA. 
1.6.4.2 Antirecombinational factor 
Satoh and Lindahl, 1992, proposed that the binding of PARP-1 to DNA 
strand breaks may serve to prevent inappropriate recombination events which could 
lead to chromosome aberrations and spurious initiation of transcription at sites of 
damage. PARP-1 could serve this function in two ways that are not necessarily 
mutually exclusive: - 
Firstly, PARP-1 might bind and prevent the access of exonucleases that could 
generate recombination intermediates until repair enzymes are recruited to the sites 
of DNA damage. Alternatively, the formation of a dense concentration of negative 
charges at the site of a break could impede the approach of any neighbouring 
duplexes of DNA which might otherwise participate in spurious recombination 
reactions, and repel other molecules from the vicinity of the breaks. 
An involvement of PARP-1 in DNA recombination is supported by the 
observation that PARP-1 -/- cells have elevated sister chromatid exchanges 
(Schreiber et al., 1995) and that the PARP-1 inhibitor 3-aminobenzamide (3-AB) is a 
potent inducer of sister chromatid exchanges (Morgan et al., 1986). Moreover, 
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Morrison et al., 1997, demonstrated that whilst severe combined immunodeficiency 
(SCID) mice deficient in DNA-PK activity were unable to perform V(D)J 
recombination, SCID-PARP-1 knock out mice were able to. Thus the absence of 
PARP-1 appears to rescue the V(D)J recombination defect seen in SCID mice and 
these data are therefore consistent with the proposal that PARP-1 serves to protect 
DNA ends from illegitimate recombination reactions. In addition, PARP-1 has also 
been found to be a component of a multiprotein complex which includes numatrin, 
B23 and nucleolin. This complex has been shown to be capable of some DNA 
recombination activities (Borggrefe et al., 1998). 
1.6.4.3 Signalling model 
Several authors have suggested the possible contribution of PARP-1 to DNA 
damage signalling. The activation of PARP-1 and synthesis of PAR are immediate 
responses to DNA damage and therefore PARP-1 may play a role in nick detection 
and stimulate repair by signalling the presence of these breaks through PAR 
formation to downstream effectors involved in the repair of DNA lesions (Lindahl et 
al., 1995). Indeed, recent evidence suggests that PARP-1 modulates p53 function 
(Malanga et al., 1998) and stimulates DNA-PK activity (Ruscetti et al., 1998). In 
addition, evidence for PARP-1 and polymer association with both of these proteins 
has been demonstrated. As PARP-1 is one of the first factors to recognise and bind 
to lesions in DNA, it is ideally positioned to directly recruit repair machinery, such 
as DNA-PK, for example. One such role for PARP-1 is its proposed role in BER. 
PARP-1 has been suggested to recruit factors involved in BER pathway whose 
activities are regulated by poly(ADP-ribosylation). 
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1.6.4.4 The role of PARP-1 in base excision repair 
Studies using DNA damaged by different DNA damaging agents have 
pinpointed a role for PARP-1 in base excision repair (BER) but not in nucleotide 
excision repair (NER). For example, the most potent activators of PARP-1 are those 
that induce DNA damage repaired by the BER pathway, including the 
monofunctional alkylating agents and IR. Other agents such as UV irradiation, 
which predominantly cause lesions that are repaired by NER, are not as potent at 
activating PARP-1 (de Murcia et al., 1994a) and any stimulation of PARP-1 activity 
by UV irradiation was shown by Satoh and Lindahl, 1992, to be due to the repair of 
minor pyridine hydrate lesions which are processed by BER. Furthermore, the repair 
of UV damage is not inhibited by PARP-1 inhibitors (Cleaver et al., 1983) and this is 
reviewed in section 1.7. 
The involvement of PARP-1 in BER was disputed until a direct link between 
PARP-1 and other proteins involved in this pathway was discovered. It has been 
suggested that PARP-1 may be a member of a multiprotein complex consisting of 
PARP-1, XRCCI, DNA ligase III and DNA polymerase ß (Menissier de Murcia et 
al., 1997) and therefore PARP-1 may be involved in recruiting components of the 
BER complex to the damaged site. An association of PARP-1 with DNA polymerase 
ß has been described by Dantzer et al., 2000. XRCC1 (X-ray repair cross 
complementing 1), a protein that acts as a molecular scaffold, interacts with all 
components of the complex individually. Accordingly, an association of PARP-1 
with XRCC1, has been demonstrated (Caldecott et al., 1996; Masson et al., 1998). 
Specifically, XRCC1 interacts with PARP-1 via its central region which contains a 
BRCT domain and is also associated with ligase III via a second BRCT domain. 
Similarly, PARP-1 strengthens its interaction with XRCC1 via its own BRCT 
domain located within the automodification domain of the protein or through its N- 
terminal zinc finger domain. Importantly, XRCC1 can be ADP-ribosylated in vitro 
and therefore PARP-1 may modulate its ability to interact with other components of 
the complex and by doing so, PARP-1 could regulate the function of the BER 
complex (D'amours et al., 1999). 
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Overexpression of XRCC1 reduces PAR synthesis in response to hydrogen- 
peroxide generated DNA strand breaks. This suggests that XRCC1 negatively 
regulates PARP-1 activity following DNA damage. Furthermore, by preventing 
autoribosylation of PARP-1 and therefore dissociation of PARP-1 from the damaged 
site, this could be a mechanism by which XRCCI indirectly participates in the 
protection of DNA ends produced during DNA damage and repair. Moreover, when 
in excess over PARP-1, ligase III can inhibit PARP-1 activity in vitro, presumably 
through competition for nick binding since ligase III has been demonstrated to 
exhibit nick binding activity (Caldecott et al., 1996). 
Alternatively, it has been suggested that PARP-1 may play an essential 
structural role in which it serves to stabilise the two broken ends thus enabling 
ligation to take place (Lindahl et al., 1995). 
1.7 Development of PARP-1 inhibitors 
Much of the evidence for the function of PARP-1 has been derived from 
studies using inhibitors of PARP-1 (reviewed in sections 1.7.1 and 4.1.1.1). The 
majority of PARP-1 inhibitors act as competitive inhibitors by competing with the 
substrate NAD+ for the nicotinamide binding domain of the enzyme. Early inhibitors 
included the nicotinamides (Fujimura et al., 1967), methylxanthines, aromatic 
amides, benzamides (Shall, 1975; Purnell and Whish, 1980) and the pyrimidine 
derivative thymidine. A number of problems are associated with these compounds as 
inhibitors of PARP-1 activity. First, lack of specificity for PARP-1, a key criterion 
for in vivo activity, has been demonstrated by many of the early compounds (Griffin 
et al., 1995a). Second, low potency and thirdly, poor solubility in aqueous solution 
have been demonstrated (Griffin et al., 1995b). All problems present as major 
obstacles to the potential use of these agents to probe the mechanism of PARP-1 
function let alone enable their use in a clinical situation. Moreover, many of the 
early inhibitors have the potential to influence a number of other cellular pathways. 
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Nicotinamide 
Nicotinamide was the first compound to be identified as an inhibitor of 
PARP-1 (Fujimura et al., 1967). Briefly, it was established by Fujimura et al that a 
five-fold reduction in the incorporation of [32P]-NAD+ into acid insoluble material 
could be achieved with 10 mM nicotinamide. Unfortunately, nicotinamide has the 
potential to influence a number of cellular pathways since NAD+ is utilised as a 
cofactor in a variety of metabolic reactions thus limiting any potential for clinical 
use. Indeed, nicotinamide is a substrate for phophoribosyl transferase and 
nicotinamide N-methyl transferase deaminase (Banasik, 1992). In addition, it 
inhibits mono(ADP-ribosyl) transferase, microsomal NADase and adenosine 
3'5'cyclic monophosphate phosphodiesterase (Shimoyama, 1994). 
Benzamide 
Benzamide (BZ) is an analogue of nicotinamide and its use as an inhibitor of 
PARP-1 was first demonstrated by Shall et al., in 1975. Benzamide and its 3- 
substituted analogues were first developed by Purnell and Whish, 1980, and most 
studies have utilised benzamides to provide an insight into the function of PARP-1 in 
DNA repair. At millimolar concentrations, these inhibitors show increased 
specificity and potency compared to the nicotinamides since they do not act as 
substrates for other NAD+ utilising enzymes. The use of benzamide as an inhibitor 
of PARP-1 is hindered by its poor aqueous solubility and although some of the 3- 
substituted analogues, for example, 3-aminobenzamide (3-AB), were shown to have 
enhanced solubility in water, through the introduction of polar substituents onto the 
ring of benzamide, studies by various research groups have suggested that these 
compounds exhibit effects on purine biosynthesis and de novo nucleotide 
biosynthesis (Cleaver, 1984; Hunting et al., 1985). 
With the aim of developing PARP-1 inhibitors with greater selectivity, 
structure activity relationships (SARs) have been elucidated and a variety of 
structural requirements for a PARP-1 inhibitor have been identified (Sestili et al., 
1990). These are illustrated in Figure 1.5. 
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Figure 1.5 Structural requirements for a poly(ADP-ribose) polymerase-1 
(PARP-1) inhibitor 
A number of structural features are required for optimum PARP-1 inhibition; 
Planarity and Aromaticity An unsubstituted aromatic or polyaromatic heterocyclic 
system is required as saturation of the ring system results in a loss of activity. 
A carboxamide group A carboxamide group is required as part of a second ring 
structure or attached to the aromatic ring system. It has been shown by Cantoni et al., 
1987, that substitution of the C=O with C=S results in a reduction in activity. 
Furthermore, Sims et al., 1982, showed that the replacement of the amide with a 
carboxylic acid or ketone renders the compound inactive. In addition, the anti 
conformation of the amide is more favourable than the syn conformation and this 
confers inhibitory activity. Indeed, derivatives with unrestricted carboxamides are 
less active (Suto et al., 1991). 
Amide proton At least one amide NH is required for putative hydrogen bonding to 
PARP-1. 
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A non-cleavable bond Introduction of a non-cleavable bond at the position 
corresponding to the 3-position of benzamide increases activity and makes the 
structure distinct from nicotinamide. 
Following these observations, Suto et al., 1991, developed a series of new 
potent inhibitors; the 5' substituted dihydroquinolinones, of which 3,4-dihydro-5- 
methoxyisoquinolin-1(2H)-one (PD128763) was the lead compound. These 
inhibitors showed improved potency and were as much as 50 -fold more potent than 
3-AB (Suto et al., 1991; Sebolt-Leobold and Scavone, 1992). 
In addition, the University of Newcastle Drug Development Group have 
developed novel inhibitors of PARP-1 for use as chemo and radiopotentiators, 
including the quinazolinones, which include, 8-hydroxy-2-methyl-quinazolin-4- 
[3H]one (NU1025) and the benzamidazoles which include 2-(4- 
hydroxyphenyl)benzamidazole-4-carboxamide (NU1085) and 2- 
methylbenzamidazole-4-carboxamide (NU1064). These compounds have been used 
in a variety of cell culture systems, including human tumour cells, to exploit the 
potentiation of a range of anticancer agents as described in more detail in section 
4.1.1.1. However, like earlier inhibitors of PARP-1, these compounds exhibit poor 
solubility in aqueous solution. More recently, the tricyclic indoles which have 
enhanced solubility and potency have been developed through a collaboration with 
Agouron Pharmaceuticals. These include the inhibitor used in the studies reported 
here, AG14361 (1-(4-dimethylaminoethylphenyl)-8,9-dihydr-7H-2,7,9a- 
benzo[cd]azulen-6-one), which has a Ki < 5nM and is described in detail in section 
3.1.2. Small molecule inhibitors of PARP-1 are shown in Figure 1.6. 
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1.7.1 Biological functions of PARP-1 as determined by inhibitors of PARP-1 
Studies have shown that chemical inhibitors of PARP-1 can effectively 
abolish the DNA damage-induced depletion of NAD+ and render cells hypersensitive 
to DNA damaging agents thus suggesting a role for PARP-1 in repair. There is now 
good evidence for the role of PARP-1 in BER (section 1.6.4.4). Many studies have 
implicated PARP-1 in the repair of IR and alkylating agent damage (reviewed by 
Shall et al., 1984). Furthermore, as described in section 4.1.1.1, the most potent 
activators of PARP-1 are the monofunctional alkylating agents and IR whose damage 
is repaired by the BER pathway. Conversely, PARP-1 inhibitors do not potentiate the 
cytotoxicity of damaging agents that are repaired by NER, for example, 3-AB did not 
inhibit the repair of UV irradiation damage or potentiate the cytotoxic effects of UV 
in human or hamster cells (Ben-Hur, 1985; Cleaver, 1983). 
Although these data indicate that PARP-1 plays a pivotal role in DNA repair, 
the limited specificity of the early PARP-1 inhibitors raises questions about the 
validity of these results. Nevertheless, the proposal that they act primarily through 
inhibition of PARP-1 is vindicated by genetic studies in PARP-1 -/- mice and trans- 
dominant inhibition which have demonstrated similar heightened sensitivity to 
alkylating agents and IR (section 1.8). Moreover, the overexpression of the DNA 
binding domain, that mimics the mechanism of the inhibitors, results in a specific 
increase in the half life of DNA lesions that are usually repaired by the BER 
pathway. 
1.8 Methods of PARP-1 depletion 
1.8.1 In vitro systems 
Elegant studies by Satoh and Lindahl, 1992, using a human cell-free system, 
showed that inhibited PARP-1 can have very different effects from PARP- 1 
deficiency. Briefly, these authors studied human cell-free extracts (containing no 
DNA) supplemented with plasmid DNA containing SSBs. The breaks were repaired 
in the presence of NAD+ but not in the absence of NAD+ or in the presence of 3AB, 
indicating that PARP-1 was a participatory factor in DNA repair. However, specific 
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depletion of PARP-1 from extracts by chromatography on DS DNA-cellulose 
resulted in extracts that repaired DNA just as efficiently as previously, but no longer 
exhibited NAD+ dependence. 
The above results indicate that in the absence of its substrate NAD+, PARP-1 
interferes with BER presumably because bound PARP-1 molecules block the access 
of repair enzymes. In this model, release of PARP-1 following automodification, or 
removal of PARP-1 from the reaction mixture, enables DNA repair by allowing the 
access of other repair enzymes. These experiments clearly suggest that inhibited 
PARP-1 could interfere with DNA repair by preventing automodification and 
subsequent removal of PARP-1 from DNA breaks, whereas in a situation with no 
PARP-1 such as in cells from knockout mice no such interference would be apparent. 
1.8.2 Antisense strategies 
Smulson and co-workers described the characterisation of cell transfectants 
with hormone-inducible expression of PARP-1 antisense RNA. Using the mouse 
mammary tumour virus (MMTV) promoter upstream of the full length, antisense- 
orientated human PARP-1 cDNA, an expression vector was constructed. The group 
then transfected HeLa cells with this PARP-1 construct and RNA expression was 
induced by dexamethosone treatment. Following 48-72 h, an 80 % depletion of 
PARP-1 activity was achieved with a corresponding 90 % reduction in PARP-1 
protein (Stevnsner et al., 1994; Ding et al., 1992; Ding and Smulson, 1994). PARP- 
1 levels returned to normal 16 h after the removal of dexamethosone. Similarly, 
Gaken et al., 1996, reported on the use of PARP-1 antisense DNA oligonucleotides 
which target the PARP-1 mRNA translation initiation site. The authors observed a 
74 % decrease in PARP-1 expression after 72 h exposure, in medium, of intact 
L1210 cells. 
In the studies described by Smulson and co-workers, cells depleted of PARP- 
1 lost their ability to efficiently rejoin DNA strand breaks at early time points 
following induction of DNA damage by treatment with the alkylating agent methyl- 
methanesulphonate (MMS). Furthermore, they were 10-fold more sensitive to MMS 
and were shown to have a slightly prolonged doubling time. Conversely, the cells 
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were not deficient in the repair of UV-induced pyrimidine dimers. In support of the 
findings with inhibitors, these data therefore suggest that decreased PARP-1 function 
leads to compromised repair and that PARP-1 participates in BER but not NER 
(Ding et al., 1992). 
1.8.3 Overexpression of the DNA binding domain 
The PARP-1 DNA binding domain (DBD) binds to DNA ends and is 
unable to undergo automodification and hence dissociation from the DNA due to the 
absence of both the automodification and catalytic domains (Smulson et al., 1998). 
This irreversible binding has previously been shown to reduce PARP-1 activity due 
to a competition for strand breaks with full length PARP-1 protein thereby 
preventing PARP-1 activation and polymer formation at the site of a break, in an 
analogous manner to PARP-1 inhibitors (Kupper et al., 1990). Such transdominant 
inhibition of PARP-1 in Chinese hamster cells overexpressing the PARP-1 DBD 
under the control of the hormone inducible MMTV promoter resulted in a 90 % 
reduction in PAR formation following IR (Kupper et al., 1990). These cells were 
also sensitised to the cytotoxic effects of IR and MNNG. These data are consistent 
with the findings of Schreiber et al., (1995) who reported that HeLa cells, which 
constitutively overexpress the DBD, were sensitised to alkylating agents and IR but 
not UV, as would be expected for a protein involved in BER. In addition, these cells 
demonstrated higher frequencies of both spontaneous and MNNG induced SCE, 
consistent with a role for PARP-1 as an anti-recombination factor. 
Overexpression of the DBD has also been shown to block unscheduled DNA 
synthesis (i. e. DNA repair) in human fibroblasts, induced by MNNG (that occurs 
during BER) but not that induced by UV irradiation (that occurs during NER), 
presumably by blocking the access of repair enzymes to the nicked DNA (Molinete 
et al., 1993). This again supports a role for PARP-1 in BER. 
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1.8.4 Cell lines 
Cell lines deficient in PARP-1 have been established by mutagenesis. 
Chatterjee and co-workers, produced a series of cell mutants deficient in PARP-1 
(Chatterjee et al., 1987). The treatment strategy used to obtain these mutants was 
based on their observation that high levels of DNA damage caused maximal 
stimulation of PARP-1 activity, resulting in depletion of cellular NAD+ and cell 
death as a consequence of ATP depletion (Berger, 1985). Chinese hamster V79 cells 
were exposed to low concentrations of MNNG to induce mutations, and surviving 
clones were then grown in nicotinamide-free medium to reduce their NAD+ levels. 
These cells were then treated with high concentrations of MNNG, an approach that 
generated cell mutants with 37-82 % of the PARP-1 activity of parental cells. 
Consistent with compromised repair, these mutants were found to have prolonged 
doubling times and an increased frequency of SCE exchange compared to parental 
cell lines. However, it should be noted that it is possible that the resulting phenotype 
could be due to other genetic abnormalities as a result of repeated drug treatment 
(secondary effect of the mutagen). Therefore, Stamato et al, isolated a series of 
PARP-1 deficient mutants by exposing CHO cells to a low dose of ethyl- 
methanesulphonate (EMS) for 16 h, followed by a 72 h incubation in drug free 
medium to allow recovery and expression of the mutant phenotype. The treated cells 
were then plated out to form colonies, replica plated and directly assayed for PARP-1 
activity. This study isolated two colonies, PADR-1 and PADR-2 which had 50 % 
less PARP-1 activity and were 20 % more sensitive to the DNA damaging agents 
EMS, DMS and MMS than control cells. However, the mutants had no increased 
sensitivity to IR. 
1.8.5 Mouse deficient models for PARP-1 
To ultimately elucidate the biological function of PARP-1, in vivo, a number 
of PARP-1 knockout mouse models have been generated independently using 
homologous recombination. The first PARP-1 knockout mouse was generated by 
Wang et al., in 1995 by interruption of part of the 2nd exon and 2nd intron of the 
PARP-1 gene. A second PARP-1 knockout mouse was created by Menissier de 
Murcia et a!., in 1997, by interruption of Exon 4 in the PARP-1 gene (section 3.1.1) 
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and a third set of PARP-1 deficient mice, disrupted in Exon 1 were developed by the 
Sugimura group (Matsutani et al., 1999 a; b). 
PARP-1 KO mice are fertile and healthy. Initial studies by Wang et al., 1995, 
suggested that their cells, derived from these mice, were not hypersensitive to 
alkylating agents or IR and therefore did not support the notion that PARP-1 
contributed to DNA repair. Indeed, the only defects in these PARP-1 KO mice were 
those of epidermal hyperplasia and spontaneous skin lesions. Thus, initially, it 
appeared that poly(ADP-ribose) was not necessary for either BER or NER. 
Studies with the other strains of PARP-1 KO mice, however, contradict some 
of these earlier results in that these mice are acutely sensitive to both N-methyl-N- 
nitrosourea (MNU) and IR. When MNU was injected, all PARP-1 deficient mice 
died within 4 weeks whilst less than half of the PARP-1 proficient mice died in this 
time. Similarly, when exposed to 8 Gy of whole body irradiation, all PARP-1 -/- 
mice died within 9 days. In contrast, none of the wild type mice had died within this 
time although by 15 days half had died (Menissier de Murcia et al., 1997). 
Cells derived from these PARP-1 deficient mice have also been demonstrated 
to be acutely sensitive to methylmethanesulfonate (MMS) and exhibited delayed 
DNA repair as measured by the comet assay, indicating a defect in the BER pathway 
(Trucco et al., 1998). These authors demonstrated that following exposure to MMS, 
PARP-1-/- MEFs displayed a severely decreased growth rate, had reduced viability 
and showed G2/M accumulation and an increased frequency of micronuclei an 
indication of chromosomal damage, compared to wild-type MEFs. Consistent with 
the findings of Menissier de murcia et al., 1997, Matsutani et al, demonstrated that 
cells derived from their mice were hypersensitive to IR and the alkylating agent 
MMS (Matsutani et al., 1999 a; b). 
The initial results presented by Wang et al., in 1995, were based on the 
capacity of cells to repair and accurately transcribe alkylated plasmids. These 
plasmids could be repaired by an alternative pathway involving methyltransferases 
and therefore the finding that the PARP-1 -/- cells were able to carry out normal 
repair is unreliable. More recently, subsequent studies by Wang et al., 1997, reported 
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that their PARP-1 -/- mice are very sensitive to alkylating agents (MNNG, for 
example) and IR thus supporting the findings of de Murcia et al., (1997). Moreover, 
in a parallel experiment, the authors demonstrated no difference in the repair of UV 
damage between the PARP-1 deficient cells and proficient cells, supportive of a role 
for PARP-1 in BER and not NER. These findings are also consistent with data from 
the chemical inhibitors, where, in particular, repair following UV was unaffected. In 
support of the findings of de Murcia et al, the same group have also demonstrated, 
that when exposed to 8 Gy whole body irradiation, PARP-1 -/- mice were 
hypersensitive and died within 10 days. In contrast, all of the PARP-1+/+ mice 
survived. 
In summary, all three independently derived PARP-1 knockout animals show 
hypersensitivity to both alkylating agents and IR, consistent with earlier observations 
with inhibitors, antisense strategies and trans dominant inhibition and this is 
indicative of a role for PARP-1 in BER. 
Conclusive evidence for a role of PARP in BER has been given by Dantzer et 
al., 1999, who demonstrated that following treatment with MMS, mouse embryonic 
fibroblasts (MEFs) derived from PARP-1 -/- mice have a reduced capacity to repair a 
single abasic site present on a circular duplex molecule. In mammalian cells, two 
distinct subpathways of BER that differ in the type of DNA polymerase required, 
have been reported (see section 1.5.1). Briefly, the short patch pathway involves 
DNA polymerase ß, XRCC1 and DNA ligase III, while the long patch pathway 
requires DNA polymerase c or S, PCNA, Dnase IV (FENI) and DNA ligase I. These 
authors demonstrated that short patch repair is half as efficient in PARP-1 -/- cells 
whilst long patch repair is almost completely abolished. In both pathways, the defect 
is in the polymerisation step. The major role for PARP-1 therefore appears to be in 
long patch repair. This is a surprising finding since an intimate association has been 
found between PARP-1 and XRCC1, ligase III and polymerase ß, all of which are 
required for short patch repair. Both PARP-1 and FEN-1 bind to the `hinge' of flaps 
of repair intermediates and therefore PARP-1 may be necessary to recruit FEN-1. 
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A second phenotype that has been observed in all PARP-1 knockout animals 
is an increase in sister chromatid exchange (SCE). Indeed, de Murcia et al, observed 
a 5-fold increase in SCEs both before and after DNA damage (Menissier de Murcia 
et al., 1997). Moreover, where measured, cells with reduced PARP-1 activity had an 
increased frequency of SCE. The ability of PARP-1 to rapidly bind DNA strand 
breaks may influence events such as homologous and non-homologous 
recombination. In support of this, evidence has shown that PARP-1 inhibition also 
results in an increased frequency of SCE (Morgan et al., 1986). These findings 
support a role for PARP-1 as an antirecombinational factor. 
All studies have shown that aberrant or reduced PARP-1 activity increased 
the sensitivity of cells to DNA damaging agents, probably due to an inhibition of 
DNA repair. 
1.9 PARP Family 
Until recently, PARP activity and ADP-ribose polymer formation, was assumed 
to result from the function of a single enzyme. In 1998, Shieh et al., observed that 
PARP-1 deficient cells had some residual PARP activity. In addition, this group 
showed that the ADP-ribose polymers formed in these cells were indistinguishable 
from those formed in PARP-1 +/+ cells, as measured, firstly by binding to boronate 
resin which has selective affinity for ADP-ribose polymers and, secondly, treatment 
with snake venom phosphodiesterase and alkaline phosphatase revealed the unique 
ribosyl-ribosyl linkages of ADP-ribose polymers. Finally, the polymers were 
digested by recombinant poly(ADP-ribose) glycohydrolase (PARG), a highly 
specific enzyme for ADP-ribose polymers. This study, together with a study by 
Smith et al., 1998, which identified a further PARP enzyme, termed tankyrase, 
demonstrated the existence of at least two structurally different PARP enzymes and 
opened up the possibility of multiple forms of PARP in mammalian cells. 
Since the initial observation by Shieh et al., (1998), a number of groups have 
attempted to identify the enzyme(s) responsible for this activity. At the time of 
writing this thesis, the de Murcia group have identified a total of 18 novel PARP 
cDNAs by sequence homology to PARP-1 and 7 PARP proteins have been 
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characterised. These enzymes exhibit differences in domain structure, sub-cellular 
localisation, tissue distribution and ability to bind DNA and these are described in 
more detail below. In addition, they are summarised in Table 1.1. 
1.9.1 PARP-2 
Three recent publications have reported the isolation of partial (Berghammer 
et al., 1999; Johansson et al., 1999) and full length (Ame et al., 1999) cDNAs from 
mouse and human encoding a protein, with considerable homology to the catalytic 
domain of PARP-1. This protein, termed PARP-2, is the closest homologue to 
PARP-1 and is a 62 kDa protein. It contains a nuclear localisation signal (NLS) and 
is activated by DNA strand breaks although its DNA binding domain is markedly 
different from PARP-1. Furthermore, the automodification domain is absent. 
Nevertheless, PARP-2 is capable of autoribosylation. This enzyme is probably 
responsible for the polymer formation in PARP-1 KO mice, first described by Shieh 
et al., in 1998. The genomic sequence of the PARP-2 promoter indicates that the 
expression pattern of this gene is different from that of PARP-1, indicating 
independent regulation and complementary roles for the two proteins. 
Schreiber et al., 2002, developed mice deficient in PARP-2 by gene 
disruption. This group demonstrated that following treatment with the alkylating 
agent, N-nitroso-N-methyl-urea (MNNU), PARP-2 -/- cells show slow DNA 
rejoining kinetics similar to those seen in PARP-1 -/- cells. A role for this enzyme in 
BER has therefore been suggested. In support of this proposal, PARP-2 also interacts 
with the 3 major proteins involved in BER, XRCC1, polymerase ß and ligase III. 
Furthermore, XRCC 1 negatively regulates PARP-2 activity as well as PARP-1 and 
PARP-1 and PARP-2 heterodimerise. PARP-1 and PARP-2 may act together with 
XRCC1 in a DNA repair complex in the BER process (Schreiber et al., 2002). In 
addition, PARP-1 and PARP-2, may compensate for the absence of each other. 
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1.9.2 PARP-3 
PARP-3 is the smallest PARP characterised so far and is only 60 kDa 
(Johansson et al., 1999). It lacks both the DNA binding domain and the 
automodification domain, resembling sPARP, an alternative form of PARP-1 that is 
not involved in DNA strand break signalling (Salimann et al., 2000). The function 
and activity of PARP-3 remain unknown to date although it may play a role in 
centrosomal duplication. 
1.9.3 PARP-4 (V-PARP) 
V-PARP is another protein that contains a domain homologous (28 %) to the 
catalytic domain of PARP-1 (Jean et al., 1999). V-PARP is one of the three proteins 
present in vaults that are large ribonucleoprotein complexes located primarily in the 
cytoplasm and which, as yet, are of no known function although they have been 
suggested to have a role in cellular transport (Jean et al., 1999). Moreover, up- 
regulation of vault proteins has been detected in multi-drug resistant cancer cell lines 
(Schroejers et al., 2000). V-PARP is a large PARP protein. It is 193 kDa in size and 
contains a BRCT domain and several putative NLS sequences. In addition, V-PARP 
contains a domain that is known to interact with the major vault protein (MVP). 
Accordingly, V-PARP has been shown to associate with and ADP-ribosylate MVP. 
This ADP-ribosylation may be involved in the regulation of vault conformation and 
consequently in the transport of molecules. However, not all V-PARP is associated 
with vaults and has been shown to localise to the mitotic spindle thus suggesting a 
role in maintaining genomic integrity. Interestingly, V-PARP does not require DNA 
for activity. 
1.9.4 PARP-5 and 6 (Tankyrase 1 and 2) 
Tankyrase-1 or PARP-5 is a 142 kDa protein that was initially identified 
through its interaction with human telomeres (Smith et al., 1998). It is a homologue 
of PARP-1, however, it lacks both the automodification and DNA binding domain 
and like V-PARP, it does not require DNA for activity. PARP-5 binds to and ADP- 
ribosylates both itself and telomeric repeat binding factor-1 (TRF-1), a protein that is 
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associated with telomeres, both in vitro and in vivo (Griffith et al., 1999). Tankyrase- 
1 therefore acts as a positive regulator of telomere length, since ADP-ribosylation of 
TRF-1 causes its release from telomeres thus allowing access to telomerase, a 
specialised reverse transcriptase that restores the telomeric sequences lost during cell 
division (Smith and de Lange, 2000). 
Tankyrase-2 (PARP-6) is a 130 kDa protein that shares 85 % amino acid 
sequence homology with tankyrase-1, however, the function of this is unknown 
although evidence suggests that it has a different role from tankyrase-1. 
Overexpression of tankyrase-1 induces a progressive telomere elongation in human 
cells (Kaminker et al., 2001) whilst, in contrast, overexpression of tankyrase-2 
results in rapid cell death by necrosis (Smith and de Lange 2000). 
Name Location Chromosome No of a. a MW (kDa) 
PARP-1 Nucleus 1g41-1g42 1014 113 
PARP-2 Nucleus 14g11.2 570 64 
PARP-3 Centrosome 3p21 533 60 
PARP-4 
(V-PARP) 
Vaults 13g11 1724 193 
PARP-5 
(Tankyrase-1) 
Cytoplasm 
and Nucleus 
8p22-p23 1327 142 
PARP-6 
(Tankyrase-2) 
Golgi 10g23.2 1165 130 
Table 1.1 PARP family members. 
Comparison of the cellular localisation, chromosome position and molecular weights 
of the known PARP family members. 
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1.10 DNA dependent protein kinase (DNA -PK) 
1.10.1 General Introduction 
The phenomenon of DNA- dependent protein phosphorylation was first 
described approximately 18 years ago in cell extracts (Walker et al., 1985). Work 
carried out by Jackson et al., in 1990 observed that Spl protein present in human 
HeLa cell nuclear extracts became phosphorylated when the extract was incubated 
under conditions suitable for in vitro transcription. Furthermore, during the 
characterisation of this phosphorylation, it was discovered that it required DNA to be 
present in the reaction and that phophorylation was most effective if the DNA 
contained binding sites for Spl. In support of the hypothesis that the kinase required 
DNA for activity, the authors observed that the addition of non-specific competitor 
DNA led to reduced SpI phosphorylation. The kinase responsible for this 
phosphorylation is termed DNA-dependent protein kinase (DNA-PK) and three 
groups simultaneously published on the existence of this enzyme (Jackson et al., 
1990; Carter et al., 1990; Lees-Miller et al., 1990). 
DNA-PK is a serine threonine kinase (phosphorylates serine or threonine 
preceding a glutamine) which is found in the nucleus of a wide range of eukaryotic 
cells and which may have functions involved in regulating gene expression, 
replication, cell cycle progression and DNA repair (Lees-Miller and Anderson, 
1991). The enzyme belongs to a recently discovered family of large, 
phosphoptidylinoitol-3 kinase (P13-K)-like proteins that include ATM, FRAP and 
ATR and function in DNA repair and cell cycle regulation. The kinase domain of 
DNA-PK has been shown to share sequence homology with the PI 3-kinase family 
that includes the above members (Hartley et al., 1995). A more detailed description 
of this family is given in section 1.13. 
Like PARP-l, DNA-PK is not an inducible gene product, rather it is 
constitutively expressed in the cell at high basal levels during normal cellular 
metabolism (Muller et al., 1998). It is estimated that a similar number of DNA-PK 
molecules are present per human nucleus as the enzyme PARP-1, ie. approximately 1 
x 105_ 1x 106 molecules per nucleus (Lindahl et al., 1995; Jackson, 1997). It has 
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also been suggested that the expression of DNA-PK may be cell type and tissue 
specific (Moll et al., 1999). 
In addition to PARP-1, DNA-PK is one of the few known cellular enzymes 
whose activity is regulated directly by DNA. Upon activation, DNA-PK 
phosphorylates various DNA-binding proteins and is most efficient at 
phosphorylating proteins bound to the same DNA molecule. In vitro substrates 
include histones, topoisomerases and various transcription factors (Anderson, 1993) 
although an in vivo target remains to be identified. DNA-PK activity is 
autoregulatory and in the absence of a substrate, autophosphorylation results in the 
dissociation of DNA-PK from DNA (Chan and Lees-Miller, 1996). 
1.10.2 Structure 
DNA dependent protein kinase is a trimeric nuclear complex that consists of 
a large protein kinase and a Ku heterodimer. Following cloning of the human gene 
for DNA-PK, the catalytic subunit was shown to be a nuclear protein of 465 kDa, 
designated DNAPKcs (Hartley et al., 1995). The gene for the catalytic subunit has 
been mapped to chromosome 8q 11 and is estimated to contain around 100 exons and 
be around 180 kbp in length (Sipley et al., 1995). The carboxyl terminal of DNA- 
PKcs (approx 500 residues) comprises the catalytic domain. 
Chiu et al., 1998, utilised cryoelectron microscopy imaging of DNA-PKcs to 
demonstrate that DNA-PKcs has an open symmetric structure with a gap separating a 
`crown shaped' top from a rounded bottom. The hollow nature of the DNA-PKcs 
interior suggests that it may interact with DNA via internalisation of double stranded 
ends. More recently, Leuther et al., 1999, demonstrated using electron 
crystallography that DNA-PKcs possess an open channel and enclosed cavity with 3 
large openings large enough to accommodate single stranded ends. Protein-DNA 
cross linking studies have revealed that DNA-PKcs makes intimate contacts with the 
DNA, suggesting that DNA might directly induce conformational alterations in the 
protein itself (Gottlieb and Jackson, 1993). 
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Human Ku is composed of two tightly associated polypeptides of 
approximately 69 and 83 kDa, designated Ku70 and Ku80, respectively. Ku70 and 
80 are biochemically distinct, and in yeast, they only share approximately 38 % 
homology over a region in the C terminal half of the protein that contains part of the 
DNA binding domain. The human Ku70 gene maps to chromosome 22g13 and the 
Ku80 gene maps to 2q33 (Cai et al., 1994). The subunits of Ku protein are tightly 
associated and do not separate during protein purification. The carboxyl terminal 
region of approximately 150 amino acid residues in both Ku70 and Ku80 are 
essential for Ku dimerization. The Ku heterodimer interacts with DNA in a two step 
mechanism, where it first recognises DNA ends and then translocates to internal sites 
(Paillard and Strauss, 1991; Zhang and Yaneva, 1992). This allows binding of 
multiple Ku molecules to a single DNA fragment. Ku binds DNA via a preformed 
channel (Walker et al., 2001). However, the precise residues that mediate the 
interactions between the Ku heterodimer and DNA remain to be identified although 
it appears that Ku70 makes the most intimate interactions (Dynan and Yoo, 1998). 
Moreover, neither subunit alone can bind DNA effectively. 
The Ku heterodimer regulates DNA-PK activity (Gottlieb and Jackson, 1993) 
by targeting the catalytic subunit to DNA and stimulating activity through direct 
protein-protein interaction. More recently, it has been determined that it is the 
extreme C-terminus of Ku80, specifically the final 12 amino acids, that contains a 
protein-protein interaction motif that mediates a highly specific interaction with 
DNA-PKcs (Gell and Jackson, 1999). This is consistent with the absence of an 
analogous Ku80 C- terminal tail in S. cerivisiae which also lacks a homologous 
DNA-PKcs protein. Notably, Ku is unable to bind DNA-PKcs in the absence of 
DNA (Suwa et al., 1994), suggesting DNA binding induces a conformational change 
that allows interaction with DNA-PKcs. In some conditions (Yaneva et al., 1997; 
Hammersten and Chu, 1998) DNA-PKcs can bind double stranded DNA ends and be 
activated in the absence of Ku, however, optimal DNA-PK activity is only exhibited 
when Ku is present suggesting that Ku is required for stabilising the binding of DNA 
by DNA-PKcs in vivo. 
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The regulation of DNA-PK occurs not only through binding to DNA, but also 
by interaction with other proteins. One clear example is binding to the high affinity 
DNA binding protein, C1D, with which DNA-PKcs interacts through a putative 
leucine zipper motif in the absence of DNA (Yavuzer et al., 1998). The physiological 
consequence of this activation is not clear but C1D is a component of the nuclear 
matrix and is activated by IR. 
1.10.3 Activation by DNA strand breaks 
Ku binds strongly to DNA ends, stem-loop and bubble structures, and to 
transitions between double stranded DNA and two single strands. 
Like PARP- 1, DNA-PK is unusual in that it is active only when bound to 
DNA (Gottlieb and Jackson, 1994). DNA-PK is activated by binding to DNA ends, 
nicks and gaps (Gottlieb and Jackson, 1993) and by linear double stranded DNA but 
not by closed, fully duplexed, circular DNA or by single stranded DNA, by 
DNA/RNA heteroduplexes or by RNA (Carter and Anderson, 1991). There is no 
preference for a particular type of strand break and therefore DNA-PK is activated by 
blunt, 5' overhanging or 3' overhanging DNA breaks with equal efficiency. 
1.10.4 Models of DNA-PK in DNA DSB repair 
The binding to and activation of DNA-PK by DNA DSBs suggested a role for 
this enzyme in DNA repair. Investigations into the DNA substrates utilised by 
DNA-PK, together with analyses of mutant cell lines (described in detail in section 
1.12.2) have revealed the DNA-PK complex has a major role in NHEJ. The most 
advocated model is that Ku binds DNA DSBs specifically via a preformed channel 
and then recruits DNA-PKcs which is then activated. The central role of Ku protein 
in the activation of DNA-PK was first demonstrated in two independent studies 
which showed that Ku protein and DNA-PKcs can be separated biochemically, that 
activity can be restored by mixing Ku and DNA-PKcs fractions and that the Ku 
protein physically recruits DNA-PKcs to DNA (Dvir et al., 1992; Gottlieb and 
Jackson, 1993). This recruitment can be demonstrated by the formation of 
distinctive complexes on an electrophoretic mobility shift assay (EMSA). 
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Several roles for DNA-PK in repair have been proposed and these are 
described below. The assembly of the DNA-PK complex at the site of a DNA 
double strand break and possible functions in repair are shown in Figure 1.7. 
1.10.4.1 Protection factor 
Like PARP-1, DNA-PK may function in detecting the presence of a DSB and 
in protecting it from the action of harmful nucleases and other proteins which could 
interfere with the assembly and functioning of DSB repair apparatus at the site of 
damage. In support of the former, DNA-PK deficient cell lines have been shown to 
accumulate deletions in their DNA (Jackson, 1996). Therefore, like PARP-1, DNA- 
PK may serve to prevent aberrant recombination events that could interfere with 
repair. 
DNA-PK could carry out this role simply by binding and blocking access to 
the damaged site until other repair factors can be recruited. Alternatively, DNA-PK 
may phosphorylate proteins that may affect or effect DNA repair. Such proteins 
might include transcription factors that have the potential to interfere with the repair 
apparatus by eliciting spurious transcription at the site of a break. To this end, of the 
many proteins which DNA-PK can phosphorylate in vitro, DNA-PK is known to 
phosphorylate the transcription factors Sp-1, c-jun and p53 (Anderson, 1993). 
Furthermore, DNA-PK is a potent inhibitor of transcription by RNA polymerase I 
which mediates transcription of large ribosomal RNA precursors (Kuhn et al., 1995). 
Finally, the kinase function may serve a regulatory role in which it ensures 
the disassembly of repair components from the site of damage following DNA repair. 
Indeed, autophosphorylation leads to the dissociation of DNA-PKcs from DNA- 
bound Ku and inactivation of kinase activity. 
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Figure 1.7 Organisation of the DNA-PK complex at the site of a break and 
possible functions in repair 
The Ku hetcrodimer hinds to DNA DSBs initially and this is followed by the binding 
of DNA-PKcs to the Ku-DNA complex. DNA-PK is then activated to phosphorylate 
a number of protein targets. DNA-PK may have a number of functions in DNA DSB 
repair and these include inhibition of transcription at sites of DNA damage and 
recruitment and / or activation of repair machinery. DNA-PK also undergoes 
automodilication, leading to its dissociation from DNA 
1.10.4.2 Recruitment and/or signalling model 
DNA-PK may recruit and/or regulate essential components of the DNA repair 
apparatus through protein-protein interactions or phosphorylation. Thus, like PARP- 
1, DNA-PK may function in a not yet understood `DNA damage surveillance 
network' in which DNA-PK serves as the primary damage sensor important for the 
essential process of DNA strand break recognition. Consistent with its proposed role 
as a primary DNA damage sensor and not as an inducible downstream effector of 
DNA damage signalling, DNA-PK, like PARP-1, is present at relatively high levels 
(up to 1% of HeLa cell nuclear protein) that is not inducible but rather a pre-formed 
protein that is activated by DNA breaks (Lee et al., 1997). 
Alternatively, or in addition, DNA-PK might function in signalling the 
presence of DNA damage through the initiation of a signal transduction pathway by 
phosphorylation of relevant substrate(s) thus alerting the cell to the presence of 
DSBs. The interactions of DNA-PK with signalling proteins and its function in 
activating components of the repair system have yet to be fully elucidated. DNA-PK 
has been suggested to act as an upstream regulator of p53. Moreover, DNA-PK has 
recently been shown to play a role in triggering induction of the p53 pathway 
following exposure to IR (Woo et al., 1998; Lees-Miller et al., 1992). However, 
various studies have yielded conflicting results and these are discussed in more detail 
in section 1.11.2. 
The final ligation step of NHEJ is mediated, at least in part, by ligase IV and 
its associated protein XRCC4. Studies in cells mutated for XRCC4 have shown that 
these proteins are essential for NHEJ (Lee et al., 1997). This is similar to the 
requirement for PARP-1 in the BER pathway, in which the complex of XRCC1 and 
DNA ligase III is used (section 1.6.4.4). XRCC4 is a substrate for DNA-PK in vitro 
and the XRCC4/ligase IV complex can interact directly or indirectly with DNA-PK 
in crude nuclear extracts (Critchlow et al., 1997; Leber et al., 1998). Thus DNA-PK 
may signal to and recruit or activate this complex. 
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Another complex that might be recruited and/or activated by DNA-PK is that 
containing the Rad50, Mrel I NBS1 complex whose nuclease activities may be 
critical in `tidying up' damaged DNA termini prior to ligation. 
1.10.4.3 Structural role 
More direct roles for DNA-PK in DNA repair have also been suggested. 
Since DNA-PK associates directly with DNA, this suggests a proximal role for the 
enzyme. DNA-PK could act as a structural framework to which enzymes bind 
(Hartley et al., 1995). A function for DNA-PK as an alignment factor in which it 
serves to hold the two chromosome ends together in a manner that will facilitate 
ligation of the two broken ends has been proposed (Jeggo et al., 1995). DNA-PK 
deficient cell lines have an increased level of chromosomal rearrangements following 
treatment with IR when compared to wild type cells (Disney et al., 1992). 
There is currently no consensus of opinion on whether the modulation of repair 
by DNA-PK is dependent on the catalytic activity of the enzyme, or, alternatively, on 
its physical presence (or both). Although the lack of clear functional substrates for 
DNA-PK during DSB rejoining has led to the proposition that DNA-PK acts 
primarily as a scaffold to hold the ends in alignment for repair to occur, an important 
study by Kurimasa et al., 1999, has demonstrated that the kinase activity of DNA- 
PKcs is needed for NHEJ. This group complemented mutant DNA-Pkcs deficient 
cell lines with cDNA for DNA-PKcs and showed that it could restore the DSB repair 
defect of these cells. When the cells were complemented with cDNA incorporating 
deletions and site directed mutations important for kinase activity, the DSB repair 
defect of these cells was not complemented. Thus expression of protein was not 
sufficient for NHEJ but additionally required kinase activity. 
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1.11 Development of DNA-PK inhibitors 
To date, only inhibitors of the phosphorylation activity of DNA-PK have 
been explored. Wortmannin, a sterol-like fungal metabolite, shown previously to be a 
potent inhibitor of P13- kinase was one of the first identified inhibitors demonstrated 
to be capable of inhibiting DNA-PK, in vitro, on the basis of similarity between the 
kinase domains of the two proteins. Wortmannin has been shown to bind directly to 
DNA-PKcs, in vivo, (Izzard et al., 1999). Wortmannin acts as a non-competitive 
irreversible inhibitor with respect to ATP (Izzard et al., 1999). 
The action of wortmannin is not entirely specific for DNA-PK, however, and 
it has been demonstrated that cells deficient in DNA-PK may be sensitised by 
wortmannin (Rosenzweig et al., 1997) and therefore this implies that other kinases 
involved in DSB repair may be inhibited by wortmannin. Indeed, wortmannin has 
been shown to inhibit the product of the AT gene, ATM (Hartley et al., 1995; 
Sarkaria et al., 1998). Furthermore, wortmannin is unstable in serum-containing 
media (Price and Yourmell, 1996) and therefore this is a major limiting factor that 
may affect the use of this compound in a clinical situation. 
The P13-kinase inhibitors, LY294002 (2-(4-morpholynyl)-8-phenyl-4H-1- 
benzopyran-4-one) and OK-1035 (3-cyano5-(4-pyridyl)-6-hydrazonomethyl -2- 
pyridone) have been identified (Vlahos et al., 1994; Take et al., 1995), both of which 
are inhibitors of DNA-PK kinase activity. Both compounds are chemically unrelated 
to wortmannin and are reversible competitive inhibitors. LY294002 is a synthetic 
compound that was designed as a P13-kinase inhibitor based on the flavonoid 
quercetin. Although the reported IC50 is much higher than that of wortmannin, 
LY294002 is widely used in cell biology as a specific P13-kinase inhibitor because it 
is much more stable in solution than wortmannin. 
OK-1035, in particular, shows promise as a more selective inhibitor of DNA- 
PK since it has been shown to inhibit DNA-PK with greater selectivity than for PI-3 
kinase. (Take et al., 1995). However, this has been disputed by Stockley et al., 2001, 
who have demonstrated an IC50 that is approximately 12-fold higher than that 
reported previously. Small molecule inhibitors of DNA-PK are shown in Figure 1.8. 
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Further inhibitor development is currently underway by the Drug 
Development Group at Newcastle University to identify potent and specific DNA- 
PK inhibitors. Despite the similarity of the ATP binding sites among protein kinases, 
it has been possible to exploit differences in the modes of ATP interaction in order to 
develop protein kinase-specific inhibitors. The inhibitor used in the studies described 
in this thesis, NU7026 (2-morpholin-4-yl)-benzo[h] chromen-4-one), is a potent, 
novel and specific inhibitor of DNA-PK and is described in more detail in section 
3.1.2. 
1.12 Methods of DNA-PK depletion 
1.12.1 Molecular strategies 
Marangoni et al., 2000, utilised a dominant negative approach to deplete cells 
of DNA-PK activity. Briefly, this group created a construct containing a 32 kDa 
fragment encoding the C-terminal region of Ku80. Expression of this construct in 
CHOK1 cells, resulted in decreased Ku-dependent DNA binding activity, a 
diminished capacity to repair DNA DSBs (as measured by pulse field gel 
electrophoresis) and decreased survival following exposure to IR. In a similar study, 
Kasten et al., 1999, demonstrated that overexpression of Ku70/Ku80 in rat cells 
resulted in a 20 % reduction in DNA-PK activity. In addition, the cells had a 
reduced capacity for DNA DSB repair and were hypersensitive to IR. More recently, 
Kim et al., 2002, created a peptide of the C terminus of Ku80 which selectively 
targeted and disrupted the interaction between the Ku complex and DNA-PKcs. Cells 
transfected to express this peptide were less efficient in their capacity to repair DSBs. 
All of these studies are therefore consistent with a role for DNA-PK in DSB repair 
and survival. 
More recently, a number of groups have utilised antisense strategies as a 
means to deplete cells of DNA-PK activity. Sak et al., 2002, constructed antisense 
oligodeoxynucleotides (AS-ODNs) targeting various regions of DNA-PKcs mRNA. 
When expressed in non-small cell lung cancer (NSCLC) cell lines, the kinase activity 
of DNA-PKcs was specifically inhibited and this corresponded with a marked 
inhibition of DNA DSB rejoining and an increase in radiosensitivity. Blenkov et al., 
50 
2002, generated AS-ODNs which down regulated Ku80 mRNA in the isogenic 
DNA-PK proficient M059K and DNA-PK deficient M059J cells. There was a 
marked decrease in the survival of the M059K cells but no change in the M059J 
cells, following exposure to IR, bleomycin and etoposide. No sensitisation of either 
cell line was demonstrated when exposed to chlorambucil or cisplatin which create 
cross links. These data are consistent with a role for DNA-PK in DSB repair. A 
further study by Omori et al., 2002, utilised antisense to Ku70 in human squamous 
cell lung carcinoma and demonstrated that the cells were more radio-and chemo- 
sensitive. 
1.12.2 Cell lines deficient in the components of DNA-PK 
The involvement of DNA-PK in DSB repair first became evident from 
analyses involving a specific series of mutant rodent cell lines (Jeggo, 1990). 
Mammalian cell mutants were isolated, many of which were derived from the 
Chinese Hamster Ovary CHOK1 cell line (Reviewed in Jeggo et al., 1995; 
Zdzienicka, 1995 and references therein). They displayed sensitivity to a range of 
DNA damaging agents. At least 11 complementation groups have been described 
(Jeggo et al., 1991; Thacker and Wilkinson, 1991). 
A subset of these mutants were found to be hypersensitive to IR and radio- 
mimetic agents with little or no cross sensitivity to other types of DNA damaging 
agents. Further studies showed them to be defective in the repair of chromosomal 
DNA DSBs (for review see Zdzienicka, 1995 and references therein). Furthermore, 
these cells were also shown to be deficient in the resolution of DNA DSBs that arise 
during V(D)J recombination, the site specific recombination process that helps 
generate the mature genes for immunoglobulin and T-cell receptor proteins in the 
developing mammalian immune system (reviewed in Lewis, 1994). Analyses of 
V(D)J recombination in wild type and mutant cells has revealed that this reaction 
proceeds via a cut and ligation process that involves DNA DSBs as intermediates. 
Moreover, providing a clear link to DSB repair processes, it was shown that it is the 
ligation and not the cutting step of V(D)J recombination that is impaired in IR- 
sensitive cell mutants. The common phenotype of these cells suggests that these 
mutants may be involved in a common pathway of DSB repair. 
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Subsequent cell fusion studies allowed these DNA DSB repair-deficient 
mutant cells to be assigned into 3 distinct complementation groups, termed IR4, IR5 
and IR7. The human genes complementing them were pre-assigned the XRCC 
nomenclature (X-ray Cross Complementing). IR 5 mutants were shown to lack a 
DNA binding activity that corresponded to Ku. In contrast, IR7 mutants contained 
normal Ku-dependent end binding activity (Getts and Stomato, 1994; Rathmell and 
Chu, 1994). Ku80 and DNA-PKcs are the products of the XRCC5 and XRCC7 
genes as demonstrated by their ability to complement the radiosensitivity defects of 
IR5 and IR7 mutants, respectively (Taccioli et al., 1994a; Boubnov et al., 1995; 
Smider et al., 1994; Blunt et al., 1995; Kirchengesner et al., 1995; Peterson et al., 
1995). Importantly, this finding provided a clear link between the DNA-PK complex 
and DSB repair. None of the rodent cell lines were defective in Ku70. However, 
targeted disruption of the gene for Ku70 in mouse cells also renders cells 
hypersensitive to IR and has allowed such cells to be designated IR6 and the gene for 
Ku70 to be designated XRCC6 (Gu et al., 1997). IR4 is complemented by XRCC4 
which is a nuclear phosphoprotein of 334 amino acids and a substrate for DNA-PK 
(Critchlow et al., 1997; Leber et al., 1998). Strikingly, homozygous deletion of 
XRCC4 confers embryonic lethality. The proposed functions of this protein in DNA 
DSB repair is described in more detail in section 5.1. 
Taken together, these studies have demonstrated unequivocally that both 
DNA-PKcs and Ku play important roles in DNA DSB repair. NHEJ is a largely 
error prone process since it does not use extensive homologies to repair the damage 
(section 1.5.2.1). Characteristically, group 4 and 7 mutants accumulate deletions in 
their DNA thus providing a link between these proteins and NHEJ. 
Despite the existence of a variety of rodent cell lines containing mutations in 
the proteins of NHEJ pathways and thus defective in DSB repair, only one glioma- 
derived cell line of human origin (M059J) has been described thus far (Allalunis- 
turner et al., 1993). M059J cells which are defective in DNA-PKcs expression and 
defective in DSB repair (Dibiase et al., 2000) are therefore group 7 mutants. M059K 
cells, proficient in DNA-PK activity, are derived from a different area of the same 
tumour and therefore have a common genetic background but cannot strictly be 
termed isogenic. 
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1.12.3 Knockout mouse models for components of DNA-PK 
The first mutant mouse model for analysing DNA-PK function was the 
spontaneously arising severe combined immunodeficiency (SCID) mouse (Bosma 
and Carrol, 1991). Biochemical and genetic studies revealed a loss of DNA-PKcs 
function in SCID cells derived from the mice (Blunt et al., 1995). This results from a 
mutation in the DNA-PKcs gene that converts Tyr-4046 codon to a stop codon thus 
creating a truncated protein that is missing the last 83 amino acids of the kinase 
domain. Although this mutated protein is highly unstable, it is still present at 
detectable levels, raising the possibility that SCID cells retain residual DNA-PKcs 
function (Danska et al., 1996). Consistent with a role for DNA-PK in DSB repair, 
SCID mice and cells derived from them are hypersensitive to IR and display defects 
in rejoining of IR-induced DSBs. 
Recently, knockout mice have been generated that are null for DNA-PKcs 
(Gao et al., 1998) or ablated for its kinase domain (Taccioli et al., 1998). Mice have 
also been produced that are defective in Ku70 or Ku80 (Zhu et al., 1996; Gu et al., 
1997). There are common phenotypes among these knock out mice and these 
include 2-5-fold increased sensitivity to IR, and a reduced ability to repair DSBs. In 
addition to these defects, mice with targeted disruptions for Ku70 and 80 are small 
and have prolonged doubling times and premature cell senescence. 
1.13 The P13-K family of enzymes 
The purification of DNA-PKcs, coupled with the determination of the 
sequences of several peptides derived from it, enabled a partial cDNA clone for 
DNA-PKcs to be isolated. The kinase domain of DNA-PKcs, located at the C- 
terminus, is very different from those of most serine/threonine kinases, instead it falls 
into the phosphatidylinositol -3-kinase family of enzymes (P13-K). Some members 
of the PI 3-kinase family function in signal transduction by phosphorylating inositol 
phospholipids (Kappeller and Cantley, 1994). A well characterised example is the 
mammalian PI 3-kinase, which phosphorylates phosphatidylinositol (PI) in response 
to a variety of stimuli, including the activation of various growth factor receptors. 
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Despite being in the `PI 3-kinase family', however, DNA-PKcs is not a lipid 
kinase but is a protein kinase. Several of the family members, including PI 3-kinase, 
itself are able to phosphorylate both lipid and protein targets and therefore the PI 3- 
kinase family can be subdivided into two distinct subgroups. The first contains 
mammalian PI 3-kinase and other lipid kinases, the other contains DNA-PKcs and a 
series of other large (> 250 kDa) proteins which are involved in controlling cell cycle 
progressions and/or functioning in DNA repair and DNA damage signalling termed 
the PI 3K-related kinases (PIKK). These proteins share considerable homology in the 
kinase domain at their 3'terminus. Outside the kinase domain, however, DNA-PKcs 
has little or no similarity. Other PI-3K related kinases include the ATM protein, ATR 
and FRAP. 
1.13.1 ATM 
ATM (ataxia-telangiectasia gene product) was identified in 1995, based on its 
role in a rare, inherited disorder, ataxia telangiectasia (AT). ATM is one of the best 
characterised DNA-PKcs-related proteins (Rotman and Shiloh, 1998). The gene is 
located on 11g22.3-q23 and is ubiquitously expressed and codes for a 370 kDa 
protein of 3056 amino acids. Although its cellular localisation is variable, it is 
primarily localised to the nucleus of proliferating cells. 
Cells from AT patients, in which the ATM gene is mutated, display reduced 
survival and an inability to activate cell cycle checkpoints following IR exposure. 
Although it is possible that ATM plays direct roles in DNA repair, the available 
evidence indicates that its primary role is in DNA damage signalling. Most normal 
proliferating cells temporarily arrest cell cycle progression at the G1/S or G2/M cell 
cycle `checkpoints' in response to DNA damage. Arrest in G1 or S-phase prevents 
replication of damaged DNA. Arrest in G2 prevents mitosis until DNA damage is 
repaired. A-T cells are deficient in the IR-induced G1/S, S and G2/M cell cycle 
checkpoints due, at least in part, to defective induction of the transcription factor p53 
in response to IR (Siliciano et al., 1997; Barlow et al., 1996) 
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1.13.2 ATR 
ATR (human AT-related) is the family member most closely related to ATM. 
The gene is located on 3q22-q24 and codes for a 301 kDa protein. This protein is 
required for the G2/M checkpoint in response to DNA damage and inhibition of 
replication (Cimprich et al., 1996; Cliby et al., 1998; Wright et al., 1998). It is also 
involved in DNA damage signalling. Purified ATR from human cell extracts displays 
a DNA-stimulated protein kinase activity that targets the N-terminal region of p53. 
Since this region of p53 has been shown to function in transcription and in 
controlling p53 protein stability, this indicates that ATR acts upstream of p53 in 
DNA damage-induced signalling pathway. 
Like ATM, ATR controls BRCA1 phosphorylation in response to IR. ATR 
forms distinct nuclear foci at the sites of stalled replication forks (Tibbetts et al., 
2000). Protein kinase mutants of human ATR display increased sensitivity to both 
IR and UV demonstrating that ATR may be a component of repair (Wright et al., 
1998). 
1.13.3 FRAP 
FRAP, also known as the mammalian target of rapamycin, (mTOR) is a 450 
kDa protein which has been shown to function in the regulation of protein translation 
in response to mitogenic signals, thus allowing progression from G1 to S phase of the 
cell cycle (Kuruvilla and Schreiber, 1999). In addition, FRAP has been proposed to 
be a regulator of cell growth (Schmelzle and Hall, 2000). 
In summary, the activation of these proteins by various forms of DNA 
damage might trigger phosphorylation cascades that impinge on the transcription, 
cell cycle and apoptotic machineries. Given that DNA-PKcs, ATM and ATR have 
all been shown to function in p53-dependent DNA damage signalling, this supports 
models in which DNA-PKcs, ATM and ATR function in distinct yet overlapping 
DNA damage detection pathways. 
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1.14 P53 
The tumour suppressor protein p53 is a key regulator of the cell cycle, it is 
also vital for the maintenance and stability of the genome. It is the most common 
target for genetic alterations in cancer, with around 50 % of tumours possessing 
mutations in the p53 gene. P53 accumulates and is activated in response to DNA 
damage and subsequently functions as a transcription factor, stimulating transcription 
of various genes. These genes produce proteins that are involved predominantly in 
cell cycle arrest or the apoptotic pathway, depending upon the extent of damage. 
The use of mouse model systems (Attardi and Jacks, 1999) and various mutant cell 
lines has led to a clearer elucidation of p53 function. 
1.14.1 PARP-1 and p53 
As described in section 1.6.4.3, PARP-1 has been implicated in signalling to 
several molecules, perhaps, most significantly, p53. The effects of PARP-1 on p53 
induction and activity have been studied using both PARP-1 inhibitors such as 3- 
aminobenzamide (3-AB) and PARP-1 deficient mice and cells derived from these. 
Different studies investigating the role of PARP-1 in p53 regulation have yielded 
conflicting results. For example, a number of studies indicate that PARP-1 
contributes to the accumulation of p53 following DNA damage whilst other studies 
have implicated a role for PARP-1 in determining the duration but not the magnitude 
of the p53 response following DNA damage. 
The carboxyl terminal fragment of PARP-1 possesses a consensus sequence 
which has been shown to facilitate protein-protein interactions with p53. Similarly, 
p53 possesses an amino acid consensus sequence that non-covalently binds PARP-1 
bound ADP-ribose polymers in a highly specific manner (Agarwal et al., 1997). 
PARP-1 has been shown to physically interact with p53. Indeed, p53 contains 3 
sequence motifs that bind PAR polymers, two of which are located in the sequence 
specific DNA binding domain (Malanga et al., 1998). Malanga et al., (1998) showed 
in vitro binding of PAR to p53. This binding involves domains within p53 and was 
subsequently shown to impair the DNA binding and transcriptional activation 
functions of the protein probably by blocking protein-DNA interactions. 
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Alternatively, negatively charged PAR could cause electrostatic repulsion between 
p53 and DNA. However, no poly(ADP-ribosyl)ation of wild type p53 can be 
detected in cells (Kumari et al., 1998; Wesierska-Gadek et al., 1996). 
PARP-1 inhibition has been found to suppress both the accumulation of p53 
and G1/S phase arrest in MEFs in response to IR (Matsutani et al., 1995). 
Specifically, following exposure to IR in the presence of 3-AB, there was a 40 % 
decrease in p53 activity and, corresponding with the suppression of p53-induced 
transactivation, MDM2 expression was considerably diminished. Reduced 
accumulation of p53 following DNA damage has also been demonstrated in cell lines 
derived from PARP-1 deficient mice and cells selected for low PARP-1 levels 
(Whitacre et al., 1995). Simbulan-Rosenthal et al., 1998, showed that partial 
inhibition of PARP-1 expression (>90 %) in a cell line expressing PARP-1 antisense 
delays the p53 response to DNA damage but the magnitude of the response was 
unaffected. 
Moreover, Agarwal et al., 1997, demonstrated that there was a reduction in 
the basal level of p53 in PARP-1 null cells in both the presence and absence of IR. 
However, in contrast to the studies described above, the authors showed that 
following IR, downstream events such as activation of p21 and G1 checkpoint were 
unaffected in these cells thus indicating that PARP-1 has no effect on p53 activity. 
Menissier de Murcia et al., 1997, reported that induction of p53 can be observed to 
some extent in PARP-1 -/- animals treated with high doses of DNA damaging agents. 
Moreover, work by Paul Jowsey (unpublished results, personal communication) has 
shown that following exposure to IR, UV or the alkylating agent temozolomide, 
inhibition of PARP-1 by the PARP-1 inhibitor used in the studies described in this 
thesis, AG14361, or loss of PARP-1, failed to show any effect on the ability of p53 
to act as a transcriptional transactivator of either p21 or MDM2. These observations 
have led to the proposal by Agarwal et al., 1997, that DNA damage-induced 
accumulation of p53 is likely to occur through both PARP- 1 -dependent and 
independent pathways but that the actual activation of p53 is probably controlled by 
a PARP-1 independent pathway. 
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In conclusion, several groups have reported defective or no p53 induction in 
PARP-1 deficient cells following DNA damage, whereas others have reported 
normal or elevated p53 induction. The differences are likely to be a result of different 
cell lines and DNA damaging agents that the different groups have used. These data 
suggest that PARP-1 is required for efficient activity and accumulation of p53 but 
not essential since PARP-1 deficient cells retain p53 activity. Interpretation of data 
regarding the role of PARP-1 in p53 induction either by comparison of proficient and 
deficient cells or the use of PARP-1 inhibitors is complicated by the fact that loss of 
PARP-1 hinders DNA repair thus providing a greater and prolonged p53 stimulus. 
1.14.2 DNA-PK and p53 
The biochemical functions of p53 may be regulated by reversible serine 
phosphorylation. Salles-Passador et al., proposed a link between p53 and DNA-PK 
in mediating the responses to IR (Salles Passador et al., 1999). 
DNA-PK has been shown to phosphorylate serines 15 and 37 in vitro (Lees- 
Miller et al., 1992). This has been reported to destabilise interactions between p53 
and MDM2 (Shieh et al., 1997), a protein that negatively regulates p53 in vivo, by 
targeting it for ubiquitin-mediated proteolysis (for review see Alarcon-Vargos and 
Ronai, 2002 and references therein). This leads to p53 stabilisation and hence to 
p53-dependent downstream events. However, initial analysis of cells defective in 
components of the DNA-PK complex have shown that they retain intact DNA 
damage checkpoints and are capable of mediating both p53 induction and 
stabilisation in response to IR (Bogue et al., 1996; Fried et al., 1996; Guidos et al,, 
1996; Huang et al., 1996; Candeias et al., 1997; Rathmell et al., 1997; Shieh et al., 
1997). For example, Jiminez et al., 1999, showed that the p53 response is fully 
functional in primary MEFs lacking DNA-PK, with normal response of p53 
accumulation, phosphorylation of p53 at residue serine 15, nuclear localisation and 
binding to DNA of p53. Furthermore, the upregulation of p53-target genes and cell 
cycle arrest occurred normally. These data therefore imply that other pathways, 
distinct from DNA-PK, can phosphorylate p53 at serine 15 in DNA-PK deficient 
cells and that DNA-PK activity is not essential for cells to mount a p53-dependent 
response to DNA damage. 
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The DNA-PK related proteins ATM and ATR are capable of phosphorylating 
p53 on serine 15 in vitro (Banin et al., 1998). Thus, ATM, ATR and possibly DNA- 
PK, might signal different but partially overlapping types of DNA damage to a 
common p53 pathway. In contrast, however, recent work using DNA-PKcs defective 
cell lines have indicated that DNA-PK activation in response to DNA damage (IR), 
is necessary, but not sufficient for the activation of sequence specific DNA binding 
by p53 through an, as yet, unknown mechanism (Woo et al., 1998). 
It is worth noting that, none of the publications listed above, analysed in 
detail the kinetics of cell cycle arrest or the timing of transactivation of p53- 
dependent downstream genes by observing multiple time points following exposure 
to IR. A study by Kachnic et al., 1999, however, has shown that whilst SCID cells 
still have p53-dependent G1 checkpoint and that the levels of p53 rise and fall in the 
SCID mouse derived MEFs in the same manner as in control cells, the loss of DNA- 
PK activity attenuates the kinetics of p53 activating downstream genes, implying that 
DNA-PK plays a role in post-translational modification of p53 without affecting the 
increase in levels in response to IR. These findings are consistent with and 
complementary to the findings of Woo et al (1998) and suggest that the ability of p53 
to activate downstream genes therefore appears to be, at least in part, dependent on 
DNA-PK 
Alternatively, DNA-PK has been demonstrated to be capable of 
phosphorylating MDM2 on serine 17, in vitro, and therefore this might be an indirect 
mechanism by which it regulates p53 activity. Phosphorylation of MDM2 results in a 
loss of binding of MDM2 to p53 protein and this, in turn, prevents inhibition of p53 
(Mayo et al., 1997). These observations are not mutually exclusive and therefore the 
effect of a loss of DNA-PK activity could be a combined lack of phosphorylation of 
p53 (resulting in impaired transactivation) and lack of phosphorylation of MDM2 
which then continues to attenuate p53 (rather than phosphorylation which results in 
less inhibition of p53). 
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Figure 1.9 The role of PARP-1 and DNA-PK in the cellular responses to DNA 
damage 
1.15 Aims of the studies described in this thesis 
The primary aim of the work described in this thesis was to investigate the 
interactive effects of PARP-1 and DNA-PK in the cellular responses to ionising 
radiation-induced DNA damage. In order to achieve the aim, data presented in this 
thesis utilised cell lines proficient or deficient (by mutation or gene knockout) in 
PARP-1 or DNA-PK in combination with novel specific inhibitors of the two 
enzymes. The characterisation of the cell lines and inhibitors used in this thesis are 
described in Chapter 3. The effect on a number of biological endpoints known to be 
modulated by PARP-1/ DNA-PK function following DNA damage were 
investigated. These included clonogenic survival (Chapter 4) and DSB formation and 
repair (Chapter 5). In addition, the ability of the two enzymes to compete for strand 
breaks and utilise one another as a substrate was explored (Chapter 6). 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 General equipment 
" ß-Liquid scintillation counter Model 1409 DSA (Wallac, Milton Keynes, UK) 
" Irradiator; Gammacell 1000 Elite (Nordian international Inc., Canada) 
" FacScan (Beckton Dickinson, Oxford, UK) 
" MR700 96-well microtitre plate reader (Dynatech, Sussex, UK) 
" Coulter counter Model Z1 (Coulter Electronics, Beds., UK) 
" Incubator (Heraeus Equipment Ltd., Beds., UK) 
" Sonicator: MSE Soniprep (Fisher Scientific, Leics., UK) 
" Spectrophotometer: Pye Unicam PV8610 (Pye Unicam, Cambridge, UK) 
" Waterbath: Grant Model W28 (BDH, Dorset, UK) 
" Centrifuges; Microcentrifuge Model S417R (BDH, Dorset, UK), MSE (Fisher 
Scientific, Leics., UK) 
"X Cell Surelock electrophoresis tank and X cell II Blot module (Invitrogen, 
Paisley, UK) 
" Power pack 200 (Bio-Rad, Herts., UK) 
" Roller Mixer model SRT1 (Stuart Scientific, Surrey, UK) 
" Automatic film developer (Fuji Photo Film Ltd., Japan) 
" HPLC 2780 separation module (Waters alliance, Watford, UK) 
" Multi-channel peristaltic pump Model 205S (Watson-Marlow, Cornwall, UK) 
" Fraction collector 2211 Superfrac (Pharmacia LKB Technology, Sweden) 
" Milipore filtration system (Milipore Corporation, Bedford, Mass., USA) 
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2.1.2 Chemicals/reagents/membranes 
All chemicals and reagents were of analytical grade unless otherwise stated 
and were purchased from either Sigma-Aldrich Company Ltd. (Dorset, UK), or BDH 
(Dorset, UK), with the exception of the items listed below. 
" p81 filter paper used in the DNA-PK assay was obtained from Whatman 
International Ltd., (Kent, UK) 
" Nucleopore polycarbonate track-etch membranes utilised in the DNA strand 
break assay and microfibre filters used in the PARP assay were obtained from 
Whatman International Ltd., (Kent, UK) 
" Isoton II and coulter pots were supplied by Coulter Electronics (Beds., UK) 
" Optiphase scintillant was supplied by Wallac Scintillation Products (Milton 
Keynes, UK) 
" Digitonin was purchased from Roche diagnostics (Sussex, UK) 
" Trypan blue was used to obtain viable cell counts and was supplied by 
Northumbria Biologicals Ltd. (UK) 
" BCA protein assay kit, albumin standard and enhanced chemiluminescence 
substrate (ECL) were purchased from Pierce-Perbio Science (Cheshire, UK) 
" NUPAGE gels and markers for western blot analysis were obtained from 
Invitrogen Ltd. (Paisley, UK) 
" Nitrocellulose membrane was purchased from Bio-Rad (Herts., UK) 
2.1.2.1 Inhibitors 
The PARP-1 inhibitor, AG14361, was synthesised as part of the Newcastle 
Anticancer Drug Development Group and Agouron Pharmaceutical collaboration. 
The DNA-PK inhibitor, NU7026, was synthesised by the Department of Chemistry, 
University of Newcastle Upon Tyne, UK. AG14361 and NU7026 were dissolved in 
100 % v/v DMSO to give 10 mM and 5 mM stock solutions, respectively, and stored 
at -20 °C. All drugs were further diluted in dimethyl sulphoxide (DMSO), as 
necessary, such that when diluted in tissue culture medium, a final concentration of 1 
% (v/v) DMSO was achieved. Drug free controls were exposed to 1% (v/v) DMSO. 
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2.1.3 Radiochemicals 
[2-14C] Thymidine (specific activity = 57 mci/mmol or 50 pCi/m1), [methyl- 
3H] Thymidine (specific activity = 41 Ci/mmol or 1mCi/ml), [32P] NAD+ (specific 
activity = 1000 Ci/mmol or lOmCi/ml) and [32P] ATP (specific activity = 3000 
Ci/mmol or 10 mCi/ml) were purchased from Amersham International (Bucks., UK). 
2.1.4 Enzymes 
" Proteinase K was utilised in the DNA strand break assay and was obtained from 
Boehringer Mannheim Biochemica (Manheim, Germany) 
" Purified DNA-PK (500 gg/ml), isolated from HeLa cells, was kindly supplied by 
G. C. M. Smith, KuDOS Pharmaceuticals (Cambridge, UK) 
" Purified human PARP-1 (1 mg/ml) was kindly supplied by K. Maegley and Z. 
Hostomsky, Agouron Pharmaceuticals (California, USA) 
2.1.5 Tissue culture supplies 
All tissue culture plasticware were obtained from NUNC (Denmark). Tissue 
culture medium and constituents were purchased from Gibco-BRL Life Technologies 
Ltd. (Paisley, UK), with the exception of the foetal calf serum which was supplied by 
Globepharm Ltd. (Surrey, UK). Additional reagents and materials were supplied as 
follows: 
" Dulbecco's phosphate buffered salts (modified) without Ca2+ and Mg2+ (DULA) 
were obtained from ICN Flow (ICN Biomedicals Inc., Irvine, UK) 
" Bijoux were supplied by Bibby Sterlin Ltd. (Staffs., UK) 
" Cells scrapers were obtained from Coming Co-Star (Bucks, UK) 
" Haemocytometer (Neubauer, UK) 
2.1.6 Cell lines and routine culture 
The following cell lines were utilised in the studies described; 
" AA8 Chinese hamster ovary. Derivative of the CHO-K1 cell line and the parent 
line for the repair deficient mutants V3 
"V3 Chinese hamster ovary. Radosensitive mutant defective in the catalytic 
subunit of DNA-PK (gene product designated XRCC7) (Blunt et al., 1995) 
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" V3YAC Chinese hamster ovary. V3 cell line transfected with a yeast artificial 
chromosome encoding human DNA-PKcs cDNA. This cell line and the 
radiosensitive mutant, V3, were a gift from Dr Penny Jeggo of the University of 
Sussex (Blunt et al., 1995; Priestly et al., 1998). 
" CHO-K1 Derived as a subclone from the parental CHO cell line initiated from a 
biopsy of an ovary from an adult Chinese hamster (Puck, 1957) Parent line for 
the repair deficient mutants xrs-6. 
" Xrs-6 Chinese hamster ovary. Radiosensitive mutant defective in Ku80, a 
subunit of the Ku protein and component of DNA-PK complex (gene product 
designated XRCC5) (Jeggo and Kemp, 1983). 
" Xrs-6-HamKu80 Chinese hamster ovary. Xrs-6 cell line transfected with 
hamster Ku80 cDNA (Singleton et al., 1997). 
" PARP-1 +/+ Spontaneously immortilised mouse embryonic fibroblasts derived 
from primary cells kindly provided by Professor Gilbert de Murcia, Ecole 
Superieure de Biotechnologie de Strasbourg, France. 
" PARP-1 -/- Mouse embryonic fibroblast. Knockout for PARP-1 through 
disruption in exon 4 which encodes the DNA binding domain of this enzyme 
(Figure 3.1). 
Specific details regarding the nature of any mutations in these cell lines are given 
in Chapter 3 (section 3.1.1). All cell lines were cultured as monolayers in plastic 
tissue culture dishes and grown in Dulbeccos modified eagles medium (DMEM) 
supplemented with 10 % (v/v) foetal calf serum (heat inactivated at 56°C for 30 
minutes), 100 U/ml penicillin, 100 µg/ml streptomycin. Glutamine was added at a 
final concentration of 2 mM. All lines were sub-cultured twice weekly to maintain 
the cells in exponential phase of growth and kept at 37°C, 5% CO2 in a humidified 
incubator. During routine sub-culturing, and in experiments, the medium was 
aspirated from the dish, the cells washed with DULA and then removed from the 
plate using an appropriate volume of 0.25 % (v/v) trypsin in DULA/EDTA 
(dihydrate form of disodium salt, 0.02 % w/v). Trypsinisation was terminated by the 
addition of fully supplemented medium. The xrs-6 and V3YAC cell lines were 
maintained under antibiotic selection by an additional supplement of Genticin 
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Sulphate which was added at a final concentration, in medium, of 300 µg/ml and 500 
µg/ml, respectively. 
Mycoplasma, are a common contaminant of cell cultures. Although they can 
produce many abnormal changes within the cell including altered protein and nucleic 
acid synthesis and chromosomal breakage, their detection is difficult since a change 
in growth or morphology is not normally apparent. Consequently, all cell lines were 
routinely tested for mycoplasma spp on a6 weekly basis. 
2.1.6.1 Frozen cell stocks 
Frozen cell stocks were stored in liquid nitrogen. Cells were preserved in 
`freezing down' medium; DMEM, supplemented as described above, with the 
exception of the addition of 10 % (v/v) DMSO. Exponentially growing cells were 
harvested by trypsinisation, counted and centrifuged at 1500 rpm for 5 minutes. The 
pellet was resuspended in an appropriate volume (approximately 106 cells/ml) of 
freeze medium into a cryovial and freezing was carried out overnight in a -80°C 
freezer at a rate of approximately 1 °C per minute before transferring to liquid 
nitrogen. The slow freezing rate in combination with the use of DMSO prevents the 
formation of ice crystals that would otherwise rupture the cells. Recovery from 
liquid nitrogen was achieved by thawing cells rapidly in a waterbath at 37°C. The 
cells were then resuspended in 9 ml fully supplemented DMEM medium and 
centrifuged at 1500 rpm for 5 mins in order to remove traces of DMSO. The 
medium was aspirated and the pellet resuspended in an appropriate volume of 
medium and transferred to a 92mm plate. 
2.2 COUNTING CELLS 
In the studies described in this thesis, cells were counted using a 
haemocytometer, or where a large number of samples were to be counted, a Coulter 
counter was employed. 
Principle A haemocytometer is a slide containing two mirrored chambers of known 
depth with a grid etched onto its lower surface. When a cover slip is placed over the 
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chambers, the depth is uniform (0.1 mm). Each chamber is divided into 9 large 1 
mm2 squares and therefore the volume of each large square is (1mm x 1mm) x 0.1 
mm = 0.1 mm3. Since 1 mm3 = 1µl, the conversion factor for 1m! =x 104'. Using 
this information, the cell number per ml of the original suspension can be calculated. 
Counting Each sample was diluted 1: 1 with 0.4 % v/v trypan blue (this gives an 
indication of the viability of the cells as only non-viable cells are stained blue) and 
then loaded into a counting chamber by capillary action. At least 100 cells were 
counted from either the 4 corner squares or all 9 squares, depending on the amount of 
cells and all counts were carried out in duplicate. Only viable cells were counted. 
Mean cell count / number of squares x dilution factor = cells/ml x 104 
Principle A Coulter counter detects cells due to a change in electrical resistance 
when they pass through a small aperture in a glass tube. This change in electrical 
resistance is detected as a voltage pulse which is proportional in height to the volume 
of electrolyte displaced and therefore the size of the cell. The number of pulses are 
counted by the machine thus giving an accurate determination of the number of cells 
in a given volume. Whilst this technique is useful for the measurement of larger 
number of cells or for a large number of samples, a major limitation is the lack of 
discrimination between viable cells, dead cells and cell clumps as well as inanimate 
particles such as dust. 
Counting For each sample, 500 µl of cell suspension was fixed in 500 . tl of Carnoys 
fixative and diluted by the addition of 9 ml Isoton II to give a total volume of 10ml. 
The counter was set to count lml of the electrolyte solution at the appropriate 
threshold settings (see below) for the cell line. Duplicate counts of each sample were 
taken and the average value used to calculate the cell number, taking into account the 
dilution factor of 20. 
An upper threshold (Tu) of 24 µni and a lower threshold (TL) of 8 µm were 
used for all cell lines, as these settings were found to give optimum correlation with 
haemocytometer counts. 
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2.3 SULPHURHODAMINE B (SRB) ASSAY 
Assay principle Sulphurhodamine B (SRB) is a bright pink aminoxanthine dye with 
two sulphonic groups, which binds electrostatically to the basic amino acid residues 
of proteins under mildly acidic conditions. The intensity of staining is therefore 
proportional to the amount of protein and therefore cell number. As described by 
Skehan et al., (1990) this assay can be used as a rapid and sensitive means by which 
cellular growth rate and growth inhibition can be measured in microtitre plates. 
2.3.1 Determination of cell growth rate 
The amount of cell suspension seeded during routine subculture and in 
experiments is dependent on the growth rate of the cells, the confluent cell density 
and the duration of the experiment. A series of cell suspensions at concentrations 
ranging from 2x 105 to 1.25 x 104 cells/ml were prepared and 100 µl of cell 
suspension was then seeded into each of the inner 60 wells (each cell suspension 
across the plate to give 10 replicates) of a 96 well microtitre plate. Medium was 
added to the outer wells in order to compensate for "edge effect", a phenomena 
which can result in abnormal growth (Dr N. J. Curtin, personal communication). A 
total of 6 plates were set up for each cell line and one plate was fixed per cell line at 
24 hr intervals by aspiration of the medium from each well followed by the addition 
of 25 µl50 % trichloroacetic acid (TCA) to each well. The plates were then stored at 
4°C, ready for staining. 
Staining was achieved by the addition of 100 µl of 0.4 % (w/v) SRB in 1% 
acetic acid (v/v) to all wells. Plates were then incubated at ambient temperature for 
30 minutes before removing the dye by rinsing five times with 1% acetic acid. 
Rinsing was performed gently but quickly in order to avoid dislodging adherent cells 
and to prevent desorption of protein bound dye. The plates were then air dried prior 
to the addition of 100 µl 10 mM Tris base (pH 10.5) to each well. The addition of 
Tris base to the cells results in the solubilisation of the stain. Plates were read at 
570nm using a MR700 96 well microtitre plate reader. 
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Calculation of results An average of the 10 absorbance readings obtained for each 
of the cell suspensions was calculated and these were plotted against time on an x-y 
plot. Doubling times (DT) were calculated by linear regression of the curve of log 
absorbance against time using GraphPad Prism software (Graphpad Inc, San Diego, 
CA, USA) and the following formula; 
log 2= DT hours. 
slope 
2.3.2 Growth Inhibition Assay 
In studies described in this thesis, the SRB assay was used to investigate 
whether or not either of the inhibitors had any inherent inhibitory effects on cell 
growth. All CHO cell lines were seeded at 1.5 x 103/well whilst the PARP-1 MEFs 
were seeded at 1.0 x 103 /well (results of cell growth rate studies). As before, 100 µl 
of cell suspension was seeded into the inner 60 wells of a 96 well microtitre plate 
whilst medium alone was added to the outer wells to compensate for edge effect. 
The cells were incubated for 24 h to allow them to adhere. Medium was aspirated 
from the wells and then replaced with 100 µl medium containing inhibitor(s) 
(dissolved in DMSO such that the final concentration of DMSO in medium was 1% 
v/v). 6 wells per drug concentration were seeded and untreated controls were 
exposed to 1% (v/v) DMSO with 12 replicates seeded. When the inhibitor(s) were 
added to the cells, a plate of untreated cells was fixed by the addition of 100 µl 50 % 
TCA in order to measure the cell density at time `zero'. Cells were exposed to the 
inhibitor for at least three full cell divisions (48 hr / 72 hr dependent on cell line) (see 
individual figure legends) before being fixed and stained as described above. 
Calculation of results An average of the absorbance readings obtained for each of 
the 12 drug free controls gave a value for the number of control cells. Likewise, the 
values obtained for the 6 replicates for each drug concentration were averaged to 
give values for the number of treated cells. Cell growth, expressed as a percentage of 
untreated controls, was then calculated and plotted against inhibitor concentration on 
an x-y plot. The IC50, defined as the concentration of inhibitor to give rise to a 50 % 
inhibition of growth of that shown by untreated controls, was calculated using a point 
to point plot using GraphPad Prism software. 
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2.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
Assay Principle HPLC is a fast, sensitive and versatile technique for the separation 
of compounds on the basis of their size, polarity, solubility or adsorption 
characterisitcs (Jones et al., 1996). 
Assay In order to evaluate the stability of NU7026, a reverse HPLC method was 
developed. Separation was achieved on a Hypersil BDS C18 5 µm column (4.6 x 
250 mm) using a mobile phase of 0.02 M ammonium formate buffer (pH 5.0) and 
acetonitrile (60: 40 v/v). Detection was at 270 nm using a PDA996 detector with a 
retention time of approximately 8 minutes observed for NU7026. 
PBS standards (1,10 and 50 µM in 1% DMSO v/v) were used to determine 
?, max and optimal separation conditions. Samples were set up in triplicate at 1,10 
and 50 µM in DMEM medium, aliquots taken at various time points and extracted 
using acetonitrile precipitation (1: 2 v/v sample : acetonitrile). 
Calculation of results Results were processed using Waters Millenium 32 
Software. See individual Figure legends for details. 
2.5 CLONOGENIC ASSAY 
Assay Principle Cell growth can be inhibited by both cytotoxic and cytostatic 
agents, however, only viable cells are able to carry out the 5-6 rounds of cell division 
required to form a visible colony. Colony forming assays show the difference 
between cytotoxic and cytostatic agents not shown in growth inhibition studies. 
Assay Cells were plated onto 60 mm plates at a density that gave a final cell number 
of 3-5 x 105 cells/ ml on the day of experiment. Dosing schedules were as described 
in figure legends. Inhibitors were added at final concentration of 1% DMSO (v/v) in 
medium 1 hr prior to irradiation and controls were exposed to 1% (v/v) DMSO. For 
y-irradiation studies, cells were subjected to a 137Cs source for appropriate exposure 
times (dose rate of 3.64 Gray/minute). 
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Following post-incubation at 37°C (see individual figure legends), the cells 
were trypsinised and resuspended in 5 ml of drug free medium and syringed using a 
23G needle to ensure a single cell suspension. A 500 µl aliquot of each cell 
suspension was fixed and counted using a coulter counter (see section 2.2.2). Cells 
were diluted in medium to give suspensions of either 1x104cells/ml or 1x103 cells/ml. 
A volume of the diluted cell suspension corresponding to a number of cells 
calculated to produce a countable number of colonies (50-200) were then seeded in 
triplicate onto 92 mm plates in 10 ml of fresh medium. The plates were then 
incubated for 7-14 days depending on the cell line, to allow for colony formation. 
Following the formation of suitably large colonies (fifty cells or more), the 
medium was aspirated from the plates and the colonies fixed by the addition of 5 ml 
carnoys fixative. After 5 min the fixative was removed and the colonies were 
allowed to dry in air. Staining was achieved by the addition of 0.4 % (w/v) crystal 
violet in water for one minute. Excess stain was gently washed off under running 
water and the plates allowed to dry. 
Calculation of results Absolute cell survival (plating efficiency) was calculated as 
the percentage of cells seeded which formed colonies i. e. (the number of colonies/the 
number of cells seeded) x 100. The relative survival of the treated cells was 
expressed as a percentage of untreated controls. 
The LD50 and LD90 (defined as the dose of y-irradiation to give 50 % and 90 
% reduction in survival) were calculated using a point to point curve plot using 
GraphPad Prism software. The potentiation factor at 10% survival (PF90) was 
calculated as follows: 
PF90 = LD90 IR alone 
LD90 IR ± AG14361 ± NU7026 
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2.6 POTENTIALLY LETHAL DAMAGE RECOVERY ASSAY 
Assay Principle Plateau phase cell cultures have a large proportion of non- 
proliferating G1 phase cells characteristic of in vivo tumours and therefore they are 
considered appropriate in vitro systems compared to exponentially growing cells for 
studying PLDR (Hahn and Little, 1972). The in vitro model used in the studies 
described in this thesis measured the increase in survival of irradiated growth 
arrested G1 phase cells following delayed plating for colony formation. 
Assay In order to induce G1 arrest prior to irradiation, cells were seeded onto 60mm 
plates at an appropriate density (2-5 x 106 /plate) and continuously cultured in the 
same media for 5 days until confluence was achieved. Cell cycle distribution to 
confirm G1 arrest in plateau phase cells was assessed by flow cytometric analysis (> 
75 % cells in G1 with less than 20 % and 5% in G2M and S, respectively) as 
described in section 2.7. Inhibitor(s) were added 1h prior to irradiation in 
conditioned medium (medium obtained from confluent cells) and the cells were 
exposed to equitoxic doses of IR (see individual figure legends for dosing schedules). 
Cells were exposed to the inhibitor(s) during irradiation and up to the time of 
subculture. Following exposure to IR, cells were trypsinised and re-seeded for colony 
formation in the absence of inhibitor(s), either immediately following exposure to IR, 
or after a 24 h post-incubation at 37°C. The capacity for PLDR was evaluated by 
calculating the recovery ratio as follows: - 
Recovery ratio 
_% survival 24 It post-IR 
% survival 0h post-IR 
Inhibition of recovery 
= 100- [ a/b x 1001 
a= (survival + inhibitor(s) 24 h post-IR) - (survival 0h post-IR) 
b= survival 24 h post-IR - survival 0h post-IR 
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2.7 FLOW CYTOMETRIC ANALYSIS OF THE CELL CYCLE EFFECTS OF 
AG14361 AND NU7026 
Assay Principle Cell cycle distribution can be determined using flow cytometric 
analysis of cells stained with the fluorescent DNA binding dye, propidium iodide 
(PI) (Ormnerod., 1994). When a single cell suspension is passed through the flow 
cytometer, an argon laser excites the fluorescence on the cells labelled with PI. The 
fluorescent light emitted by the labelled cells is focused onto a photomultiplier tube 
and the electrical signal thus generated is proportional to the number of fluorescent 
molecules on each cell. As size and DNA content of the cells is characterised by light 
scatter and fluorescence emission, respectively, resolution of a scatter plot (forward 
scatter vs side scatter which gives the number of cells vs DNA content) allows the 
fraction of cells in G1, S and G2 to be estimated (Figure 2.1). An important feature 
of this technique is that it allows measurements to be made separately on each 
individual cell within the suspension in turn and not as average values for a whole 
cell population. 
A 
z 
0 G1 M 
°S / 
0 
DNA content 
Figure 2.1 Schematic representation of a scatter plot illustrating the 
relationship between DNA content, and cell cycle phase 
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Sample preparation Cells were seeded on to 60mm plates at an appropriate density 
to allow at least 10,000 cells to be analysed per sample on the day of the experiment. 
Inhibitor(s) were added at a final DMSO concentration of 1% v/v (see individual 
figure legends for dosing schedules). The medium (containing floating cells) from 
each plate was transferred to a labelled bijoux. The cells from each plate were 
harvested by the addition of an appropriate volume of 0.25 % v/v trypsin combined 
with the medium collected earlier and then centrifuged at 1500 rpm for 5 minutes. 
The supernatant was aspirated off and the pellet resuspended in lml ice cold PBS 
before transferring to a labelled Eppendorf. The sample was then centrifuged for a 
further 5 minutes at 3000 rpm and the pellet fixed in 70 % (v/v) Ethanol in PBS and 
left on ice for at least 2 hrs. The pellet is stable for 1 month at 4°C. On the day of 
analysis, the cells were pelleted by centrifugation as above and resuspended in 800 µl 
PBS, 100 µl Ribonuclease A (Rnase 1 mg/ml) and 100 µl PI (400 µg/ml), and 
incubated at 37°C for 30 minutes. The cells were then placed on ice until analysis. 
Flow Cytometry Flow cytometric analysis was performed using a Becton 
Dickinson FacScan equipped with an argon ion laser (excitation at 488 nm) using 
emission filter 600 nm (Pi). At least 10,000 individual cells from each cell 
suspension were analysed for their level of fluorescence and the data obtained were 
plotted on a FL2 (PI) plot using Cell Quest Version 1.2.2 to give cell cycle profiles. 
An example profile is shown in Figure 3.12. 
2.8 DNA STRAND BREAK ASSAY 
Assay Principle Neutral and alkaline elution are techniques which provide 
quantitative analysis of DNA double and single strand breakage, respectively 
(Bradley and Kohn, 1979, Kohn et al., 1981). Fragments of DNA are separated on 
the basis of size using polycarbonate filters which impede the passage of larger DNA 
fragments, allowing smaller fragments to pass through more quickly. The rate of 
elution is therefore proportional to the relative size of the DNA strand. Alkaline 
elution is carried out at pH 12 which denatures the DNA, whilst neutral elution is 
carried out at a pH of 9.6 such that the DNA remains duplexed, allowing the 
quantification of double strand breaks. Adaptations of the technique also allow the 
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measurement of alkali labile sites, DNA-protein crosslinks and DNA interstrand 
crosslinks. The sensitivity of the assay has been calculated to be 1 DNA lesion/107 
nucleotides. To increase the precision of the assay, an internal standard was used. 
This accounts for any differences in elution rate between samples which are a result 
of variation in pump channel efficiency thus eliminating intersample differences. 
Preparation of the filters Polycarbonate filters with a2 cm diameter and a pore 
size of 0.2 p. M were moistened in ice-cold phosphate buffered saline (PBS) pH 7.2 
and placed shiny side up onto 16 x 25 mm polyethylene filtration funnels. These 
filters have a low capacity for protein or DNA adsorption. To prevent leakage of the 
system and create a tight seal, a rubber gasket was then centralised over the filter. 
This was followed by the filtration funnel top which was screwed on tightly and 
covered in foil since visible light can produce DNA strand breaks which would have 
the potential to interfere with the interpretation of results. A small volume (1- 2.5 
ml) of PBS was passed through each of the filters to ensure that they were dripping 
correctly and then a 50 ml syringe barrel was connected to each funnel. Airlocks 
were released by placing a depressed Gilson tip into the hole of the funnel. 20 ml 
PBS was (then) added to each barrel and the filters allowed to drip freely by means 
of capillary action and gravitational pull until 10 ml remained. The eluent tube 
attached to each of the filter holders was clamped and the apparatus stored at 4°C. 
Sample preparation Sample cells were plated onto 60mm plates at a density that 
gave a final cell number of 5x 105 cells/ ml on the day of experiment. Internal 
standard cells were seeded into 92 mm plates to allow for an equivalent number of 
cells compared to the sample cells to be added to each filter on the day of 
experiment. Sample and internal standard cells were labelled for 1-2 generations. 
Sample cells were labelled with [2-14C] thymidine at a final concentration of 0.016 
µCi/ml (this is preferred over [3H] thymidine as it does not impede cell growth or 
affect DNA elution rate and is less damaging to DNA). Internal standard cells were 
labelled with [methyl-3H] thymidine at a final concentration of 0.1 µCi/ml. 
Following 24 h, the medium was aspirated and the cells were washed lx with 
DULA, in order to remove any unincorporated label. The cells were then 
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resuspended in fresh medium and incubated at 37°C for at least 2h to allow for the 
label to be chased into high molecular weight DNA. 
For y-irradiation studies, sample cells were trypsinised, resuspended in 
culture medium containing inhibitor(s) and transferred into bijoux bottles prior to 
irradiation (see individual figure legends for dosing schedules). Cells were kept on 
ice before, during and after irradiation to prevent cellular repair. Where cells were 
allowed to recover following irradiation, they were post-incubated at 37°C in a 
waterbath for the desired amount of time prior to elution, as described in the results. 
The internal standard cells were resuspended in PBS and irradiated at 100 Gy for 
neutral elution, 3 Gy for alkaline elution studies shortly before elution and held on 
ice until eluted. All handling of cells was carried out in the dark to prevent further 
damage to the DNA. 
Elution protocol Approximately 5x105 sample cells were loaded onto each filter 
and an equal number of internal standard cells, as determined by haemocytometer 
count, were added to each filter. The tubing was unclipped and the cells allowed to 
drain onto filter. The cells were then washed with 2 ml lysis buffer or elution buffer 
(see appendix) for alkaline elution or neutral elution, respectively. The clips of the 
filtration funnels were fastened and the cells were treated with 1.5 ml lysis or elution 
buffer (alkaline or neutral elution, respectively, see appendix) containing 0.5 mg/ml 
proteinase K for 1h in order to remove any protein associated with the DNA. The 
clips were unfastened and the cells washed with 2 mM EDTA, pH 10 (alkaline 
elution only). The eluent tubes from the filtration funnels were attached in numerical 
order to the corresponding tubing on a multichannel peristaltic pump that is in turn 
attached to a fraction collector. The syringe barrels were then reattached and 25 ml 
elution buffer was added to each barrel. 
The pump was set at a slow and constant speed of (2 ml/h). The fraction 
collector was programmed to collect 8 fractions over 12 hrs at 90 minutes per 
fraction into scintillation vials containing l5mls scintillation fluid. Following 12 hrs 
the pump was continued for a further 20 minutes to collect any sample remaining in 
the tubes into fraction 9. The tubing was then disconnected from the filtration 
funnnels and 0.4 M NaOH pumped through for another 20 minutes to flush the 
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system of any remaining counts, the filtration funnels were then dismantled and the 
filters placed on the bottom of fresh scinitillation vials. 1M HCl (0.4 ml) was added 
to each filter, the vial capped and the filter baked for 1 hour at 60°C to allow 
depurination of the DNA. Apuriniuc sites are converted to strand breaks by this 
procedure, causing the DNA to fragment and be released from the filters. To 
neutralise the acid, 2.5 ml 0.4 mM NaOH was then added to each vial and the vials 
shaken and left at room temperature for 1 hour. 15 ml of scintillant was added to 
each vial. All vials were capped, shaken and then placed in racks onto a scintillation 
counter. The levels of 3H (fraction of internal standard DNA) and 14C (fraction of 
sample DNA) present in each of the vials were determined using a1 minute dual 
label count. 
Calculation of results The total amount (T) of either 3H or 14C initially applied to 
the filter was calculated for each sample by the addition of the counts from all 10 
fractions (where the tenth `fraction' contains the filter). The number of counts 
retained on the filter after each fraction had eluted (R) was then determined using 
cumulative addition and the fraction of total (R/T) was then calculated. The data was 
plotted as the fraction of [14C] thymidine remaining on the filter against the fraction 
of [3H] thymidine using a double log scale and a reverse x axis, to give the elution 
profile (An example profile is given in Figure 2.2 ). 
Regression analysis of each profile was performed to calculate the relative 
retention (R. R) of each sample i. e. the fraction of sample DNA retained on the filter 
when 50 % of the internal standard had eluted, using a point to point curve plot using 
GraphPad Prism software as shown in Figure 2.2. In order to put a numerical value 
on the difference of the elution profile of irradiated/drug treated samples compared to 
untreated controls, which would also facilitate inter-experimental comparisons, 
relative elution (the ratio of elution of DNA after treatment compared to an untreated 
control) was then calculated using the following equation :- 
Relative elution (RE) = [log control RR] - [log sample RR] 
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Figure 2.2 Calculation of Relative Retention 
Representative elution profile and the readings taken in order to calculate the 
`relative retention' (RR) for control untreated and treated samples, from which 
relative elution (RE) values can be calculated as ; [log A]-[log B]. 
Repair 
= 100 - [a/b x 1001 
a= RE xh post-IR 
6= RE 0h post-IR 
Inhibition of repair 
=100-[c/dx100] 
c= (% repair + inhibitor(s) xh post-IR) - (% repair oh post-IR) 
d =% repair xh post-IR -% repair 0h post-IR 
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2.9 WESTERN BLOTTING 
Assay Principle Western blotting is the separation and immunodetection of specific 
proteins. The power of the technique lies in the simultaneous detection of a specific 
protein by means of its antigenicity and its molecular mass. Proteins are first 
separated by mass under the denaturing conditions of SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then specifically detected by immunoassay. 
Sodium dodecyl sulphate (SDS) is an anionic detergent that binds to the non- 
polar regions of amino acids. Treatment of proteins with SDS dissociates them into 
linear polypeptide structures and the negative charges provided by the bound 
detergent predominate over the intrisic polypeptide charges so that they have a 
constant mass: charge ratio. Migration of these anionic proteins within 
polyacrylamide gels in an electric field is thus dependent on the overall mass (size) 
of the proteins. 
Western blotting is a method by which proteins, previously separated by 
SDS-PAGE are immobilised ('blotted') on a membrane support by electrophoresis 
transfer and subsequently detected using specific antibodies that will recognise and 
bind to the target protein on the membrane. The panel of antibodies used in the 
studies described in this thesis are shown in Table 2.1. Following application of 
these primary antibodies, enzyme conjugated secondaries were used. These 
secondaries are specific to the species of the primary antibodies. When conjugated 
with horseradish peroxidase (HRP), these secondary antibodies allow detection of 
target proteins using an ECLTM chemilluminescent system and visualisation of the 
immune complex using X-ray film. 
Sample preparation Cell lysates were prepared by the addition of 100 µl of SDS 
lysis buffer (see appendix) to a2 ml plate. The cells were then collected into an 
Eppendorf using a cell scraper. (Cells were maintained on ice throughout sample 
preparation). Each cell lysate was sonicated for lOs at an amplitude of 10 microns 
and either stored on ice until loading onto the gel or frozen at -20°C. Following 
protein estimation (section 2.10), samples were diluted in lysis buffer and 4x sample 
buffer (see appendix) was added to give a final concentration of 2.5 µg/µ1. Sample 
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buffer contains DTT which acts as a reducing agent, cleaving any disulphide bonds 
within/between the polypeptide chains. Samples were then boiled for 10 mins at 
95°C in order to allow full denaturation of the proteins present in the sample. 
Protein separation by SDS-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
Directly after heating, 20 µl (50 µg) samples were loaded onto either 4-20 % tris- 
glycine or 3-8 % tris-acetate precast polyacrylamide gels capable of separating 
proteins ranging from 4-250 kDa and 40-400 kDa, respectively, (choice dependent 
on size of protein to be separated). A pre-stained molecular weight maker (5 µl) 
was loaded. This permits the molecular weights of the translated proteins to be 
determined by comparing their mobility with the mobility of the marker peptides 
under the same conditions. 
Gels were run in SDS electrode (running) buffer (see appendix) at a constant 
voltage of 200 V for approximately 45 minutes or until the dye front reached the 
bottom of the gel. Since the proteins within the sample are all negatively charged, 
they migrate from the positive anode (where they are loaded) to the negative cathode 
according to polypeptide size. 
Immunoblotting Transfer of separated proteins from the gel to HybondTM C 
nitrocellulose membrane was achieved by the application of an electric current which 
passed through the gel in the direction of the membrane, carrying with it the protein. 
The membrane was soaked in transfer buffer (see appendix) for 30 minutes prior to 
blotting. The transfer apparatus was set up as described in the manufacturers 
instructions and the proteins were transferred overnight in lx transfer buffer using a 
constant voltage of 30 V or at 100 V for 1h on ice. 
Following electrophoretic transfer, the membrane was incubated (with 
constant agitation) for one hour in TBS-Tween (see appendix) containing 5% non- 
fat milk. This was necessary to `block' all of the unoccupied non-specific binding 
sites of the membrane prior to immunodection as it prevents background binding of 
antibodies to these sites. Primary antibodies were diluted (see table 2.1) in TBS- 
Tween 5% milk and applied to the membrane. During this time, an antibody- 
antigen complex will form. Incubation in primary antibody was performed for one 
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hour. Following four 5 min washes in TBS-Tween, a peroxidase conjugated goat 
anti-mouse/rabbit secondary antibody (DAKO, UK), diluted 1: 1000 in milk TBS- 
Tween (5 % milk), was added to the membrane and incubated for one hour. After 
this final incubation, four 15 minute washes in TBS-Tween were performed before 
detection of proteins by enhanced chemiluminescence (ECL). 
PROTEIN ANTIBODY SPECIES COMPANY DILUTION 
PARP-1 H250 Rabbit Santa Cruz, 1: 1000 
CA 
Ku70 AHP 316 Rabbit Serotec, 1: 1000 
Oxford, UK 
Ku80 AHP317 Rabbit Serotec, 1: 1000 
Oxford, UK 
DNA-PKcs Ab4 cocktail Mouse Stratech 1: 1000 
Scientific, 
Lambs, UK 
Topo IIa 18511 Rabbit * 1: 500 
Actin Clone AC-40 Mouse Sigma, 1: 1000 
Dorset, UK 
Table 2.1 Table of primary antibodies 
* Kindly provided by Dr Elaine Wilmore, Biochemictry and Genetics, University of 
Newcastle upon Tyne (Cowell et al., 1998) 
ECL development Chemiluminescence is the emission of light from a substance, 
which by chemical reaction, is caused to be in an excited state. The ECLTM detection 
system involves the oxidation of HRP (by peracid) followed by peroxidation and 
excitation of luminol, a cyclic diacylhydrazide. In alkaline conditions this excited 
luminol decays to ground state with the emission of light. The emission is detected 
by exposure to X-ray film. 
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Following the final wash in TBS-Tween, ECL detection was 
performed according to the instructions of the manufacturer Briefly, the membrane 
was incubated in a solution comprising one part detection solution (1) and one part 
detection solution (2). After 1 minute the detection solution was poured off, the 
membrane wrapped in cling film and then exposed to X-ray film for the desired time 
(usually between 10 seconds and 5 minutes). The film was developed using an 
automatic developer. 
2.10 PROTEIN ASSAY 
Assay Principle The method utilised was the bicinchoninic acid (BCA) protein 
assay. This method combines the reduction of Cu 2+ to Cu'+ by protein in alkaline 
medium (the biuret reaction) with the colorimetric detection of the cuprous cation 
(Cu 1) using a reagent containing bicinchoninic acid forming a purple colour which 
is proportional to the protein concentration. 
Assay Albumin standard containing bovine serum albumin (BSA) at 2 mg/ml was 
used to prepare six standard solutions of 0.2,0.4,0.6,0.8,1.0 and 1.2 mg/ml. 
Samples were typically diluted 1: 10 with dH2O. Standards, samples and dH2O 
blanks were loaded in 10 µl volumes in quadruplicate onto 96 well plates. BCA 
reagent A (25 mis) and BCA reagent B (5 mis) were combined and 190 µl of the 
mixture was added to each well and then mixed on a plate shaker for 30 seconds. 
The plate was covered in cling film and incubated at 37 °C for 30 minutes. 
Absorbance at or near 562 nm was read on a plate reader and unknown protein 
concentrations were calculated from the standard curve, taking into account the 10- 
fold dilution factor. 
2.11 PARP PERMEABILISED CELL ASSAY 
Assay principle PARP activity was measured in whole cells by using a modification 
of the published method by Halldorsson et al., (1978) The principle of this technique 
relies on the incorporation of the ADP-ribose moiety of [32P]-NAD+ into acid- 
insoluble ADP-ribose polymer. The presence of a DNA oligonucleotide (see 
appendix) activates PARP-1 which uses both itself and intracellular proteins as 
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poly(ADP-ribose) acceptors. The amount of radiolabel incorporated into the polymer 
is directly proportional to PARP activity. As neither the NAD+ nor oligonucletide 
can enter intact cells, the plasma membrane was rendered `permeable' by either 
hypotonic shock or treatment with digitonin (see appendix). 
NAD+ :A stock solution of approximately 6 mM NAD+ was freshly prepared in 
sterile water on the day of each assay. The optical density (OD) at 260 nm of a 1/100 
dilution of this stock NAD+ solution was measured using spectrophotometer and a1 
cm silica cuvette. The Molar extinction coefficient (c) for NAD/NADH at 260 nm = 
18000 and therefore 18. OD =1 mM NAD+ (Beer Lambert Law). The absolute 
molarity of the stock solution was calculated and a working solution of 600 µM 
NAD+ was prepared to which approximately 10 PCi [32P] NAD+ was added. The 
volume of radiolabel added was adjusted according to its current specific activity, a 
reflection of half life and rate of degradation. 
Preparation of the permeabilised cells All cells were harvested by trypsinisation 
and the cells counted using a haemocytometer (see section 2.2). The cells were then 
washed once in ice cold DULA and the pellet resuspended into ice cold digitonin at a 
density of 3x 107 cells/ml. Following 5 minute incubation on ice, 9 volumes of ice- 
cold isotonic buffer (see appendix) was added and the extent of permeabilisation was 
determined by a trypan blue exclusion haemocytometer count. If kept on ice, the 
cells remain useable for up to 1 hour. 
Assay The components of the reaction mixture (5 µl oligonucleotide (see 
appendix), 50 µl NAD+ and 8 µl 50 x inhibitor/100 % DMSO) were added to 15 ml 
polycarbonate conical bottomed tubes and positioned in a shaking waterbath at 26°C. 
The volume was made up to 100 µl with sterile water and the final concentrations of 
each of the reaction components are shown in Table 2.2. Each sample was performed 
in quadruplicate. The previously prepared cell suspension(s), were warmed at 26°C 
for 7 minutes. The reaction was initiated by the addition of 300 µl of the required cell 
suspension at 5 second intervals to each of the reaction tubes using an Eppendorf 
repeat dispenser. Each tube was then thoroughly vortexed and incubated for 5 
minutes before the reaction was terminated by the addition of 2 ml ice cold TCA (10 
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% w/v TCA, 10 % w/v Na pyrophosphate). Assay blanks (To) which correct for non- 
specific binding of free [32P]-NAD+ to the filter were prepared by adding 2 ml TCA 
before the addition of cell suspension, thereby, preventing the reaction being 
initiated. Following the addition of TCA, all tubes were plunged into ice and left for 
at least an hour to allow precipitation of acid-insoluble material. 
Table 2.2 Permeabilised PARP Assay Reaction Mixture 
Reagent Stock 
Concentration 
Final 
Concentration 
NAD 600 µM 75 µM 
Oligonucleotide 200 µg/ml 2.5 µg/ml 
Drug/DMSO 50 x drug/ 
100 % DMSO v/v 
1x drug/ 
1% DMSO v/v 
In order to separate the TCA -precipitated macromolecules which include 
poly(ADP-ribosylated) proteins from the soluble components such as free [32P]- 
NAD the reaction mixtures were filtered using a Millipore filtration system GF/C 
(25 mm) microfibre filters were moistened with 10 % TCA and placed rough side 
upwards onto the filter holder of the Millipore filtration apparatus. The funnel 
assembly was then secured tightly on top. The contents of the tubes were added to 
individual funnels and each was rinsed 5 times with TCA (1 % w/v TCA, 1% w/v 
Na pyrophosphate) under gentle suction pressure. The filters were removed, air 
dried and placed into scintillation vials containing 10 ml scintillation fluid. Four 
standards (S) containing 5 µl of the 600 . tM NAD+ + [32p]-NAD+ solution were 
prepared. All vials were counted on aß particle scintillation counter for 2 minutes. 
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Calculation of results The number of DPM which represent 1 pmol NAD+ (C ) was 
calculated from the mean DPM of the four standards (SM), which for a 600 µM 
NAD+ stock (5 µl of a 600 µM = 3000 pmol) is; 
Sn1/3000 = DPM/pmol NAD+= C 
The pmol NAD+ present in each of the samples (Cs) was then calculated by 
first subtracting the mean of the To samples (Tom) from each of the sample counts 
thus removing non-specific background counts. The value obtained (Po) for each 
sample was then divided by the number of DPM equivalent to 1 pmol NAD+ (C) to 
give pmol NAD+ in each sample (Cs). As 300 µl of cell suspension was used per 
sample, this was converted to pmol NAD+ in 1 ml of cell suspension. Finally, using 
the cell count taken prior to the experiment, results were expressed as pmol NAD+ 
incorporated/106 cells. 
2.12 PURIFIED PARP-1 ASSAY 
Assay Principle The activity of purified PARP-1 was assayed by modification of 
the permeabilised cell assay. The enzyme was activated by the same 
oligonucleotide(s) and activity was again measured by the incorporation of [32P]- 
NAD+ into acid insoluble material. The reaction components were also the same, 
except for the addition of histones that serve as the acceptor proteins for the ADP- 
ribose polymers. 
Purified PARP-1 working solution: Immediately before the assay, purified 
PARP-1 protein (see section 2.1.4) was diluted 1/500 in PARP-1 buffer (see 
appendix) to give a2 µg/ml working solution. 
NAD+ working solution: A fresh solution of 1mM NAD+ (see section 2.11) was 
made up on the day of assay and approximately 10 ttCi [32P]-NAD+, s. a. =1000 
Ci/mmol, was added. As in the permeabilised cell assay, the volume of radiolabel 
added was adjusted according to its current specific activity, a reflection of half life 
and rate of degradation. 1 ml NAD+, 5µl histone solution and 25 µl oligonucleotide 
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(see Table 2.3 for stock concentrations) were then added to 1.5 ml NAD+ buffer (see 
appendix). 
Assay 50 pl aliquots of the NAD+ working solution were dispensed into 15 ml 
polycarbonate conical bottomed tubes. 1 pl 100 x inhibitor/100 % DMSO was then 
added to each tube and the tubes warmed in a shaking waterbath at 26°C. Each 
sample was carried out in quadruplicate. The reaction was initiated by the addition 
of 50 pl purified PARP-1 working solution to each tube at 5 second intervals using 
an Eppendorf repeat dispenser. The final concentration of each of the reaction 
components are shown in Table 2.3. Each tube was then thoroughly vortexed and 
incubated for 5 minutes before the reaction was terminated by the addition of 25 pl 
ice cold TCA (99 % w/v TCA, 1% w/v Na pyrophosphate). Assay blanks (To) were 
prepared by the addition of 25 pl TCA prior to the addition of purified PARP-1 
protein, thereby preventing the reaction from being initiated and accounting for non- 
specific binding of free [32P]-NAD+ to the filter. 
Table 2.3 Purified PARP-1 Assay Reaction Mixture 
Reagent Stock Concentration Final Concentration 
NAD 1 mm 200 µM 
Oligonucleotide 200 µg/ml 1 µg/m1 
Drug/DMSO 100 x/100 % DMSO v/v lx/1 % DMSO v/v 
Histories 1 mg/ml 1 µg/m1 
PARP-1 protein 1 mg/ml 1 µg/m1 
The tubes were left on ice for 30 minutes to allow precipitation of acid 
insoluble material. The samples were then filtered using a Millipore filtration system 
as in the permeabilised cell assay. Each sample was washed 5 times with 5% w/v 
TCA/ 1% w/v Na pyrphosphate. Four standards (S) containing 5 µl of the 1 mM 
NAD+ + [32p]-NAD+ solution were prepared. All vials were counted on aß particle 
scintillation counter for 2 minutes. 
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Calculation of results The mean of the To samples (Tom) values were subtracted 
from sample counts. The values thus obtained were converted to pmol NAD+ in each 
sample by reference to mean standard counts (SM) (5 µl 1 mM NAD+ = 5000 pmol), 
as described for the permeabilised cell assay. Results were expressed as pmol NAD+ 
incorporated/gg protein. 
2.13 IMMUNO DOT-BLOT TO DETECT ADP-RIBOSE POLYMER 
FORMATION 
Assay Principle This is an assay which is based on a technique first described by 
Afar et al., 1998, and has been optimised in the Northern Institute for Cancer 
Research It relies on the immunodetection of ADP-ribose polymer bound to a 
membrane using a specific antibody which shows no cross reactivity with DNA, 
RNA and monomers of ADP-ribose or NAD+ (Kawamitsu et al., 1984; Menard and 
Poirier, 1987). Although the methodology is very similar to the PARP permeabilised 
cell assay, this assay has the advantage of requiring much smaller cell numbers and it 
does not involve the use of radioactivity. 
P-NAD+ assay Dot blot 
Cell permeabilisation Digitonin Digitonin 
PARP activity Maximally stimulated by Maximally stimulated by 
oligonucleotide oligonucleotide 
Substrate 75 µM NAD+ with 3 P- 75 µM NAD+ 
NAD+ 
Reaction time 6 minutes 6 minutes 
Product measured Amount of P-NAD Amount of polymer >10 
incorporated in reaction subunits detected with 
time monoclonal antibody 
Detection method ß emission scintillography Chemiluminescence 
Quantification 3000 pmol hot NAD PAR purified polymer 
standard 
Cells required 1 million/reaction 3-10,000/reaction 
Table 2.4 Comparison of PARP permeabilised cell assays 
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Preparation of permeabilised cells All cells were harvested by trypsinisation and 
the cells counted using a haemocytometer (see section 2.2). The cells were washed 
once in ice cold PBS and the pellet resuspended into ice cold permeabilisation buffer 
(see appendix) supplemented with 0.015 % digitonin at a density of 3x105 cells/ml. 
Following 1 minute incubation on ice, 4 ml ice cold permeabilisation buffer/ml cells 
was added and the cells pelleted by centrifuging at 1500 rpm for 10 minutes at 0°C. 
The pellet was then resuspended in ice cold permeabilisation buffer at 1.25 x 107 
cells/ml and the extent of permeabilisation determined by a trypan blue exclusion 
haemocytometer count. If kept on ice, the cells remain useable for up to 1 hour. 
Assay The cells were warmed to 30°C in a shaking waterbath. 34 µl aliquots of 
reaction buffer, 25 pl aliquots of oligonucleotide and 1 µl 100 x inhibitor/100 % 
DMSO were dispensed into 15 ml polycarbonate conical bottomed tubes. The final 
concentration of each of the reaction components are shown in Table 2.5. The 
reaction was initiated by the addition of 5x105 cells (40 µl) to each tube and 
terminated after 6 minutes by the addition of an excess of AG14361 (termination 
buffer, see appendix). The tubes were vortexed and transferred to ice. 
Table 2.5 Immuno dot-blot Assay Reaction Mixture 
Reagent Stock Concentration Final Concentration 
NAD 1 mm 300 µM 
Oligonucleotide 200 µg/ml 50 µg/ml 
Drug 100 x/100 % DMSO v/v lx/1% DMSO v/v 
Termination buffer 
(AG14361) 
1.25 µM 1 µM 
Immunodetection of ADP-ribose polymer All samples were diluted in PBS and 
1000,3000 or 5000 cells (total volume 50 µl) / sample were loaded in duplicate onto 
Hybond-N membrane by addition to separate wells of a 96-well manifold. 100 µl 
TCA (10 % w/v TCA, 2% w/v Na pyrophosphate) was then added to each well 
followed by 200 µl 70 % v/v ethanol. The wells were aspirated and the membrane 
was rinsed in PBS three times and then incubated (with constant agitation) for one 
hour in PBS-tween containing 5% (see appendix) non fat milk in order to block all 
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of the unoccupied non-specific binding sites of the membrane. The membrane was 
then incubated overnight at 4°C (with constant agitation) in primary antibody (see 
appendix) at a final concentration of 2.5 µg/ml in PBS-milk tween. Following two 5 
minute washes in PBS-tween, an anti-mouse secondary antibody (DAKO) diluted 1/ 
1000 in PBS-milk tween was added to the membrane and incubated for one hour at 
room temperature. After this final incubation, four 15 minute washes in PBS-Tween 
were performed before enhanced chemiluminescence (ECL) detection on 
photographic film as described in section 2.9. 
2.14 PURIFIED DNA-PK ASSAY 
Assay Principle Upon activation by DNA strand breaks, DNA-PK phosphorylates 
several DNA binding substrates in vitro including the tumour suppressor protein, 
p53, the SV40large T antigen and several transcription factors using ATP as a 
substrate (Anderson and Lees-Miller, 1992). In this assay, the presence of a double 
stranded oligonucleotide, activates DNA-PK which phosphorylates both itself and a 
wt p53 peptide substrate flanking serine 15 on native p53 (EPPLSQEAFADLLKK) 
(Finnie et al., 1995). The amount of [32P] incorporated into the peptide substrate and 
therefore bound to the filter is proportional to DNA-PK activity and is determined by 
liquid scintillation counting. 
Assay The components of the reaction mixture (1 µl of; purified DNA-PK, 
oligonucleotide, peptide and inhibitor/DMSO) were added on ice into an eppendorf 
and the volume made up to 9 µl with DNA-PK buffer (see appendix). The reaction 
was initiated by the addition of 1 µl 500 . tM ATP containing 0.5 µCi [32P] ATP (s. a 
3000 Ci/mMol). Each tube was thoroughly vortexed and incubated for 10 minutes at 
30°C. The reaction was terminated by the addition of 10 µl 30 % (v/v) acetic acid 
and enzyme activity quantitated by spotting half the reaction onto phosphocellulose 
paper, washing and subjecting to liquid scintillation counting. Assay controls were 
prepared by carrying out the reaction in the absence of oligonucleotide. Four 
standards (S) containing 5 µl of the 500 µM ATP + [32P]-ATP solution were also 
prepared by spotting onto phosphocellulose paper and eliminating the washing step. 
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Table 2.6 Purified DNA-PK Assay Reaction Mixture 
Reagent Stock Concentration Final Concentration 
ATP 500 µM 50 µM 
Oligonucleotide 100 gg/ml 10 µg/ml 
Drug 10 x/10 % DMSO v/v lx/1% DMSO v/v 
Peptide 2 mM 200 µM 
DNA-PK 500 µg/ml 50 µg/ml 
Measurement of DNA-PK activity in nuclear extracts For comparison of enzyme 
activities in the cell lines, DNA-PK activity was assayed in nuclear extracts. Nuclear 
extracts were obtained using a cell lytic nuclear extraction kit and following 
manufacturers instructions (Sigma-Aldrich Company Ltd. Dorset, UK). DNA was 
removed from the extracts using high salt elution (fast flow DEAE sepharose, 
Amersham Pharmacia, Bucks, UK). Protein concentrations of extracts were 
quantified using a standard protein assay protocol as described in section 2.10. 
Samples were diluted to give stock concentrations of 50 mg/ml. 50 pg aliquots were 
then assayed for DNA-PK activity. 
Calculation of Results Results were expressed as pmol ATP incorporated /µg 
protein. The mean of the no oligonucleotide assay control values were subtracted 
from sample counts. The values thus obtained were converted to pmol ATP in each 
sample by reference to mean standard counts (SM) (5 µ1500µM ATP = 2500 pmol) 
as described for the permeabilised cell assay. 
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2.15 COMBINED PURIFIED PARP-1 AND DNA-PK ASSAYS 
Based on the known molecular weights of the enzymes (116 kDa for PARP-1 
and 623 kDa for the DNA-PK holoenzyme), enzymes were added at 1; 1,1; 2, and 1; 3 
molar ratios (see Figure legends for details). 
When PARP-1 activity was assayed in the presence of DNA-PK, the enzymes 
were mixed prior to addition to the reaction mix and carried out as for the purified 
PARP-1 assay described in section 2.12. Where specified, ATP (50 µM final 
concentration) was added to the reaction mix. Conversely, when DNA-PK was 
assayed in the presence of PARP-1, the assay was carried out as described in section 
2.14, with the exception that the buffer used was the same as the final buffer used in 
the purified PARP-1 assay (see appendix for buffer constituents). DNA-PK activity 
(when ATP and p53 peptide were present) was not compromised by the alterations in 
the constituents of the assay buffers. The enzymes were mixed prior to addition to 
the reaction mix. Where specified, NAD+ (200 µM final concentration) was added to 
the reaction mix. 
2.16 PURIFIED ENZYME ASSAYS FOR THE COMPARISON OF 
WORTMANNIN AND NU7026 AGAINST THE PIKK FAMILY OF 
ENZYMES 
The following assays were performed by staff at KuDOS pharmaceuticals, 
Cambridge, UK. Mammalian DNA-PK (500 ng/ml) was isolated from HeLa cell 
nuclear extract following chromatography utilising Q-sepharose, S-sepharose and 
Heparin agarose. DNA-PK (250 ng) activity was measured at 30°C, in a final volume 
of 40 µl, in buffer (see appendix) and 1 mg of the substrate GST-p53N66 (the amino 
terminal 66 amino acid residues of human wild type p53 fused to glutathione S- 
transferase) in polypropylene 96 well plates. Varying concentrations of inhibitor (in 
DMSO at a final concentration of 1% v/v) were added to the reaction mix. After 10 
minutes of incubation, ATP was added to give a final concentration of 50 µM along 
with a 30 mer double stranded DNA oligonucleotide (final concentration of 0.5 
ng/ml) to initiate the reaction. After 1h with shaking, 150 µl of phosphate buffered 
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saline (PBS) were added to the reaction and 5 µl then transferred to a 96 well opaque 
white plate containing 45 µl of PBS per well, where the GSTp53N66 substrate was 
allowed to bind to the wells for 1 h. To detect the phosphorylation event on the serine 
15 residue of p53 elicited by DNA-PK, a p53 phosphoserine-15 antibody (Cell 
Signaling Technology, Beverly, MA) was used in a basic ELISA procedure. An anti- 
rabbit HRP conjugated secondary antibody (Pierce-Perbio Science, Cheshire, UK) 
was then employed in the ELISA before the addition of chemiluminescence reagent 
(Renaissance, New England Nuclear) to detect the signal as measured by 
chemiluminescent counting via a TopCount NXT (Perkin Elmer-Packard). 
The protocols used to detect ATM kinase and ATR kinase activities were 
performed essentially according to the methodologies described previously (Banin et 
al., 1998; Tibbetts et al., 1999). ATM and ATR were immunoprecipitated using 
rabbit polyclonal antisera raised to the COOH-terminal 400 amino acids of ATM, 
and antisera raised to amino acids 400-480 of ATR respectively. The PI 3-Kinase 
assay was performed essentially as described previously (Wymann et al., 1996), 
using baculoviral derived recombinant pl 10a and p85a (a kind gift from Prof. Mike 
Waterfield, Ludwig Institute, London). 
The concentration(s) of inhibitor(s) to inhibit kinase activity by 50 % (IC50 values) 
for the compounds in all the enzymes assays were derived from sigmoidal plots using 
the graphic package Prism, in which the enzyme activity in the varying concentration 
of compounds was plotted against the concentration of compound. 
2.17 PERMEABILISED DNA-PK ASSAY 
Assay Principle A DNA-PK permeabilised cell assay was developed by 
modification of the purified DNA-PK assay described in section 2.14 and the PARP 
permeabilised cell assay, described in section 2.11. The enzyme was activated by the 
same 30 bp double stranded blunt-ended oligonucleotide (see appendix) and activity 
was measured by the binding of 32P labelled phosphate groups onto phospho-specific 
cellulose filter paper as described for the purified DNA-PK assay. 
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Preparation of the permeabilised cells All cells were harvested by trypsinisation 
and the cells counted using a haemocytometer (see section 2.2). The cells were then 
washed once in ice cold DULA and the pellet resuspended into ice cold digitonin at a 
density of 6x 107 cells/ml. Following a5 minute incubation on ice, 9 volumes of 
ice-cold isotonic buffer (see appendix) was added and the extent of permeabilisation 
was determined by a trypan blue exclusion haemocytometer count. If kept on ice, 
the cells remain useable for up to 1 hour. 
Assay The components of the reaction mixture (25 µl ATP spiked with 0.5 pCi 
[32P]- ATP (s. a 3000 Ci/mMol), 10 µl oligonucleotide, 4 µl50 x inhibitor/100 % 
DMSO and 4 µl NAD+) were added to 15 ml polycarbonate conical bottomed tubes 
and positioned in a shaking waterbath at 30°C. The volume was made up to 50 µl 
with sterile water. The previously prepared cell suspension(s) were warmed at 30°C 
for 7 minutes. The reaction was initiated by the addition of 150 µl of the required cell 
suspension at 5-second intervals to each of the reaction tubes using an eppendorf 
repeat dispenser. The final concentrations of each of the reaction components are 
shown in Table 2.7. Each tube was then thoroughly vortexed and incubated for 10 
minutes at 30°C before the reaction was terminated by the addition of 100 µl 60 % 
(v/v) acetic acid. Assay blanks (To) which correct for non-specific binding of free 
[32P] to the filter were prepared by adding 100 µd 60 % (v/v) acetic acid before the 
addition of cell suspension, thereby preventing the reaction being initiated. 
Following addition of acetic acid, all tubes were plunged into ice before spotting half 
the reaction onto phosphocellulose paper, washing and subjecting to liquid 
scintillation counting. Four standards (s) containing 5 µl of the ATP + [32P] ATP 
solution were also prepared by spotting onto phosphocellulose paper and eliminating 
the washing step. 
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Table 2.7 Permeabilised DNA-PK Assay Reaction Mixture 
Reagent Stock Concentration Final Concentration 
ATP 400 µM 50 µM 
Oligonucleotide 200 µg/ml 10 µg/ml 
Drug 50 x/ 100 (v/v) % DMSO 1x/1% (v/v) DMSO 
NAD 3.75 mM 75 µM 
Calculation of Results Results were expressed as pmol ATP incorporated/ 106 cells. 
The number of DPM which represent 1 pmol ATP (C ) were calculated from the 
mean DPM of the four standards (SM), which for a 400 µM ATP stock (5 pl of 400 
µM = 2000 pmol) is: - 
Sn1/2000 = DPM/pmol ATP =C 
The pmol ATP present in each of the samples (Cs) was then calculated by 
first subtracting the mean of the To samples from each of the sample counts thus 
removing non-specific background counts. The value obtained for each sample was 
then divided by the number of DPM equivalent to lpmol ATP (C) to give pmol ATP 
in each sample. As 150 µl cell suspension was used per sample, this was converted 
to pmol ATP in 1 ml of cell suspension (Taking into account the fact that only half of 
the reaction was spotted onto the filter). Finally, using the cell count taken prior to 
the experiment, results were expressed as pmol ATP incorporated per 106 cells. 
2.18 CURVE FITTING AND STATISTICAL ANALYSIS 
All graphs presented in this thesis were prepared using GraphPad Prism 
(GraphPad Software, Inc, California, USA), and either point to point, linear or 
sigmoidal dose response curves were fitted using linear or non-linar regression 
analysis. 
To test for differences between groups of data and assess their significance, 
unpaired Student's t-tests were used unless stated otherwise. A Student's two-tailed 
unpaired t-test assumes a Guassian distribution and equal standard deviations. Ap 
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value of <0.05 was deemed to mean that the groups of data were significantly 
different at a5% confidence interval. 
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CHAPTER 3 
CHARACTERISATION OF CELL LINES AND THE NOVEL 
PARP-1 AND DNA-PK INHIBITORS, AG14361 AND NU7026 
3.1 Introduction 
As a major approach to elucidating the physiological roles of PARP-1 and 
DNA-PK in DNA repair, a number of techniques have been developed which result 
in aberrant or reduced cellular PARP-1 or DNA-PK activity. These are described in 
sections 1.8 and 1.11 and include mutant or knockout cell lines deficient in either of 
the two enzymes and small molecule inhibitors. Molecular strategies include the 
development of anti-sense constructs and dominant negative approaches. The studies 
presented in this thesis utilised cell lines proficient or deficient (by mutation or gene 
knockout) in PARP-1 or DNA-PK in combination with novel specific inhibitors of 
the two enzymes. 
3.1.1 Choice of cell lines 
Comparative studies of cell lines that have a common origin but different 
radiosensitivity provide valuable model systems where a greater understanding of the 
relationship between radiation damage and biological effects is sought. In order to 
facilitate data comparison, the Chinese hamster ovary (CHO) cell lines (see section 
2.1.6) were selected for study in this thesis as they have been previously used in 
many studies investigating the cellular responses to IR. Moreover, well-established 
hamster cell lines are easily manipulated and have high plating efficiencies, 
properties that are advantageous when using techniques such as the clonogenic assay 
as an endpoint. 
Radiation sensitive mutants have been isolated and categorised into 11 
complementation groups designated XRCC1-11. The Chinese hamster xrs-6 and V3 
cell lines used in the studies described in this thesis are deficient in the genes XRCC5 
and XRCC7, which encode the Ku80 and DNA-PKcs components of DNA-PK, 
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respectively. The xrs-6 cell line was the first radiation sensitive rodent mutant to be 
described (Jeggo and Kemp, 1983) and analysis of these mutants has provided a link 
between DNA-PK and DSB repair (Taccioli et al., 1994a). These cells have been 
shown to harbour a splice site mutation that results in a 13 bp insertion and frame 
shift thus giving rise to a `null' phenotype (Singleton et al., 1997). Although these 
cells are only partially complemented by transfection with human Ku80 cDNA, full 
complementation can be achieved with hamster Ku80 cDNA (Singleton et al., 1997) 
and therefore the cell line used in studies described in this thesis is transfected with 
hamster cDNA. The V3 cells are derived from the hamster CHO AA8 cell line. They 
have an inactivating mutation (premature termination at residue 4024 important for 
kinase function) in the C-terminal region of one allele important for DNA-PKcs 
function (Blunt et al., 1995). The DNA-PKcs deficiency was complemented by the 
stable transfection of a yeast artificial chromosome (YAC) encoding the human 
XRCC7 gene. 
As a means to evaluate the biological contribution of PARP-1 during 
embryonic development, postnatal life and following genotoxic stress, various 
groups have generated PARP-1 knockout (KO) mice by interruption of Exon 1, Exon 
2 or Exon 4 (section 1.8.5). The PARP-1 knockout mouse embryonic fibroblasts 
(MEFs) used in the studies described in this thesis are disrupted in exon 4 of the 
PARP-1 gene by homologous recombination (Figure 3.1). Confirmation that these 
cells are disrupted in exon 4 has been carried out within the department ( P. Jowsey, 
unpublished results). Briefly, the wild type PARP-1 gene contains two EcoRI sites, 
which upon digestion give rise to a 9.6 kb fragment. The disruption of the PARP-1 
gene by the insertion of a neomycin resistance cassette (phosphoglycerate kinase 
promotor followed by the neo gene) into exon 4 of the PARP-1 locus introduces an 
extra EcoRI site which upon digestion produces a 3.3 kb fragment. Southern blotting 
using a radiolabelled probe (kindly provided by Gilbert de Murcia, Ecole Superieure 
de Biotechnologie de Strasbourg) produced bands at the corresponding fragment 
sizes thus confirming the genotype of the PARP-1 -/- cells. 
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In view of the fact that the primary MEFs were slow growing (doubling time 
approximately 50 h) and were unable to form colonies, spontaneously immortilised 
derivatives were derived. Analysis of the p53 status of these cell lines during the 
course of this research established that the p53 basal levels were unusually high in 
the PARP-1 +/+ cells compared to the PARP-1 -/- cells. The p53 gene was 
sequenced and it was found that the PARP-1 -/- had a wt p53 sequence but the 
PARP-1 +/+ had an inactivating p53 mutation which rendered p53 unable to act as a 
transcriptional transactivator ; Asp to Glu substitution at codon 278 within the 
conserved region of the DNA binding domain (P. Jowsey, unpublished results). This 
mutation may be a product of the development of the cells from embryonic cells 
through senescence and immortilisation. The significance of a difference in the 
functional status of p53 with respect to the results obtained in this thesis is explored 
where appropriate. 
3.1.2 Inhibitors 
At the time of writing this thesis AG14361 and NU7026 were the current 
benchmark inhibitors of PARP-1 and DNA-PK, respectively. 
AG14361 is a tricyclic benzamidazole (Figure 3.2) and is a competitive 
inhibitor with respect to NAD+ (Canonkoch et al., 2002). It is highly soluble and 
exhibits good in vitro stability and in vivo (mouse) pharmacokinetics. Additionally, 
at concentrations and doses that are non toxic per se, this inhibitor demonstrates 
potent chemo-and radiosensitising activity both in vitro and in vivo (Calabrese et al., 
in press). Notably, AG14361 is approximately 10-fold more potent (Ki < 5nM) than 
NU1025 (Ki = 50 nM) (Canonkoch et al., 2002) and approximately 1000-fold more 
potent than 3-AB (Ki =3 µM) (Skalitzky et al., 2003). 
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Figure 3.2 Structure of AG14361 
NU7026 is an analogue of the P13-kinase inhibitor LY294002 (2- 
(morpholin-4-yl)-8-phenyl-chromen-4-one) and is a competitive reversible 
inhibitor with respect to ATP. 
Figure 3.3 Comparison of the structures of LY294002 and NU7026 
The relative inhibitory potencies and specificities of NU7026 and 
Wortmannin against the PIKK family of enzymes (P13-K, DNA-PK, ATM and ATR) 
were compared (Table 3.1). Wortmannin and NU7026 are approximately equipotent 
against DNA-PK. However, whilst wortmannin is primarily a PI 3-K inhibitor, being 
at least 90-fold more active against P13-K than DNA-PK or ATM, NU7026 is more 
selective for DNA-PK with a 60-fold greater potency against this enzyme than PI 3- 
K and inactive against both ATM and ATR. Thus in contrast to wortmannin, 
NU7026 demonstrates excellent specificity for DNA-PK. 
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Enzyme NU7026 
IC50 (µM) 
Wortmannin 
IC50 (µM) 
DNA-PK 0.23 ± 0.01 0.26 t 0.02 
PI 3-K 13.0 ± 3.00 0.003 f 0.00 
ATM > 100 0.30 f 0.05 
ATR > 100 4.4 t 0.18 
Table 3.1 Comparison of inhibitor potencies and specificities against the PIK-K 
family enzymes. 
Reproduced with permission from G. C. M Smith, KuDOS Pharmaceuticals, 
Cambridge, UK. Each IC50 value represents the mean of 3 independent experiments 
± SEM (section 2.16). 
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3.2 Aims 
The aim of this initial results Chapter was to fully characterise the cell lines 
and enzyme inhibitors used in this thesis, in order to identify optimal cell line and 
inhibitor combinations/concentrations for subsequent investigations. The following 
parameters were evaluated: - 
Cell line characterisation 
" Growth rates 
" Western blotting of PARP-1, Ku80, Ku70 and DNA-PKcs protein levels 
" PARP and DNA-PK enzyme activity 
" Radiosensitivity 
Inhibitors 
" Effect of inhibitors on PARP and DNA-PK enzyme activity 
" Stability of NU7026 under assay conditions 
" The effect of inhibitors per se on growth and cell survival 
" The effect of the inhibitors per se on cell cycle distribution 
3.3 Results 
3.3.1 Cell growth rate of cell lines 
The density of cell suspension seeded during routine subculture and in 
experiments is dependent on the growth rate of the cells, the density at which the 
cells reach confluence and the duration of the experiment. The mean cell growth 
rate in DMEM medium was determined for each of the cell lines using the SRB 
assay as described in section 2.3.1. This enabled the exposure period to the inhibitors 
to be adjusted to ensure that each cell line was exposed, in the exponential phase of 
growth, for a period equivalent to 3 cell doublings in growth inhibition studies 
(section. 2.3.2). An average growth rate of 12 ±1h was observed for all CHO cell 
lines. The PARP-1 +/+ and PARP-1 -/- MEFs both had a mean growth rate of 23 ±1 
h. (Table 3.2). 
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Cell line Doubling Time (Hours) 
AA8 11 
V3 13 
V3YAC 12 
CHOK1 11 
Xrs-6 12 
Xrs-6 Ku80 13 
PARP-1 -/- 22 
PARP-1 +/+ 24 
Table 3.2 Control cell doubling times 
Cell growth rates were measured by SRB assay and doubling times were calculated 
by linear regression of the curve of log absorbance against time as described in 
section 2.3.1. 
3.3.2 Protein expression 
The protein levels of Ku80, Ku70, DNA-PKcs and PARP-1 were determined 
in all cell lines by Western blotting. Briefly, cell lysates were prepared from 
exponentially growing cells and loaded onto denaturing polyacrylamide gels as 
described in section 2.9 DNA-PKcs was resolved on 3-8 % Tris-acetate gels and all 
other proteins were separated on 4-20 % Tris Glycine gels. Following 
electrophoresis, proteins were electrotransferred onto nitrocellulose and probed for 
target proteins using specific antibodies (Table 2.1). Purified PARP-1 and DNA- 
PKcs were also run as controls on the gel, where appropriate. 
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As expected, PARP-1 -/- MEFs contained no detectable PARP-1 protein and 
no DNA-PKcs protein was detected in extracts from V3 cells. However, both 
proteins are present in all other cell lines as demonstrated by bands of 116 kDa and 
470 kDa, respectively (Figure 3.4). The levels of DNA-PKcs in the V3YAC cells 
were greater than that observed in the parental AA8 cell line and this may reflect 
overexpression of human DNA-PKcs by the YAC. Conversely, the levels of DNA- 
PKcs in the PARP-1 -/- cells were lower than that observed in the PARP-1 +/+ cells. 
All cell lines showed bands for Ku80 except for the xrs-6 cells which failed to 
express detectable levels of Ku80 protein. Intriguingly, there were higher levels of 
Ku80 in the PARP-1 +/+ cell line when compared to the PARP-1 -/- cell line. 
Furthermore, whilst Ku70 was of parental level in all cell lines, only very low levels 
of Ku70 were detectable in the xrs-6 cells. 
In summary, Ku80 was stable in the absence of both PARP-1 and DNA- 
PKcs, DNA-PKcs was stable in the absence of both Ku80 or PARP-1 and PARP-1 
was stable in the absence of DNA-PKcs or Ku80. Finally, Ku70 was stable in the 
absence of PARP-1 or DNA-PKcs but was not stable in absence of Ku80. 
3.3.3 Enzyme activity 
DNA-PK and PARP-1 assays were carried out to determine whether the lack 
of detectable protein in the xrs-6, V3 and PARP-1 -/- cells, as assessed by Western 
blotting, correlated with an absence of the corresponding enzyme activities and to 
ensure that DNA-PK activity was present in the V3YAC, PARP-1 +/+ and PARP-1 - 
/- and xrs-6 HamKu80 cell lines and that PARP-1 activity was present in the PARP-1 
+/+, V3, V3YAC, xrs-6 and xrs-6 HamKu8O cell lines. PARP and DNA-PK 
enzyme activity were determined using a permeabilised PARP assay (section 2.11) 
and a purified DNA-PK assay (section 2.14), respectively. 
As expected, there was DNA strand break activatable PARP activity in all 
cell lines except for the PARP-1 -/- MEFs (Figure 3.5). PARP activity ranged from 
100 pmol NAD incorporated per 106 cells for the xrs-6 cells to 150 pmol NAD per 
106 cells for the V3 cells. PARP activity was slightly but significantly different in the 
V3YAC and V3 cells (129 ±7 pmol compared to 149 ±2 pmol p=0.06). The xrs-6 
102 
cells had approximately 25 % lower PARP activity than the xrs-6 HamKu80 cells 
(102 ± 10 pmol compared to 135 ± 8.6 pmol p=0.02). It should be noted, however, 
that the PARP-1-/- cells retained a small but significant residual PARP activity (4 ± 
0.3 pmol compared to 132 ± 3.8 pmol in the PARP-1 +/+ cells) that was not 
stimulated by the oligonucleotide (figure for - oligo = 5.6 ± 2.8 ) and is therefore 
strand break independent. This minority activity is probably attributable to PARP-2 
which together with PARP-1 has also been implicated in BER (Schreiber et al., 
2002). Indeed, unlike PARP-1, PARP-2 activity is not stimulated by blunt DNA ds 
ends (de Murcia, personal communication) but is stimulated by a variety of other 
BER intermediates, including nicks, flaps and cruciforms. The oligonucleotide used 
in this thesis would therefore not be expected to activate PARP-2. Activity in the 
absence of oligonucleotide possibly represents PARP-2 stimulation by strand breaks 
in cellular DNA arising endogenously or as a result of cell manipulation. 
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Figure 3.5 Comparison of PARP activity in all cell lines 
Comparison of PARP activity in all cell lines in the absence (white bar) or presence 
of oligonucleotide (black bars) determined using the permeabilised PARP assay 
described in section 2.11. Data are the mean ± SEM of 3 independent experiments. 
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DNA-PK activity (Figure 3.6) was measured using nuclear extracts as 
described in section 2.14. No activity was measured in the absence of 
oligonculeotide (data not shown) which served as a control. DNA-PK activity 
reflected that of protein expression and ranged from 500 - 750 pmol ATP 
incorporated per µg nuclear protein. There was no significant detectable DNA-PK 
activity compared to a -oligo control in the xrs-6 (p = 0.43) or V3 (p = 0.72) cell 
lines, deficient in Ku80 and DNA-PKcs, respectively, thus indicating that both the 
DNA binding activity of the Ku70/80 heterodimer and DNA-PKcs protein are 
essential for the kinase activity of the DNA-PK complex. Furthermore, whilst DNA- 
PK activity was detectable in all other cell lines, it was higher in the V3YAC cell line 
(750 pmol ATP/µg protein) compared to the other DNA-PK proficient cell lines 
(-500 pmol ATP/µg protein). As suggested for protein expression, this could reflect 
overexpression of human DNA-PKcs by the YAC. Despite lower levels of DNA- 
PKcs protein in the PARP-1-/- cells, there was no significant difference in the DNA- 
PK activity between the PARP-1+/+ and PARP-1 -/- cell lines (p= 0.63). In 
summary, these results confirm that transfection of DNA-PKcs or Ku80 cDNA into 
the V3 and xrs-6 cell lines, respectively, restores kinase activity 
Figure 3.6 Comparison of DNA-PK activity in all cell lines 
Comparison of DNA-PK activity in all cell lines. DNA was extracted from nuclear 
extracts using hi-trap columns (section 2.14) and DNA-PK activity was quantified 
using the purified DNA-PK assay. Data are the mean ± SEM of 3 samples from a 
single experiment 
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3.3.4 Radiosensitivity of cell lines 
The impact of the loss of Ku80, DNA-PKcs or PARP-1 on the radiosensitivty 
of the cell lines was measured using a clonogenic survival assay as described in 
section 2.5. In exponentially growing cells, IR induced a dose dependent reduction in 
cell survival in all of the cell lines (Figure 3.7). The IR doses required to reduce 
survival by 50 % (LD50) and 90 % (LD90) are summarised in Table 3.3. The LD90 
values ranged between 1-6.5 Gy. The xrs-6 cells, PARP-1 -/- MEFs and V3 cells 
were significantly more sensitive to IR than the enzyme-proficient transfected cell 
lines (4.4,3.3 and 3.7-fold, respectively, p<0.05). The Ku80 deficient cells were the 
most sensitive to IR with an LD90 of 1.0 f 0.01 compared to 6.5 ± 0.3 in the parental 
CHOKI cell line. Transfection of Ku80 into the xrs-6 cells significantly increased 
the radioresistance of this cell line (p = 0.045) and they were only 1.5-fold more 
sensitive than parental CHOKI cells. Similarly, DNA-PKcs transfected V3 cells 
were significantly more radioresistant than the V3 cells alone (p = 0.034) and only 
1.3-fold more sensitive to IR than parental AA8 cells. These data are consistent with 
the hypothesis that PARP-1 and DNA-PK are required for the recovery from 
radiation induced DNA damage. 
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Figure 3.7 Cytotoxicity of IR in cell lines with different PARP-1 or DNA-PK status 
The effect of increasing doses of IR on the clonogenic survival of exponentially 
growing: -   PARP-1 +/+ cells; Q PARP-1-/- cells; V V3YAC cells; 0 V3 cells; " 
xrs-6 Ku80 cells; 0 xrs-6 cells. Cells were irradiated and reseeded for colony 
formation immediately. Data are the mean ± SEM of at least 3 independent 
experiments. 
Cell line LDsp (Gy) LD90 (Gy) Fold sensitivity 
AA8 2.9±0.10 5.6±0.07 
V3YAC 1.3±0.00 4.4±0.04 1.3 
V3 0.4 ±. 0.01 1.2±0.01 3.7 
CHOK1 2.7 ± 0.20 6.5 ± 0.3 
Xrs-6 Ku80 1.5 ± 0.00 4.4 ± 0.2 1.5 
Xrs-6 0.27±0.01 1.0±0.01 4.4 
PARP-1+/+ 2.4±0.22 5.5±0.2 
PARP-1 -/- 0.9 ± 0.01 1.7 ± 0.00 3.3 
Table 3.3 The effect of increasing doses of IR on clonogenic cell survival 
Comparison of the LD50 and LD90 values resulting from the exposure of 
exponentially growing cells to increasing doses of IR. The values represent the mean 
± SEM of at least 3 independent experiments. Fold sensitivity was calculated as a 
ratio of, LD90 of parental cell line/ LD90 of transfected cell line or LD90 of 
transfected cell line/ LD90 of enzyme deficient cell line 
3.3.5 Effect of AG14361 and NU7026 on PARP-1 and DNA-PK enzyme activity 
AG14361 and NU7026 were used at 0.4 . tM and 10 pM in all experiments 
described in this thesis. For AG14361, this represents a standard dose for which 
Agouron Pharmaceuticals screened all potential inhibitors and was selected because 
it caused >_ 80 % depletion of cellular PARP activity, and was sufficient to cause 
maximum potentiation of temozolomide (a clinically used monofunctional DNA 
methylating agent) whilst being less than 1/10 of the concentration of AG14361 
which caused detectable growth inhibition (Calabrese et al., in press). For NU7026, 
the choice of dose was based upon clonogenic assays which determined the 
minimum dose required to produce maximal potentiation in whole cells following 4 
Gy IR. These experiments are described in section 4.3.1.1. In order to ensure that 
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Figure 3.8 The effect of AG14361 and NU7026 on purified PARP-1 and DNA- 
PK activity 
The effect of AG14361 on purified PARP-1 (A) and DNA-PK (B) activity and the 
effect of NU7026 on purified DNA-PK (C) and PARP-1 activity (D). Data are the 
mean ± SEM of at least 3 independent experiments. 
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PARP-1 and DNA-PK activity were sufficiently depleted by the concentrations of 
inhibitors used in the experiments described in this thesis, PARP-1 and DNA-PK 
activity were measured in the presence and absence of the inhibitor(s). 
Briefly, the concentration(s) of AG14361 and NU7026 required to inhibit 
PARP-1 and DNA-PK activity, respectively, by 50 % (IC50) were determined by 
using purified enzyme assays. In addition, the effect of AG14361 on DNA-PK 
activity and the effect of NU7026 on PARP-1 activity were tested. Figures 3.8 C and 
D show that NU7026 inhibited purified DNA-PK activity with an IC50 of 0.44 ± 0.01 
pM whilst NU7026 had no inhibitory effect on purified PARP-1 activity up to 10 
µM. Similarly, Figure 3.8 A shows that AG14361 inhibited purified PARP-1 activity 
with an IC50 of 20.3 ±2 nM. AG14361 had no inhibitory effect on purified DNA-PK 
activity up to 100 nM (Figure 3.8B). 
Permeabilised PARP assays were carried out to assess the effects of 
AG14361 in whole cells as described in section 2.11. The IC50 values were; 68.4 ±4 
nM, 56.3 ±4 nM, 59.6 ±3 nM and 15 ±2 AM for the MAC, V3, PARP-1 +/+ and 
PARP-1 -/- cells, respectively (Data not shown). Permeabilised cells are not in the 
physiological state, however, and therefore it could be argued that that this assay 
does not demonstrate the entry and activity of the inhibitor in intact cells. Studies 
were therefore carried out in V3YAC cells treated with AG14361 before washing 
with PBS to remove residual inhibitor and subsequently permeabilising the cells. The 
assay was then performed in the absence of added inhibitor. As can be seen in Figure 
3.9, there was no significant difference in the potency of AG14361 against PARP 
whether the inhibitor was present prior to or following permeabilisation (Compare 
IC5o pre-permeabilisation of 71.6 ± 2.3 nM to the IC50 post permeabilisation of 68.4 
± 3.5 nM) p=0.1. 
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Figure 3.9 Effect of AG14361 on PARP activity in permeabilised V3YAC 
cells 
Dose response to AG14361 in permeabilised V3YAC cells treated with inhibitor; 
  before permeabilisation ; 0, after permeabilisation. Permeabilised cell assay 
was carried out as described in section 2.11. Data are the mean ± SEM of at least 
3 independent experiments. 
3.3.6 Stability of NU7026 under assay conditions 
Studies assessing the stability of AG14361 under various assay conditions, 
including light and medium, have been carried out by Agouron Pharmaceuticals and 
within the department. Importantly, the compound was shown to be stable under 
these conditions (personal communication; Calabrese et al., in press). However, at 
the initiation of these studies, details concerning the stability of NU7026 were 
unknown. The stability of NU7026 under the assay conditions of medium, light and 
freeze thawing was therefore evaluated by developing a reverse phase HPLC method 
(see section 2.4 ). For medium and light stability studies, triplicate samples were set 
up in DMEM medium or PBS, respectively, at 1,10 and 50 µM and aliquots were 
taken every 2h up to 24 h. Freeze thaw samples were set up in 100 % DMSO (n=1) 
at 1,10 and 50 µM and stability tested up to 3 freeze thaws. At time zero, the area 
under the peak is directly proportional to the concentration of NU7026 (Figure 3.10). 
For example, in the freeze thaw study, the area under the peak for 50 gM is 5 times 
larger than the corresponding area for 10 µM (1715048 compared to 376565.7) and 
this is true for all parameters tested. 
There were no significant differences in the area under the peaks whether the 
samples had been exposed to light or maintained in the dark for 24 h (For example, 
Figure 3.10B; 223300 for 10 µM compared to 239598 for 10µM, p=0.09) and this 
was true for all concentrations of NU7026. Similarly, there was no significant 
difference in peak area, at all doses of NU7026, between samples that were 
maintained in medium for 24 h and those that were analysed immediately (For 
example, Figure 3.1OA; 279721 for 10 µM compared to 289314 for 10 µM, p= 0.08). 
Finally, there was no significant change in peak area for all doses of NU7026 
following 3 freeze thaws p= > 0.05 (Figure 3.1 OC). 
In summary, these data indicate that no degradation of compound occurred 
under any of the assay conditions tested and therefore demonstrates that NU7026 is 
stable, by HPLC, in DMEM medium at room temperature for 24 h, is unaffected by 
exposure to light for 24 h and is not influenced by freeze thawing up to 3 times. 
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Figure 3.10 Stability of NU7026 under assay conditions of medium, light and 
freeze-thaw 
A, Medium stability, 0h (white bars), 24 h (black bars); B, Light stability, 0h 
(chequered bars), 24 h light (white bars), 24 h dark (black bars); C, Freeze thaw, 0 
(white bars), 3 (black bars) 
3.3.7 The effect of the inhibitors on growth and survival 
Although it has been demonstrated that mice deficient in PARP-1 or DNA- 
PK are viable, the possibility that the use of a chemical inhibitor of either of the 
enzymes could result in non-specific effects on the growth or viability of the cells 
remained. The effects of the inhibitors on growth was assessed by SRB assay (see 
section 2.3.2) in all cell lines. Briefly, exponentially growing cells were continuously 
exposed to increasing concentrations of AG14361 (0.1,1,10 and 100 µM) or 
NU7026 (1,2,5,10 and 50 µM) for ?3 cell doublings (CHO cells lines, 48 h, PARP 
MEFs, 72 h). Using the percentage of control cell growth, the concentrations of 
AG14361 and NU7026 required to inhibit cell growth by 50 % (G150) was calculated 
for all cell lines and the results are summarised in Table 3.4. Owing to its limited 
solubility, the highest achievable concentration of NU7026 at 1% (v/v) DMSO in 
aqueous medium was 50 µM. Both inhibitors inhibited the growth of all cell lines in 
a concentration-dependent manner. In response to NU7026, there was no evident 
growth inhibition up to 10 µM whilst a modest but significant growth inhibition of 
approximately 20 % was seen at 20 µM in all cell lines. Similarly, exposure to 
AG14361 did not cause any growth inhibition up to 1 µM whilst a modest growth 
inhibition (approximately 10 %) was seen at 10 µM in all cell lines. Representative 
graphs for the growth inhibitory effects of NU7026 and AG14361 are shown in 
Figure 3.11 a and b, respectively. Figure 3.11 a shows that there was no significant 
difference in the sensitivity of matched cells proficient or deficient in DNA-PK to 
NU7026 (p= 0.8). Similarly, Figure 3.1 lb shows that there was no significant 
difference in the sensitivity of matched cells proficient or deficient in PARP-1 to 
AG14361 (p = 0.65). 
In summary, there were no noteworthy differences in G150 values for 
AG14361 (ranging from 30 - 34 µM). Similarly, no marked differences in G150 
values were seen for NU7026 with values ranging from 30 to >50 µM, 50 µM being 
the limit of solubility for NU7026 (Table 3.4). 
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Figure 3.11 Growth inhibition by NU7026 and AG14361 
A, Growth of V3YAC cells (U) and V3 cells (0) following a 48 h continuous 
exposure to increasing concentrations of NU7026. B, Growth of PARP-1 +/+ cells 
(U) and PARP-1 -/- cells (Q) following a 72 h continuous exposure to increasing 
concentrations of AG14361. Data are normalised to DMSO alone controls and are 
the mean ± SEM from at least 3 independent experiments. 
Cell line AG14361 
G150 (µM) 
NU7026 
Glso (µM) 
AA8 30.5 f 3.9 >50 
V3YAC 32.0 ± 4.9 >50 
V3 31.6 ± 2.4 >50 
CHOK1 33.5 ± 1.8 35.1 ± 5.8 
Xrs-6 Ku80 31.5 t 2.9 30.0 t 3.7 
Xrs-6 32.5 t 2.2 31.2 ± 5.4 
PARP-1 +/+ 33.4 ± 1.8 >50 
PARP-1 -/- 34.1 ± 1.5 >50 
Table 3.4 The effect of AG14361 and NU7026 alone on cell growth 
Comparison of the GI50 values of AG14361 and NU7026 following continuous 
exposure for at least 3 cell doublings to increasing concentrations of either AG14361 
or NU7026. The level of growth inhibition was assessed as compared to 1% DMSO 
alone controls by SRB assay. Data are the mean ± SEM from at least 3 independent 
experiments. 
The plating efficiencies, which reflect the ability of the cells to form colonies, 
in the presence of AG14361 or NU7026, alone, at the concentrations used in all 
experiments (0.4 and 10 p. M, respectively) were measured in order to evaluate their 
relative cytotoxicity. The exposure time for clonogenic assays was 16 hrs 
(approximately one cell cycle) as opposed to the 48/72 h incubation time used for the 
evaluation of growth inhibition. Since both inhibitors were dissolved in DMSO prior 
to adding to medium, the plating efficiencies in the presence of 1% (v/v) DMSO 
were also measured. On comparing the plating efficiencies (Table 3.5), there is no 
significant difference between colony formation in the presence or absence of 
AG14361 or NU7026 compared to 1% (v/v) DMSO controls (p > 0.05). 
110 
Furthermore, the plating efficiencies in the presence of 1% (v/v) DMSO were not 
significantly different from the DMSO-free controls (p= > 0.05). 
All drug exposures shown in the results Chapters were therefore conducted at 
a final concentration of 1% (v/v) DMSO and growth inhibition or cytotoxicity data 
were normalised to 1% (v/v) DMSO alone or drug alone controls. 
Cell line Control PE PE +1% 
(v/v) DMSO 
PE + 0.4 µM 
AG14361 
PE + 10 µM 
NU7026 
V3YAC 73.7±1.5 73.0±1.1 72.4±2.1 74.3 ± 0.9 
V3 74.6 1.2 74.1±1.5 73.2 ± 2.2 73.1 ± 0.1 
Xrs-6 Ku80 87.0 ± 1.5 86.9 ± 1.4 87.2 ± 1.5 86.3 ± 4.8 
Xrs-6 82.9±1.4 83.1±1.4 81.0±3.6 84.1±1.8 
PARP-1 +/+ 68.0± 1.5 67.0±2.4 66.0±3.2 68.0± 1.2 
PARP-1 -/- 64.0 ± 1.2 63.0 ± 2.4 63.0 ± 1.1 64.0 ±. 0.8 
Table 3.5 Plating efficiencies (PE) of cell lines in the presence or absence of 1% 
(v/v) DMSO, 0.4 µM AG14361 or 10 p. M NU7026 
Cells were continuously exposed for 16 h to either 1% (v/v) DMSO, 0.4 µM 
AG14361 or 10 µM NU7026 and cell survival determined by colony formation 
(section 2.5). Data are the mean ± SEM of at least 5 independently dosed samples 
from at least 3 independent experiments. 
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3.3.8 The effect of the inhibitors on cell cycle phase distribution 
P13-kinase is required for many cellular processes that include growth factor 
signalling (Cospedal et al 1999; Puglianello et al 2000) and inhibition of P13- kinase 
has been shown to result in G1/S block of the cell cycle (Chang et al., 2003). 
Accordingly, inhibitors of P13-kinase induce cell cycle arrest. Although NU7026 is 
more selective for DNA-PK than PI3-kinase, in vitro, (Table 3.1), at higher 
concentrations it is able to inhibit P13- Kinase. The 10 gM dose used in whole cell 
studies could therefore potentially affect P13- Kinase activity which would be 
manifested as a cell cycle blockade. Similarly, it is possible that AG14361 could 
exhibit non-specific effects that could result in cell cycle effects. 
Flow cytometric analysis (FACS) was used to investigate whether NU7026 or 
AG14361 (at the concentrations used in all experiments) were associated with an 
arrest of cell division in a specific phase of the cell cycle. Initially, exponentially 
growing cells were seeded onto 92 mm dishes and allowed to adhere for 24 h before 
addition of inhibitor(s). The cell cycle distribution was then followed for 96 h, with 
samples taken for FACS analysis at 24 h intervals (section 2.7). The mean cell cycle 
phase distribution was calculated for all samples and a representative cell cycle 
profile is shown in Figure 3.12. The mean cell cycle phase distributions of the 
inhibitor treated cells were compared to that of untreated control cells. Figure 3.13 
shows that, in the absence of DNA damage, there was no significant difference in 
cell cycle distribution between any of the cell lines. Moreover, 0.4 µM AG14361 or 
10 µM NU7026, alone or in combination, produced no significant changes in the cell 
cycle phase distribution in any of the cell lines tested (p = >0.05). 
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Figure 3.12 Representative cell cycle profile 
of exponentially growing cells 
Cells were seeded and flow cytometric analysis 
carried out as described in section 2.7. 
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Figure 3.13. The effects of AG14361 and NU7026 on cell cycle phase distribution 
A, V3YAC cells; B, V3 cells; C, PARP-1+/+ cells; D, PARP-1-/- cells; E, xrs-6 
Ku80 cells; F, xrs-6 cells. Bars represent: - Black bars, Cells alone ; White bars, + 0.4 
pM AG14361 ; Checkered bars, + 10 pM NU7026; Dotted bars, 
+AG14361+NU7026. Each bar represents the mean ± SEM of samples taken at 24, 
48 and 96 h, and analysed by flow cytometry, as described in section 2.7. 
3.4 Discussion 
The major aim of this Chapter was to confirm the protein and enzyme activity 
status of all the cell lines. A lack of Ku80, DNA-PKcs and PARP-1 protein 
expression in the xrs-6, V3 and PARP-1-/- cells, respectively, was confirmed and a 
corresponding lack of DNA-PK or PARP-1 activity demonstrated. PARP-1 and 
DNA-PK activity were present in all other cell lines. The results demonstrate clearly 
that all the cell lines are of the correct phenotype. 
The Ku complex was stable in the absence of either PARP-1 or DNA-PKcs. 
This is in line with previous observations which have shown that both Ku protein and 
DNA end binding activity are found in DNA-PKcs defective mutants (Danska et al., 
1996; Rathmell and Chu, 1994). In the absence of Ku80, lower levels of Ku70 
protein were observed. It has been suggested that the two Ku components stabilise 
one another, and therefore in agreement with data from others, these data suggest that 
inactivation of Ku80leads to dramatic destabilisation of both itself and Ku70 
(Errami et al., 1996; Blunt et al., 1996; Danska et al., 1996). In support of this 
suggestion, it has been demonstrated that co-translation of both subunits is required 
for heterodimerisation of active Ku and therefore individual Ku subunits may be 
degraded when not dimerised. Although there was no detectable Ku80 protein in the 
xrs-6 cells, evidence in the literature suggests that these cells harbour an intact but 
nonexpressed Ku80 allele which can be reactivated by treatment with azacytidine 
(Singleton et al., 1997). This indicates that the gene has been silenced by 
hypermethylation at promoter regions. Moreover, these cells may revert 
spontaneously in cell culture and therefore in line with this notion, all cells were used 
at passage 15 or lower in all experiments and periodic Western blot analyses were 
carried out to re-confirm the phenotype of the cells. 
The V3YAC cells expressed levels of DNA-PKcs protein which were greater 
than that observed in parental hamster cells. This could reflect overexpression of 
DNA-PKcs by the YAC. Alternatively, rodent cells have as much as 5-fold less 
DNA-PKcs than human cells and therefore the higher levels of DNA-PKcs in the 
V3YAC cells could be a reflection of this. In contrast, however, the levels of Ku 
protein in hamster and human cells are comparable (Chan et al., 1996; Yumoto et al., 
1998). The levels of kinase activity approximately reflected that of protein 
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expression whereby the V3YAC cells had higher levels of DNA-PK activity than the 
other DNA-PK proficient cell lines. 
The PARP-1 +/+ cells expressed considerably higher Ku80 and DNA-PKcs 
protein levels than the PARP-1 -/- cells. A number of publications have demonstrated 
interactions between DNA-PK and PARP-1 or Ku and PARP-1 (Galande and 
Kowhi-Shigomatsu, 1999; Ruscetti et al., 1998) and therefore the presence of one 
protein may enhance the stability of the other protein in a similar manner to Ku70 
and Ku80, described above. This observation was not investigated further, however, 
it would be interesting to investigate the effect AG14361 on Ku80 or DNA-PKcs 
protein levels following exposure to IR in PARP-1 +/+ cells. Despite similar levels 
of PARP-1 protein, the level of PARP-1 activity was approximately 25 % lower in 
the xrs-6 cell line compared to the xrs-6 Ku80 cell line. This implies a functional 
association of these two proteins in response to DNA damage. In contrast, despite 
having lower levels of DNA-PKcs protein, PARP-1 -/- cells had the same amount of 
DNA-PK activity compared to the PARP-1 +/+ cells. Similarly, the V3 cells have 
the same amount of PARP-1 activity as the V3YAC cells thus indicating that the 
activity of one enzyme does not require the presence of the other for stimulation. It 
should also be noted that there was no loading control for the DNA-PKcs Western 
blot and therefore the different protein levels could simply reflect differences in 
loading accuracy. 
The enzyme assays also demonstrated that the PARP-1 -/- cells possess 
approximately 3.9 ± 0.5 % PARP activity compared to their wild type counterparts 
which is not oligonucleotide inducible and which cannot be attributed to PARP-1. 
This activity may be attributed to the activity of alternative PARP proteins that have 
recently been described. Indeed, there are now thought to be at least 18 members of 
the PARP family and these include PARP-2, V-PARP and tankyrase although 
PARP-2 is the only homologue which has been so far reported to be activated by 
DNA damage (section 1.9). 
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The presence of an alternative PARP activity in PARP-1 -/- MEFs (developed 
by Wang et al., 1995, and disrupted in exon 2) has been previously described by 
Shieh et al., 1998, who showed that following treatment with MNNG, these cells 
were able to synthesise polymer that was indistinguishable in structure from that 
produced in the PARP-1 +/+ cells. In addition, a reduction in intracellular NAD+ 
concentration occurred with the formation of polymer thus supporting the suggestion 
that the polymer formation in these cells was due to PARP protein. As with PARP-1, 
this residual activity was induced by DNA damage, however, this is in contrast to the 
studies described in this Chapter which have shown that the residual PARP activity 
in the PARP-1 +/+ cells was not stimulated by oligonucleotide (Figure 3.5). The 
difference in these results could be due to the fact that the authors utilised a different 
technique for stimulating PARP activity, preferring to damage endogenous DNA 
using MNNG rather than introducing an exogenous oligonucleotide as was used in 
the studies described here. Furthermore, the authors did not permeabilise the cells as 
a means to measure PARP activity but measured the accumulation of PAR instead. 
Studies carried out by Ame et al., 1999, in the de Murcia cells, disrupted in 
exon 4, have attributed this activity to PARP-2 which is both DNA-damage and 
strand break inducible despite the absence of a zinc finger. As described in section 
3.3.3, PARP-2 would not be activated by the blunt ds oligonucleotide used in the 
studies described in this thesis although endogenous strand breaks or those arising as 
a result of the permeabilisation process could activate it. Therefore PARP-2 could be 
the alternative PARP activity in these cells. 
A more recent study by Sallmann et al., 2000, using the Wang cells, have 
described an alternative PARP activity that is independent of strand breaks but can 
be induced by DNA damage. The cloned cDNA of the PARP protein was identical 
to the catalytic domain of PARP-1 but the DNA binding domain was absent. The 
authors proposed that the protein was an alternative product of the PARP gene 
produced by transcription of the PARP gene from an alternative transcription start 
site downstream of the disrupted area of exon 2 in these particular PARP-1 -/- MEFs. 
The group named this PARP, sPARP-1. Significantly, the disrupted area of the 
PARP-1 gene is also upstream of this putative alternative transcription site in the 
exon 4 PARP-1 -/- MEFs used in the studies described in this thesis and therefore 
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sPARP-1 could possibly be produced in these cells. Moreover, the characteristics of 
sPARP-1 are more consistent with the data presented in this Chapter and could 
therefore be responsible for the residual activity detected in the PARP-1 -/- cells. 
The residual activity in the PARP-1 -/- knockout cells is inhibited by 0.4 µM 
AG14361 (Figure 6.4). In terms of interpretation of results, therefore, the effects of 
AG14361 cannot be attributed solely to the inhibition of PARP-1. However, 
correlations with results from the PARP-1 -/- knockout cells will enable conclusions 
to be drawn about the function of PARP-1 bearing in mind this constraint. 
Studies into the roles and functions of PARP-1 and DNA-PK in DNA repair 
have demonstrated that a relationship exists between enzyme status and IR sensitivity 
as described in sections 1.8.4 and 1.12.2. The effect of increasing doses of IR on cell 
survival was evaluated in all cell lines using a clonogenic assay as described in 
section 2.5. In agreement with published data, cell lines deficient in DNA-PKcs, 
Ku80 or PARP-1 were approximately 4-fold more sensitive to IR than their 
proficient counterparts (Table 3.3) demonstrating that mutation in either PARP-1 or 
DNA-PK confers sensitivity to IR. Transfection with a YAC encoding human DNA- 
PKcs restored the radioresistance of V3 mutant cells. Similarly, in line with previous 
studies which have shown that hamster Ku80 cDNA can significantly restore the 
radioresistance in the xrs-6 mutants (Singleton et al., 1997), the xrs-6 Ham KuSO 
cells were only 1.5-fold more sensitive than the parental CHOK1 cell line. 
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PARP-1 and DNA-PK inhibitors have helped to elucidate the function and 
physiological effects of the two enzymes (sections 1.7.1 and 1.11). A number of 
hypotheses regarding the relative functions of PARP-1 and DNA-PK in DNA repair 
now exist and these are discussed in detail in sections 1.64 and 1.10.4. More 
recently, there has been interest in the clinical potential of inhibitors of PARP-1 and 
DNA-PK as potential radio- or chemo-sensitisers (Griffin et al., 1995; Boulton et al., 
1999). The potential of AG14361 and NU7026 to act as radiosensitisers has been 
investigated in detail in Chapter 4. Since completion of these studies, more potent 
inhibitors of PARP-1 and DNA-PK have been developed. However, potency is not 
necessarily the single most important factor in the selection of a radiosensitiser for 
clinical trials. Other criteria of importance are: 
" Lack of inherent cytotoxic or cytotastic properties in vitro 
" Ability to selectively potentiate cytotoxic drug action in vivo 
" Solubility, stability and ease of formulation 
" Extent of metabolism and activity of metabolites 
" Pharmokinetic considerations such as half life in the plasma and biodistribution 
A major criterion for a compound to act as a radiosensitiser requires that inherent 
cellular cytotoxicity and growth inhibtory effects are low. Before attempting to 
modulate the cytotoxicity of JR by the use of the PARP-1 inhibitor, AG14361, or the 
DNA-PK inhibitor, NU7026, (alone and in combination), the direct cellular effects of 
these inhibitors were investigated by means of growth inhibition studies carried out 
in all cell lines using the SRB assay (section 2.3.2). and cytotoxicity studies using 
colony forming assays (section 2.5. ). 
Each of the inhibitors reduced cell growth in a concentration dependent 
manner. Critically, both AG14361 and NU7026 were found to be non-growth 
inhibitory or cytotoxic per se at the concentrations (0.4 gM and 10 µM, respectively) 
and duration of experiments carried out in this thesis. Significantly, 0.4 µM 
AG14361 is as much as 75-fold lower than the mean cell GI50 and at this dose, the 
mean cell growth as a percentage of control is 100 %. Similarly, 10 µM NU7026 is 
3.5-fold lower than the mean cell G150 and at this dose, the mean cell growth rate as 
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% of control is >95 %. Higher concentrations of the inhibitors, however, did 
significantly reduce cell growth in all the cell lines tested. 
Since DNA is continually undergoing repair of endogenous damage, it could 
be speculated that the cellular effects of either AG14361 or NU7026, alone, are a 
result of the inhibition of repair of intrinsic levels of DNA damage. However, 
AG14361 was equally growth inhibitory in both PARP-1 +/+ and PARP-1 -/- and 
similarly, NU7026 was equally growth inhibitory in DNA-PK proficient and 
deficient cell lines and therefore the cytostasis associated with the inhibitors cannot 
be attributed to inhibition of target enzymes. 
Previous data in the literature also found no evidence to imply that inhibition 
of endogenous PARP-1 activity is responsible for the cytostatic effects of PARP-1 
inhibitors at higher concentrations. Hunting et al., 1985, carried out growth 
inhibition analysis on a number of PARP-1 inhibitors and showed that there was no 
correlation between the extent of growth delay and the potencies of the compounds 
as inhibitors of PARP-1. It cannot be ruled out, however, that the growth inhibitory 
effects of AG14361 could be attributable to the inhibition of other PARP family 
members that might be critical for growth or survival. 
It is also possible that AG14361 is acting on other crucial NAD+ utilising 
enzymes in the cell such as the mono(ADP-ribosyl) transferases and ADP-ribosyl 
cyclase. As these enzymes also bind NAD+ and mediate the catalytic cleavage to 
ADP-ribose and nicotinamide, it is likely that some features of the NAD+ binding 
site (and hence inhibitor binding site) will be held in common. Rankin et al., 1989, 
showed that PARP-1 inhibitors at micromolar concentrations were specific for 
PARP-1 but that at millimolar concentrations, mono(ADP-ribosyl) transferases were 
also inhibited. A later study by Banasik et al., 1992, comparing the ability of a wide 
range of compounds to inhibit PARP-1 and mono(ADP-ribosyl) transferase, also 
showed that at micromolar concentrations PARP-1 was inhibited whilst at millimolar 
concentrations, mono(ADP-ribosyl) transferase was also inhibited. Mono(ADP- 
ribosyl) transferase can ADP-ribosylate the GTP-binding regulatory G1 protein 
(Tanuma et al., 1988). G proteins play a major role in cell signalling and similarly, 
cyclic ADP-ribose, formed by the action of ADP-ribosyl cyclase, also plays an 
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important role in cell signalling (Lee et al., 1999). Thus, inhibition of mono(ADP- 
ribosyl) transferase or ADP-ribosyl cyclase could disrupt cellular signal transduction 
pathways, potentially resulting in growth inhibition and cell death. 
Similarly, the observation that NU7026 caused growth delay at high 
concentrations in all cell lines, including the DNA-PKcs deficient V3 cells and Ku80 
deficient xrs-6 cells, implies that although NU7026 has direct growth inhibitory 
activity, it is not a DNA-PK related cytostasis. It is more likely that NU7026 has 
some non-specific effects through inhibition of other pathways that are required for 
cell growth. For example, P13- kinase is required for signalling through several 
growth factor receptor pathways and inhibition of this enzyme results in a GUS cell 
cycle block (Chang et al., 2003). As discussed in section 1.13, DNA-PK shares 
homology with P13- kinase and NU7026 is known to inhibit this enzyme at higher 
concentrations (Table 3.1). The growth inhibitory effects of both AG14361 and 
NU7026 did not result in cytotoxicty, however, as even a 16 h exposure to each of 
the drugs did not cause a significant reduction in clonogenic survival (Table 3.5). 
In purified enzyme assays, 10 µM NU7026 completely inhibited DNA-PK 
activity whilst having no effect on PARP-1 activity and, similarly, 0.4 gM AG14361 
completely inhibited PARP-1 activity whilst having no effect on DNA-PK activity. 
No assay for the detection of polymer in intact cells was available for the 
measurement of PARP-1 activity. As an alternative, however, a pemeabilisd cell 
assay was used to measure the inhibitory effect of AG14361 on PARP-1 activity as 
this is considered to reflect the intact cell situation better than cell-free assays with 
recombinant or purified protein. AG14361 was more potent in a purified PARP-1 
assay compared to the permeabilised cell assay (lower IC50 value), however, 0.4 µM 
fully inhibited PARP activity in the permeabilised cell assay. 
Permeabilsed cells are not in the physiological state, however, and it is 
therefore possible to argue that this assay does not demonstrate the entry and activity 
of inhibitor(s) in intact cells. Studies were therefore carried out where cells were 
treated with inhibitor before washing with PBS to remove residual inhibitor and 
subsequently performing the assay in the absence of added inhibitor. Any PARP-1 
inhibition can only result from inhibitor that has transported into cells. The potency 
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of AG14361 was similar in the two assays with IC50 of 71.6 ± 2.3 and 68.4 ± 3.5, 
respectively. These data suggest that AG14361 easily traverses the cell membrane 
(as predicted on the basis of size and charge). In addition, this is probably a 
reflection of the inhibitor being bound very tightly to PARP-1 prior to the process of 
permeabilisation. Similar experiments were not carried out with NU7026 since no 
adequate whole cell or permeabilised DNA-PK assay was available, however, 10 µM 
is at least 20-fold the purified IC50 and should therefore sufficiently deplete cells of 
DNA-PK activity. This has been confirmed by studies in the following Chapter 
which have used maximal potentiation of a fixed dose of IR as an endpoint. In these 
experiments 10 gM NU7026 was sufficient to maximally potentiate IR cytotoxicity. 
In summary, the studies described in this Chapter confirm that the 
concentrations of inhibitor(s) used in the studies described in this thesis are sufficient 
to inhibit the cellular enzymes completely. Furthermore, they are both non-growth 
inhibitory or cytotoxic at these doses. Moreover, the inhibitors were not associated 
with the arrest of cell division in a specific phase of the cell cycle. This confirms that 
NU7026 does not target P13-K at the dose used since a GI/S block would have been 
observed. Furthermore, these data suggest that in the absence of DNA damage, 
neither PARP-1 or DNA-PK are required for cell cycle regulation. 
3.5 Summary 
The studies described in this Chapter have shown that; - 
" Cell lines deficient in either PARP-1 or DNA-PK are approximately 4-fold more 
sensitive to IR than parental cell lines 
" The Ku complex is stable in the absence of functional PARP-1 or DNA-PKcs 
protein, however Ku70 is unstable in the absence of Ku80 protein. 
" There is no detectable DNA-PK activity in the absence of Ku80 or DNA-PKcs 
" Concentrations of NU7026 and AG14361 that cause profound inhibition of 
DNA-PK and PARP-1, respectively, are not cytotoxic or growth inhibitory and 
do not affect cell cycle phase distribution per se. 
120 
" AG14361 does not inhibit DNA-PK activity and NU7026 does not inhibit PARP- 
1 activity. 
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CHAPTER 4 
RADIO- AND CHEMO-SENSITISATION BY INHIBITORS OF 
PARP-1 AND DNA-PK IN CELL LINES PROFICIENT OR 
DEFICIENT IN PARP-1 OR DNA-PK 
4.1 Introduction 
DNA is the molecular target for many cancer therapies. Indeed, anticancer 
agents that target DNA are some of the most effective agents in clinical use. DNA is 
an important subcellular target of ionising radiation (IR). IR induces a wide array of 
different DNA lesions which result in the production of single and double stranded 
DNA breaks either directly or indirectly through the generation of reactive free 
radicals or as a consequence of DNA repair pathways (reviewed in section 1.3.4.1). 
The integrity of cellular DNA is of paramount importance for survival and cells have 
evolved efficient mechanisms for both DNA damage recognition and repair in order 
to ultimately maintain genomic integrity (see section 1.5). In response to IR, cells 
initiate a complex response that includes the arrest of cell cycle progression and the 
activation of DNA repair pathways. 
Although a detailed review of cell cycle function and control is beyond the 
scope of this thesis, the function of the DNA damage checkpoints is of importance 
when considering carcinogenesis, cancer therapy and DNA repair. If DNA damage 
checkpoints fail, the cell will experience the consequences of replicating a damaged 
template, whether that is mutation fixation resulting from replication of modified 
bases, loss/rearrangement of genetic material due to replication of a broken template 
or failure to engage apoptosis in the presence of high levels of DNA damage. DNA 
damage checkpoints are at four stages of the cell cycle; one at the GUS transition, 
one during progression through S phase, one at the G2/M boundary and the mitotic 
spindle assembly checkpoint (Figure 4.1). Cell cycle arrest is therefore critically 
important to allow for cellular repair of IR induced damage before replication. 
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Figure 4.1 Schematic representation of the cell cycle 
Diagram illustrating the different phases of the cell cycle and their relative duration. 
Cell cycle checkpoints are represented by an asterix. 
Radiotherapy is the treatment of choice for many solid tumours and remains 
one of the most effective tools in the treatment of cancer. However, there are 
considerable differences in the outcome for treatment of tumours of differing type 
and tumour radioresistance is the main obstacle to clinical success. Consequently, 
intrinsic radiosensitivity of a tumour is an important determinant of its response to 
radiotherapy. Mutant cell lines that are sensitive to IR have contributed 
considerably to our understanding of intrinsic radiation sensitivity and have 
pinpointed a major role for DNA repair in this process (sections 1.8.4 and 1.12.2). 
Indeed, the capacity for repair has been shown to correlate with tumour responses to 
radiotherapy (Fox and Roberts, 1987, Barret and Hill, 1998). Resistance of cancer 
cells to radiotherapy is therefore thought to be largely a consequence of their ability 
to repair radiation- induced DNA damage. DNA repair mechanisms should therefore 
provide useful pharmacological targets as a means of sensitising tumour cells to IR. 
PARP-1 and DNA-PK are two enzymes that are activated by DNA strand 
breaks and considered to be key players in DNA damage recognition and signalling 
(Watters et al., 1999). As confirmed in Chapter 3 (Figure 3.7), mutant or knockout 
cell lines deficient in either of these enzymes are highly radiosensitive. Although 
their relative roles in DNA repair are not clearly defined, inhibition of these enzymes 
has serious effects on the survival of cells following exposure to various DNA 
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damaging agents. PARP-1 and DNA-PK therefore represent attractive targets for the 
development of potent and specific inhibitors as chemo and radio-sensitisers for 
cancer therapy. 
4.1.1 Inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein 
kinase as radiosensitisers and chemopotentiators. 
The purpose of the following two sections is to review the literature tracing 
the use of inhibitors of PARP-1 and DNA-PK as radio-and chemo-sensitisers. The 
development of these inhibitors is described in sections 1.7 and 1.11. 
4.1.1.1 Inhibitors of PARP-1 
Nicotinamide was the first compound to be identified as a PARP-1 inhibitor 
(Fujimura et al., 1967 ; Clark et al., 1971). The use of a PARP-1 inhibitor as a means 
to potentiate DNA damage was originally suggested by Durkacz et al., in 1980. In a 
classic study, it was demonstrated that 4 classes of PARP-1 inhibitor (nicotinamides , 
benzamides, methylanthines and the pyrimidine derivative, thymidine) and 
deprivation of NAD+ can inhibit DNA strand break rejoining and potentiate 
cytotoxicity in L1210 cells following treatment with the monofunctional alkylating 
agent dimethyl sulphate (DMS). Indeed, 3-aminobenzamide (3AB) inhibited repair 
and enhanced cytotoxcity of DMS 4-fold whereas its non PARP-1 inhibitory 
analogue 3 aminobenzoic acid did not. Radiopotentiation by nicotinamide was first 
described in 1970 (Calcutt, 1970). Subsequently, Berger et al, 1982, showed that 
L1210 leukaemia bearing mice co-treated with nicotinamide or 6-aminonicotinamide 
and 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) had a higher survival than those 
treated with BCNU alone. The validity of these results, however, were questionable 
since nicotinamide is a substrate for other enzymes. 
Benzamide, an analogue of nicotinamide, has been found to enhance the cell 
killing of the radiomimetic drug, bleomycin in HeLa cells and mice bearing Ehrlich 
ascites tumours (Sakamoto, 1983). Furthermore, in vivo potentiation of the alkylating 
agent dacarbazine (DTIC) and bleomycin in Ehrlich ascites tumours with 3-AB has 
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been demonstrated (Kato et al., 1988). 3-methoxybenzamide was shown to 
potentiate the effects of bleomycin (Huet and Laval, 1985a) and the alkylating agent 
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) (Jacobson, 1984). Although crucial 
to early studies probing the function of PARP-1, benzamide and its derivatives have 
a number of drawbacks including a lack of potency and these have been described in 
more detail in section 1.7.3AB potentiates IR but not UV, consistent with a role for 
PARP-1 in BER and not NER. However, potentiation has also been reported with 
this group of inhibitors for agents that are not repaired via the BER pathway. The 
cross linking agent, cisplatin, for example (Chen and Pan 1988). 
Since 1980, many studies have shown that a variety of PARP-1 inhibitors can 
potentiate the cytotoxicity of a wide range of DNA damaging agents (Molinete et al., 
1993; Ding and Smulson, 1994; Curtin et al., 2000). Consequently, the clinical 
potential of this class of agents has led to the development of diverse classes of 
potent PARP-1 inhibitors (Tentori et al., 2002; Griffin et al., 1995; Skalitzky et al., 
2003). 
The 5' substituted dihydroquinolinones of which 3,4-dihydro-5- 
methoxyisoquinalin-1(2H)-one (PD128763) is the lead compound were developed by 
Suto et al., 1991. This compound was demonstrated to potentiate cytotoxicity and 
inhibit the repair of DNA damage caused by IR (Arundel-Suto et al., 1991) and 
monofunctional alkylating agents (Sebolt-Leopold and Scavone, 1992). Using 
structure based design, the Newcastle Drug Development Group have developed 
novel PARP-1 inhibitors for use as chemo- and radiosensitisers. The quinazolinones 
are 2-3 orders of magnitude more potent than the benzamides. Boulton et al., 1995, 
compared NU1025 with 3-AB in L1210 cells and demonstrated that NU1025 was 
50-fold more potent at potentiating the cytotoxicity of the alkylating agent, 
temozolomide. Importantly, this work correlated PARP-1 with the repair of single 
strand breaks (SSBs). Delaney et al., 2000, showed that NU1025 potentiated the 
cytotoxicity of temozolomide and the topoisomerase I inhibitor, topotecan in a 
panel of 12 human tumour cell lines with equal potency to PD 128763. A study by 
Bowman et al., 1998, tested mechanistically diverse agents and showed that NU1025 
potentiated the cytotoxicity of the methylating agent 5-(3-methyl-l- 
triazeno)imidazole-4-carboxamide (MTIC), IR and bleomycin 3.5,1.4 and 2-fold, 
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respectively. Another compound, NU1064 increased the activity of MTIC to a 
similar extent. A later study by Bowman et al., 2001, demonstrated differential 
effects of NU1025 on topoisomerase I and II poisons. The cytotoxicity of the topo I 
poison, camptothecin, was increased 2.6-fold but the cytotoxicity of the topo II 
poison, etoposide was not increased when NU1025 was co-incubated. This re- 
inforced the role of PARP-1 in the repair of SSBs. 
Convincing evidence for in vivo radiopotentiation with a PARP-1 inhibitor 
was obtained using PD128763 (Leopold and Sebolt-Leopold, 1990). Using a mouse 
tumour model, Leopold and Sebolt-Leopold demonstrated that PD128763 + 2.5 Gy 
IR caused a 10-15 day increase in tumour growth delay of SCC7 sarcomas compared 
to irradiation alone. However, acute hypotension and hypothermia were observed in 
the mice following treatment suggesting that this inhibitor had other cellular targets 
apart from PARP-1. 
Despite having IC50 values in the micromolar range, the benzamides need to 
be used at high concentrations in the millimolar range to potentiate the cytotoxicity 
of DNA damaging agents in vitro. Furthermore, there was considerable overlap 
between the concentrations required to potentiate drug cytotoxicity and the growth 
inhibitory effects of the compounds when used alone. Similarly, the quinazolinones 
have IC50 values in the nanomolar range but need to be used at high micromolar 
concentrations in cell culture for effective potentiation. In contrast, the PARP-1 
inhibitor used in the studies described in this thesis, AG14361, has been 
demonstrated to exhibit high activity in in vitro whole cell assays at sub-micromolar 
concentrations (Calabrese et al., 2003, in Press). 
4.1.1.2 Inhibitors of DNA-PK 
Wortmannin (WM), a sterol like fungal metabolite, shown previously to be a 
potent inhibitor of P13-kinase was one of the first compounds demonstrated to be 
capable of inhibiting DNA-PK in vitro. Indeed, WM has been shown to potentiate 
IR-induced cytotoxicity at concentrations that inhibited cellular DNA-PK activity 
(Boulton et al., 1996a; Boulton et al., 1999; Chernikova et al., 1999; Rosenzweig et 
al., 1997). Boulton et al., 1999, showed that WM inhibited DSB repair and not SSB 
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repair thus adding weight to the argument that DNA-PK is involved in DSB and not 
SSB repair. Furthermore, Muller et al., 1998, demonstrated that WM sensitised 
murine cells to bleomycin and Plumb and Kaye, 1999, have shown that WM is able to 
increase DSBs caused by the topo I poison, topotecan (topo I poison only induces 
SSBs, which are considered to convert to DSBs at the repliation fork). Boulton et al., 
2000 showed that WM potentiated etoposide cytotoxicity in parental CHOK1 cells 
whilst no potentiation was seen in the Ku80-deficient xrs-6 cells which are deficient 
in DNA-PK activity. Thus, with regard to its effects on DNA DSB repair and cell 
killing, DNA-PK is most likely the target of WM. However, WM is primarily a P13- 
K inhibitor and is known to inhibit other P13-kinase family members including the 
ataxia telangiectasia gene product, ATM or ATR (Table 3.1). Therefore, although 
WM clearly inhibits DNA-PK, the ability of WM to potentiate IR induced 
cytotoxicity could also be mediated, at least in part, via an inhibition of ATM or 
ATR (Hartley, 1995). 
The compound LY294002 (2-(4-morpholynyl-2-pyridone) and its derivatives 
are chemically unrelated to WM (section 1.11, Figure 1.8) and are reversible 
competitive inhibitors with respect to ATP (Vlahos et al., 1994). LY294002 has 
been shown to sensitise cells to IR (Rosenzweig et al., 1997) and to topotecan 
(Plumb and Kaye, 1999). In addition, these compounds have been shown to increase 
the DNA damage caused by other cytotoxic agents which generate DSBs such as 
bleomycin (Hosoi et al., 1998) and the nitrogen mustards (Muller et al., 2000) As 
stressed for WM, however, there is no clear evidence that the potentiation seen with 
LY294002 or any of its derivatives is due to an inhibition of DNA-PK and not due to 
the inhibition of other PIKK family members. 
There is a requirement for more potent and specific PARP-1 and DNA-PK 
inhibitors to probe further the physiological functions of PARP-1 and DNA-PK and 
to address the therapeutic potential of PARP-1 and DNA-PK inhibition for the 
treatment of human cancer. AG14361 represents the first inhibitor of PARP-1 with 
the required pharmacological properties of potency, specificity and solubility and in 
vivo anti-tumour activity. NU7026 represents the first potent and specific inhibitor of 
DNA-PK. 
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4.1.2 Potentially lethal damage recovery (PLDR) 
Non-proliferating cells exposed to IR demonstrate substantially higher 
survival than proliferating cells, or cells induced to start a proliferative cycle shortly 
after irradiation (Phillips and Tolmach, 1966; Little, 1969). Consistent with this, slow 
growing tumours are more radioresistant than rapidly growing cancers as they have a 
larger proportion of non-cycling cells, a consequence of local tumour 
`microenvironments' such as cell and vascular density as well as availability of 
oxygen and nutrients. Indeed, quiescent (Q) cells constitute the majority of the 
tumour cell population of some of the most radioresistant tumours which include 
connective tissue and bone carcinomas (Guichard et al., 1984). These 
`microenvironments' are thought to cause enhancement of recovery from `potentially 
lethal damage' (PLDR) (Hahn and Little, 1972). 
Potentially lethal damage (PLD) has been operationally defined as damage 
that can be either modified to non-lethal damage or `fixed' to lethal damage by 
altering conditions following exposure to IR (Phillips and Tolmach, 1966). 
Significantly, an increase in PLDR has been shown to be proportional to an increase 
in non-cycling or Q cells which are thought to be the resistant compartment within a 
tumour (Nakatsugawa and Dewey, 1984). Moreover, radiation survival analysis of 
synchronously dividing cells has demonstrated that cells irradiated during the G2 and 
M phases of the cell cycle are more radiosensitive compared to cells irradiated during 
G1 and S (Sinclair, 1969). In agreement with these findings, Hahn and Little, 1974, 
demonstrated that the process of PLDR occurred primarily in the GI phase of the cell 
cycle. Recovery from PLD is therefore an important phenomenon that probably 
enhances the resistance of tumour cells to IR. 
Plateau phase cell cultures have a large proportion of non-proliferating G1 
phase cells, characteristic of in vivo tumours, and therefore they are considered 
appropriate in vitro systems compared to exponentially growing cells for studying 
PLDR (Little et al., 1973). In this model, plateau phase cultures are exposed to IR 
and then allowed to recover for various periods of time before being counted and 
seeded, at low density, in order to induce proliferation and hence colony formation. 
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This gives a measure of the radiosensitivity of the cells. This model was first used 
with established human and rodent cell lines (Hahn and Little, 1974) and later 
applied to cell lines derived from specific human tumours (Weichselbaum et al., 
1977; Weichselbaum et al., 1980; Weichselbaum et al., 1982a; Weininger et al., 
1978 ). The in vitro model used in the studies described in this Chapter measured the 
increase in survival of irradiated growth-arrested G1 phase cells following delayed 
plating for colony formation (Figure 4.2). 
The existence of PLDR following irradiation has been demonstrated in 
various experimental human tumour cells in vitro (Guichard et al., 1984; Kinsella et 
al., 1984; Arundel and Leith, 1986) and in vitro studies have demonstrated that 
significant PLDR occurs in human tumour cells exposed to doses of IR which are 
similar to the doses used in clinical radiotherapy. For example, Courtenay et al., 
1982, studied PLDR in 9 tumour cell lines derived from tumours of varying 
radiocurability. Three cell lines from tumours considered incurable showed a 
considerably higher recovery from PLD than 3 cell lines obtained from tumours 
considered curable. In line with this observation, Weichselbaum et al., 1977, 
reported a human osteosarcoma line with a 24-fold PLDR following 7 Gy IR. Based 
on these findings, tumours which are radioresistant are more likely to contain cells 
proficient in PLDR. Guichard et al., 1984, proposed that PLDR may contribute to 
radiotherapy failure under certain conditions. 
Recovery comparable in magnitude to that found in vitro has been shown in 
in vivo experimental tumours. The existence of PLDR in vivo was first described in 
several different rodent tumour systems (Guichard et al., 1982; Phillips and 
Tolmach, 1966). Guichard et al., 1984, investigated PLDR in human tumour 
xenografts. Tumours were implanted subcutaneously into the flank of athymic mice 
and removed at various times from 0 to 24 h after IR. The tumours were then 
dissociated into single cell suspensions, counted and seeded at low densities for `ex 
vivo' colony formation. The recovery ratio was compared for tumours of low and 
intermediate curability. In line with in vitro studies, the authors demonstrated that 
the capacity for PLDR was greater in those tumours of lower curability. Furthermore, 
this group, along with others, demonstrated that the larger the tumour, the greater the 
amount of recovery (Hahn and Little, 1972; Little et al., 1973; Tubiana et al., 1977). 
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Figure 4.2 Schematic representation of the proposed mechanism for potentially 
lethal damage recovery (PLDR) 
Non-proliferating cells exposed to IR are known to undergo PLDR, leading to 
substantial increases in survival. This diagram depicts the PLDR model used in the 
studies described in this thesis. Following arrest in GI, cells were irradiated and 
either re-seeded for colony formation immediately or following 24 h recovery. Cell 
survival was assessed by colony formation as described in section 2.5. The proposed 
mechanism for PLDR is that when cells are maintained in a non-cycling state 
following irradiation they are able to repair `potentially lethal damage' that would 
otherwise be fixed to lethal damage following progression through S phase of the cell 
cycle. 
Consistent with this, larger tumours generally have a higher proportion of G1 phase 
cells as a consequence of local tumour micro-environments, including oxygen and 
nutrient deprivation. Furthermore, in vivo PLDR in human tumour xenografts is 
similar to or greater than that observed in rodent tumours (Hahn and Little, 1972; 
Little et al., 1973; Tubiana et al., 1977; Shipley et al., 1975; Urano et al., 1976)). 
The ability to enhance the radiosensitivity of radioresistant cell lines has 
considerable potential for clinical application. Current interest in clinical 
radiosensitisation has focused on hypoxic radiosensitisers and chemical 
radiosensitisers such as the halogenated pyrimidine analogs (Adams, 1992; Gregoire 
et al., 1999; Horsman, 1995). Little effort, however, has been made to develop new 
therapeutic techniques that might reduce PLDR in human tumours. Several early 
reports, using either cell lines mutationally inactivated in DNA-PK, or PARP-1 
inhibitors, showed a reduction in PLDR in non-proliferating cells (Illkias, 1990; Li et 
al., 1998; Huet and Laval, 1985; Arundel-Suto et al., 1991; Rudat et al., 1998). The 
potential of novel potent small molecule inhibitors of PARP-1 and DNA-PK to 
prevent PLDR is therefore an important consideration in the assessment of their 
therapeutic application. 
Early studies of PLDR have investigated the effects of PARP-1 inhibitors. 
These studies used the classical PARP-1 inhibitors, nicotinaminde (Ben-Hur et al., 
1984a) or the aromatic amide, 3-AB following IR (Burgman and Konings, 1989; 
Utsumi and Elkind, 1994; Huet and Laval, 1985; Brown et al., 1984; Ben Hur et al., 
1984b). All showed that inhibition of PARP-1 could reduce the PLDR capacity of 
cells. In one study, the effect of four chemical classes of PARP-1 inhibitors 
including nicotinamide and 3-AB on IR-induced PLDR in plateau phase CHO cell 
cultures were compared. Following 12 Gy, untreated cells exhibited a 5-6 fold 
increase in survival over a6h period compared to cultures that were re-plated 
immediately. 10 mM 3-AB or nicotinamide reduced PLDR by at least 50 % 
compared to controls, with 3-AB being a more potent inhibitor than nicotinamide 
(Brown et al., 1984). A different study by Huet and Laval, 1985, however, showed 
that although 3-AB could significantly reduce PLDR in CHO cells, nicotinamide did 
not. No studies have been carried out with inhibitors of DNA-PK, to date. However, 
it has been demonstrated that cell lines deficient in DNA-PK have a reduced capacity 
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for PLDR thus suggesting a role for DNA-PK in PLDR. These studies are described 
in more detail in section 4.4. 
4.2 Aims 
Overview The area of mammalian DNA repair and its relationship to cancer and 
therapeutic approaches is rapidly growing. One of the main aims of the Newcastle 
Drug Development Group is to develop novel compounds that increase the efficacy 
of anticancer agents and such `resistance modifying agents' should ideally be 
inherently non-toxic and selectively sensitise tumour cells to IR and 
chemotherapeutic agents. 
The aim of this results Chapter was to evaluate the ability of the novel PARP-1 
and DNA-PK inhibitors AG14361 and NU7026, respectively, to act as chemo- or 
radio-sensitisers and PLDR inhibitors: - 
" Investigate the effects of the inhibitors on cell survival following IR in 
exponentially growing cell lines proficient or deficient in DNA-PK or PARP-1 
" Investigate the effects of the inhibitors on PLDR following IR in growth arrested 
cell lines proficient or deficient in DNA-PK or PARP-1 
" Investigate the effects of the inhibitors on cell cycle progression following 
subculture of irradiated G1 arrested cells 
" Investigate the effect of NU7026 on cell survival following treatment with the 
clinically relevant chemotherapeutics etoposide and bleomycin in exponentially 
growing cell lines proficient or deficient in DNA-PK 
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4.3 Results 
The initial in vitro screening ofNU7026 and AG14361 utilised purified human 
enzymes or conditions which facilitated access of the compound to their respective 
targets, permeabilised cells, for example. This only provides data on the inhibitory 
potency of the compounds. Other considerations include interactions with cellular 
components and intracellular metabolism as well as permeation of the inhibitors 
through the cell membrane, all of which influence the inhibitory potency of a novel 
compound in intact cells. It is therefore important to assess the ability of a novel 
compound to act in an intact cell situation. Data presented in this Chapter 
investigated the whole cell effects of AG14361 and NU7026 in response to IR. 
Paired cell lines (described in section 3.1.1) proficient or deficient in PARP-1 or 
DNA-PK were used as models to confirm that PARP-1 and DNA-PK are the targets 
of AG14361 and NU7026, respectively. 
4.3.1 Radiosensitisation by AG14361 and NU7026, in vitro 
The roles of PARP-1 and DNA-PK in the cellular responses to IR has been 
extensively reported in the literature. Clonogenic survival (as described in section 
2.5 ) was used as the biological endpoint for the assessment of the cytotoxicity of IR 
and the effect of AG14361 and NU7026 (alone or in combination) in exponentially 
growing cells. 
4.3.1.1 Effect of increasing doses of NU7026 in the presence or absence of a 
fixed dose of IR 
Cell survival following exposure to increasing concentrations of the DNA-PK 
inhibitor, NU7026, alone, and in combination with a fixed dose of IR was 
investigated in the DNA-PK deficient and proficient V3 and V3YAC cell pair and 
the PARP-1 proficient and knockout cell lines. An equitoxic dose of IR was used for 
each cell line that would cause only moderate cellular cytotoxicity alone 
(approximately 30 % cell kill) (see Figure 3.7) but that would allow potentiation of 
IR cytotoxicity to be measured (V3YAC, 2 Gy; PARP-1 +/+, 2 Gy; V3,0.1, Gy; 
PARP-1 -/-, 0.14 Gy). Exponentially growing cells were pre-incubated with 
I 
inhibitor for 1 hr and post-incubated for 16 hrs at 37°C before seeding for colony 
formation in drug-free medium. 
NU7026, alone, did not significantly reduce survival up to a concentration of 
20 [M However, the highest achievable concentration of 50 µM decreased survival 
by approximately 20 % in all cell lines. For example, (Figure 4.3 (a) A), the plating 
efficiency (which is a measure of a cells ability to form colonies) of the V3YAC cells 
was 67 ±3 in the presence of 1% DMSO and this was significantly reduced to 55 t 
2 in the presence of 50 gM NU7026 alone (p = 0.02). This is consistent with the 
growth inhibitory data described in the previous Chapter, where NU7026 inhibited 
cell growth in a concentration dependent manner. Doses up to 20 µM had no 
significant effect on growth, however, doses above 20 µM gave a modest inhibition 
of growth of approximately 20 % in all cell lines. As discussed in Chapter 3, it is 
possible that this is due to an effect on P13- kinase since the survival and growth 
effects of NU7026 also occur in the DNA-PK deficient V3 cell line. 
Radiosensitisation of V3YAC, PARP-1 ++ and PARP-1 -/- cells by NU7026 
was concentration dependent, with concentrations >_ 5 µM giving maximal 
potentiation (Figure 4.3 (a) and 4.3 (b)). At these doses, there was a 2.5-3-fold 
potentiation of 2 Gy IR in V3YAC and PARP-1 +/+ cells and a 2-fold potentiation of 
0.1 Gy in PARP-1 -/- cells. As expected, no significant radiopotentiation with 
NU7026 was seen in the V3 cells, p=>0.05 (Table 4.1). Analysis of the survival 
curves gave the concentration of NU7026 required to reduce cell survival of 
irradiated cells by 50 % (LC50 value). These were; 3.4 ± 0.1 µM (V3YAC); > 50 µM 
(V3); 1.3 ± 0.01 µM (PARP-1 +/+); 1.9 ± 0.03 µM (PARP-1 -/-). 
10 µM was selected as the concentration of NU7026 for use in subsequent 
studies described in this thesis, unless otherwise stated, as it should allow maximal 
potentiation of IR without being growth inhibitory or cytotoxic per se. As described 
in Chapter 3,0.4 gM AG14361 was used as a standard dose as it is 100 x Ki and <5 
% of the G150 and is sufficient for maximum chemosensitisation (Calabrese et al., in 
press).. 
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Cell line /Dose 
NU7026 (µM) 
V3YAC V3 PARP-1 +/+ PARP-1 -/- 
1 1.2±0.20 1.0±0.04 1.6±0.20 1.7±0.06 
2 1.6±0.13 1.1±0.01 2.6±0.15 2.0±0.04 
5 2.5±0.32 1.0±0.03 3.0± 0.11 1.9±0.02 
10 2.6±0.21 0.9±0.04 3.1±0.15 2.2±0.03 
20 2.4±0.24 1.2±0.04 3.0 ± 0.22 2.3 ± 0.08 
50 2.8±0.22 0.9 ± 0.02 3.2 ± 0.18 2.4±1.1 
Table 4.1 Comparison of the effect of increasing concentrations of NU7026 on 
the cytotoxicity of IR 
Figures represent the killing enhancement factor for each dose of NU6026 (survival 
in the presence of NU7026 alone / survival NU7026 + IR). Data are derived from 
the experiments shown in Figure 4.3 and are the mean ± SEM from at least 3 
independent experiments. 
4.3.1.2 The cytotoxic effect of increasing doses of IR in the presence or absence 
of a fixed concentration of AG14361 and/or NU7026 
As described in Chapter 3 (see Figure 3.7), there was a dose dependent 
reduction in cell survival following treatment with IR. Cell lines deficient in PARP- 
1 or DNA-PK were approximately 4-fold more sensitive to IR than their proficient 
counterparts. The effect of fixed concentrations of AG14361 or NU7026 (alone or in 
combination) on the cytotoxicity of increasing doses of IR were studied in 
exponentially growing cells. Briefly, cells were pre-incubated with inhibitor(s) for 1 
hr before irradiation and then post-incubated in the presence of inhibitor(s) for a 
further 16 hrs at 37°C before seeding for colony formation in drug free medium. 
Figures 4.4(a)A and 4.4(b)A show that in the presence of fixed concentrations 
of AG14361 and NU7026 (alone or in combination) the dose-dependent reduction in 
survival induced by IR was enhanced in exponentially growing V3YAC and PARP-1 
+/+ cells. In both cell lines, AG14361 reduced survival by at least 1.5-fold for all 
doses of IR whilst NU7026 reduced survival by 2-fold for all doses of IR. 
Combination of the inhibitors reduced survival by at least 5-fold for all doses of IR. 
The magnitude of the potentiation was observed to increase as the dose of IR was 
increased. For example, in the V3YAC cell line, survival following 2 Gy IR was 
reduced 5-fold when AG14361 and NU7026 were used in combination. However, 
survival following 6 Gy IR was reduced 34-fold in the presence of both AG14361 
and NU7026. 
Potentiation of IR cytotoxicity by the inhibitors, alone and in combination, 
was quantified utilising `potentiation factor' values calculated at a survival of 10 % 
(PF90). PF90 values were defined as a ratio of the dose of IR alone that reduced cell 
survival to 10 % divided by the dose of IR that reduced survival to 10 % when co- 
incubated with a fixed dose of PARP-1 or DNA-PK inhibitor. The values are 
summarised in Table 4.2. Both inhibitors used alone potentiated the cytotoxicity of 
IR in the enzyme proficient V3YAC and PARP-1 +/+ cells and similar PF90 values 
were obtained for these cell lines. Greater than additive effects were observed when 
the inhibitors were co-incubated. For example, the mean PF90 values for AG14361 
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Treatment/ 
Cell line 
IR + AG14361 IR + NU7026 IR + AG14361 
+ NU7026 
V3YAC 1.40 ± 0.00 1.51 ± 0.04 2.78 ± 0.04. 
V3 1.30 ± 0.01 1.0±0.00 1.3 ± 0.03 
PARP-1 +/+ 1.37 ± 0.00 1.69 ± 0.03 2.81 ± 0.19 
PARP-1 -/- 1.03 ± 0.01 1.12±0.01 1.13±0.00 
Table 4.2 Comparison of the PF90 values derived from the IR survival curves in 
Figures 4.3 a and b 
All mean PF90 values (+ SEM) were calculated from the ratio of the individual LD90 
values. The mean LD90 values for IR + inhibitor(s) were all significantly different 
from the mean LD90 values for IR alone in the same cell line (p: 5 0.05, n=>3, two- 
tailed Student's t-test), excluding the LD90 values for IR + inhibitor in the cell line 
lacking its corresponding target enzyme (see below). 
2 The bold PF90 values, which are not significantly different from unity, demonstrate 
the lack of potentiation by the inhibitor in the cell line which lacks its corresponding 
target enzyme. 
and NU7026 in the V3YAC cell line were 1.4 and 1.5, respectively but when used in 
combination, the PF90 value was 2.8 as opposed to the expected additive value of 2.1. 
Whilst significant radiosensitisation by AG14361 was observed in all cell 
lines with PARP-1 activity (PF90 values 1.3-1.4), there was no significant 
radiosensitisation of the PARP-1-/- cells (PF90 = 1.03, p=0.12). Similarly, NU7026 
caused significant radiosensitisation in the DNA-PK proficient cell lines (PF90 values 
1.1-1.7) but it did not significantly potentiate the cytotoxicity of IR in the DNA-PK 
deficient V3 cells (PF90 = 1, p=0.8). These data support the hypothesis that 
AG14361 and NU7026 are mediating their potentiating effects specifically by the 
inhibition of their target enzymes, PARP-1 and DNA-PK, respectively. 
AG14361 significantly potentiated IR cytotoxicity in the DNA-PK deficient 
V3 cell line (PF90 = 1.3). However, the radiosensitivity of PARP-1-/- cells was only 
slightly reduced by treatment with 10 µM NU7026 (PF90 =1.12) although this is 
significant by a two tailed Student's t test (p = 0.04). 
4.3.1.3 Determination of exposure time required to achieve maximal 
potentiation of IR with AG14361 
Experiments were carried out to determine the length of exposure time 
required to obtain maximum potentiation of IR-induced cytotoxicity in parental 
CHOK1 cells. Briefly, cells were irradiated with 4 Gy IR (which causes 
approximately 75 % cell kill) in the presence or absence of 0.4 µM AG14361 and 
post-incubated for different periods of time before being seeded for colony formation 
in drug-free medium. Potentiation was similar (2-2.5-fold) for all time points and 
extending the incubation period with AG14361 beyond 30 minutes did not result in 
any further potentiation (Figure 4.5). 
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Figure 4.5 Sensitisation of CHOK1 cells to 4 Gy IR by exposure to AG14361 for 
varying times ;  IR alone; Q IR + 0.4 µM AG14361. Data are normalised to 
DMSO alone or drug alone controls and are the mean ± SEM of at least 3 
independent experiments. 
4.3.2 Chemopotentiation by NU7026 
Studies were carried out to identify other cytotoxic agents for use in 
combination with DNA-PK inhibitors. Damaging agents that produce DNA DSBs 
either directly, or as repair intermediates, and which therefore may require DNA-PK 
mediated repair were chosen. The direct cellular effects of the clinically useful 
chemotherapeutic agents, bleomycin and etoposide and the effect of a fixed 
concentration of NU7026 were determined by means of growth inhibition studies 
carried out using the SRB assay in the DNA-PKcs deficient cell line V3 and its 
proficient counterpart, V3YAC. The studies with etoposide were carried out as part 
of an undergraduate project carried out by Gillian Newton, under my supervision. 
4.3.2.1 The growth inhibitory effects of bleomycin in the presence or absence of 
NU7026 
Bleomycin is a `radiomimetic' drug and therefore produces similar lesions to 
IR which include both single and double strand breaks and base release. The active 
biological species of bleomycin are oxygen free radicals that cause scission of DNA 
through an oxidative process (section 1.3.4.2). As such, bleomycin would be 
expected to activate DNA-PK. A 48 hour continuous exposure of V3YAC and V3 
cells to an increasing concentration of bleomycin resulted in a concentration- 
dependent inhibition of cell growth (Figure 4.6) with G150 values of 3 µg/ml and 0.3 
pg/ml, respectively (Table 4.3). V3 cells were therefore 10-fold more sensitive to 
bleomycin than their proficient counterparts, indicating a major role for DNA-PK in 
the repair of bleomycin-induced DNA damage. The ability of NU7026 to potentiate 
this growth inhibition was investigated. In the V3YAC cells the GI50 value was 
reduced to 0.34 pg/ml in the presence of 10 µM NU7026. This gave a corresponding 
fold decrease in GI50 (PF50) of 8.8, which was significant (p < 0.05). The G150 value 
in the V3 cells obtained for bleomycin co-incubated with 10µM NU7026 (0.3 
µg/ml) was the same as that obtained with bleomycin alone. 
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4.3.2.2 The growth inhibitory effect of Etoposide in the presence or absence of 
NU7026 
Etoposide is a topoisomerase II (topo II) poison that acts by `trapping' topo II 
as a cleavable complex at an intermediate step following DNA strand scission but 
before religation thereby giving rise to DNA DSBs (section 1.3.4.2). Western blot 
analyses were carried out to assess the topo IIa protein levels in the V3YAC and V3 
cell lines as sensitivity to topo II poisons is related to topo II protein expression 
(Asano et al., 1996; Stacey et al., 2000). As can be seen in Figure 4.7 A, topo Hoc 
levels were the same in both cell lines and this was verified by probing for actin as a 
loading control. The concentration-dependent effects of a 48 h continuous exposure 
to etoposide in the presence or absence of 10 gM NU7026 on the growth of V3YAC 
and V3 cells were evaluated. Cell growth in the presence of etoposide alone was 
inhibited in a concentration-dependent manner in both cell lines (Figure 4.7 B and 
Q. NU7026 potentiated the growth inhibitory effect of etoposide in the V3YAC cells 
(Table 4.3), reducing the G150 value of 2.3 gM for etoposide alone to 0.95 gM and 
this gave a PF50 value of 2.4. The V3 cells were 8 -fold more sensitive than V3YAC 
cells to etoposide alone (GI50 = 0.3 µM) and no significant potentiation of growth 
inhibition was obtained in the presence of 10 µM NU7026 (GI50 = 0.31 µM, p= 
0.15). 
In order to ascertain whether the potentiation of growth inhibition by NU7026 
reflected a potentiation in the cytotoxicity of etoposide, these studies were extended 
by investigating the dose dependent effects of a 24 h continuous exposure to 
etoposide on cell survival in these cell lines by clonogenic assay. Figure 4.8 shows 
that in both cell lines, etoposide treatment resulted in a concentration-dependent 
decrease in survival. The LD50 was 4.7 µM and 6.8 µM for the V3 and the V3YAC 
cell lines, respectively. In the presence of 10 µM NU7026, the LD50 of the V3YAC 
cells was reduced to 2.7 µM giving a PF50 value of 2.5. No additional significant 
effect on survival with the co-incubation of NU7026 was seen in the V3 cells (LDso 
= 4.4 µM, p= 0.16). 
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4.3.3 Potentially lethal damage recovery 
The degree of PLDR following IR treatment was assessed in all cell lines and 
this was correlated with their inherent radiosensitivity. In addition the effects of 
AG14361 and NU7026 on PLDR were examined. 
4.3.3.1 Cell cycle arrest by using conditioned or serum free medium 
In order to compare the effects of IR and the additional effects of AG14361 
and NU7026 in non-cycling cells, various methods of non-drug induced cell cycle 
arrest were investigated. Previous data suggest that serum-free medium (Chou and 
Langan, 2003) or conditioned medium (that which has been obtained from confluent 
cells) (Davis et al., 2001) can be used. The suitability of these methods for both 
inducing and maintaining cell cycle arrest without cell death was therefore 
investigated in the parental CHOK1 cell line. Briefly, confluent or sub-confluent 
cells were counted at time `0' and their medium replaced with either conditioned or 
serum-free medium. Triplicate cell counts for each sample were then taken at 24 h, 
48 h and 96 h thereafter and plotted on an x-y graph against time (Figure 4.9). 
Samples were also taken at 0,24 and 96 h for cell cycle analysis by flow cytometric 
analysis, as described in section 2.7. 
In all cells, the rate of cell growth was dramatically slowed down by both 
treatments. Indeed, the growth of the cells in serum-free medium almost completely 
arrested, having only undergone 1-2 doublings between 24 and 96 h as opposed to 
the expected 6-8 doublings. Likewise, the growth of cells in conditioned medium 
underwent far fewer doublings over the 96 h than expected (around 2-3 rather than 
8). In addition, by 96 h some cell death had occurred in both the serum-free and 
conditioned medium as floating cells were present in the medium. 
Corresponding cell cycle profiles (Figures 4.1Oa and 4.1 Ob) show that the sub 
confluent cells in serum-free medium arrested in G1 at 24 h but that there was a 
large sub-G1 (apoptotic) peak by 96 h accounting for 54 % of the cell cycle phase 
distribution. In conditioned medium, the sub-confluent cells demonstrated an 
increase in G1 by 24 h from 28 % to 47 % with a corresponding decrease in G2/M 
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Figure 4.9 Growth of CHOK1 cells when placed in conditioned or serum free 
medium: - Growth of confluent (filled symbols) and subconfluent (open symbols) 
when exposed to conditioned (squares) or serum-free medium (circles). Data are the 
mean ± SEM of triplicate cell counts taken at 24,48 and 96 h, from a single 
representative experiment. 
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Figure 4.10 (a) Cell cycle analysis of CHOK1 cells exposed to serum free-medium 
Cell cycle phase distribution was analysed using flow cytometric analysis as described in 
section 2.7. Treatment schedules are indicated on individual plots. 
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Figure 4.10 (b) Cell cycle analysis of CHOKI cells exposed to conditioned 
medium Cell cycle phase distribution was analysed using flow cytometric analysis as 
described in section 2.7. Treatment schedules are indicated on individual plots. 
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and S phases and, notably, only a very small sub G1 peak was observed by 96 h (6 
%) at which point the cells can be seen to be escaping from G1 into S as they move 
into the next cell cycle. Confluent cells were already G1 arrested at 0h (>70 % of 
cells in GI) and when cultured in serum free or conditioned medium, this G1 arrest 
was maintained over the 96 h. However, as with the sub-confluent cells, a large sub 
G1 (apoptotic) peak comprising 59 % of the total cell population was seen in the 
serum-free medium but this was only 6% of the cells held in conditioned medium. 
In summary, these experiments were a useful prelude to conducting PLDR 
experiments. They have demonstrated that both confluent and subconfluent cells can 
be held in GI by serum starvation or by culturing in conditioned medium. Confluent 
cells maintained in conditioned medium were selected as the most appropriate 
system for investigating PLDR in non-cycling cells, as cells remained in the GI 
phase of the cell cycle for the duration of the experiment and there was minimal 
accumulation of a sub-G1 population of cells, indicative of apoptosis. 
4.3.3.2 PLDR 
Cells arrested in G1 as described above (confirmed by flow cytometric 
analysis as described in section 2.6; >75 % cells in G1 with less than 20 % and 5% 
in G2M and S, respectively) were irradiated in conditioned medium at approximately 
equitoxic doses of IR (V3YAC, 6 Gy; V3,1.4 Gy; PARP-1 +/+, 5 Gy; PARP-1 -I-, 
1.4 Gy) such that the survival of cells which were immediately re-plated was <5 %. 
Cells were seeded immediately following IR or after post-incubation in conditioned 
medium at 37°C for varying times up to 24 h (recovery period). Inhibitor(s) were 
added 1h prior to irradiation and were present during the recovery period, where 
indicated. The capacity for PLDR was quantitated by calculating the recovery ratio 
as described in section 2.6. 
Initially, the PLDR capacity of V3YAC and V3 cells as a function of post- 
incubation time before subculture (0,4,6 and 24 h) was examined (Figure 4.11). 
The delay in subculture, which allows quiescent cells to repair PLD, resulted in a 
clear increase in cell survival. In both cell lines, PLDR was observed at 4h 
(V3YAC, 6.0-fold; V3,1.4-fold) and it was maximal by 6 h. (V3YAC, 8.3-fold; V3, 
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1.75-fold). No further significant enhancement in survival was seen in either cell line 
by extending the post-IR incubation time to 24 h. The reduced PLDR in the V3 
cells compared to the V3YAC cells indicates a requirement for DNA-PK function in 
PLDR. 
PLDR in all cell lines was compared and the effects of AG14361 and 
NU7026 on PLDR were investigated. Following a 24 h delay in subculture, the 
surviving fraction of V3YAC and PARP-1 +/+ cells (recovery ratio) was increased 
8.7 ± 0.4-fold and 6.7 ± 0.5-fold, respectively, p= <0.05, (Figure 4.12 A, Q. There 
was no significant difference in the surviving fraction of inhibitor treated cells 
compared to control cells when seeded for colony formation immediately following 
IR (data not shown). PLDR was significantly reduced in both cell lines by AG14361 
(71 % and 74 %, for V3YAC and PARP-1 +/+ cells, respectively) as shown in Table 
4.4 (% inhibition was calculated as described in section 2.6). 10 µM NU7026 fully 
abolished recovery in both cell lines. Whilst both inhibitors alone substantially 
prevented PLDR, more dramatically, when used in combination, AG14361 and 
NU7026 not only completely abolished PLDR, but reduced survival significantly 
below that observed in cells exposed to IR-alone and re-plated immediately. For 
example, (Figure 4.12 A), when growth arrested V3YAC cells were irradiated, 
survival was 0.38 % if the cells were re-plated immediately. Survival was increased 
to 3.3 % by a 24 h delay in re-plating, but the presence of AG14361 and NU7026, in 
combination, during the recovery period reduced survival to 0.064 %, approximately 
6-fold lower than the cells which were re-plated immediately post-IR. This 
represents a 50-fold radiosensitisation. 
4.3.3.3 Recovery form potentially lethal damage in cells deficient in PARP-1 or 
DNA-PK 
PLDR was reduced approximately 5-fold in the V3 cells (recovery = 1.70 t 
0.02 -fold) and approximately 2.5-fold in the PARP-1 -/- cells (recovery = 2.70 ± 
0.3- fold), compared to their proficient counterparts (Figure 4.12 B and D), 
consistent with the differential in radiosensitivity of exponentially growing cells 
(Figure 3.7). This modest recovery was fully inhibited by AG14361 or NU7026, 
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Figure 4.12 Effects of AG14361 and NU7026 on recovery from IR-induced 
potentially lethal damage in growth arrested cells: - A, V3YAC ; B, V3; C, PARP- 
1 +/+ ; D, PARP-1 -I- . Cells were treated with approximately equitoxic doses of IR 
in the presence or absence of 10 µM NU7026 or 0.4 µM AG14361 (6 Gy, V3YAC; 
1.4 Gy, V3; 5 Gy, PARP-1 +/+; 1.4 Gy, PARP-1 -/-) and either plated immediately 
(white bars) or following a 24 h post-incubation to allow for PLDR (black bars). 
Cells were replated in the absence of inhibitors. Data are the mean ± SEM of at least 
3 independent experiments. 
Treatment/ 
Cell line 
IR + AG14361 IR + NU7026 IR + AG14361 
+ NU7026 
V3YAC 71±2.2 110±0.8 122±0.55 
V3 92 ± 3.2 0±0.00 90 ± 2.1 
PARP-1 +/+ 73.5 ± 3.87 104 ± 1.89 112 ± 2.01 
PARP-1-/- 6.0±2.2 93±2.17 95±3.00 
Table 4.4 Effect of AG14361 and NU7026 on IR- induced potentially lethal 
damage. Figures represent the % inhibition of recovery for each inhibitor in each 
cell line. Inhibition of recovery of > 100 % arises when the survival of drug-treated 
cells after 24 h PLDR is below the survival of cells seeded immediately. Figures are 
calculated as described in section 2.6. Data are the mean ± SEM of at least 3 
independent experiments 
respectively. As expected, no significant inhibition of PLDR was obtained by the use 
of NU7026 in the V3 cell line (p= 0.8). However, when AG14361 was used in the 
PARP-1 -/- cell line there was a small, but significant inhibition of PLDR (6 %, p= 
0.04). 
PLDR was also assessed in the xrs-6 and xrs-6 HamKu8O cell lines (Figure 
4.13). The cells were irradiated with approximately equitoxic doses of IR (xrs-6 
HamKu80,5 Gy; xrs-6,1.2 Gy) and either re-plated immediately or following 24 h 
recovery at 37°C. Strikingly, the xrs-6 cells showed no significant PLDR (fold 
recovery = 1.11 ± 0.13). However, this deficiency was rescued by the transfection of 
Ku80 which gave a PLDR of 6.4 ± 0.9-fold, comparable with the V3YAC cells (8.7- 
fold). 
4.3.3.4 Analysis of cell cycle progression following subculture 
Given that radiation influences the cell cycle checkpoints and induces G1 and 
G2 arrest, it was speculated that effects on cell cycle progression may be involved in 
the mechanism of inhibition of PLDR by the inhibitors. Indeed, members of the P13- 
kinase family (i. e. ATM and ATR) function in both cell cycle progression and DNA 
damage-induced cell cycle checkpoints (section 1.13). Moreover, earlier PLDR 
studies with wortmannin (WM) (data not shown) demonstrated a failure to produce 
visible colonies following subculture into drug-free medium, indicative of a 
permanent G1 block. Collado et al., 2001, showed that following arrest in G1, the 
kinase inhibitors WM and LY294002 induced a permanent arrest in cell growth 
resulting in a senescent-like phenotype, at least partially through the inhibition of 
P13-K. 
The effect of AG14361 and NU7026 on cell cycle progression was 
investigated in the V3YAC and V3 cells by flow cytometric analysis. Briefly, 
growth arrested G1 phase V3YAC and V3 cells were pre-incubated with inhibitor for 
1 h, irradiated with equitoxic doses of IR (see section 2.6) in the presence or absence 
of inhibitor and subcultured in drug free medium following 24 h recovery at 37°C. 
The cell cycle distribution was examined immediately and 24,48 and 72 h thereafter 
(Figures 4.14 a, b, c). 
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Following release from G1, V3YAC cells progressed into S and G2M phase 
with a reduction of G1 from 81 % to 50 %, with a corresponding increase in S, from 
9% to 25 %, and G2/M, from 10 % to 25 % over 72 hrs (Figure . 4.14(a), (b) and 
(c) 
A), corresponding to a near normal phase distribution (Figure 3.13). Similarly, in the 
V3 cells, following release from GI arrest, the G1 fraction decreased from 69 % to 
35 % and the S and G2/M phases increased from 12 % to 20 % and 19 % to 45 %, 
respectively, over the next 72 hrs (Figure 4.14 (a), (b) and (c) B). This represents a 
slight accumulation in G2/M compared to untreated exponentially growing V3 cells 
(Figure 3.13B). 
Neither NU7026 nor AG14361 affected the cell cycle distribution of 
exponentially growing cells (Figure 3.13). However, NU7026 caused a progressive 
accumulation of irradiated V3YAC cells in G2/M following release from G1, 
consistent with the observed G2 accumulation in the V3 cell line. NU7026 did not 
affect the cell cycle progression of irradiated V3 cells. It was apparent that the 
majority of cells treated with IR + NU7026 remained arrested at the initial G2 
checkpoint and were unable to progress to the second cell cycle as even 72 hours 
after subculture 74 % cells remained in G2/M. In contrast, AG14361 had virtually 
no effect on the cell cycle phase distribution perturbations caused by irradiation of 
V3YAC cells following release from G1, but caused a transient increase in G2/M at 
24 h (41 % compared to 30 % in cells irradiated alone) which was gradually lost over 
the next 48 h in the V3 cells. 
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Figure 4.14(a) The effect of NU7026 and AG14361 on cell cycle progression 
24 h post subculture; A, V3YAC cells; B, V3 cells 
Cells were seeded and analysed by flow cytometry as described in section 2.7. 
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Figure 4.14(b) The effect of NU7026 and AG14361 on cell cycle progression 
48 h post subculture; A, V3YAC cells; B, V3 cells 
Cells were seeded and analysed by flow cytometry as described in section 2.7 
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Figure 4.14(c) The effect of NU7026 and AG14361 on cell cycle progression 
72 h post subculture; A, V3YAC cells; B, V3 cells 
Cells were seeded and analysed by flow cytometry as described in section 2.7. 
4.4 Discussion 
In this Chapter, recovery from radiation damage, as assessed by clonogenic 
survival, has been demonstrated in both exponentially growing and plateau phase 
cells. The biological effects of AG14361 and NU7026 on cell viability were also 
investigated. In particular, the ability of these inhibitors, used alone or in 
combination, to radiosensitise paired cell lines proficient or deficient in either DNA- 
PK or PARP-1 was evaluated. 
The studies presented in this Chapter have demonstrated that inhibition of either 
PARP-1 or DNA-PK radiosensitises cells and therefore mimics the effects of loss of 
enzyme. NU7026 potentiated IR cytotoxicity in a concentration dependent manner in 
all cell lines except the DNA-PK deficient V3 cells (Figure 4.3). These studies give a 
measure of inhibitor potency in intact cells. The IC50 of NU7026 in a purified DNA- 
PK assay was 0.44 µM (Figure 3.8 Q. The results presented here, demonstrate that 
higher concentrations of the inhibitor are needed to potentiate the cytotoxicity of IR 
in whole cells (at least 1 µM) than to inhibit the enzyme in a purified assay. One 
possible reason for this difference is that the ATP concentration in the cell-free assay 
is only 50 µM compared to an intracellular ATP concentration of around 2mM (Leist 
et al., 1997) which will have a significant impact on the activity of NU7026 which is 
competitive with respect to ATP. 
The effects of fixed concentrations of NU7026 and AG14361 (that which cause 
maximum IR potentiation in the absence of intrinsic cytotoxicity) on cell survival 
following increasing doses of IR in exponentially growing cells were measured 
(Figure 4.4 a, b). NU7026 potentiated IR cytotoxicity in exponentially growing 
DNA-PK proficient but not deficient cell lines. Similarly, AG14361 potentiated IR 
in PARP-1 +/+ but not PARP-1 -/- cell lines. These data are consistent with the 
observation that both PARP-1 and DNA-PK deficient cell lines were 4-fold more 
sensitive to IR alone than their proficient counterparts, and provide confirmation that 
the inhibitors mediate their effects on IR-induced cytotoxicity specifically via 
inhibition of their target enzymes. This work is supported by clonogenic survival 
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assays carried out in the DNA-PK deficient human glioma cell line, M059J and their 
proficient counterpart, M059K. In these studies 50 µM NU7026 potentiated IR 
cytotoxicity in the M059K cells but did not significantly potentiate IR in the M059J 
cells (G. C. M Smith, KuDOS Pharmaceuticals; personal communication). 
Inhibition of PARP-1 or DNA-PK therefore reduces the `threshold dose' (dose at 
which IR becomes toxic) and increases cytotoxicity at higher doses. When used in 
combination, the inhibitors caused at least additive effects for the potentiation of 
cytotoxicity. These results are consistent with the findings of Boulton et al., 1999, 
who showed that combined use of wortmannin and the PARP-1 inhibitor, NU1025, 
gave additive effects for the potentiation of IR cytotoxicity and suggest that the two 
enzymes do not function solely in a common pathway, because using both inhibitors 
has a greater effect than either one alone. It is generally assumed that the inhibition 
of BER and NHEJ is the cause of the enhanced cytotoxicity observed with PARP-1 
and DNA-PK inhibitors, respectively. However, data presented in Chapter 5 (section 
5.3.3) have shown that AG14361 also inhibits DNA DSB repair in cells exposed to 
IR and therefore this may contribute to the cytotoxic mechanism. 
The studies presented in this Chapter are the first to evaluate radiosensitisation 
by a small molecule selective inhibitor of DNA-PK. The data are consistent with 
recent reports which have utilised several alternative strategies to selectively deplete 
or inhibit DNA-PK function in human tumour cell lines; antisense oligonucleotides, 
small interfering RNAs and aC terminal peptide which targets Ku80 and prevents 
DNA-PKcs binding to Ku (Sak et al., 2002; Blenkov et al., 2002; Kim et al., 2002; 
Omori et al., 2002). These have been previously described in section 1.12.1. In 
summary, in all reports, a loss of DNA-PK activity correlated with radiosensitisation 
and inhibition of DNA repair. 
Maximum potentiation of 4 Gy IR cytotoxicity by AG14361 was achieved in 
CHOK1 cells by 30 minutes, with no further increases in potentiation being achieved 
by extending the exposure period to 24 h. (Figure 4.5). This is consistent with the 
previous findings of Ben Hur et al., (1985) and Arundal-Suto and Scavone (1991), 
who showed that following exposure to IR, <_2 hrs is sufficient to yield near maximal 
potentiation with the PARP-1 inhibitor, PD128763. There are two possible 
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explanations for this finding: - Either the majority of repair occurs within 30 minutes 
and therefore it is the initial time which is critical for the inhibition of PARP-1 and 
therefore potentiation, or because AG14361 is a very potent inhibitor, it binds PARP- 
1 so tightly that it is not removed following washing and plating into drug-free 
medium. That the majority of repair occurs by 30 minutes is supported by data 
presented in Chapter 5 where enzyme proficient cells were shown to repair at least 
50 % of IR-induced SSBs and DSBs within 30 minutes (sections 5.3.5 and 5.3.2). 
One potential way to distinguish between these two possibilities would be to irradiate 
the cells and then delay the addition of AG14361 by 30 minutes to see if 
radiosensitisation can still be achieved. 
Owing to the collaborative nature of this project, studies on the exposure time 
required to achieve maximal radiosensitisation with NU7026 were carried out by 
Lloyd Kelland and colleagues of the CRC centre for Cancer Therapeutics, Sutton. 
Studies were carried out to assess the clonogenic survival of CH1 cells following 3 
Gy IR in the presence or absence of 10µM NU7026 and either a 3,6 or 24 h post- 
incubation period. This group concluded that a6h post-incubation period was 
sufficient to achieve maximal radiosensitisiation with NU7026 (personal 
communication). 
Ideally, paired cell lines should be isogenic, differing only in the gene of interest. 
However, this is rarely the case, and as described in Chapter 3, it was established 
during the course of this research that in contrast to the PARP-1 -/- MEFs which had 
retained wild type p53 following spontaneous immortilisation, the PARP-1 ++ 
MEFS used in this study were shown to have acquired a mutation in p53 thus 
rendering the protein unable to act as a transcription factor. This was confirmed by 
the observation that the PARP-1 +/+ cells were unable to cause the induction of the 
p53 inducible genes, MDM2 and p21 following IR (Paul Jowsey, Northern Institute 
for Cancer Research, unpublished results). Nevertheless, both the DNA-PK and 
PARP-1 inhibitors, were able to radiosensitise the PARP-1 +/+ cell line, despite the 
lack of functional p53. This ability to radiopotentiate cells regardless of p53 status 
increases the range of tumours for which the use of the inhibitors may be effective 
since as many as 50 % of tumours carry a p53 mutation. 
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These observations are in general agreement with earlier data with the PARP-1 
inhibitors, NU1025 and NU1085 which enhanced the growth inhibitory effects of 
temozolomide and topotecan in a panel of 12 human tumour cell lines regardless of 
p53 status (Delaney et al., 2000). Similarly, AG14361 enhanced the growth 
inhibitory activity of the radiomimetic drug, bleomycin, with equal potency in the 
p53 wt HM 16 cell line and their HPV E6 degraded p53 null (HCT116 N7) pair; 
PF5Ö values; HCT116 = 1.3 ± 0.4, HM 16 N7 = 1.3 ± 0.8 (p= 0.4) (Gemma 
Swaisland, Northern Institute for cancer Research, unpublished results). 
The correlation between DNA-PK function and IR-induced double strand break 
repair is well documented (section 1.12.3). However, few studies have addressed the 
involvement of DNA-PK in the repair of DNA lesions generated by antitumour 
agents and subsequent cell survival. Data presented in this Chapter assessed the 
ability of NU7026 to potentiate the effects of the clinically used chemotherapeutic 
agents, etoposide and bleomycin. Previous studies have demonstrated that all six 
members of the xrs complementation group (defective in Ku80 binding component 
of DNA-PK) are hypersensitive to topo II poisons (Jeggo and Kemp, 1983; Jeggo et 
al., 1989). In addition, it has been demonstrated that these cells are defective in the 
rejoining of etoposide-induced DSBs (Caldecott et al., 1990) and that etoposide 
resistance is restored by transfection of Ku80 cDNA into the mutant cell line (He et 
al., 1996), thus implicating DNA-PK in the repair of topo II - induced lesions. 
In this Chapter, results are presented which show that the growth inhibitory 
activity of etoposide differed between the DNA-PKcs deficient (V3) cell line and its 
proficient counterpart (V3YAC). The V3 cells were at least 8-fold more sensitive to 
etoposide (Figure 4.7), confirming studies comparing V3 and parental AA8 cells 
which showed that the V3 cells were more sensitive to etoposide (Jeggo et al., 1989). 
Similarly, Erikkson et al., 2002, demonstrated that in CLL tumour samples, DNA- 
PKcs protein expression correlated with sensitivity to topo II inhibitors. 
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NU7026 sensitised V3YAC cells to etoposide treatment bringing their sensitivity 
to approximately the same level as the V3 cell line. NU7026 failed to potentiate 
etoposide in V3 cells demonstrating that NU7026 potentiates etoposide specifically 
via DNA-PK inhibition. The most direct interpretation that is consistent with the 
results presented here is that loss of or inhibition of DNA-PK potentiates Topo II 
poison cytotoxicity by inhibiting DNA-PK mediated NHEJ of DSBs generated from 
cleavable complexes. However, the mechanisms may be distinct. NU7026 could bind 
and `block', thus preventing topo II mediated resealing of breaks that would 
otherwise reverse normally whereas in cells deficient in DNA-PK activity, the 
mechanism might be an inability to mediate rejoining of frank double strand breaks 
that arise directly or indirectly from cleavable complexes. These data differ from 
those of Jin et al., 1998, who reported that Ku, but not DNA-PKcs was implicated in 
the sensitivity of top II poisons. An explanation for the difference in results is 
apparent when we consider that these authors utilised murine SCID fibroblasts. It has 
been well documented that certain SCID cell lines have as much as 15 % residual 
DNA-PK activity (Blunt et al., 1996). Notably, the V3 cell line used in these studies 
has no detectable DNA-PKcs protein or DNA-PK activity (Figures 3.4 and 3.6). 
NU7026 also enhanced bleomycin induced growth inhibition 9-fold in V3YAC 
cells but had no effect in the V3 cells (Figure 4.6). Previous studies have 
demonstrated that xrs-6 and SCID cells, defective in Ku80 and DNA-PKcs, 
respectively, are sensitive to bleomycin and demonstrated that wortmannin sensitised 
two human tumour cell lines to bleomycin (Hosoi et al., 1998). More recently, 
Oliviera et al., 2002, demonstrated that wortmannin enhanced choromosomal 
damage induced by bleomycin. Wortmannin has also been shown to sensitise MDR 
cells when combined with bleomycin (Kim et al., 2000). These data strengthen the 
argument that DNA-PK is involved in the repair of DNA lesions induced by 
bleomycin, and that NU7026 acts by inhibiting this repair. 
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For a compound to be an effective resistance modifier it should: - 
" Enhance the cytotoxicity of the damaging agent with little or no inherent toxicity 
of its own. 
" Allow selective killing of tumour cells and modulation of dose to obtain tumour 
control without enhancing the undesirable toxicity to normal tissues. 
With respect to the inhibitors used here, a 16 hr exposure to 10 µM NU7026 or 
0.4 µM AG14361 alone did not significantly reduce cell survival (Table 3.5) whereas 
survival in combination with IR at the LD90 level was reduced by both inhibitors, 
alone and in combination. Thus, NU7026 and AG14361 fulfill the first requirement 
for a resistance modifier, described above. 
DNA repair in tumour cells may be one cause of therapeutic failure. Where 
an enzyme is overexpressed in a tumour as a mechanism of resistance, the use of a 
selective inhibitor is predicted to allow treatment of these tumours which would 
otherwise become radio and chemo-resistant. Several groups have investigated 
whether DNA-PK activity or content correlate with IR sensitivity in different tumour 
types. Sirzen et al., 1999, demonstrated that both DNA-PK content and activity 
correlate with intrinsic radiosensitivity in lung carcinoma. Similarly, Zhao et al., 
2000, showed that DNA-PK activity correlated with IR sensitivity in oesophageal 
cancer cell lines. Several groups have also demonstrated increased DNA-PK activity 
and a corresponding increase in resistance in cell lines treated with antitumour agents 
which induce DNA DSBs as part of their mechanism: - nitrogen mustards (Muller et 
al., 1998), the topo II poison, doxorubicin (Shen et al., 1998, ) and the vinca alkaloid 
vincristine (Erikkson et al., 2002). In addition, levels of DNA-PK activity appear to 
be closely associated with the development of chlorambucil drug resistance in 
chronic lymphocytic leukaemia (CLL) (Muller et al., 1998 a, b). In a study of 
patients with relapsed CLL, DNA-PK activity was invariably elevated, and this 
correlated with chlorambucil resistance in ex vivo cytotoxicity assays conducted on 
patient peripheral blood lymphocytes (Muller et al., 2000). Additionally, enhanced 
expression of DNA-PK participates in the development of multiple drug resistance 
(MDR); Kim et al., 2000 demonstrated a 3-fold increase in DNA-PK activity in 
MDR variants compared to parental drug sensitive cells. 
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These studies demonstrate that overexpression of DNA-PK activity may be a 
novel cellular adaptation mechanistically contributing to the resistance of cancer 
cells to both IR and chemotherapeutic drugs. These tumour-specific alterations are 
likely to be important in terms of therapeutic exploitation. 
Drug resistance can arise as a result of various biochemical mechanisms that are 
described in section 1.4. The precise mechanism by which DNA-PK mediates 
resistance to drugs is unknown although it is presumed to be due to an increase in the 
repair of cellular DNA damage induced by IR and chemotherapeutic drugs. 
Alternatively, DNA-PK may serve as a receiver and transmitter of signals that 
contribute to drug resistance by other mechanisms such as detoxification. From the 
studies presented in this thesis, inhibition of DNA-PK may be an important strategy 
to enable the preferential killing of tumour cells by radiotherapy and cancer agents, 
particularly where an overexpression of DNA-PK is implicated as a resistance 
mechanism. 
Elevated expression of PARP-1 may be associated with malignant progression. 
For example, Yano et al., 2002, found significantly higher PARP-1 mRNA in 
primary colorectal tumours in patients with liver metastasis and suggested that this 
could be related to an increased repair capacity of tumour cells which in turn enables 
cells with metastatic potential to survive. In this context, Bieche et al., 1996, 
reported that PARP-1 mRNA expression was higher in human breast cancer tissue 
than in adjacent normal breast tissues. Nomura et al., 2000, found that PARP-1 
mRNA expression was elevated in hepatocellular carcinoma but not in normal liver. 
These data suggest an important role for enhanced PARP-1 expression in human 
cancers and could potentially allow selective treatment of tumour cells. 
Alternatively, lower intracellular NAD+ concentrations are observed in tumours 
compared to normal tissues (Jedeiken and Weinhouse, 1955; Glock and McLean, 
1957). Furthermore, in hypoxic cells, NAD+ levels are reduced by at least 3-fold 
(Wilson et al., 1977) and consequently the NAD+/NADH ratio is lowered and 
NADH is itself able to inhibit PARP-1 activity (Ueda and Hayaishi, 1982). As NAD+ 
is the substrate for PARP-1, the potency of PARP-1 inhibitors which act in a 
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competitive manner will be dependent on the NAD+ concentration. Therefore low 
NAD+ levels and high NADH/NAD+ ratios in tumour cells has the potential to 
increase the antitumour selectivity of PARP-1 inhibitor sensitisation to IR and 
chemotherapeutic agents. 
There is some evidence to date for selective sensitisation of tumour cells in vivo. 
AG14361 caused significant in vivo radiosensitisation in mice bearing LoVo 
xenografts. Indeed, a local IR dose of 2 Gy for 5 days caused a 19 day growth delay 
which was extended to 37 days with the administration of 15 mg/kg AG14361. 
Furthermore, no local tissue toxicity was observed either with IR alone or in 
combination with AG14361 and AG14361 did not induce hypothermia which has 
been observed in mice treated with a dose of PD 128763 required for 
radiopotentiation (Calabrese et al., in press). 
The application of repair inhibitors would be particularly advantageous in 
tumour cells that have lost compensatory repair pathways. Loss of heterozygosity of 
ATM is a common event in lymphoid malignancy and frequent inactivating 
mutations of the ATM gene have been reported in patients with leukaemia 
(Stankovic et al., 2002). ATM is considered to function in the DSB repair pathway 
of homologous recombination (HR). It has been proposed that non-homologous end- 
joining (NHEJ) may function as a back up or complementary pathway for DSB 
repair and vice- versa. DNA-PK is the major complex required for NHEJ and 
therefore inhibition of DNA-PK on an ATM deficient background may be an 
important means of selectively targeting tumour cells. 
It is therefore fitting that 30-40 % of CLL patients have decreased ATM 
(Reviewed in Boultwood et al., 2001), and significantly 30-40 % of relapsed CLL 
patients have overexpressed DNA-PK (Muller et al., 1998; Erikkson et al., 2002) 
thus suggesting that DNA-PK might be a compensatory mechanism for the loss of 
ATM. In support of this hypothesis, there is synthetic lethality between mutation in 
ATM and DNA-PKcs during murine embryogenesis (Gurley et al., 2001). Moreover, 
there is also embryonic lethality in PARP-1 and ATM double knockout mice 
(Menissier de Murcia et al., 2001) and therefore there is potential for the 
development of selective therapeutic strategies via the inhibition of a complementary 
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non-defective pathway as this should significantly decrease the ability of these 
tumours to withstand therapy without a corresponding increase in normal tissue 
sensitivity. 
In summary, the issue of antitumour selectivity is particularly important in 
chemo-potentiation where the anti-tumour selectivity of systemic therapy is limited. 
In radiotherapy, where sensitive tissues can be excluded from the radiation field, 
PARP-1 and DNA-PK inhibitors may have the greatest utility. 
Ionising Radiation PLDR 
The response of human tumours to radiotherapy varies considerably from 
patient to patient. An understanding of the molecular repair processes which lead to 
maximal tumour cell recovery following IR is important for radiotherapy since 
modification of these processes by biological modifiers may increase the therapeutic 
index. 
Tumour cells have an exceptional ability to adapt to altered micro- 
environmental conditions such as reduced nutrients or oxygen availability and 
changes in pH. DNA repair mechanisms rank high amongst the defence mechanisms 
of cancer cells. As described in the introduction (section 4.1.2), non-proliferating 
cells exposed to IR are known to undergo PLDR, leading to substantial increases in 
survival compared to proliferating cells, or cells induced to start a proliferative cycle 
shortly after irradiation (Phillips and Tolmach, 1966; Little, 1969) Evidence for 
PLDR in the non-proliferating compartment of tumours is very sparse, however, 
experimental and clinical observations suggest that this radiation resistant cell 
fraction is capable of re-entering the proliferation cycle and repopulating the tumour 
following IR-induced killing of the proliferating tumour compartment 
(Weichselbaum and Little, 1982; Barendson et al., 2001). Since radioresistant 
tumours are able to carry out high levels of PLDR compared to those tumours 
considered curable, PLDR is considered to be a significant factor in determining 
tumour responses to radiotherapy (Barendsen et al., 2001). The precise molecular 
mechanisms underlying PLDR are at present unknown although it has been 
suggested that DNA is the target (Frankenber-Schwager et al., 1987). 
151 
Studies described in this Chapter have shown that increased radiosensitivity 
due to deficiency or inhibition of either DNA-PK or PARP-1 is not limited to 
proliferating cells but also occurs in G1 arrested cells (Figures 4.12 and 4.13). As 
described in section 4.1.2, early studies indicated that PARP-1 inhibitors could 
reduce the PLDR capacity of cells. More recently, the effect of loss of PARP-1 has 
been investigated. Rudat et al., 2001, demonstrated that in C060 hamster cells, 
PLDR following IR treatment was completely abolished due to the transdominant 
inhibition of poly(ADP-ribosyl)ation. Chaterjee and Berger, 2000, compared PLDR 
following 1-6 Gy and a6h recovery in growth arrested CHO V79 cells and the 
mutant derivatives ADPRT54 and ADPRT351. These mutant cell lines have been 
previously demonstrated to have 5-11 % PARP-1 activity compared to V79 parental 
cells (Chatterjee et al., 1989). In marked contrast to the results obtained with 
inhibitors of PARP-1 and those obtained with transdominant inhibition, Chaterjee 
and Berger, 2000, demonstrated that mutant V79 cells deficient in PARP-1 activity 
were proficient in PLDR and therefore concluded that PARP-1 does not participate 
in PLDR. The results derived from these studies are not consistent and therefore the 
data presented in this Chapter compared two techniques for removing PARP-1 
activity; gene knockout and a novel, specific inhibitor, to analyse the role of PARP-1 
in PLDR. 
As PLD is dose-dependent (Guichard et al., 1984), the initial survival level 
needed to be similar in all cell lines, and therefore they were irradiated with equitoxic 
doses to allow for comparison of PLDR capacity. In all cell lines, with the exception 
of the Ku80 deficient xrs-6 cells, a delay in subculture resulted in a higher surviving 
fraction than immediate subculture (Figures 4.12 and 4.13). PLDR was significantly 
reduced in cell lines deficient in either DNA-PK or PARP-1 compared to their 
proficient counterparts, demonstrating a role for both PARP-1 and DNA-PK in 
PLDR and that the capacity for PLDR reflected the inherent radiosensitivity of the 
cell lines. For example, the V3 cells only recovered 2-fold following a 24 h delay in 
subculture compared to an 8-fold recovery in the V3YAC cells. This reflects the 4- 
fold higher radiosensitivity of exponentially growing V3 cells compared to V3YAC 
cells at the LD90level (Table 3.3). Similarly, Li et al., 1998, reported that SCID cells 
demonstrated a lack of PLDR following delayed plating. Mice or cell lines deficient 
152 
in Ku have a more severe phenotype than those deficient in DNA-PKcs and therefore 
it was not surprising to find that the xrs-6 cells were unable to carry out any PLDR. 
Similar studies showed that delayed plating of Ku80 deficient xrs-5 cells, did not 
significantly modify cell survival suggesting a deficiency in PLDR (Illiakis et al., 
1990). These data suggest a possible role for Ku in the recovery of PLDR that is 
independent of DNA-PKcs. Possible independent functions for Ku in DNA repair 
are reviewed in Chapter 5 (see section 5.4.2). 
The effect of inhibitors of PARP-1 and DNA-PK in the proficient cell lines 
was comparable with loss of the enzyme. Inhibition of both enzymes had a more 
profound effect on PLDR than inhibition of one enzyme combined with the lack of 
the other and this is consistent with the data where DNA DSB repair was 
investigated (Chapter 5). AG14361 slightly, but significantly inhibited PLDR in the 
PARP-1 -/- cells. A possible explanation for this is that AG14361 may additionally 
inhibit PARP-2, which has also been implicated in DNA repair (Schreiber et al., 
2002). 
When PLDR was measured in the V3YAC and V3 cell lines over time, the 
surviving fraction of cells increased up to a maximum at 6 hours with no further 
enhancement in survival being achieved by extending the recovery period to 24 h 
(Figure 4.11). The lower survival under conditions that promote growth may 
therefore be interpreted as a fixation of repairable DNA damage during progression 
of cells through the cell cycle under post-IR conditions (Figure 4.2). DNA-PK 
activity but not content is expressed in a cell cycle dependent manner (Lee et al., 
1997) and increases as cells approach G1/S phase transition. This might be connected 
to the fact that PLDR largely occurs in G1 and may explain both the reduced PLDR 
in DNA-PK deficient cells and the extremely potent inhibition of PLDR by NU7026. 
Referring back to the studies carried out by Chaterjee and Berger, 2000, 
discussed earlier, which suggested that PARP-1 is not involved in PLDR, the 
difference in conclusions is likely to be due to the different cell models which have 
been utilised. The cells used by this group were grown in nicotinamide deficient 
medium for over 3 months in order to isolate clones with constitutively reduced 
NAD levels (Chatterjee et al., 1989). In addition, this group utilised high 
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concentrations of the mutagen MNNG to select cells deficient in PARP-1 activity. 
The resulting mutant cell lines have slower doubling times and increased frequency 
of SCE compared. to parental cell lines (Chatterjee et al., 1987). Although this is 
consistent with compromised DNA repair due to PARP-1 deficiency, it is likely that 
this phenotype is due to other genetic abnormalities instead of or in addition to 
reduced PARP-1 activity. Indeed, treatment with high concentrations of MNNG 
would cause multiple mutations at different gene loci as opposed to a mutation that is 
related directly to PARP-1 deficiency. 
Cell cycle arrest at either the G1 or G2 checkpoint is important to ensure 
proper DNA replication, DNA integrity and mitotic cell division. The magnitude of 
G2 delay has been shown to reflect the degree of IR-induced DNA damage and cell 
radiosensitivity (Nagasawa et al., 1994). Cell cycle analysis following IR treatment, 
reported here, showed that DNA-PK deficient V3 cells had an increased and 
prolonged G2 arrest. Similarly, NU7026 in combination with IR caused a substantial 
and prolonged G2 arrest in V3YAC cells which was greater than that observed in the 
V3 cells. In Chapter 5, data is presented which demonstrates that more DSBs remain 
60 minutes post-IR in the presence of NU7026 than in the absence of DNA-PK and 
therefore this re-inforces the notion that the G2 arrest is reflecting levels of DNA 
damage. Consistent with these findings, Lee et al., 1997 concluded that permanent 
G2 arrest following DNA damage is a feature common to cell lines defective or 
impaired in DNA-PK activity. In addition, Rosenzweig et al., 1997, demonstrated 
that WM treated SW480 cells had a prolonged G2/M delay with > 50 % of cells 
arrested 50 h post-IR. Alternatively, DNA-PK might perform a novel function and be 
involved in the exit from the G2 checkpoint control. 
AG14361 had a small effect on the proportion of G2 cells following IR and 
this is consistent with the findings of Jacobson et al, 1985, who reported that PARP- 
1 inhibitors enhanced G2 arrest following treatment with alkylating agents. As with 
the DNA-PK deficient or inhibited cells, this could reflect higher levels of damage 
compared to untreated cells or a cell cycle progression function for PARP-1. The 
mechanism of PARP-1 and DNA-PK in cell cycle arrest remains to be clarified. 
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In the context of PLDR and cell cycle progression, it is possible that 
inhibition or absence of either of the enzymes serves to delay the cells from re- 
entering the cell cycle thus preventing colony formation. In addition, there may be 
cellular intolerance to concurrent blockade at these two distinct cell cycle 
checkpoints. Both DNA-PK and PARP-1 are induced when cells enter the cell cycle 
from a quiescent state (Cai et al., 1994) and therefore this could account for the 
enhanced survival of enzyme proficient cells compared to deficient cells. In the case 
of a tumour this could enhance the repopulation of a tumour and therefore inhibitors 
of PARP-1 and DNA-PK should prevent this. 
In conclusion, the data presented here suggest that pharmacological inhibition 
of DNA-PK and PARP-1, both alone and in conjunction, represents a promising 
strategy for tumour sensitisation. The mechanism by which these inhibitors of 
PARP-1 and DNA-PK sensitise cells have been further investigated in the following 
Chapters by evaluating the inhibition of DNA repair (Chapter 5) and the interaction 
of the enzymes (Chapter 6). 
4.5 Summary 
The studies presented in this Chapter have shown that; 
" Inhibition of PARP-1 or DNA-PK has potent radiosensitising effects in both 
exponentially growing and radioresistant non-cycling cells 
" Capacity for PLDR reflects radiosensitivity 
" Both PARP-1 and DNA-PK are involved in the capacity of cells to recover from 
PLD 
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CHAPTER 5 
INHIBITION OF DNA REPAIR BY INHIBITORS OF PARP-1 
AND DNA-PK IN CELL LINES PROFICIENT OR DEFICIENT IN 
PARP-1 OR DNA-PK 
5.1 Introduction 
DNA double strand breaks (DSBs) are the most cytotoxic lesion that are 
induced by IR and radio-mimetic chemicals, and can also be generated during certain 
site-specific recombination processes or when a DNA polymerase encounters 
damage on its template. DNA DSBs can result in the direct inactivation or mutation 
of a key gene, leading to cell death or impaired cell function. Alternatively, being 
highly recombinogenic, unrepaired DSBs can lead to chromosomal translocations 
that generate highly unstable dicentric chromosomes or acentric chromosome 
fragments leading to genome rearrangement. 
Ionising radiation (IR) induces a spectrum of DNA damage lesions ranging 
from an isolated lesion (for example, base modifications, AP sites, SSBs and DSBs) 
to a `cluster of lesions'. Such `multiply damaged sites' (MDS) are a unique feature of 
DNA modifications caused by IR and some radiomimetic drugs and many different 
forms of MDS are generated due to the plethora of types of oxidative lesions 
produced by IR. MDS consist of two or more lesions, within a distance of 10 to 15 
base pairs or occurring within one or two helical turns of the DNA. The lesions can 
be situated on the same strand or opposing strands. The simplest MDS is a DSB 
(Figure 5.1), however, as described in section 1.3.4.1, the frequency of IR-induced 
damage is in the order of base damage > SSB>DSB>crosslinks. Hence, 80 % of 
MDS consist of base damages or AP sites whilst only 20 % of the total consist of 
DSBs. Thus, whilst DSBs are the most recognisable clustered lesions, they may 
constitute a small fraction of the total. 
The more complex a lesion, the less likely correct repair will occur. 
Importantly, clusters are difficult to repair and thus potentially lethal or mutagenic 
lesions can be formed. For example, when two base damages are situated in opposing 
strands and are more than three base pairs apart, partial repair of both base damages 
156 
ý-ý 
ýý 
W 
a a ý 
ý ý 
ý 
A 
. ýý 
ý - 
ý 
W 
a a ý 
O 
V 
W 
a a ý 
ý ý 
N 
C 
m 
m C1 
J 
ý-, 
Cý 
aý 
b 
M en 
can occur at the same time, resulting in the production of a DSB. Since the formation 
of DSBs is of biological importance, the lethality of IR is therefore believed to be 
due to the production of these clusters of lesions. 
DNA repair is known to occur via several pathways in living cells (section 1.5). 
Two fundamentally different pathways may be utilised to remove DSBs from the 
genome of eukaryotic cells; HR and NHEJ, of which NHEJ is thought to comprise at 
least 80 % of DSB repair in mammalian cells (Weaver, 1995). These pathways may 
compete, co-operate or act sequentially. In the past few years, major advances have 
been made in the identification of the factors required for DSB repair as well as in 
the analysis of the biochemical function of the individual proteins. The major factors 
involved in HR and NHEJ are described in sections 1.5.2.1 and 1.5.2.2 and shown in 
Figure 5.2. 
The known NHEJ factors include Ku70, Ku80 and DNA-PKcs which comprise 
the DNA-PK holoenzyme but their precise function in repair and the critical target 
proteins are not known. The interaction between Ku protein and DNA-PKcs has been 
extensively investigated and recent studies have begun to map the sequences within 
the Ku heterodimer that are required for repair function (Singleton et al., 1997; Jin 
and Weaver, 1997). In Ku70, all mutations that impair dimerization, DNA end 
binding and DNA-PK activation affect repair. Additional participants in the DNA- 
PK mediated NHEJ repair pathway include XRCC4 and ligase IV and the recently 
identified co-factor artemis (Reviewed in Jeggo and O'Neill, 2002 and references 
therein). XRCC4 and ligase IV form a tight and specific complex, with the 
interaction being mediated by the non-catalytic C-terminal region of ligase IV that 
contains two copies of the BRCT domain (Koonin et al., 1996). Briefly, XRCC4 
binds to DNA ends as a dimer and each monomer in this dimer binds, in turn, a 
monomer of ligase IV thus creating a tetrameric protein complex. This is ideally 
suited to allow ligation of two strands. Although the role that XRCC4 plays in repair 
is unknown, the activity of ligase IV is stimulated by its association with XRCC4 
(Grawunder et al., 1997). Taken together, XRCC4 might serve to activate ligase IV 
and target it to the DNA-PK containing DNA NHEJ complex. 
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Before DNA ligase IV can execute ligation, the ends need to be `tidied up'. A 
function for the RAD50-Mrel l-NBS1 complex has been suggested. Artemis, a 
recently identified nuclease, interacts with DNA-PKcs and has been suggested to be 
required for efficient DSB repair (Moshous et al., 2001). Indeed, DNA-PK 
phosphorylation specifically regulates the activity of artemis (Ma et al., 2002). The 
exact function of artemis in DNA DSB repair is unknown, however, it is reasonable 
to suggest that this enzyme may be responsible for the endonucleotic activity that 
removes overhanging ends in preparation for repair (reviewed in Jeggo and O'Neill, 
2002). 
Deficiency in factors required for successful execution of NHEJ leads to 
defective V(D)J recombination, hypersensitivity to IR and defective DSB repair. 
Among the mutants, DNA-PKcs and artemis mutants are least severe, having no 
obvious phenotype other than the general defects described above. Interestingly, 
although the artemis mutants are hypersensitive to IR, they have been reported to be 
proficient in DSB repair (Nicolas et al., 1996). Ku mutants have an intermediate 
severity, with prolonged doubling times due to a loss of proliferating cells and 
premature senescence. The XRCC4 and ligase IV mutants are the most severe, 
resulting in embryonic lethality. Intriguingly, it has been shown that deletion of Ku 
in these cells rescues the embryonic lethality (Karanjawala et al 2002). 
The mechanism of DSB repair by homologous recombination (HR) is only 
partially understood, though many models have been proposed. The loss of RAD54 
leads to recombinational deficiencies and DSB repair defects (Bezzubova et al., 
1997). The absence of RAD51 causes the accumulation of chromosomal 
abnormalities and cell death (Sonoda et al., 1998). Tsuzuki et al., in 1996, 
suggested that HR is essential in vertebrate cells, however, the precise role is unsure. 
As shown in Figure 5.2, evidence suggests that the RAD50-MRE11-NBS1 complex 
participates in the repair of DNA DSBs via either NHEJ or HR (D'Amours and 
Jackson, 2002; Petrini, 1999). Indeed, in its absence, NHEJ is reduced 50-fold and 
HR is delayed. 
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BER of MDS 
One of the major pathways to repair base lesions, AP sites and SSBs is the 
BER pathway which is a multi-step process involving the sequential action of several 
proteins (reviewed in section 1.5.1 ). BER is therefore likely to be involved in the 
repair of clustered damage sites induced by IR. Importantly, MDS with a base 
damage situated close to and in the opposite strand to a SSB could be converted to a 
DSB. It has been proposed that repair of such MDS may enhance the number of 
DSBs in the DNA following treatment with IR (Ward, 1988). Since the induction of 
DSBs has been correlated with IR-induced cell death (Macmillan et al., 1993), their 
production needs to be minimised. Several mchansims have been proposed that are 
likely to prevent the conversion of non-lethal lesions or mutagenic lesions into lethal 
DSBs. Firstly, preferential repair of damage on one strand before the other has been 
suggested and secondly DSB formation may be prevented through the production of 
repair intermediates. The latter mechanism is particularly relevant when considering 
the role of PARP-1 in BER. A role for PARP-1 has been proposed as an 
antirecombinational factor and as a protection factor. In this regard, PARP-1 could 
ensure that SSB repair intermediates are never left unprotected and therefore remain 
unavailable to form part of a DSB during partial repair of MDS. 
In summary, it is therefore likely that the NHEJ and BER machinery may 
interact to enhance the repair of complex lesions. There is good evidence for the 
function of PARP-1 and DNA-PK in BER and NHEJ, respectively (reviewed above 
and in sections 1.6.4.4. and 1.10.4) and therefore this is one way in which the two 
enzymes might interact in response to IR. Moreover, accumulating evidence has 
indicated a role for PARP-1 in DSB rejoining (reviewed in section 5.4.3). 
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5.2 Aims 
The aim of this third results Chapter was to investigate the repair of DSBs and 
SSBs following treatment with IR, in paired cell lines proficient or deficient in 
PARP-1 or DNA-PK, in order to elucidate the mechanism underlying the increased 
radio sensitivity of PARP-1 and DNA-PK deficient cell lines. In addition, the effect 
of AG14361 and NU7026 on the repair of DSBs and SSBs was investigated. In order 
to allow comparison of these results with cytotoxicity data presented in Chapter 4, 
AG14361 and NU7026 were used at concentrations of 0.4 gM and 10 µM, 
respectively, in all experiments described below, unless otherwise stated. 
5.3 Results 
5.3.1 Induction of DSBs as a function of radiation dose in exponentially growing 
CHOK1 cells 
The DSB levels following increasing doses of IR was investigated in the 
CHO-K1 cell line by neutral elution (Figure 5.3 A and B). This allowed a dose of IR 
to be chosen for subsequent DNA DSB repair assays that a) would enable a high 
level of DSBs to be induced such that the full extent of inhibition of DSB rejoining 
by the PARP-1 or DNA-PK inhibitors (alone and in combination) could be evaluated 
and b) was still within the sensitivity limit of the technique. A parental cell line was 
chosen since the initial level of damage induced by a particular dose of IR should be 
the same in all cell lines, regardless of their radiosensitivity status, as the initial yield 
of IR-induced DNA lesions mainly reflects physical and chemical processes rather 
than being dependent on the physiological state of the cells (Olive, 1998). The 
induction of DNA DSBs as a function of radiation dose is considered to be linear 
(Frankenberg-Schwager, 1989) and therefore a relationship exists between the rate of 
DNA eluted and the dose of irradiation. With increasing doses of IR, followed by 
immediate elution so that no repair would occur, a dose dependent increase in the 
rate of elution was observed (Figure 5.3B). Relative elution (RE) values were 
calculated from the elution profile (Figure 5.3A), as described in section 2.8. Figure 
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5.3B demonstrates that RE increased with the dose of IR up to 75 Gy and the level of 
strand breaks reached a plateau between 75 and 100 Gy, a reflection of the limit of 
sensitivity of the technique. A dose of 75 Gy was therefore used in all DNA DSB 
repair studies described in this Chapter. 
5.3.2 Kinetics of DSB repair in cell lines proficient or deficient in PARP-1 or 
DNA-PK 
The kinetics of DNA DSB repair following exposure to 75 Gy IR over a 60 
min time period were compared in cell lines proficient or deficient in PARP-1 or 
DNA-PK (Figure 5.4). Briefly, DSB levels were measured by neutral elution either 
immediately after IR or following either a 10,30 or 60 minute recovery period at 
37°C in order to allow repair to occur. In order to quantitate the difference in the 
elution profile of irradiated cells compared to a non-irradiated control, and allow 
inter-experimental comparisons, RE values were calculated, and from these % repair 
and % inhibition of repair were calculated as described in section 2.8 
In the PARP-1 proficient (PARP-1 +/+) and the DNA-PK proficient 
(V3YAC) cells, DNA DSBs were rejoined rapidly, with the majority of strand break 
rejoining (-60 %) occurring within the first 30 minutes and 81 % and 89 %, 
respectively, of DSBs rejoined by 60 min (Figure 5.4 A, B). By contrast, in the V3 
(deficient in DNA-PKcs) and PARP-1 -/- cell lines, higher DNA DSB levels 
remained at 60 min post-IR with only 61 % and 58 % DNA DSB rejoined, 
respectively. 
Interestingly, within the first 30 minutes, the V3 cells repaired DSBs with the 
same fast kinetics as the V3YAC cells with 50 % of the breaks being rejoined within 
21 ±3 and 17 ±2 minutes, respectively. Furthermore, there was no significant 
difference in the amount of DSBs that had rejoined within the 30 minute period, 60 
% (V3YAC) and 58 % (V3), p= 0.19. However, in the V3 cells, no significant 
increase in rejoining occurred during the following 30 minutes. This data implies that 
initial repair up to 30 minutes of -60 % of the lesions is not DNA-PKcs dependent 
but subsequent repair is DNA-PKcs dependent. 
161 
O 
O 
Uý 
ý 
ý 
0 
0 
_T 
O l() 
Oý 
r 
iieda8 % 
jiedaä % 
Jiedalq % 
Iýa 
LO oý N bA 
.., W 
rLO 
rLO 
ý N 
0 ý b G) 
N 
0 a, x aý 
ý ý 3 
ý ý 
aý U 
ý ý y 
U 
ý y 
ý x 
d 
ý 
ý ý 
4° 
ir 
... 
U 
O 
00 
ºýr 
cd 
ý 
Ü 
ZI; 
ý ý aý 0 
ý 
ý 
ý 
Q 
äa 
ý" 
ý 
CI) 
A 
d 
ýo N z ýý F-i 4-o 
0 
y 
V 
.. r ý 
ý 
04 
UD 40 ýC 
Ln 
ý 
ý ý u U 
M 
Q 
ti 
. -r 
aý U 
U 
ý 
M 
ý 
ý 
ý 
In contrast, the PARP-1 -/- cells were defective in rejoining DSBs at these 
early time points and were only able to repair 32 % of breaks within 30 minutes, 
taking 55 ±4 minutes to repair 50 % of their DSBs compared to 16 ±2 minutes in 
the PARP-1 +/+ cells. These data suggest that PARP-1 makes an important 
contribution to the very early stages of DSB repair. 
Strikingly, in the Ku80 deficient xrs-6 cells, 99 % of DSBs remained 
unrejoined following 60 minute post-IR incubation, demonstrating that no significant 
repair (p = 0.13) had occurred during this time period (Figure 5.4C). This deficiency 
in repair was restored by complementation with Ku80 cDNA. Like the other enzyme 
proficient cell lines, the xrs-6 Ham Ku80 cells carried out the majority of rejoining 
within the first 30 minutes with 50 % of breaks rejoined within 26 minutes and 82 % 
of breaks rejoined within 60 min. 
5.3.3 The effect of AG14361 and NU7026 on DNA double strand break repair. 
To determine if the inhibitors also modulated DNA DSB repair and in order 
to investigate the mechanism underlying the single and combined effects of the 
inhibitors on cytotoxicity following IR, DNA DSB levels were assessed in the 
presence or absence of AG14361 and/or NU7026 at 10,30 and 60 min post-IR. The 
percentage of inhibition of repair values are summarised in Table 5.1. The 
production of DSBs is not attributable to a direct effect of the inhibitors on the 
integrity of DNA since the elution profiles of DNA from cells exposed to AG14361 
or NU7026 alone for 60 minutes was the same as that for untreated controls (data not 
shown). 
As the greatest difference in repair between the enzyme deficient and 
proficient cell lines was seen at 60 min post-IR and the majority of DSBs had 
rejoined during this period (Figure 5.4 A, B and C), the % repair in the presence of 
inhibitor(s) 60 minutes post-IR are compared in Figure 5.6 and these are described in 
more detail below. Representative elution profiles for V3 and V3YAC cells are given 
in Figure 5.5. As expected, NU7026 had no significant effect on the limited repair 
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Figure 5.6 Effects of AG14361 and NU7026 on DNA DSB repair 60 minutes post- 
IR 
A; V3YAC cells; B, V3 cells; C, PARP-1 +/+ cells; D, PARP-1 -/- cells. Cells were pre- 
incubated with inhibitor(s) for 60 min, exposed to 75 Gy IR and post-incubated for 60 
min in the absence of inhibitor(s) before harvesting for neutral elution. Data are the 
mean ± SEM of at least 3 independent experiments. 
A 
Cell line V3YAC V3 
Inhibitor 
(s)/Time 
(Min) 
AG14361 NU7026 AG14361 
+ NU7026 
AG14361 NU7026 AG14361 
+NU7026 
10 37±8 5412 74±4 53±6 3±3 53±2 
30 20±2 41±0.4 82±3 72±3 -3±2 71±4 
60 40±6 55±3 95±4 55±3 0 50±1 
4 42±2 65±4 99±3 49±3 0 47±2 
24 17±3 25±2 89±3 40.1±2 0 39±2 
B 
Cell line PARP-1 +/+ PARP-1 -/- 
Inhibitor 
(s)/Time 
(Min) 
AG14361 NU7026 AG14361 
+ NU7026 
AG14361 NU7026 AG14361 
+NU7026 
10 36±3 53±2 69±3 9.4±5 33±3.2 41±2.5 
30 23±1 37±4 68±5 6.3±0.5 49.1±3.5 57±5 
60 25±2.9 50±3.8 80±5.1 4.5±3.2 40±4.8 45±2.9 
Table 5.1 Table of % Inhibition of repair by AG14361 and NU7026 
A, V3YAC and V3 cells; B, PARP-1 +/+ and PARP-1 -/- cells. Values were 
calculated as described in section 2.8 and are the mean f SEM of at least 3 
independent experiments. 
capacity of the V3 cells, p =0.16, and similarly, AG14361 did not significantly 
inhibit repair in the PARP-1 -/- cells, p=0.8 (Figure 5.6B and D). NU7026, did, 
however, inhibit repair in the PARP-1 -/- cells by 40 ±5% (p= < 0.001) and 
AG14361 inhibited repair in the V3 cells by 55 ±3% (p = <0.001). In the V3YAC 
cell line, (Figure 5.6A) AG14361 and NU7026 significantly inhibited DSB repair by 
40 ±6% (p = <0.001) and 55 ±4%, (p =<0.001) respectively, compared to the 
drug free control. Repair in the V3YAC cells in the presence of NU7026 was below 
that of the V3 cells. Very similar results were obtained in the PARP-1 +/+ cells 
(Figure 5.6C), with AG14361 and NU7026 inhibited the rejoining of DSBs by 25 ±3 
% (p = <0.001) and 50 ±4% (p = <0.001), respectively. Repair in the PARP-1+/+ 
cells in the presence of AG14361 was not significantly different from repair in the 
PARP-1 -I- cells. 
Consistent with the radiosensitisation data with the inhibitors, described in 
Chapter 4, at least additive effects on DSB repair inhibition were observed when the 
inhibitors were co-incubated in enzyme-proficient cells. The combined effect of the 
inhibitors in V3YAC cells led to an almost total inhibition of repair (95 ±4 %) but 
the V3 cells were able to achieve approximately 60 % repair in the presence of both 
AG14361 and NU7026. In the PARP-1 +/+ cells, AG14361 and NU7026, in 
combination, inhibited repair by 80 ±5% whereas the same combination only 
inhibited repair in the PARP-1 -/- cells by 45 f3%. These data suggest that 
inhibition of both enzymes has a more profound effect than inhibition of one 
enzyme, combined with a lack of the other. 
The effects of the inhibitors at the earlier time points of 10 and 30 minutes 
were also assessed. The % repair at these time points are presented in Table 5.2. 
Repair in the V3YAC cells in the presence of NU7026 followed the same kinetics of 
repair as the DNA-PK deficient V3 cells, with an initial fast component followed by 
an insignificant amount of repair occurring between 30 and 60 minutes post-IR 
incubation (Figure 5.8 A and B ). Interestingly, at all time points, repair in the 
V3YAC cells in the presence of NU7026 was lower than in the V3 cells indicating 
that inhibition of DNA-PK has a more profound effect on DSB repair than a lack of 
the enzyme. 
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V3YAC V3 PARP-1 +/+ PARP-1 -/- 
10 min 40.0 ± 2.1 32.2 ± 2.4 45.0± 1.8 18.8 ± 1.7 
10 min 27.8±2.2 16.3±2.2 27.0±2.5 16.9±0.96 
+AG14361 
10 min 20.4 ± 3.1 34.0± 3.5 22.3 1.6 12.7 1.45 
+NU7026 
10 min 11.0±2.1 12.5±2.2 14.3±2.1 11.2±3.1 
+AG14361 
+NU7026 
30 min 60.0 ± 7.9 57.0 ± 3.6 59.0 ± 4.4 32.0 ± 2.1 
30 min 49.7 ± 1.8 17.0 ± 2.1 44.0 ± 3.0 29.2 ± 3.7 
+AG14361 
30 min 36.7 ± 2.5 61.7 ± 3.8 38.9 ± 1.4 16.3 ± 3.2 
+NU7026 
30 min 11.6±2.4 34.0±2.6 11.2±2.9 13.7±2.2 
+AG14361 
+ NU7026 
Table 5.2 Table of % repair values at 10 and 30 min post-IR 
Values were calculated as described in section 2.8 and are the mean I SEM from at 
least 3 independent experiments. 
DNA DSB repair in the PARP-1+/+ cells in the presence of AG14361 
followed the same kinetics as observed in the PARP-1 -/- cells, however, in contrast 
to the effect of NU7026 in the V3YAC cells, at 10 and 30 minutes, repair was lower 
in the absence of PARP-1 rather than in the presence of AG14361 (Table 5.2). 
5.3.4 The effects of AG14361 and NU7026 on double strand break (DSB) repair 
at 4 and 24 hours 
The longer term repair and the effects of the inhibitors on DNA DSB repair 
were investigated by assessing DNA DSB levels in the V3YAC and V3 cells 4 and 
24 h post-IR (Figure 5.7). DNA DSB repair was complete by 4h in the V3YAC 
cells but 33 % of DSBs still remained at this time in the V3 cells, although by 24 h, 
only 5% of DSBs remained such that there was no significant difference between the 
number of breaks rejoined in the V3YAC and the V3 cells at 24 h (p= 0.84). These 
data demonstrate that the DNA-PK deficient V3 cells are able to repair DNA DSBs 
nearly completely but with slower kinetics than the V3YAC cells. Incubation of 
V3YAC cells with AG14361 retarded DSB repair by 42 ±2% and 17 ±3% at 4 and 
24 h, respectively. NU7026 hindered repair of DSBs by 65 ±4% and 25 ±2%, at 4 
and 24 h, respectively. The combination of inhibitors completely inhibited repair at 
4h and by approximately 90 % at 24 h (p <0.05 for all values). These results are 
summarised in Figure 5.8 A. NU7026 exerted no significant additional effect on the 
repair in the V3 cells (p= 0.09), however, inclusion of AG14361 inhibited DSB 
repair by 49 ±3% (p= <0.001) and 40 ±2% (p = <0.001) at 4 and 24 h, 
respectively. Due to time constraints, similar experiments in the PARP-1 +/+ and 
PARP-1 -/- cells were not carried out. 
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Figure 5.7 Effects of AG14361 and NU7026 on DNA DSB repair at 4 and 24 h post- 
IR 
A, V3YAC cells; B, V3 cells. Cells were pre-incubated with inhibitor(s) for 60 min, 
exposed to 75 Gy IR and post-incubated in the presence of inhibitor(s) for 4 or 24 h before 
harvesting for neutral elution. Data are the mean f SEM of at least 3 independent 
experiments. 
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5.3.5 The effects of AG14361 and NU7026 on single strand break (SSB) repair 
The effects of AG14361 and NU7026 on the repair of DNA SSBs induced by 
6 Gy IR (which caused approximately 90 % cell kill in parental AA8 cells, see 
Figure 3.7) were investigated 60 min post-IR in the V3 and V3YAC cells by alkaline 
elution. As would be predicted, SSB repair in the absence of inhibitors was equally 
effective in both the V3YAC and V3 cell lines (Figure 5.9A and 5.9B, respectively), 
with 85 % of breaks rejoined within 60 minutes. Whilst AG14361 inhibited SSB 
repair by 38±2%(p=<0.05) and 39±3 % (p = <0.05) in both the V3YAC and V3 
cells, respectively. NU7026 had no significant effect in either cell line (p= >0.05). 
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Figure 5.9. Effects of AG14361 and NU7026 on DNA SSB repair 
A, V3YAC cells; B, V3 cells. Cells were pre-incubated in the presence or absence of 
inhibitor(s) for 60 min, exposed to 6 Gy IR and post-incubated for 60 min before 
harvesting for alkaline elution. Data are the mean ± SEM of at least 3 independent 
experiments. 
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5.4 Discussion 
The most important mechanism promoting survival of a tumour following IR 
is the faithful repair of DNA DSBs. Eukaryotic cells have evolved specific pathways 
for processing DNA DSBs by either homology dependent or non-homologous repair 
pathways (reviewed in section 1.5). 
The techniques of neutral and alkaline filter elution were used to evaluate the 
repair capacity of paired cell lines proficient or deficient in PARP-1 or DNA-PK. 
The effect AG14361 and NU7026 on the repair of DNA DSBs and DNA SSBs in 
these cell lines were also investigated. 
5.4.1 Repair of DSBs in cells deficient in DNA-PK 
Data presented in this Chapter have demonstrated that whilst extensive DNA 
damage was observed immediately after irradiation in all cell lines, DSBs were 
rejoined rapidly in the parental V3YAC cells (80 % complete by 60 minutes). In the 
DNA-PKcs deficient V3 cells, DSBs were initially repaired rapidly with about half 
of the DSBs rejoined within 30 minutes but subsequent repair was slow (Figure 5.4). 
The deficiency in DSB repair was even more pronounced in the Ku80 deficient xrs-6 
cells, with no significant rejoining observed within the 60 min post-IR incubation. 
However, the Ku80 transfectant cell line was able to repair the DSBs proficiently. 
These data are consistent with many studies that have demonstrated a 
cessation of strand break rejoining following an initial short period of repair in DNA- 
PK deficient cells (Lees-Miller et al., 1995; Biedermann et al., 1991; Allalunis- 
Turner et al., 1995; Chang et al., 1993). However, these groups utilised relatively 
short periods of post-IR incubation. Rejoining in the V3 cells was further studied by 
allowing prolonged post-IR incubation times (up to 24 hours) to assess the ultimate 
fate of IR-induced DSBs in the genome of these DNA-PK deficient cells (Figure 
5.8). Surprisingly, despite lacking DNA-PK activity, repair in the V3 cells 
nevertheless approached completion by 24 h, demonstrating that the V3 cells are 
only slightly less proficient than the V3YAC cells at rejoining DNA DSBs by 24 h. 
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These results are consistent with data published by Diabase et al., 2000, who 
compared the rejoining of DNA DSBs in the DNA-PK proficient human glioma cell 
line M059K and the isogenic but DNA-PK deficient M059J cell line (Allalunis- 
Turner, 1995) using pulse field gel electrophoresis (PFGE). PFGE, like neutral 
elution detects DSBs by physically measuring the changes in the average size of the 
cellular DNA (as shown by the migration rate of DNA through an agarose gel) where 
the average size of DNA molecules is inversely proportional to the number of DSBs. 
Consistent with the data presented in this Chapter, rejoining of DSBs in both these 
cell lines was biphasic (fast and slow component) and was nearly complete following 
30 h post-IR. Moreover, as with the data presented here with the V3 cells, the 
authors demonstrated that the slow component of repair removed the majority of 
DNA DSBs in cells lacking DNA-PK activity. Similarly, a study by Nevalidine et 
al., 1997, also showed that the SCID defect results in much slower rate of repair of 
DSBs, but not high levels of residual breaks. 
These data are therefore indicative of a DSB repair pathway that remains 
active in the absence of DNA-PKcs. A number of lines of evidence indicate that 
although DNA-PKcs highly stimulates the NHEJ pathway, in its absence a slower 
repair pathway still operates (Dibiase et al., 2000). The slower component of repair 
is probably mediated by DNA-PKcs-independent NHEJ, but may also involve HR 
which requires a complex of DNA repair proteins including RAD5 1, BRCA1, 
BRCA2, XRCC2 and ATM (Jackson, 2002). 
NHEJ and HR probably represent alternative or overlapping pathways for the 
repair of the same types of lesion. Genetic evidence in the literature suggests that 
these pathways, whilst distinct, might compete (Roth and Wilson, 1985), co-operate 
(Richardson and Jasin, 2001) or, depending on the persistence or accumulation of 
DSBs, act sequentially for the repair of the same DSB (Saintigny et al., 2001) and 
this may be a function of the cell cycle. For example, DNA-PK activity is highest in 
the G1/S phases of the cell cycle and SCID, V3 and xrs-6 cells are most sensitive to 
IR in the G1 phase of the cell cycle (Lee et al,. 1997), and therefore NHEJ is thought 
to act predominantly in these phases of the cell cycle. In contrast, HR is restricted to 
the S and G2 phases of the cell cycle when a sister chromatid is available to serve as 
a template (Takata et al., 1998) and as such its primary function appears to be to 
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repair DSBs which arise frequently during DNA replication (Haber, 1999; Sonoda et 
al., 1998). These data therefore suggest that the two pathways play distinct and 
independent roles. 
If these two pathways are in competition for DSBs, eliminating one should 
increase the contribution of the other. Consistent with this hypothesis, Mateos et al., 
1994, observed elevated DSB rejoining in mammalian NHEJ mutants in late S/G2 
that could be attributed to the HR pathway. Moreover, consistent with the theory 
that the inactivation of NHEJ shifts DSBs to the competing HR pathway, a number 
of groups have demonstrated increased HR in the absence of either Ku 70, Ku80 or 
DNA-PKcs (Pierce et al., 2001; Allen et al., 2002). Significantly, Fukushima et al., 
2001, demonstrated that abrogation of HR activity by targeting RAD54 in Ku70-/- 
cells led to at least additive increases in IR sensitivity. Most recently, Allen et al., 
2002, sought to test the effects of DNA-PKcs on DSB-induced HR by comparing 
HR-mediated gene conversion in V3 cells and V3 cells complemented with human 
DNA-PKcs. The DNA-PKcs proficient cells had at least a 2-fold reduction in DSB- 
induced HR suggesting competition between DNA-PKcs and the HR apparatus. 
Delacote et al., 2002, studied the impact of alteration of late NHEJ on HR. They 
demonstrated that IR-induced recombination was stimulated by both the XRCC4 
mutation and wortmannin treatment, as assessed by the stimulation of Rad5I foci 
assembly which represent the assembly of the homologous recombination complex at 
the molecular level. 
However, there is no consensus of opinion on the role of HR in NHEJ 
defective mutants. Liang et al., 1996a, have reported that DSB-induced HR 
frequencies in mammalian cells are not affected by a defect in Ku80. In contrast, 
Fukushima et al., 2001, demonstrated that the frequency of intrachromasomal HR 
induced by I-SceI restriction enzyme was increased in the absence of Ku but not in 
the absence of DNA-PKcs, an observation that contradicts the findings of Allen et 
al., 2002. Moreover, earlier studies to those by Delacote et al, 2002, suggested that a 
defect in XRCC4 shows very little effect on HR (Pierce et al., 2001). 
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In support of a slow component of NHEJ, studies have shown that whilst HR 
is largely an error free process, the slow component of repair in DNA-PK deficient 
cells is largely error prone (Loebrich et al., 1995). This is supported by the 
observation that loss of Ku is associated with impaired fidelity of repair in cell free 
systems (Liang et al., 1996b). However, other authors have observed faithful and 
efficient repair in Ku and/ or XRCC4 deficient cells (Kabotyanski et al., 1998). 
Similarly, Tzung et al., 1998, found no decrease in the fidelity of DSB rejoining in 
Ku80 deficient xrs6 cells. 
Single strand annealing (SSA) is another homology-dependent DSB repair 
mechanism (reviewed in section 1.5.2.3) that is not error-free and, as it does not 
require the presence of a sister chromatid, this repair pathway might also operate in 
the G1/ early S phases of the cell cycle. It is therefore possible that SSA accounts for 
the backup repair pathway in NHEJ deficient cells and generates the genomic 
rearrangements seen in these cells. Contrary to this, however, as described above, 
cells deficient in NHEJ have a marked defect in DSB rejoining in G1/early S (Jeggo, 
1998a) which suggests that no efficient alternative pathway present in this cell cycle 
phase can fully compensate for the loss of NHEJ. Furthermore, given the much 
slower repair in the V3 cells compared to the V3YAC cells, if this system is capable 
of rejoining DSBs then it must be considerably less efficient than DNA-PKcs 
mediated repair. 
As a consequence of the different mutant and knockout cell lines and assay 
end-points used by the various groups, current data therefore do not distinguish 
between the different DSB repair pathways as a mechanism for the slow repair 
observed in DNA-PK deficient cell lines. It is possible that both pathways may 
operate under certain conditions and that they are not necessarily mutually exclusive. 
Indeed, the Mrel l/RAD50/NBS1 complexes have roles in both NHEJ and HR. 
Furthermore, evidence is accumulating regarding interactions between DNA-PKcs 
and proteins that influence HR such as ATM which is a potential target of DNA- 
PKcs phosphorylation. 
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It was intriguing that the V3 cells were able to repair DNA DSBs with the 
same kinetics as the parental V3YAC cells for the first 30 minutes, which accounted 
for as much as 60 % of the total breaks rejoined. In contrast, the PARP-1 -/- cells 
only repaired 32 % of breaks within this time and with slower kinetics. In addition, 
the xrs-6 cells were unable to carry out any significant repair within this time. It is 
possible that the early and rapid repair in the V3 cells, which is absent in both the 
PARP-1 -/- and xrs-6 cells, represents the repair of a specific subset of lesions of 
different complexity that do not require DNA-PKcs (although it obviously requires 
Ku and PARP-1). Indeed, as discussed in section 5.1, DSBs induced by IR can be 
exceptionally complex due to the proximity of base lesions and single strand breaks 
and as many as 10 lesions may be present in a complex DSB. 
A number of groups have investigated the consequences of a lack of Ku80 on 
DNA DSB repair (Chen et al., 1996; Wachsberger et al., 1999; Liang et al., 1996a). 
A previous study by Kemp et al., 1984, demonstrated that whilst xrs-6 cells were 
defective in DSB rejoining following 90 Gy IR, as measured by neutral elution, they 
were still able to repair -40 % of their breaks within 2 hrs. The data presented in this 
Chapter are more consistent with the results this group obtained with xrs-5 cells 
(independently isolated but also mutated in Ku80) which were only able to repair 
approximately 10 % of breaks even when time was extended to 4 h. The data 
presented in this Chapter, in agreement with others, demonstrated that transfection of 
Ku80 eDNA into the Ku80 defective cell line restores the DSB repair deficiency in 
xrs-6 cells (Ross et al., 1995). Despite evidence that DNA-PKcs might function 
independently of Ku in DNA repair, as suggested by biochemical studies showing 
that DNA-PKcs has weak DNA binding kinase activity (Yaneva et al., 1997) and 
suggestions that it plays a structural role as well as a signal transduction role by 
tethering the DNA ends and providing scaffolding for assembly of repair complexes 
(Jackson and Jeggo, 1995; Jeggo et al., 1995; Roth et al., 1995), the data presented in 
this Chapter indicate that Ku is required for efficient repair at least in the first 60 
minutes, whereas both Ku and DNA-PKcs are required at later time points. 
As described in section 5.1, the repair of clustered lesions formed following 
exposure to IR can lead to the formation of DSBs through the repair of closely 
associated lesions. For example, a DSB may be formed through the incision of an AP 
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site by AP endonuclease when the AP site is opposite or near to another AP site or 
SSB or when lesions within a clustered damage site are repaired simultaneously as 
opposed to sequentially. Hashimoto et al., 2001, demonstrated that Ku could inhibit 
the nicking activity of the human BER enzyme, endonuclease III, thereby preventing 
the formation of a free DSB. It should therefore be considered that a fraction of the 
unrejoined DSBs in the xrs-6 cells may reflect a component of clustered lesions 
being converted to DSBs. 
The relative repair capacities of the cell lines, correlates with the 
radiosensitivity data presented in Chapter 3, section 3.7, which showed that the 
DNA-PKcs deficient V3 cells were less sensitive to IR than the Ku80 deficient xrs-6 
cells (Table 3.3). In support of these findings, Ku-deficient mice have a more severe 
phenotype compared to DNA-PKcs -/- mice in terms of growth characteristics. In 
addition, Ku-deficient primary MEFs exhibit severe growth retardation and early 
senescence whilst DNA-PKcs -/- primary MEFs are normal in these aspects. The 
more severe DNA repair deficiency of the Ku-inactivating mutation in the xrs-6 cells 
compared to the ability of the V3 cells to carry out the same amount of repair as 
parental V3YAC cells within the first 30 minutes could be due to DNA-PKcs 
independent functions for Ku in DSB repair or reflect residual DNA-PKcs protein in 
the V3 cells that is sufficient to carry out some (Ku-dependent) activities. Although 
Ku may be a component of HR, this is unlikely as the evidence reviewed above 
indicates that Ku competes for HR by preventing access of nucleases and other 
factors involved in this repair mechanism. 
The exact nature of the mutation in the V3 cells has not been determined (see 
section 3.1.1) and these cells have not been shown definitively to represent a null- 
function mutation. Consequently, there is the potential existence of mutant DNA- 
PKcs protein which may retain sufficient activity to mediate some, albeit limited, 
DSB repair. However, it is unlikely that the initial fast repair in the V3 cells is due to 
residual DNA-PKcs, as Western blot analyses demonstrated an absence of detectable 
DNA-PKcs protein (Figure 3.4) and there was undetectable DNA-PK activity in V3 
cell extracts (not significantly different from the minus oligonucleotide control) 
compared to 750 pmol ATP/µg protein in control V3YAC cells (Figure 3.6). 
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Furthermore, 10 µM NU7026 had no additional inhibitory effect on the repair of 
DSBs or potentiation of cytotoxicity (sections 5.3.3 and 4.3.1.2) in the V3 cells. 
In other systems, however, there may be residual DNA-PKcs activity. For 
example, SCID cells have been shown to have detectable DNA-PKcs transcripts and 
as much as 15 % residual DNA-PKcs protein (Blunt et al., 1996). In addition, the 
presence of DNA-PKcs transcripts in M059J cells, albeit at 20-fold reduced levels 
compared to M059K cells, have been demonstrated (Galloway et al., 1999; Lees- 
Miller et al., 1995). In terms of the repair defect of these cell lines, mutant protein 
could possibly exert a dominant negative effect rather than simply reflecting a loss of 
DNA-PK activity (Jeggo, 1997). 
The data presented here, and studies published elsewhere, point to a role for 
Ku in mediating the ligation of DNA ends independently of DNA-PKcs. Indeed, the 
molar ratio of Ku to DNA-PKcs in mammalian cells ranges from 3: 1 to 15: 1 (Chan et 
al., 1996; Yumoto et al., 1998) and therefore Ku is in excess if its function is 
restricted only to being the regulatory protein of DNA-PK. 
In support of the suggestion that the Ku heterodimer may have roles in DNA 
repair that are independent of DNA-PKcs, Gao et al., 1998, utilised a gene targeting 
study to generate embryonic stem (ES) cells with abrogated DNA-PKcs expression. 
Briefly, the authors inserted a neomycin resistance gene into exon 6 in the opposite 
transcriptional orientation from that of the DNA-PKcs gene. This prevented 
translation of a functional DNA-PKcs protein and thus represents a null mutation. 
The cells were further characterised for RNA protein and DNA-PK activity. Analysis 
of these cells demonstrated a phenotype very similar to the SCID phenotype. 
Surprisingly, these cells, unlike characterised Ku70-deficient ES cells, had the same 
radiosensitivity as their wild type or heterozygous mutant counterparts. The authors 
therefore concluded that these findings suggest that Ku may have DNA-PKcs- 
independent functions in DNA repair. 
172 
5.4.2 DNA-PK independent roles for Ku in DNA DSB repair 
The role of Ku in DNA DSB repair is likely to be in the very early stages of 
DSB repair, most likely the initial recognition of the DNA end. Ku may act solely as 
a sensor of DNA damage by binding and signalling to other repair proteins such as 
DNA-PKcs or activating other repair pathways. Alternatively, one hypothesis to 
explain the hypersensitivity to DNA damaging agents and the inability to join DNA 
ends is that the absence of functional Ku proteins results in a lack of end protection, 
causing the broken DNA molecules to be susceptible to exonucleolytic degradation. 
This suggests that Ku may have a more direct role in DSB repair involving the 
protection of DNA ends from degradation and competing with the HR apparatus 
thereby enhancing the accuracy of NHEJ. 
This hypothesis has been studied previously and with different outcomes. 
Many reports found that DNA ends are more degraded in Ku-defective mutants than 
wild type cells (Taccioli et al., 1994; Roth et al., 1995; Rathmell and Chu, 1994; 
Liang. et al., 1996; Getts and Stamato, 1994), However, Kabotyanski et al., 1998 
demonstrated that the degradation of linear plasmids was not significantly decreased 
in Ku80 deficient cells nor was there an increase in the frequency of deletions. 
These authors suggested an alternative role for Ku in aligning or stabilising 
intermediates in end joining rather than in protecting ends from degradation. 
As originally proposed by Thode et al., 1990, DNA ends must be held in 
juxtaposition by an `alignment protein'. The Ku heterodimer has been put forward 
as a candidate for an alignment factor during NHEJ. The recent crystal structure of 
the Ku heterodimer (Walker et al., 2001) has shown that Ku is well designed to 
structurally support broken DNA ends and bring the DNA helix into phase across the 
junction during end processing and ligation. Current models suggest that Ku can 
associate to form a bridging complex thus allowing DNA ends to be held in 
appropriate configuration for end processing and subsequent ligation (Yaneva et al., 
1997; Cary et al., 1997; Pang et al., 1997). Furthermore, Ku has the ability to 
translocate along DNA molecules in an ATP-independent manner (DeVries et al., 
1989). This `sliding clamp' behaviour of Ku implies the existence of a channel in 
Ku that may well be suited to hold the ends of two molecules aligned in preparation 
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for ligation. The ability of Ku to self associate has been demonstrated both 
biochemically (Ramsden and Gelert, 1998) and by atomic force microscopy (Cary et 
al., 1997; Pang et al., 1997; Feldmann et al., 2000). 
To this end, Cary et al, 1997, used a combination of electron and atomic force 
spectroscopy to visualise Ku in association with DNA. The authors showed that 2 
molecules of DNA bound Ku can associate thus giving rise to the formation of DNA 
loops and therefore resulting in a physical tethering of the DNA ends. Consistent 
with this, direct evidence has been presented by Feldmann et al, 2000, who used a 
plasmid rejoining assay to demonstrate that the capability to align DNA termini is 
lost in xrs-6 cells compared to parental CHOK1 cells, decreasing the stability of 
DNA ends and thereby compromising both the efficiency and accuracy of NHEJ. 
In support of a direct role for Ku in mediating end ligation independent of 
DNA-PKcs, Ramsden and Gellert, 1998, demonstrated that purified eukaryotic 
ligases, I, III and IV are stimulated by Ku. Ligation of a 60 bp blunt ended substrate 
by recombinant DNA ligase 1 was stimulated >1 00-fold by co-incubation with Ku 
in a concentration-dependent manner. DNA ligase IV, purified from HeLa cells, was 
also strongly stimulated by Ku. Notably, Ku stimulation of ligation was most 
efficient when the juxtaposed ends cohered poorly. These results are consistent with 
a role for Ku in bridging and stabilising two ends, yet maintaining accessibility of the 
ends to the ligase thus increasing the efficiency of NHEJ. 
Several of the components of the NHEJ pathway which include ligase IV and 
XRCC4 may also be involved in DNA-PKcs independent rejoining of DNA DSBs 
and could fulfil such an alignment function (Wilson et al., 1997; Baumann and West, 
1998; Boulton and Jackson, 1996; Seide et al., 1996). Furthermore, it is conceivable 
that Ku and XRCC4 may act together to allow assembly of DNA-protein complexes 
at sites of DNA damage to enable the rejoining of broken DNA ends. In fact Ku has 
recently been shown to recruit the XRCC4-ligase IV complex to DNA ends 
(Kabotyanski et al., 1998). However, it has been shown more recently by Calsou et 
al., 2003, that both Ku and DNA-PKcs are required for the recruitment of XRCC4 
and ligase IV. 
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Other possible interrelated functions for Ku are helicase and ATPase 
activities. Ku translocation into the DNA away from the ends may also facilitate end 
joining by unwinding DNA ends through its intrinsic helicase activity thereby 
allowing microhomology alignments to occur (Tuteja et al., 1994). 
In summary, the roles of DNA-PKcs and Ku in end joining are currently 
unclear. The rapid, early repair in the DNA-PKcs deficient V3 cell line suggests that 
either multiple pathways of DSB rejoining are active in this early phase or that DNA- 
PKcs has a purely regulatory or damage sensory role. In contrast, Ku80 deficient 
cells were drastically defective in DSB repair suggesting critical roles for Ku which 
according to the published literature, may include the protection of ends from 
degradation, orientation of ends for ligation and the recruitment of DNA-PKcs and/or 
additional factors necessary for successful end joining. 
5.4.3 Repair of DSBs in cells deficient in PARP-1 
It has been generally assumed for many years that PARP-1 has very little 
role, if any, in the repair of DSBs. In general, the literature is lacking an analysis of 
PARP-1 function in DSB repair although molecular evidence indicates that PARP-1 
interacts with DSBs as well as SSBs. Using plasmid DNA digested with a variety of 
restriction enzymes and other endonucleases to produce defined fragments of DNA 
of known structure, Benjamin and Gill, 1980, measured the activation of PARP-1 by 
measuring poly(ADP-ribose) (PAR) synthesis. Blunt-ended DNA DSBs were 10 
times more effective at activating PARP-1 and supporting PAR synthesis than SSBs. 
This was subsequently confirmed by (Weinfield et al., 1997) who showed using 
highly purified enzyme that DNA DSBs were more potent activators of PARP-1 than 
SSBs. Moreover, two early reports have shown that the rejoining of DSBs induced 
by the electroporation of restriction enzymes into cells was delayed by the classical 
PARP inhibitor 3-aminobenzamide (3-AB) (Chung et al., 1991; Bryant and Johnston, 
1993). These observations, implying an important role for PARP-1 in the processing 
of DSBs, have largely been overlooked among the burgeoning evidence for a role for 
PARP-1 in BER. 
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To the best of my knowledge this is the first description of a direct analysis of 
DNA DSB repair following exposure to IR in a PARP-1 knock out cell line. The 
data presented in this Chapter are consistent with PARP-1 activity being required for 
recovery from IR-induced DNA DSBs especially at early time points (< 60 minutes). 
However, these data do not prove a direct role for PARP-1 in NHEJ. Whilst PARP-1 
could have a direct role in the DNA DSB repair process, in which DSBs arise due to 
a retardation in DSB rejoining, it may have a more indirect modulatory role. To this 
end, PARP-1 could serve as a backup function for the deficiency in DNA-PKcs 
described above, thus allowing ligation of breaks at early time points following 
initiation of damage in the absence of DNA-PKcs. Alternatively, a function for 
PARP-1 as an anti-recombinogenic factor has been proposed (Lindahl et al., 1995) 
and therefore PARP-1 may function indirectly in end-joining by protecting ends from 
illegitimate homologous recombination thus promoting DNA-PK mediated NHEJ. 
This hypothesis is consistent with evidence showing that an additional loss of PARP- 
1 function in DNA-PK deficient SCID mice can rescue the block in V(D)J 
recombination that typifies the SCID phenotype (Morrison et al., 1997). 
The PARP-1-/- cells were particularly defective in DSB repair at early time 
points and therefore this suggests that PARP-1 may be important for alterations in 
the chromatin structure that occur initially in strand break rejoining to allow access 
of multifactorial DNA-repair complexes. This could hold true for both BER and 
NHEJ. Alternatively, the increased DSBs measured in the absence of PARP-1 may 
arise from a subset of complex IR-induced lesions being converted to DSBs. As 
described above (section 5.1), one of the hallmarks of IR is the formation of multiply 
damaged or clustered sites (see section 5.1). These complex lesions include abasic 
(AP) sites, base lesions or SSBs that may be repaired by the BER pathway in which 
PARP-1 is intimately involved. Unrepaired or poor efficiency of repair of clustered 
lesions as a result of PARP-1 deficiency could result in the production of DSBs 
although in the studies described in this thesis there was no greater accumulation of 
DNA DSBs in PARP-1 -/- cells compared to those irradiated and eluted immediately. 
Studies by Lomax et al., (Unpublished results, personal communication), have 
demonstrated that simple clustered lesions are repaired sequentially thus limiting the 
formation of DSBs to <2 %. For example, a SSB or AP site inhibits the excision of a 
base lesion on the opposite strand. However, in the experiments described in this 
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thesis, the possibility that in the absence of PARP-1, the kinetics of DNA DSB 
formation and repair could be altered, such that the slower net decrease in DSBs 
could be a function of an increase in DSB formation instead of or as well as reduced 
repair cannot be excluded. 
In support of the suggestion that the effect of a loss of PARP-1 is actually due 
to a subset of lesions being converted to DSBs, a recent study by Noel et al., 2003, 
investigated the rejoining kinetics of normal and PARP-1 knockout mouse 3T3 
fibroblasts to neocarzinostatin (NCS) induced DSBs by PFGE. In comparison to IR, 
this drug does not induce a large spectrum of lesions but creates only frank DSBs. In 
contrast to the data presented here with IR, no significant difference in the rejoining 
kinetics of both cell lines was found and therefore the authors concluded that PARP- 
1 is unlikely to play a role in the repair of DSBs at least in the absence of other types 
of DNA damage. 
A number of publications demonstrate an interaction and co-operation 
between PARP-1 and DNA-PK either functionally or physically (Ruscetti et al., 
1998; Ariumi et al., 1999; Morrison et al., 1997; Galande and Kohwi-Shughematsu., 
1999). Significantly these enzymes have been shown to automodify one another in 
cell free extracts (Ariumi et al., 1999; Ruscetti et al., 1998). Specifically, Ruscetti et 
al., 1998, showed that PARP-1 can poly(ADP-ribosylate) DNA-PK which leads to an 
activation of the modified protein. Whilst it is very unusual to find an example of 
poly(ADP-ribosyl)ation activating a DNA-binding enzyme it is relevant in this 
context as it could be postulated that a lack of PARP-1 protein would lead to reduced 
DSB rejoining as a reflection of a down-regulation of DNA-PK activity. However, in 
the studies described in this thesis, DNA-PK activity was shown to be the same in 
both the PARP-1+/+ and PARP-1 -/- cells (Figure 3.6). Furthermore, it is 
noteworthy that both AG14361 and NU7026 were able to further inhibit repair in the 
DNA-PK deficient and PARP-1 deficient cell lines, respectively, suggesting that 
although the two enzymes might inhibit DNA DSB repair indirectly by modulating 
the activity of the other enzyme, they also possess independent functions in DNA 
DSB repair. 
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5.4.4 Interactive effects of Ku and PARP-1 in DNA DSB repair 
Notably, both PARP-1-/- and Ku80 deficient cells were defective in DSB 
repair at early repair times in contrast to the normal early-phase repair in the V3 
cells. Although possible DNA-PKcs independent roles for Ku in DSB repair have 
been discussed in section 5.4.2, this repair could be a function for PARP-1 or indeed 
a combined role for PARP-1 and Ku. An intimate association between PARP-1 and 
Ku has been demonstrated in co-immunoprecipitation studies (Ruscetti et al., 1998;, 
Morrison et al., 1997, Galande and Kohi-Shigamatsu., 1999). Ku70 possesses a high 
affinity motif for PAR binding (Pleshke et al., 2000) and as described in section 
3.3.3, Figure 3.5, Ku80-deficient xrs-6 cells had as much as 25 % less PARP activity 
than the isogenic xrs-6 HamKu8O cells. Moreover, PARP-1 -/- Ku80-/- cells are 
embryonic lethal (Henrie et al., 2002). Taken together, these data suggest that Ku 
and PARP-1 may have overlapping roles in the repair of DNA damage. 
5.4.5 The effect of AG14361 and NU7026 on DNA DSB repair 
It could be argued that the DSB rejoining capacity measured in the DNA- 
PKcs deficient V3 cells results from compensatory processes activated as a result of 
this defect, and for which the cells may have been selected during mutant isolation. 
Indeed, these cells may have adapted to this pathological state by altering their 
normal DNA damage responses and this could be true for any of the cell lines tested. 
Consequently, DSB rejoining in the presence of inhibitors of either DNA-PK or 
PARP-1 was evaluated. 
It should be borne in mind, however, that a mutation in an enzyme and its 
inhibition are two distinct phenomena and therefore these two approaches could give 
very different outcomes. Nevertheless, chemical inactivation of either PARP-1 or 
DNA-PK caused changes in DSB rejoining which were very similar to those 
observed after genetic inactivation of the proteins i. e. drastic reduction in the level of 
strand breaks rejoined. 
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When the inhibitors were used at the concentrations required to potentiate 
cytotoxicity, inhibition of PARP-1 or DNA-PK did not completely block repair but 
slowed it down considerably (Figure 5.8). These results are consistent with the 
findings of Boulton et al., 1999, who showed that both the PARP-1 inhibitor, 
NU1025, and the DNA-PK inhibitor, wortmannin increased net DSB levels induced 
by 100 Gy IR over a3h time period, as assessed by neutral elution. When used in 
combination, approximately additive effects were seen throughout the 3h time 
period. Moreover, Rudat et al., 2001 assessed the influence of overexpressing the 
DNA binding domain (DBD) of PARP-1 (under the control of the dexamethosone 
promoter) on the rejoining kinetics of IR-induced DNA DSBs using pulse field gel 
electrophoresis. This is an analogous situation to the use of PARP-1 inhibitors where 
it is the poly(ADP)ribosylation step that is inhibited rather than the ability to bind 
DNA strand breaks. Following treatment with 60 Gy IR, the fast component of DNA 
DSB rejoining was reduced from 60 % to 20 % when the PARP-1 DBD was 
overexpressed compared to control cells. The authors followed repair over 25 hrs 
and demonstrated that inhibition of PARP-1 activity induced a shift from rapid to 
slow DSB rejoining but less than 1% of breaks remained following 25 h post-IR. 
Inhibition of DNA-PK had a more pronounced effect on DSB rejoining than 
lack of enzyme at all time points measured (Table 3.2). As can be seen in Figure 5.8, 
DSB rejoining in the V3 cells approached completion by 24 h but only 70 % of the 
breaks, had rejoined at 24 h in the V3YAC cells treated with NU7026. In contrast, 
repair in the PARP-1 -/- cells was not significantly different from repair in the 
PARP-1 +/+ cells treated with AG14361 at 60 min (Figure 5.6 C and D). It was 
particularly striking that combined inhibition of both enzymes resulted in a profound 
inhibition of DNA DSB repair. Exposure to both inhibitors for 60 min resulted in a 
complete inhibition of repair in the V3YAC cells and 80 % inhibition in the PARP-1 
+/+ cells. Even at 4h and 24 h, the majority of breaks remained unrejoined (99 % 
and 90 %, respectively) in the V3YAC cells exposed to both inhibitors. In contrast, 
repair was only inhibited by 50 % in the V3 and 45 % in the PARP-1 -/- cells by co- 
incubation with both inhibitors and this was not significantly different from the 
inhibition observed with the appropriate inhibitor alone (i. e. V3+AG14361 and 
PARP-1-/- +NU7026). This suggests that the cells may have upregulated 
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compensatory repair mechanisms and/or that inhibition of repair enzymes can have a 
greater effect than the loss of the enzyme. 
The dissociation kinetics of PARP-1 and DNA-PK from DNA ends will be 
changed dramatically by the presence of potent inhibitors of these enzymes. PARP-1 
and DNA-PK undergo automodification when activated by DNA strand breaks and 
this reaction is essential to release PARP-1 and DNA-PKcs from DNA ends (Satoh 
and Lindahl, 1992; Merkle et al., 2002). Wortmannin has been demonstrated to 
block DNA-PK at DNA ends and prevent their processing by DNA polymerisation, 
degradation or ligation (Calsou et al., 1999). Satoh and Lindahl, 1992 also 
demonstrated, in a cell free-assay, that inactive PARP-1 sequestered DNA ends and 
prevented repair. Similarly AG14361 and NU7026 will block PARP-1 and DNA- 
PK, respectively, at DNA ends. Thus AG14361 could modulate DSB repair 
indirectly by binding and preventing access to DNA-PK rather than through an 
inhibition of PARP-1. However, the clear effect of an absence of PARP-1 on the 
rejoining kinetics of DSBs implicates PARP-1 directly in DSB repair. As well as 
interfering with the access of the other enzyme, these protein bound DNA termini 
could hinder assembly of the enzyme complexes required for successful execution of 
all modes of NHEJ and HR. This could easily explain the more pronounced effect of 
inhibited enzyme versus a lack of enzyme. 
In support of this hypothesis, Sak et al., 2002, compared the effect of an 
antisense oligodeoxynucleotide (As-ODN) specific for the translational start of 
DNA-PKcs mRNA with wortmannin on the kinetics of DSB repair over a4h period 
following exposure to 30 Gy. In both cases the fraction of DSBs rejoined was 
reduced 60 min post-IR compared to untreated control cells and the AS-ODN and 
wortmannin were equally as effective. However, whilst the cells treated with the SIR 
went on to repair the majority of their breaks within the following 4 h, wortmannin 
continued to significantly retard rejoining >4 h following IR. The authors suggest 
that the inhibitor renders the site inaccesible for repair by other pathways whilst, by 
contrast, the SIR physically removes DNA-PKcs and leaves DNA ends accessible to 
DNA-PK independent (slow repair) pathways. 
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Interestingly, in contrast to the inhibition of DNA-PK, at early time points 
(10 and 30 min), PARP-1 inhibition was not as deleterious as a lack of enzyme 
suggesting that PARP protein-protein interactions are important. Proximal SSBs on 
complementary strands could be stabilised and repaired by a two step process when 
PARP-1 is functioning. As described above, in the absence of PARP-1, this process 
could fail and therefore lead to the formation of DSBs. Inhibited PARP-1 on the 
otherhand would still bind these strands but would remain bound and therefore in 
effect could also stabilise DNA ends thus preventing their conversion to DSBs at 
early time points following IR. However, inhibited PARP-1 compared to lack of 
PARP-1 would prevent the access of other repair factors (as described above) leading 
to increased DSB formation at later time points. For example, DNA polymerases 
could stall on the DNA in the vicinity of an unrepaired nick occupied by PARP-1 (de 
Murcia et al., 1994b). 
The similar effects on DNA DSB repair seen with either lack of or inhibition 
of PARP-1 and DNA-PK favours the idea that the enzyme activities are required for 
processing of DNA ends, and that the effect of the inhibitor(s) are not solely due to a 
block of DNA breaks. These enzymes therefore probably regulate some aspects of 
repair such as the recruitment of repair factors, rather than functioning as mechanistic 
components of repair. 
5.4.5 Neutral elution as a technique to measure DNA DSB breaks 
Various experimental approaches have been developed for the measurement 
of DSBs in DNA. Neutral elution provides an accurate and quantitative evaluation of 
DNA DSB levels, however, the interpretation of elution data is controversial. It has 
been suggested by Flentje et al., 1993, that neutral elution measurement of DSBs 
may be influenced by the presence of SSBs. Importantly, these authors suggested 
that the initial fast component of the biphasic repair kinetics measured by neutral 
elution may be attributable to the interference of SSBs rather than the measurement 
of DSBs. This is particularly relevant to the data presented in this Chapter, as if this 
were to be the case, the ability of V3 cells to initially repair the breaks induced by IR 
and the apparent inability of PARP-1 -/- cells to repair these breaks could actually be 
a reflection of an effect on the repair of SSBs and not DSBs in a PARP-l proficient 
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and deficient background. This consideration has important implications for the 
interpretation of the data presented in this Chapter. 
Clear evidence to the contrary, however, has been presented by Prise et al., 
1989, who showed that DNA from cells treated with hydrogen peroxide (which 
induces mainly SSBs) did not elute under neutral conditions at a significantly higher 
rate than DNA from untreated cells. Moreover, Johnston et al., 1991, treated CHO 
cells with camptothecin (a topoisomerase I inhibitor) for 60 minutes and eluted the 
DNA under alkaline or neutral conditions. Under alkaline conditions, extensive 
elution was recorded. In contrast, very little elution occurred under neutral 
conditions. These results verify those of Prise et al., (1989), demonstrating that the 
presence of SSBs in the DNA does not affect the rate nor the extent of elution of 
DNA containing DSBs under neutral conditions. 
Neutral elution does not distinguish between DNA DSBs resulting from 
impaired rejoining of DNA ends and those induced during cell death. It could 
therefore be argued that rather than reflecting reduced rejoining, the high percentage 
of remaining DSBs in the presence of inhibitor(s) 24 h post-IR, may be due to the 
induction of apoptosis where endonuclease activity would give rise to DNA 
fragmentation. However, in the parental V3YAC cells, exposed to the same 
supralethal dose of IR, where < 1% of cells would be predicted to survive, all DSBs 
had nevertheless rejoined. Furthermore the data presented by Diabase et al., 2000, 
(discussed in section 5.4.1. ) who used PFGE, a technique that distinguishes between 
degradation and DNA repair, showed no evidence for apoptosis, expressed as DNA 
degradation in their experiments even at 30 h post-IR. 
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5.4.6 The effects of AG14361 and NU7026 on SSB repair 
SSB repair in the absence of inhibitors was equally effective in both the 
V3YAC and V3 cell lines, with 85 % repair occurring within 60 min. AG14361 
inhibited repair in both cell lines whilst NU7026 had no significant effect. 
The initial observation that PARP-1 inhibition reduced SSB rejoining was 
demonstrated by Durkacz et al., 1980, who showed that the PARP-1 inhibitor, 3AB, 
reduced the fraction of SSBs rejoined in L1210 cells following treatment with either 
DMS or MNNG. Other authors, using the comet assay, have shown that the 
rejoining of radiation-induced SSBs was dramatically reduced in PARP-1 knockout 
cells and significantly delayed by PARP-1 inhibitors in L1210 cells (Bowman et al 
2001) and PARP-1 +/+ 3T3 cells (Atorino et al., 2001; Trucco et at., 1998). 
In contrast, Vodenicharov et al., 2000, demonstrated that BER was efficient 
in cells lacking PARP-1 by measuring the repair of plasmid DNA following IR and 
proposed that the hypersensitivity of PARP-1 knock out cells to irradiation is not due 
to a defect in repair itself but rather results from greatly reduced poly(ADP-ribose) 
formation during base excision repair. Furthermore, depletion of PARP-1 by 
antisense RNA has been shown to result in a delay in strand break rejoining in HeLa 
cells at early time periods of recovery following MMS induced DNA SSBs, as 
measured by alkaline elution. However, consistent with the findings of Vodenicharov 
et al., (2000), at later time points (90 minutes) the extent of repair in these cells did 
not differ from that of control cells (Ding et al 1992). It is therefore not possible to 
attribute the potentiating effects of AG14361 to a single repair pathway 
A study by Weinfeld et al., 1997, showed that whilst PARP-1 could be 
activated by both DSBs and SSBs, DNA-PK could only be activated by DSBs, and it 
was not activated by nicks or SSBs and did not participate in BER. The ability of the 
DNA-PK deficient V3 cells to repair SSBs to the same extent as the parental V3YAC 
cells coupled with the lack of a significant effect of NU7026 on SSB repair was 
therefore predictable. The recent finding of a SSB binding site in DNA-PK 
(Hammersten et al., 2000) is relevant, however, as DNA-PK could bind SSBs but 
only play a role in their recognition and/or signalling (to PARP-1 for example). If 
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this were the case, however, binding of DNA-PK in the presence of NU7026 would 
presumably block access to PARP-1 resulting in an apparent increase in SSBs. As 
this was not the case, either DNA-PK has no significant role in SSB repair or PARP- 
1 binds a SSB before DNA-PK. 
5.4.7 Consequences of DSB repair for survival 
The results described in this Chapter and the previous Chapter, demonstrate a 
correlation between the ability to recover from PLD in non-cycling cells and DSB 
repair capacity, i. e. those cells which were defective in PLDR were also defective in 
DNA DSB repair. Strikingly, there was no evidence of any PLDR within 24 h in the 
xrs-6 cells which were incapable of carrying out any DNA DSB repair in 60 minutes. 
It has been shown previously that the increase in survival of yeast cells held after 
irradiation under non-growth conditions is accompanied by the disappearance of 
DSBs from DNA (Frankenberg-Schwager et al., 1980). The level of damage 
remaining post-IR in cells may be critical for survival and therefore recovery 
processes manifested during the post-IR period may be a determinant of 
radiocuribility. Thus, an enhancement in recovery seen following delayed plating of 
growth arrested cells could reflect repair under non-growth conditions. Conversely, 
the reduced survival seen in those cells forced to replicate immediately following IR 
could represent `fixation' of DNA damage. These results are consistent with various 
studies which have attempted to elucidate the molecular mechanism underlying PLD 
recovery and concluded that it is a reflection of enhanced fidelity of repair under non 
growth conditions. 
A further study by Frankenberg Schwager et al., in 1987, studied DSB repair 
under growth and non-growth conditions in the rad54 yeast mutant which has a 
temperature sensitive conditional mutation for DSB repair. The authors 
demonstrated that at the temperature permissive for DSB rejoining, recovery from 
PLD occurred after prolonged holding under non-growth conditions. In contrast, at 
the temperature restrictive for DSB rejoining, the extent of PLDR was negligible. 
They concluded that PLDR is due to the difference of DNA DSB repair under 
immediate and delayed plating conditions. 
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The almost complete and long term abrogation of DNA DSB repair observed 
with the combined use of inhibitors following 24 h post-IR incubation would easily 
explain their potent radiosensitising effects in both proliferating and growth arrested 
cells. Although the DNA-PK deficient V3 cells repaired to the same extent as the 
parental V3YAC cells following 24 h recovery, they were approximately 4-fold more 
sensitive to IR. Slower kinetics of repair would lead to longer-term persistance of 
DSBs that could cause cytotoxicity. 
5.5 Summary 
It is well established that PARP-1 mediates BER by binding to nicks but its 
higher affinity for DSBs, although first described by Benjamin and Gill in 1980 and 
more recently by D'silva et al., 1999, has lacked a functional interpretation. The 
data presented in this Chapter, implicates PARP-1 in the processing and repair of 
DNA DSBs and provides a rationale for its affinity for DSBs. The data presented in 
this Chapter indicate that DNA-PK is not involved in SSB repair, and that whilst it is 
involved in DNA DSB repair, DNA-PKcs is not absolutely necessary. However, 
DNA-PKcs does increase the speed of the repair process very significantly. 
In summary, the data presented in this Chapter have shown that; 
"A lack of or inhibition of either DNA-PK or PARP-1 results in a deficiency 
in DSB rejoining 
" DNA-PKcs deficiency does not have a profound effect on the proportion of 
DNA DSBs repaired but decreases the kinetics with which it occurs 
"A secondary (slow) DSB repair activity is present in the absence of DNA- 
PKcs 
" Ku may have DNA-PKcs independent functions in DNA DSB repair 
" Inhibition of PARP-1 and DNA-PK retards NHEJ and BER and may block 
further downstream processing of DNA ends leading to an almost total 
inhibition of repair 
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CHAPTER 6 
RECIPROCAL REGULATION OF PARP-1 AND DNA-PK AT 
DNA ENDS 
6.1 Introduction 
Both PARP-1 and DNA-PK have important roles to play in DNA damage 
recognition and repair and therefore it is reasonable to suggest that they may co- 
operate to minimise genomic damage caused by DNA strand interruptions. 
Both enzymes are present at similar levels of approximately 1x 106 
molecules per cell, both are non inducible gene products, present constitutively 
within the cell and they share many of the same proposed mechanisms in DNA 
repair. Specifically, both PARP-1 and DNA-PK are suggested to have anti- 
recombinational, protection and DNA damage-inducible signalling properties (see 
sections 1.6.4 and 1.10.4). Moreover, they are activated by the same types of DNA 
conformation and they share many of the same in vitro substrates, which include p53. 
In addition, both enzymes are substrates for ICE-like proteases during apoptosis 
(Shakelford et al., 1999; Kauffman et al., 1992). It is therefore possible that PARP-1 
and DNA-PK might interact with one another either functionally or physically and 
that the two enzymes may regulate one another through posttranslational 
modification. Furthermore, PARP-1 and DNA-PK may compete or co-operate with 
one another at sites of DNA damage. The properties of the two enzymes are 
compared in more detail in Table 6.1. 
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Property DNA-PK PARP-1 
Abundance 10 molecules per cell 10 molecules per cell 
Inducible No No 
Structure Trimeric : Ku70, Ku80 + Monomeric :3 domains ; 
catalytic subunit DBD, AMD and catalytic 
Activated by DNA DSBs DNA SSBs and DSBs 
Fold activation by DNA 10-fold (when Ku is 100-500-fold 
ends present) 
Mechanism Acts as two heterotrimers, Kinetic studies suggest 
one either side of the 2 molecules bind 1 either 
break side of the break 
DNA repair pathway NHEJ BER 
Implicated in NHEJ 
Proposed mechansim(s) Phosphorylation mediates Chromatin relaxation 
of repair recruitment/activation/inac and/or PAR formation 
tivation of key DNA mediates recruitment/ 
repair machinery activation of repair 
factors. 
Proposed mechanism in P53 P53 
signalling 
DNA damaging agents IR, Bleomycin, Nitrogen IR, bleomycin, 
that enzyme deficient mustards, topo II poisons monofunctional alkylating 
cells are hypersensitive agents, Topo I poisons 
to 
Sensitisation by IR, bleomycin, nitrogen IR, bleomycin, 
inhibitors to mustards, topol and II monofunctional alkylating 
poisons, agents, Topo I poisons 
Phenotype of KO mice Deficient in V(D)J Hypersensitive to MNNG 
recombination, DSB and IR 
repair, hypersentive to IR 
Limitations of current Primarily P13-K inhibitors Lack potency, specificity 
inhibitors and solubility 
Novel Inhibitors NU7026 AG14361 
IC50 DNA-PK = 0.44. tM Potent IC50 PARP-1= 23 
nM 
Table 6.1 Comparison of the properties of DNA-PK and PARP-1 
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Evidence that PARP-1 and DNA-PK may interact physically comes from a 
study by Ruscetti et al., 1998, that utilised a Ku antibody to trap proteins from a 
HeLa cell nuclear extract. Amongst other proteins, both PARP-1 and DNA-PK were 
trapped and eluted from the column, thus implicating a physical association for these 
two enzymes. Further evidence implicating a physical association between the two 
enzymes comes from the demonstration that PARP-1 and DNA-PK consistently co- 
immunoprecipitate, suggesting that these enzymes are co-localised within the cell 
(Morrison et al., 1997; Ruscetti et al., 1998). Furthermore, it has been demonstrated 
that PARP-1 and the Ku autoantigen, form a complex before binding to matrix 
attachment sequences (Galande and Kohwi-Shigematsu, 1999). 
In addition, Ruscetti et al., 1998, showed that PARP-1 could be 
phosphorylated by DNA-PK and that PARP-1 can poly(ADP-ribosylate) DNA-PK. 
Given that PARP-1 is known to alter the activities of various nuclear proteins 
through ADP-ribosylation, it might be expected that poly(ADP-ribosylation) of 
DNA-PK would affect its activity. Consistent with this, the study by Ruscetti et 
a1., 1998, showed that poly(ADP-ribosylation) of DNA-PK caused activation of the 
enzyme. 
PARP-1 activity is thought to be regulated through phosphorylation, in vivo, 
(Aoufouchi and Shall, 1997) and PARP-1 serves as a substrate for DNA-PK, in vitro, 
(Ruscetti et al., 1998). These latter studies showed that phosphorylation of PARP-1 
has no detectable effect on activity and therefore phosphorylation of PARP-1 may 
affect some other property of the enzyme. Ariumi et al., 1999, also found that 
phophorylation of PARP-1 by DNA-PK had little effect on PARP-1 activity. 
However, the authors showed that the presence of DNA-PK with PARP-1 markedly 
inhibited PARP-1 activity both in the presence or absence of ATP. Since 
phosphorylation is therefore not likely to be responsible for this inhibition, the 
authors suggest that an alternative mechanism may be that of competition for DNA 
ends between these two enzymes although they point out that a more direct 
mechanism may be involved. 
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In order to investigate whether there is a functional interaction between the 
two enzymes, studies by Weinfield et al., 1997 and D'Silva et al., 1999, have 
investigated the relative affinities of the two enzymes for DNA strand break types. 
Evidence suggests that the two enzymes have preferences for different types of 
breaks. For example, PARP-1 has a greater preference for blunt ends and single 
stranded nicks. In addition, PARP-1 is attracted to a wider range of DNA breaks and 
ends. Both enzymes, however, are activated by DSBs and therefore it is possible that 
despite competing for DNA ends, they may co-operate at the site of a break to repair 
DSBs. For example, PARP-1 may bind initially in order to open the chromatin 
structure and protect the strand ends thus enabling access to DNA-PK. 
Further evidence for a functional interaction between PARP-1 and DNA-PK 
comes from a study by Morrison et al, 1997. SCID mice, defective in DNA-PKcs are 
unable to carry out V(D)J recombination whilst SCID-PARP-1 knockout mice are 
able to carry out this process and therefore the absence of PARP-1 appears to rescue 
V(D)J recombination in DNA-PK defective mice. This implies that PARP-1 
normally serves as an anti-recombinational factor in which it binds to DNA ends, 
preventing illegitimate recombination reactions from occurring. These findings 
serve to reinforce the notion that PARP-1 might bind DNA ends first, thereby acting 
as a protection factor prior to DNA-PK-mediated DSB rejoining. The authors also 
demonstrate that animals defective in both enzymes have a far lower survival rate 
than those with deficiencies in either one alone. The two enzymes may serve as `back 
up' functions for one another. Indeed, PARP-1 may have a function in DNA damage- 
inducible signalling (see section 1.8.4.2). However, since there are no apparent cell 
cycle control defects in PARP-1 -/- cells, Lindahl et al., 1995 have tentatively 
proposed that PARP-1 does indeed play a role in a damage inducible signalling 
pathway but that a backup function may exist in which DNA-PK might be involved. 
The final evidence, to date, for a functional interaction between PARP-1 and 
DNA-PK comes from investigations which have employed inhibitors of the two 
enzymes alone and in combination. When used in conjunction with one another, the 
DNA-PK inhibitor, wortmannin and the PARP-1 inhibitor, NU1025, were shown to 
produce at least additive effects for inhibiting DSB break repair and potentiating IR 
cytotoxicity (Boulton, et al., 1999). For example, wortmannin gave a dose 
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enhancement factor (at 10 % survival) of 4.5, whilst NU1025 gave a dose 
enhancement factor of 1.7. When used in combination, an enhancement factor of 7.8 
was observed. These data are supported by the results presented in Chapters 4 and 5 
with AG14361 and NU7026. 
6.2 Aims 
Given that PARP-1 and DNA-PK bind with high selectivity to DNA strand 
breaks they may regulate one another's activity through post-translational 
modification and/or they may compete with one another or co-operate for binding at 
sites of DNA damage. Previous Chapters have investigated the effect of inhibitors of 
these enzymes on survival (Chapter 4) and DNA repair (Chapter 5) following 
exposure to IR. However, in order to fully exploit the potential of PARP-1 and DNA- 
PK inhibitors for cancer therapy, a mechanistic understanding of their interactions is 
essential. The aim of this final results Chapter was therefore to investigate the 
interaction of PARP-1 and DNA-PK at DNA ends using both purified enzyme assays 
and a permeabilised cell assay. Enzyme activity was modulated by the use of 
NU7026 or AG14361, and by inclusion or exclusion of enzyme substrates. The 
paired cell lines, proficient or deficient in PARP-1 or DNA-PK, utilized in the 
previous Chapters, were also used to compare the effects of loss of enzyme as 
opposed to enzyme inactivation. 
AG14361 and NU7026, were used at 0.4 µM and 10 µM, respectively, and a 
30 bp double stranded blunt-ended oligonucleotide (see appendix) was used to 
stimulate the activity of both enzymes in all studies described in this Chapter, unless 
otherwise stated. 
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6.3 Results 
6.3.1 Concentrations of enzymes and DNA ends 
There are about one million molecules each of PARP-1 and DNA-PK in the 
cell (Lindahl et al., 1995; Jackson, 1997). Therefore, approximately equimolar 
concentrations of PARP-1 and the DNA-PK holoenzyme were used in the 
experiments described here, (based on their published molecular weights of 116 and 
-623 kDa, respectively), unless otherwise specified. In order to minimize direct 
competition of enzyme molecules for DNA oligonucleotide ends, the ratios of the 
numbers of DNA ends to enzyme molecules were at greater than 10: 1 in all assays. 
Exact ratios (to the nearest whole number), which are dependent on the assay used, 
are given in Table 6.2. 
Enzyme/Assay DNA ends: 
PARP-1 
DNA ends: 
DNA-PK 
PARP-1 Assay 12: 1 1O.: 1 
DNA-PK Assay 13: 1 12: 1 
Table 6.2 Ratio of individual enzymes to DNA ends in the purified PARP-1 and 
DNA-PK assays 
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6.3.2 Regulation of purified PARP-1 activity 
The effect of AG14361, NU7026 and purified DNA-PK in the presence or 
absence of its substrate, ATP, on purified PARP-1 activity was investigated (Figure 
6.1A) using a purified PARP-1 assay as described in section 2.1.2.. 
As expected, PARP-1 activity was almost completely inhibited by the 
inclusion of AG14361 (99 ±5%, p= <0.001), whereas NU7026 alone had no 
significant effect (p = 1). However, when DNA-PK was added to the assay, PARP-1 
activity was significantly inhibited by 30 ±3% (p = <0.001). The addition of ATP as 
substrate for DNA-PK reversed this DNA-PK-dependent PARP-1 inhibition such 
that there was no significant difference in activity between PARP-1 alone and PARP- 
1 in the presence of DNA-PK and its substrate, ATP (p = 0.07). Further inclusion of 
NU7026 restored the PARP-1 inhibition to 43 ±5% (p = <0.001). In summary, 
whereas active DNA-PK did not modulate PARP-1 activity, the presence of inactive 
DNA-PK (due to lack of ATP substrate or inhibition by NU7026) caused significant 
PARP-1 inhibition. 
The effects of inactive DNA-PK were investigated further by increasing the 
molar ratios of DNA-PK to PARP-1 (Figure 6.1B). PARP-1 activity was decreased 
in a concentration-dependent manner by DNA-PK in the absence of ATP, with a 
molar ratio of 3: 1 resulting in >90 % inhibition of PARP-1 activity. However, this 
inhibition was completely reversed by the inclusion of ATP (p = <0.001). When 
compared to PARP-1 alone, although a 3-fold excess of DNA-PK in the presence of 
its substrate, ATP, did not inhibit PARP-1 activity, it did not stimulate it either thus 
suggesting that DNA-PK does not stimulate PARP-1 activity. 
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Figure 6.1 (A) The effect of AG14361, NU7026 and DNA-PK in the presence or 
absence of ATP on purified PARP-1 activity; (B) The effect of increasing the molar 
ratio of DNA-PK to PARP-1 from 1: 1 to 3: 1 on PARP- 1 activity. Data are the mean 
of 3 replicate samples, each from 3 independent experiments ± SEM. 
6.3.3 Regulation of purified DNA-PK activity 
The effect of AG14361, NU7026 and purified PARP-1 in the presence or 
absence of its substrate, NAD+, on purified DNA-PK activity was investigated 
(Figure 6.2A) using a purified DNA-PK assay as described in section 2.1.4. DNA- 
PK activity was completely inhibited by 99 ±5% (p = <0.001) when NU7026 was 
present in the reaction mixture, whereas AG14361 alone had no significant effect (p 
= 0.09). When PARP-1 was included in the assay, DNA-PK activity was inhibited by 
82 ±3% (p = <0.001) and, similar to the effects of DNA-PK on PARP-1 activity, 
when its substrate NAD+ was added, the inhibition of DNA-PK activity was relieved, 
unless AG14361 was also included, in which case DNA-PK activity was inhibited by 
92 ±4% (p = <0.001). In summary, whereas active PARP-1 did not modulate DNA- 
PK activity, the presence of inactive PARP-1 (due to lack of NAD+ substrate or 
inhibition by AG14361) caused significant DNA-PK inhibition. 
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As with the effect of DNA-PK on PARP-1 activity, increasing the molar 
ratios of PARP-1 to DNA-PK resulted in a concentration-dependent inhibition of 
DNA-PK, which was reversible by the inclusion of NAD+ (Figure 6.2B). A molar 
ratio of 3: 1 inhibited DNA-PK activity by >95 %. In addition, when compared to 
DNA-PK alone, although a 3-fold excess of PARP-1 in the presence of its substrate, 
NAD+, did not inhibit PARP-1 activity, nor did it stimulate it thus indicating that 
PARP-1 does not stimulate DNA-PK activity in this assay. 
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Figure 6.2 (A) The effect of AG14361, NU7026 and PARP-1 in the presence or 
absence of NAD+ on purified DNA-PK activity; (B) The effect of increasing the 
molar ratio of PARP-1 to DNA-PK from 1: 1 to 3: 1 on DNA-PK activity. Data are 
the mean of 3 replicate samples, each from 3 independent experiments ± SEM 
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6.3.4 PARP-1 and DNA-PK heteromodification 
In the purified enzyme assays used here, histones were used as substrates for 
poly(ADP-ribosylation) by PARP-1, and a p53 peptide as a substrate for 
phosphorylation by DNA-PK. In order to investigate whether PARP-1 and DNA-PK 
could act as acceptors for covalent modification, purified PARP-1 and DNA-PK 
assays were carried out in the absence of histones or p53 peptide, respectively. No 
PARP-1 activity was detectable in the absence of histones, but the addition of DNA- 
PK caused a concentration-dependent increase in activity, which was stimulated 
further by the inclusion of ATP (Figure 6.3A). Similarly, no DNA-PK activity was 
detectable in the absence of the p53 peptide, but the addition of PARP-1 caused a 
concentration-dependent increase in activity, which was stimulated further by the 
inclusion of NAD+ (Figure 6.3B). 
PARP-1 activity was restored to similar levels in the presence of DNA-PK 
and ATP as achieved by the inclusion of histones (Figure 6.1 (a)). In contrast, the 
highest activity obtained for DNA-PK, in the presence of PARP-1 and NAD+, was 
-10 fold lower compared to the inclusion of p53 peptide (Figure 6.2 (a)). 
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Figure 6.3 (A) Effect of increasing concentrations of DNA-PK (± ATP) on PARP-1 
activity in the absence of histone substrate; (B) Effect of increasing concentrations of 
PARP-1 (± NAD) on DNA-PK activity in the absence of p53 peptide substrate. 
Data are the mean of 3 replicate samples from 3 independent experiments ± SEM. 
6.3.5 Effect of the inhibitors on PARP activity in permeabilised cells 
Cell lines proficient or deficient in either DNA-PK (V3YAC and V3) or 
PARP-1 (PARP-1 +"+ and PARP-1'') were rendered nucleotide-permeable by 
digitonin treatment and PARP-1 activity was measured using a permeabilised PARP- 
1 cell assay, as described in section 2.11. PARP-1 activity was slightly, but 
significantly different in the V3YAC and V3 cells (129 ±7 pmol compared to 149 ± 
2 pmol NAD/106 cells, respectively, p=0.05), (Figure 6.4A and 6.4B). The inclusion 
of 50 . tM ATP in the V3YAC cells significantly stimulated PARP-1 activity to 150 t 
2 pmol NAD/106 cells, p=0.02, up to the level of the V3 cells. PARP-1 activity 
remained unchanged in the V3 cells with the addition of ATP (p = 0.7). As expected, 
AG14361 completely inhibited PARP-1 activity (97 ±5 %) in all PARP-1 proficient 
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Figure 6.4 The effect of AG14361 and NU7026 on PARP-1 activity in 
permeabilised cells. 
Samples were treated either in the presence of ATP (white bars) or absence of ATP 
(black bars). Results are the mean of 3 replicate samples each from 3 independent 
experiments ± SEM. (A) V3YAC cells; (B) V3 cells; (C) PARP-1+i+ cells; (D) 
PARP-1'' cells. 
cell lines. In contrast, NU7026 reduced PARP-1 activity by 61 ±4% (p = <0.001) in 
the V3YAC cells, by 59 ±5% in the PARP-1 +/+ cells and by 71 ±3% in the 
PARP-1 -/- cells, whilst having no significant effect in the V3 cells (p = 1). 
As described in Chapter 3 section 3.3.3, the PARP-1'/' cells retained a small, 
but significant residual activity (4 ± 0.3 compared to 132 ± 3.8 pmol in the PARP- 
l+i+ cells) (Figure 6.4C and 6.4D) and this minority activity is probably attributable 
to PARP-2, which together with PARP-1 has also been implicated in BER (Schreiber 
et al., 2002). AG14361 completely inhibited this residual activity (p= <0.01). 
NU7026 inhibited PARP activity in the PARP-1'1' cells to a similar extent to its 
inhibition of PARP activity in PARP-1 +/+, V3YAC and V3 cells (p = <0.001), 
indicating that DNA-PK inhibition also modulates this second PARP activity. 
Earlier studies were carried out in the V3YAC and V3 cells using a self 
complementing palindromic sequence of 10 nucleotides which forms a double 
stranded blunt ended hairpin that stimulates PARP-1 activity (Grube, 1991) (see 
appendix). Whilst very similar results were obtained in the V3YAC cells, with a 
comparable level of PARP-1 activity (136 ±8 pmol compared to 129 ±7 pmol , 
Figure 3.5) and 99±3 % and 45±5 % inhibition of activity when AG14361 and 
NU7026 were added to the reaction mix, respectively, this oligonucleotide failed to 
stimulate DNA-PK activity when added to a purified DNA-PK assay (data not 
shown). This effect of NU7026 in the presence of this type of oligonucleotide is 
therefore interesting and the implications of this observation will be considered in the 
discussion. 
6.3.6 Immuno dot-blot method for the detection of ADP-ribose polymer 
formation 
The activity measured by [32 P] incorporation from radiolabelled NAD+ into 
TCA precipitable counts in the permeabilised cell assay may not be solely 
attributable to the activity of PARP-1. Poly(ADP-ribosylation) reactions are also 
carried out by other enzymes which include the mono(ADP-ribosyl) transferases and 
NAD glycohydrolases , as well as other members of the PARP family. Furthermore, 
although label from the ADP-ribose moiety of NAD+ is incorporated into acid 
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insoluble material, this still does not constitute as proof of ADI'-ribose polymer 
Iornlattoil. 
An alternative 'immuno' dot-blot strategy was therefore used as a means to 
confirm the permeabilised cell assay results. Briefly, the technique involves the 
permcabilisation ofcells and activation of PARP-1 by oligonucleotide in the same 
manner as the radiolabelled permeabilised cell assay. To measure PARP- I activity, 
however, samples are blotted onto a membrane and a specific antibody to ADP- 
ribose polymer which shows no cross reactivity with DNA, RNA, monomers of 
AI)P-ribose or NAD' (Menard el al., 1987) is used to detect the levels of ADP- 
ribose polymer synthesized during the reaction and bound to the membrane, as 
described in section 2.1.3. The intensity ot'the 'dot' is a reflection ofthe amount of 
polymer bound to the membrane. 
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Figure 6. S Dot Not measuring the effect of A( 14361 and NU7026 on I RP-1 
activit's' : A. V3YAC cells; B, V3 cells; -0, absence of oligonuclcotidc_ I O. 
presence ol'oligonucleotide 
Consistent with the radiolabelled assay data (see Figure 6.4A and 6.413), 
oligonucleotide stimulated PARP-1 activity can be seen in both the V3YAC and V3 
cells. Furthermore, AG 14361 fully inhibited this stimulation in both cell lines. 
Whereas NU7026 had no effect on PARP-1 activity in the V3 cells, a small reduction 
in activity can be seen in the V3YAC cells. I lowever, as no dcnsitometry was carried 
out, this reduction in activity cannot be quantitated although it is clear that the 
dil'Icrence is not as large as the 61 % inhibition observed in the radiolabelled assay 
(Figure 6.4A). 
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6.3.7 Development of a DNA-PK permeabilised cell assay 
Attempts were made to adapt the PARP permeabilised cell assay into a 
permeabilised cell assay specific for DNA-PK activity (section 2.17). To be 
considered specific for DNA-PK, the activity measured needed to be both DNA 
strand break dependent and absent in the DNA-PK deficient cells 
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Figure 6.6 DNA-PK activity in permeabilised V3YAC and V3 cells and the 
effect of 10 µM NU7026. Absence of oligonucleotde (white bars); presence of 
oligonucleotde (black bars). Data are the mean of 3 replicate samples from 3 
independent experiments ± SEM. 
A small but significant amount of oligonucleotide activatable kinase activity 
can be seen in the V3YAC cells, however, this only accounts for 14 ±5% of the 
total kinase activity measured, p=0.01 (Figure 6.6). No significant oligonucleotide 
stimulated activity can be seen in the DNA-PK deficient V3 cells (p = 0.07), 
indicating that the activity measured in the V3YAC cells is DNA-PK specific. 
NU7026 inhibited total kinase activity in the V3YAC cells by 37 ±3% (p = 0.006) 
whilst having no significant effect in the V3 cells (p = 1). High levels of non-specific 
kinase activity were present both in the presence of NU7026 in the V3YAC cells, 
and in the V3 cells in the absence of NU7026. 
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6.4 Discussion 
The activity of purified PARP-1 and DNA-PK were modulated by the use of 
specific inhibitors and by deprivation of enzyme substrates. Importantly, in the 
context of the data presented in this Chapter, the studies described in Chapter 3 
demonstrated that NU7026 is not a direct inhibitor of PARP-1 and AG14361 is not a 
direct inhibitor of DNA-PK. The purified enzyme studies described in this Chapter 
have confirmed this observation and demonstrated that PARP-1 has no effect on 
DNA-PK activity towards a peptide substrate and DNA-PK has no effect on PARP-1 
for ADP ribosylation of histones, provided their substrates (ATP and NAD+, 
respectively) are present. However, in the absence of substrate, inactive DNA-PK 
inhibited PARP-1, and inactive PARP-1 inhibited DNA-PK, both in a concentration- 
dependent manner. Similarly, Ariumi et a!., 1999, have shown that co-existence of 
DNA-PK markedly inhibited PARP-1 activity in the absence of ATP substrate, as 
assessed by its auto-ADP-ribosylating activity. However, in contrast to the results 
presented here, this suppression of activity also occurred in the presence of ATP. 
This group also demonstrated that the presence of PARP-1 had no effect on the auto- 
phosphorylation activity of DNA-PK in either the presence or absence of NAD+. 
Since the suppression of one enzyme activity by co-incubation with the other 
enzyme occurs in the absence of substrate this reduction in activity is not likely to be 
due to modification of each other (phosphorylation of PARP-1 or ADP-ribosylation 
of DNA-PK). One possible explanation for the mechanism of inhibition of PARP-1 
by DNA-PK and vice versa would be a competition for DNA ends between the 
enzymes, although a more direct mechanism could also be involved. In the studies 
described in this Chapter, however, an excess of ends were used, and therefore 
competition between the enzymes should have been minimized. 
An alternative mechanism for the suppression of the activity of one enzyme 
by the other could be through blocking/sequestering of DNA ends that serve as 
important activators for both enzymes. Both PARP-1 and DNA-PK undergo 
automodification (phosphorylation of DNA-PKcs and poly(ADP-ribosylation) of 
PARP-1) when activated by DNA strand breaks, and this reaction is important to 
allow dissociation of PARP-1 or DNA-PK from DNA ends (Merkle et al., 2002; 
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Smulson et al., 1998)). Therefore, it is conceivable that in the absence of substrate, 
one enzyme will remain bound at the site of DNA damage and prevent the access of 
the other one, thus reducing their activity. In support of this, Satoh and Lindahl, 1992, 
demonstrated that in the absence of NAD+ , PARP-1 persisted on the breaks and 
DNA repair of a nicked plasmid DNA was abrogated. Addition of NAD+, such that 
automodification and release of PARP-1 from breaks occurred, allowed the repair 
process to proceed. 
Accordingly, the data presented in this Chapter have shown that the addition 
of substrate (NAD+ for PARP-1 and ATP for DNA-PK) to the reaction mixture 
negated the enzyme inhibitory effect (Figures 6.1(a) and 6.2(a)). This is therefore 
likely to be because the presence of substrate enables the dissociation of the 
enzyme(s) from the DNA ends due to automodification, thus allowing access of the 
other enzyme. In contrast, however, as described above, Ariumi et al., 1999, 
showed that the suppression of PARP-1 activity by DNA-PK was unchanged when 
ATP was present. This could reflect that the mechanisms of PARP-1 inhibition by 
the lack of ATP or presence of ATP are distinct. For example, in the absence of ATP, 
a `blocking' mechanism maybe responsible. However, the suppression of PARP-1 
activity in the presence of ATP, might reflect phosphorylation of PARP-1 and a 
subsequent inactivation of its enzyme activity. Indeed, PARP-1 has been shown to 
exist as a phosphoprotein (Bauer et al., 1994) and heteromodification and modulation 
of enzyme activity (poly(ADP-ribosylation) of DNA-PK by PARP-1, and 
phosphorylation of PARP-1 by DNA-PK) has also been demonstrated (Ariumi et al., 
1999; Ruscetti et al., 1998). 
Under normal, physiological conditions, both enzyme substrates are likely to 
be present at sufficient levels to maintain full enzyme activity. The data presented in 
the previous Chapter suggests that, physiologically, in the presence of substrates 
these enzymes will co-operate in DNA repair. There are instances, however, where a 
depletion of substrate(s) could occur. For example, following extreme damage to the 
DNA, PARP- 1 activation could seriously reduce the cellular NAD+ concentration, 
which in turn could deplete the ATP reserves of the cell. Similarly, perturbations in 
nuleotide synthesis (for example, with antipurine antimetabolites) or when 
mitochondiral respiration is compromised (for example, by loss of membrane 
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potential) could drastically reduce cellular ATP. However, these scenarios are likely 
to be so cytotoxic that a negative effect on DNA repair whilst it might occur, would 
be largely irrelevant in terms of cell survival. 
The effect of addition of NU7026 to the PARP-1 assay in the presence of 
DNA-PK (Figure 6.1) and the addition of AG14361 to the DNA-PK assay in the 
presence of PARP-1 (Figure 6.2) was to inhibit PARP-1 and DNA-PK activity, 
respectively. As the inhibitor(s) both act by inhibiting the catalytic activity of their 
respective enzymes and only target their respective enzymes, it is unlikely that this 
effect is due to an inhibition of heteromodification. This effect could be explained 
by inhibition of automodification and dissociation of one enzyme preventing access 
of the other enzyme to DNA in a similar manner to a lack of substrate. In support of 
this hypothesis, wortmannin has been demonstrated to block DNA-PK at DNA ends, 
and prevents their processing by DNA polymerization, degradation, or ligation 
(Calsou et al., 1999). Similarly, 3AB hindered the dissociation of PARP-1 from 
nicked plasmid DNA thus preventing its repair (Satoh and Lindahl 1992). 
The observation that inactive PARP-1 inhibited DNA-PK activity by 82 % 
but that inactive DNA-PK only inhibited PARP-1 by 30 % suggests that PARP-1 has 
a greater affinity than DNA-PK for the 30 bp blunt ended oligonulcotide, used in the 
studies described in this Chapter, if the model of blocked ends as a cause of 
inhibition is valid. These data are consistent with the lower Kd app value of PARP-1 
(116 pmol) for blunt ends compared to DNA-PK (1312 pmol) (D'silva et al 1999). 
This suggests that when DNA-PK and PARP-1 are in direct competition for binding 
to a break it would be bound preferentially by PARP- 1. This could be to protect the 
ends from illegitimate recombination prior to DNA-PK binding and executing repair 
of the break. Surprisingly, despite its purported predominant role in BER, which 
produces only DNA SSBs, these authors also found that PARP-1 had a higher 
affinity for blunt ends compared to nicks and 3' single base overhangs (Kd app = 467 
pM and 332 pM, respectively). These data are also consistent with the findings of 
Benjamin and Gill, 1980, who showed that PARP-1 had a higher affinity for blunt 
ends over 3' overhangs, 5' overhangs and SSBs. 
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Under competitive binding conditions, PARP-1 bound ends would be 
predicted to predominate. However, the numbers of DNA ends in the assays used 
here were in at least 10-fold excess compared to the numbers of molecules of each 
enzyme, and therefore direct competition of the two enzymes for binding to a single 
DNA end should have been minimised. Even under these conditions, the presence of 
one inactive enzyme had a significant effect on the activity of the other. A possible 
explanation for these observations is that PARP-1 and Ku form a molecular complex 
in the absence of DNA (Galande and Kohwi-Shigematsu, 1999). The location of Ku 
at DNA ends serves to recruit and activate DNA-PKcs. Thus it may be envisaged that 
Ku, by forming a DNA-independent complex with PARP-1, may co-locate DNA- 
PKcs and PARP-1 to the same DNA ends, even in the presence of excess free ends. 
Under these conditions, interactive functioning of the enzymes would be inevitable. 
From the data presented in this thesis it is apparent that in the event of co- 
localisation of the two enzymes, each enzyme needs to be catalytically active (i. e. in 
the presence of substrate and absence of inhibitor) to permit the catalytic activity of 
the other. Whether this functionality is dependent on auto- or heteromodification was 
not determined. However, it has been proposed that co-localisation of PARP-1 and 
DNA-PK on the same DNA ends increases the likelihood that they modify one 
another in response to DNA damage. PARP-1 possesses 6 sites which match the 
DNA-PK target sequence (Anderson and Lees-Miller, 1992; Bannister et al., 1993) 
and 4 of these sites reside in the catalytic domain of PARP-1. Conversely, DNA- 
PKcs contains a peptide motif which binds free ADP-ribose polymers with high 
specificity (Pleschke et al., 2000). 
Several groups have attempted to assess whether these enzymes modify one 
another and if so, what effect this has on enzyme activity. Both Ruscetti, et al., 1998 
and Ariumi et al., 1999, independently showed that DNA-PK could phosphorylate 
PARP-1 and that PARP-1 can poly(ADP-ribosylate) DNA-PK using purified 
enzymes and autoradiography. In addition they both demonstrated that this 
heteromodification only occurred when dsDNA was present. Ariumi et al., 1999, 
further demonstrated phosphorylation of PARP-1 by DNA-PK in nuclear extracts 
obtained from the DNA-PK proficient M059K human glioma cell line whilst this 
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phosphorylation was absent in the DNA-PK deficient M059J cells. 
(immunoprecipitation of enzyme assay products). 
In the studies presented by Ruscetti et al., 1998, phosphorylation of PARP-1 
had no apparent effect on PARP-1 activity. Conversely, they showed that poly(ADP- 
ribosylation) activated DNA-PK since activation of DNA-PK by PARP-1 was 
dependent on the presence of NAD+ and did not occur in the presence of the PARP-1 
inhibitor, 1,5, dihydro-isoquinoline. One point of caution, however, is that their data 
could be alternatively interpreted. Thus, rather than causing the `activation' of 
DNA-PK, the addition of NAD+ to the reaction mix could actually be reflecting the 
abrogation of `inhibition' and this interpretation would be more consistent with the 
data presented here (Figure 6.2A), and the `competition for ends' hypothesis. 
Moreover, the authors did not measure DNA-PK activity alone in the absence of 
PARP-1 for comparison and thus it is not possible to differentiate between these 
different scenarios. 
Consistent with the data presented here, Ariumi et-al., 1999, demonstrated 
that whilst purified DNA-PKcs and Ku70/80 can be poly(ADP-ribosylated) by 
PARP-1 in vitro, the presence of PARP-1 had no effects on the autophosphorylation 
activity of DNA-PK. Similarly, DNA-PK can phosphorylate PARP-1 but in support 
of previous findings by (Dvir et al., 1992) this has no effect on its DNA binding or 
catalytic activity. 
The studies described in this Chapter have shown that in the absence of 
histone cofactors, PARP- 1 activity was not measurable, but activity was restored by 
the inclusion of DNA-PK, and stimulated further by the addition of ATP. Similarly, 
DNA-PK activity was not measurable in the absence of the p53 peptide, unless 
PARP-1 was included, and stimulated further by the addition of NAD+. It is 
interesting that neither enzyme was able to automodify itself in the absence of 
histones or peptide substrate. Without carrying out SDS-PAGE, followed by 
autoradiography on the reaction mixtures, it is not possible to distinguish whether the 
phosphorylation or poly(ADP-ribosyation) reactions represent automodification, 
heteromodification or a mixture of both. 
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The studies presented here, in the presence of histones or peptide have shown 
that the addition of one enzyme in the presence of its substrate does not stimulate the 
activity of the other above that of the enzyme alone. However, in the absence of 
histone or peptide, the restoration of one enzyme activity by the presence of the other 
is likely to reflect availability of acceptors/targets rather than a direct stimulation of 
PARP-1 by DNA-PK and vice versa. Consistent with this, the stimulatory effect of 
DNA-PK (+ATP) on PARP-1 activity was similar to the levels achieved by the 
inclusion of histones. In contrast, the highest DNA-PK activity observed following 
stimulation by PARP-1 and NAD+ was 10-fold lower compared to the inclusion of 
the p53 peptide. In the case of PARP-1, histones (1.32 pmol) were replaced by a 
roughly equivalent amount of DNA-PK, (0.81 pmol), whereas in the case of DNA- 
PK, peptide (2 nmol) was replaced by PARP-1 protein (0.77 pmol), resulting in a 
much lower concentration (> 2000-fold) of available substrate for phosphorylation. 
In conclusion, inactive DNA-PK can inhibit PARP-1 and vice versa, and each 
enzyme can act as a target for heteromodification by the other; i. e. DNA-PKcs, or 
Ku, is a target for poly(ADP-ribosylation) and PARP-1 is a target for 
phosphorylation. Modification of one another could affect, negatively or positively, 
some other property of the enzymes apart from their catalytic activity, such as, 
interactions with other components of DNA repair complex. For example, it would 
be interesting to determine whether the interaction(s) between PARP-1 and polo 
and/or XRCCI (Caldecott et al., 1996) are affected by DNA-PK mediated 
phosphorylation. Similarly, it will be interesting to analyse the effect of PARP-1 
mediated poly(ADP-ribosylation) on the interactions between DNA-PK, ligase IV 
and XRCC4. 
A direct confirmation of the experiments with purified enzymes was provided 
by the PARP-1 assays in permeabilised cells proficient or deficient in DNA-PK or 
PARP-1, where the enzymes are present in normal cellular concentrations, and the 
introduced oligonucleotides may associate with other chromatin proteins. Briefly, in 
permeabilised cells, NU7026 or reduced ATP concentration inhibited PARP-1 
activity in the DNA-PK proficient cells. Earlier studies with a self complementing 
palindromic sequence of 10 nucleotides which forms a double stranded blunt ended 
hairpin showed a 45 % reduction in PARP activity in permeabilised V3YAC cells 
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when NU7026 was added. However, recent studies by Leuther et al., 1999, have 
shown that a 14mer oligonucleotide is the smallest DNA capable of forming a stable 
Ku-DNA complex and studies by Yoo and Dynan, 1999, have shown that efficient 
kinase activation requires DNA longer than 12 bp. Consistent with these findings, 
this 10 mer oligonucloetide was unable to stimulate DNA-PK activity in a purified 
DNA-PK assay (data not shown). As DNA-PK would be unlikely to be able to 
assemble on this oligonucleotide, a potential mechanism for the effect of NU7026 
could be that DNA-PK was able to bind to endogenous breaks. The process of 
permeabilisation has been shown to cause DNA damage and hence induce 
intracellular stress responses (Haldrosson et al., 1978). 
Whilst the methodology of the dot blot is very similar to a standard 
permeabilised cell assay, it has the advantages of not using radioactivity and requires 
lower cell numbers (Table. 2.4). Consistent with the radiolabelled assay data (Figure 
6.4A and 6.4B), oligonucleotide stimulated PAR formation can be seen in both the 
V3YAC and V3 cells and this was fully inhibited by AG14361 in both cell lines. 
Whereas NU7026 had no effect on PARP-1 activity in the V3 cells, a small reduction 
in activity can be seen in the V3YAC cells. However, as no densitometry was carried 
out, this reduction in activity cannot be quantitated although it would appear that the 
difference is not as large as the 61% inhibition observed in the radiolabelled assay. 
This could be due to the number of cells loaded per well being too high such that the 
oligonucleotide treated sample is already at the saturation level of the assay in terms 
of signal intensity thus resulting in a loss of differentiation between oligonucleotide 
alone and oligonucleotide in the presence of NU7026.. The cell number therefore 
needs to be optimized. The data from this experiment are only preliminary and 
clearly this assay requires optimisation. Nevertheless, the data obtained are in 
general agreement with those presented in the rest of this Chaper (Figure 6.4A and 
B). 
A disadvantage of this technique is that whilst only de novo synthesis of 
polymer is measured in the radiolabel assay, in this technique, all polymer, including 
any pre-exisitng polymer, will be bound by the antibody. This phenomenon could be 
responsible for the small amount of polymer detected in the presence of AG14361 
and in the absence of oligonucleotide. During the course of the work described in this 
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thesis, this assay has been optimized within the Northern Institute for Cancer 
Research (NICR) for use in a clinical trial which began in May 2003, using potent 
PARP-1 inhibitors in combination with the anti-cancer agent temozolomide. 
Attempts were made to use the permeabilised cells for an oligonucleotide- 
activatable DNA-PK-specific assay but there proved to be very high levels of non- 
specific kinase activity both in the presence of NU7026 in the V3YAC cells, and in 
the V3 cells in the absence of NU7026. This is in contrast to the PARP permeabilised 
cell assay, where < 5% PARP activity was present in the absence of oligonucleotide, 
and none in the presence of AG14361. The strongest indication that this assay can 
measure at least to an extent, DNA-PK activity is the fact that the activity was 
stimulated by oligonucleotide in the V3YAC cells but not in the V3 cells. These 
results are consistent with those of Ariumi et al., 1999, who attempted to measure 
DNA-PK phosphorylation in nuclear extracts from M059 J and K cells in the 
presence or absence of sonicated calf thymus DNA. The group showed that although 
there was a high level of phosphorylation in the absence of DNA, a large induction 
of protein phosphorylation was induced in the presence of DNA. Moreover, this 
only occurred in the DNA-PK proficient M059K cells and not in the M059J cells. 
Although NU7026 fully inhibited the `kinase' activity in the V3YAC cells, it 
brought activity to below that seen in the absence of activating oligonucleotide. 
There are two possible reasons for this. Firstly, despite being tested against other 
members of the P13-K family and showing no activity against any of them at the 
concentration used in these assays, NU7026 could be inhibiting other kinases in the 
cell of which there is estimated to be greater than 500 (estimated that 2% of all 
proteins are kinases). However, NU7026 had no effect in the V3 cells which would 
also possess these kinases. Alternatively, therefore, NU7026 could be inhibiting 
DNA-PK activity that has been stimulated by endogenous breaks or those which 
have been induced during the permeabilisation process. 
207 
The data presented in this Chapter provide evidence for interaction and reciprocal 
regulation of DNA-PK and PARP-1 activity at DNA ends. PARP-1 and DNA-PK 
share similar biochemical properties (Table 6.1) which include the ability to bind 
DNA strand breaks, automodify in response to DNA binding and dissociate from 
DNA following automodification. Whereas DNA-PK is known to play an important 
role in the DSB repair pathway NHEJ, prior evidence for the participation of PARP- 
1 in this pathway has not been established. The results presented in this Chapter 
demonstrate that PARP-1 is able to bind blunt ended DSBs with high affinity. 
It is worth noting that since both PARP-1 and DNA-PK are present at 
approximately 1 million copies per human cell, both are likely to be present in excess 
over the levels of DNA strand breaks generated under normal physiological 
circumstances, even following 75 Gy IR which at approximately 40 DSBs per Gy 
would induce 3000 DSBs per cell. All studies described in this Chapter were carried 
out when activating ends were in excess. The data therefore do not provide direct 
insights into the interplay between DNA-PK and PARP-1 in vivo. 
6.5 Summary 
In summary, the data presented in this Chapter have shown that: - 
" PARP-1 and DNA-PK activities were not affected by the presence of the 
other enzyme, as long as it was active (substrate present or absence of 
inhibitor). 
" Inactive DNA-PK inhibited PARP-1, and inactive PARP-1 inhibited DNA- 
PK, both in a concentration-dependent manner. 
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CHAPTER 7 
SUMMARY AND FUTURE DIRECTIONS 
The primary aim of the work described in this thesis was to investigate the 
interactive effects of PARP-1 and DNA-PK in the cellular responses to ionising 
radiation-induced DNA damage. In order to achieve the aim, data presented in this 
thesis utilised cell lines proficient or deficient (by mutation or gene knockout) in 
PARP-1 or DNA-PK in combination with novel specific inhibitors of the two 
enzymes. These cell lines were characterised in Chapter 3. The effect on a number of 
biological endpoints known to be modulated by PARP-1/ DNA-PK function 
following DNA damage were investigated. These included clonogenic survival 
(Chapter 4) and DSB formation and repair (Chapter 5). In addition, the ability of the 
two enzymes to compete for strand breaks and utilise one another as a substrate using 
both purified enzymes and a permeabilised cell assay was explored (Chapter 6). 
At the time of writing this thesis, AG14361 and NU7026 were the current 
benchmark inhibitors of PARP-1 and DNA-PK, respectively. AG14361 is the first 
inhibitor of PARP-1 with the required pharmacological properties of potency, 
specificity, solubility and in vivo activity to address the therapeutic potential of 
PARP-1 inhibition for the treatment of human cancer. On the basis of extremely 
promising pre-clinical data (Calabrese et al., In press) further analogue development 
resulted in the identification of a compound which combines the potency and efficacy 
of AG14361 with improved pharmacological properties. This PARP-1 inhibitor is 
currently undergoing Phase 1 clinical trials under the auspices of Cancer Research 
UK. Wortmannin is primarily a strong and selective inhibitor for P13-kinase whilst 
the DNA-PK inhibitor used in the studies described in this thesis is, in contrast, a 
potent and selective inhibitor of DNA-PK. Thus, NU7026 has limited activity against 
P13-Kinase and members of the P13-kinase like family of enzymes, including ATM 
and ATR, which share structural similarities in the kinase domains. More recently, 
the Northern Institute for Cancer Research (NICR) in collaboration with KuDOS 
Pharmaceuticals (Cambridge) has identified new candidate compounds of sufficient 
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potency to be clinical candidates. These compounds are now currently being 
characterised in preclinical antitumour efficacy studies. 
The work described in this thesis, exploring the properties of these inhibitors 
in cell culture, has been instrumental in providing the information required to 
facilitate the design of experiments for in vivo evaluation using tumour xenografts in 
nude mice. Mechanisms by which these novel inhibitors function were studied by 
evaluating the relationship between the inhibition of DNA repair and potentiation of 
cytotoxicity. 
The main cytotoxic lesion induced by IR is the DNA DSB, which occur at a 
low frequency of approximately 40 per Gray per cell. Critically, their induction has 
been correlated with IR-induced cell death (Macmillan and. Steel, 1993). Details of 
DSB repair mechanisms are not well understood in mammalian cell systems. 
However, radiosensitive mutants have been isolated which are defective in the repair 
of DSBs (reviewed in sections 1.8.4 and 1.12.2 ). Genetic analysis of these radiation 
sensitive cell lines has generated a large body of evidence suggesting crucial roles for 
DNA-PKcs and Ku70/80 in NHEJ but it is not clear whether they function directly or 
whether they primarily function indirectly by sensing damage and activating other 
factors involved in the processing of DNA ends. 
Although the precise biological role of PARP-1 has not been elucidated, there 
is a wealth of evidence to suggest that inhibition of PARP-1 impedes DNA repair 
(Satoh and Lindahl 1992) and enhances the cytotoxicity of DNA damaging agents 
such as IR (Ben-Hur et al 1984) and alkylating agents (Durkacz 1980). PARP-1 is a 
member of the BER complex comprised of XRCC1, DNA ligase III and polymerase 
P. The generation of PARP-1 deficient mice by homologous recombination has 
clearly demonstrated the involvement of PARP-1 in the maintenance of genomic 
integrity due to its role in BER. In contrast, the literature is lacking an analysis of 
PARP-1 function in DSB repair although molecular evidence indicates that PARP-1 
interacts with DSBs as well as SSBs (reviewed in section 5.4.3). 
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The studies described in Chapter 4 demonstrated that under conditions that 
resulted in inhibition of DNA single and double strand break repair (hallmarks of 
PARP-1 and DNA-PK deficiency, respectively), NU7026 and AG14361 sensitised 
cells to IR as measured by colony forming assay. NU7026 did not potentiate IR in the 
DNA-PKcs deficient cell line, confirming its specificity for DNA-PK. Similarly, 
AG14361 did not potenitate IR in the PARP-1 -/- cells, confirming that 
radiosensitisation in the PARP-1 proficient cells was due to the inhibition of PARP-1. 
In the absence of IR, the inhibitor(s) did not affect cell survival, indicating that they 
are non toxic per se. As with the inhibition of DNA DSB repair, when used in 
combination, the effects on survival were at least additive. Further data presented in 
Chapter 4 suggest that inhibition of PLDR in radioresistant non-proliferating cells by 
novel potent and specific inhibitors of PARP-1 and DNA-PK may be an important 
means by which to achieve clinical radiosensitisation. 
The data presented in Chapter 5 evaluated the repair of DSBs and SSBs 
following treatment with IR in paired cell lines proficient or deficient in PARP-1 or 
DNA-PK in order to elucidate the mechanism underlying the increased 
radiosensitivity of PARP-1 and DNA-PK deficient cell lines. In addition, the effect of 
AG14361 and NU7026 on the repair of DSBs and SSBs was investigated in order to 
allow comparison with cytotoxicity data presented in Chapter 4. A lack of or 
inhibition of either DNA-PK or PARP-1 resulted in a deficiency in DSB rejoining. 
Notably, these data implicate PARP-1 in the processing and repair of DNA DSBs. In 
contrast, SSB repair was not reduced in the absence of or inhibition of DNA-PK 
indicating that whilst DNA-PK is involved in DNA DSB repair, it is not involved in 
SSB repair. When the inhibitors were used in combination, a profound and long term 
inhibition of DNA DSB repair was observed. 
The results presented in Chapter 4 and 5, demonstrate a correlation between 
the ability to recover from IR-induced DNA damage and DSB repair capacity. This 
was particularly striking when comparing the ability to recover from PLD in non- 
cycling cells with their ability to repair DSBs. For example, the xrs-6 cells which 
carried out no DSB repair were also completely deficient in PLDR. Repair processes 
following IR may therefore be a key determinant of cell survival. Despite having a 
defect in the initial fast component of DSB repair, when repair was followed over 24 
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h in DNA-PKcs deficient cells, all breaks were eventually repaired. However, these 
cells are hypersensitive to IR and therefore slower kinetics of repair would lead to 
longer-term persistence of DSBs that could cause cytotoxicity. The almost complete 
and long-term abrogation of DNA DSB repair observed with the combined use of 
inhibitors following 24 h post-IR incubation could easily explain their radiosensitising 
effects in both proliferating and growth arrested cells. Since most cells in human 
tumours cycle slowly or are non-cycling, the investigation of the DNA repair 
processes in these cells maybe important for cancer therapy. 
Overall, a correlation between enzyme status, DNA repair and survival was 
observed and very similar results were obtained when use of inhibitors was compared 
to the use of knockout or mutant cell lines. The studies presented in this thesis have 
shown that inhibition of DNA-PK or PARP-1 activity increased sensitivity of cells to 
IR possibly due to an inhibition of repair. The evidence presented also indicates that 
the combination of a PARP-1 inhibitor with a DNA-PK inhibitor could prove a 
powerful strategy for radiosensitisation of tumours. 
As described in Chapter 4, increased DNA-PK activity (specifically caused by 
elevation of DNA-PKcs levels) has been widely demonstrated both in cell culture and 
in samples from patients with relapsed chronic lymphocytic leukaemia and correlates 
with the resistance of tumour cells to IR and bifunctional alkylating agents. Such 
tumour specific alterations are likely to be important in terms of therapeutic 
exploitation and where DNA-PK is overexpressed, the use of a selective inhibitor 
would be predicted to allow preferential treatment of these tumours, which would 
otherwise become radio- or chemo-resistant. Disregulation of cellular functions is a 
hallmark of cancer and DNA repair pathways may be lost, making the cell dependent 
on complementary repair pathways. In such a case, the cells would be hypersensitive 
to inhibitors of the remaining pathway. For example, a cell which has lost the 
capacity for homologous recombination would be dependent on NHEJ to repair DNA 
DSBs. Combination of a DNA-PK inhibitor with an agent causing DNA DSBs would 
be predicted to be selectively toxic. Human tumours are frequently defective in ATM 
or BRCA1 and BRCA2, implicated in HR of DSBs. The additional inhibition of 
DNA-PK mediated NHEJ may be predicted to highly radiosensitise these tumours. 
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In order to full exploit the potential of PARP-1 and DNA-PK inhibitors for 
cancer therapy, a mechanistic understanding of their interactions is essential. The 
studies in Chapter 6 aimed to investigate the interaction of PARP-1 and DNA-PK at 
DNA ends using both purified enzyme assays and permeabilised cell assays. In the 
presence of limiting substrate and/ or inhibitor DNA-PK or PARP-1 inhibit the 
activity of each other indicating competition for DNA ends. However, in the studies 
described, DNA ends were in excess over the enzymes, thereby minimising 
competition. In addition, cell based studies suggest that in the presence of adequate 
substrate, these enzymes co-operate. The data presented in this thesis therefore 
suggests reciprocal regulation and co-operation of DNA-PK and PARP-1 at sites of 
DSBs. 
The interaction between PARP-1 and DNA-PK at the site of a break requires 
further investigation as the results described in Chapter 6 were still at a preliminary 
stage at completion of this project. A CASE studentship project in collaboration with 
KuDOS pharmaceuticals is currently underway to further test the hypothesis that 
PARP-1 and DNA-PK compete for DNA double strand breaks and that different 
affinities for the type of end affects this competition. The relative affinities of 
purified DNA-PK and PARP-1 for different types of DNA end will be investigated by 
measuring their activation by synthetic oligonucleotides with a variety of ends, 
including blunt ends and 3', 5' overhangs. The effect of altering substrate 
concentrations, oligonucleotide concentration and enzyme ratios will also be 
investigated. The downstream effects of enzyme activation on DNA repair will be 
determined by measuring the rejoining of oligonucleotides with different ends in cell 
extracts from cell lines proficient and deficient in PARP-1 and DNA-PK. The role of 
PARP-1 and DNA-PK on the fidelity of repair will also be investigated using plasmid 
rejoining assays. 
Although both PARP-1 and DNA-PK are thought to play a number of 
different roles within the cell, the most researched area and that evaluated in this 
thesis, is their function in DNA repair. PARP-1 activation has also been recognised as 
a novel factor mediating ischaemia/reperfusion injury and inflammatory tissue 
damage, and a dependence of NF-kB activation following DNA damage on PARP-1 
protein or activity has been proposed as a mechanism. Thus, PARP-1 inhibitors could 
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be important in the treatment of a broad spectrum of diseases, including cancer, 
strokes and heart attacks. 
In conclusion, the results presented in this thesis demonstrate the therapeutic 
potential of PARP-1 and DNA-PK inhibitors as radiosensitisers, confirm that the 
inhibitors mediate their effects specifically by inhibition of their target enzymes and 
indicate that inhibition of DSB repair is the most plausible mechanism for their 
radiosensitising effects. Furthermore, the studies employing inhibitor combinations 
suggest reciprocal regulation and interaction of DNA-PK and PARP-1 and 
demonstrate that the use of combined inhibitors provides extremely potent 
radiosensitising effects with implications for future anticancer clinical strategies. 
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ABSTRACT 
The DNA repair enzymes, DNA-dependent protein kinase (DNA-PK) 
and poly(ADP-ribose) polymerise-1 (PARP-1), are key determinants of 
radio- and chemo-resistance. We have developed and evaluated novel 
specific Inhibitors of DNA-PK (NU7026) and PARP-1 (AC14361) for use 
in anticancer therapy. PARP-1- and DNA-PK-deficient cell lines were 
4-fold more sensitive to Ionizing radiation (IR) alone, and showed reduced 
potentially lethal damage recovery (PLDR) In G. cells, compared with 
their proficient counterparts. NU7026 (10 µM) potentiated IR cytotoxicity 
(potentiation factor at 90% cell kill (PF90) = 1.51 t 0.041 In exponentially 
growing DNA-PK proficient but not deficient cells. Similarly, AC14361 
(0.4 ELM) potentiated IR In PARP-1+i+ (PF90 = 1.37 t 0.03) but not 
PARP-1"'- cells. When NU7026 and AG14361 were used in combination, 
their potentiating effects were additive (e. g., PF0 = 2.81 t 0.19 in 
PARP-1+1+ cells). Both Inhibitors alone reduced PLDR -3-fold in the 
proficient cell lines. Furthermore, the Inhibitor combination completely 
abolished PLDR. IR-induced DNA double strand break (DNA DSB) re- 
pair was Inhibited by both NU7026 and AG14361, and use of the inhibitor 
combination prevented 90% of DNA DSB rejoining, even 24-h postirra- 
diation. Thus, there was a correlation between the ability of the inhibitors 
to prevent IR-induced DNA DSB repair and their ability to potentiate 
cytotoxicity. Thus, Individually, or in combination, the DNA-PK and 
PARP-1 Inhibitors act as potent radiosensitizers and show potential as 
tools for anticancer therapeutic Intervention. 
INTRODUCTION 
Enzyme-mediated repair of DNA DSBs' is a major mechanism of 
resistance to radiotherapy, and inhibition of DNA DSB repair is thus 
a strategy for radiopotentiation. This study focuses on the use of novel 
inhibitors of the DNA-PK and PARP-1, both of which are DNA strand 
break-activated enzymes and key components of DNA damage rec- 
ognition, repair, and signaling pathways. 
Two DNA DSB repair pathways in eukaryotes are NHEJ and 
HRR (1). Important components in these repair pathways are the PI 
3-K-related protein kinase family of enzymes. These DNA dam- 
age-activated serine/threonine protein kinases include DNA-PK, 
ATM, and ATR (2). The DNA-PK holoenzyme comprises a het- 
erodimer of M, -70,000 and -80,000 polypeptides, known as Ku, 
which binds to DNA strand breaks, recruiting and activating the M, 
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470,000 catalytic subunit, termed DNA-PKcs (3). Numerous stud- 
ies have shown that cells lacking either functional DNA-PKcs or 
Ku80 through mutation or gene knockout are hypersensitive to IR 
and cross-linking agents (3-6). DNA-PK, together with the 
XRCC4/DNA ligase IV complex and the recently identified cofac- 
tor Artemis, is specifically required for NHEJ (7,8), with -80% of 
DNA DSBs repaired by this pathway (9). 
The first identified inhibitor of the PI 3-K-related protein kinase 
enzyme family was the fungal metabolite Wortmannin. Although 
primarily used as a PI 3-K inhibitor, it was also shown to potentiate 
IR-induced cytotoxicity and inhibit DNA DSB repair at concentra- 
tions that inhibit cellular DNA-PK (10-13). The recently synthesized 
molecule NU7026,2-(morpholin-4-yl)-benzo[h]chomen-4-one, a 
novel and specific inhibitor of DNA-PK, has been evaluated in this 
study. 
PARP-1 is a Mr 116,000 enzyme that is an important component of 
the BER complex required for DNA SSB repair (14-16). Loss of 
PARP-I function, using molecular genetic techniques or inhibition, 
causes radiosensitization and potentiates the cytotoxicity of mono- 
functional alkylating agents (17-19). Thus, PARP-1 inhibitors are 
predicted to improve the efficacy of radio and certain types of chemo- 
therapy. It is generally assumed that the inhibition of BER is the cause 
of the enhanced cytotoxicity. However, we have recently reported that 
a PARP-1 inhibitor (NU1025) also inhibits DNA DSB repair in cells 
exposed to IR, and this may contribute to the cytotoxic mechanism 
(12). 
Convincing evidence for in vivo radiopotentiation with a PARP-1 
inhibitor was obtained using PD128763 (20). Using a murine tumor 
model, Leopold and Seebolt-Leopold demonstrated that PD128763+ 
IR caused a 10-15-day increase in growth delay compared with 
irradiation alone. The clinical potential of this class of agents has led 
to the development of diverse classes of potent PARP-l inhibitors 
(21-23). The tricyclic benzamidizole 1-(4-dimethylaminomethyl- 
phenyl)-8,9-dihydro-7H-2,7,9a-benzo[cd]azulen-6-one) AG14361 has 
been used in this study (23). 
Radiosensitization by deficiency or inhibition of either DNA-PK or 
PARP-1 is not limited to proliferating cells. Nonproliferating cells 
exposed to IR are known to undergo PLDR leading to substantial 
increases in survival compared with proliferating cells or cells in- 
duced to start a proliferative cycle shortly after irradiation (24,25). 
Several early reports, using either cell lines mutationally inactivated in 
DNA-PK or PARP-1 inhibitors, showed a reduction in PLDR in 
nonproliferating (quiescent) cells (26-30). Local tumor conditions, 
such as cell and vascular density, as well as availability of oxygen and 
nutrients, frequently result in a high fraction of nonproliferating cells. 
PLDR after irradiation is considered to be an important determinant of 
radioresistance and has been demonstrated in tumor cell lines and in 
an experimental tumor model (31-33). Thus, the potential of small 
molecule inhibitors of DNA-PK and PARP-1 to prevent PLDR is an 
important consideration in the assessment of their therapeutic appli- 
cation. 
Here, we describe the biological effects of both AG14361 and 
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NU7026 in cell culture models. We have investigated the ability of 
these inhibitors, used alone or in combination, to radiosensitize both 
proliferating and quiescent paired cell lines proficient or deficient in 
either DNA-PK or PARP-l. In addition, their effects on DNA DSB 
repair were investigated. 
MATERIALS AND METHODS 
Drugs. NU7026 was synthesized in the Department of Chemistry, Univer- 
sity of Newcastle upon Tyne. AG 14361 was synthesized by Pfizer GRD, CA 
(23). NU7026 and AG 14361 were dissolved in anhydrous DMSO at stock 
concentrations of 5 and 10 mM, respectively, and stored at -20°C. Drugs 
(alone or in combination) were added to cell cultures so that the final DMSO 
concentrations were kept constant at 1% (v/v). 
Cell Lines and Culture. Primary PARP-1+i+ and PARP-1-'- MEFs were 
a gift from Professor Gilbert de Murcia, Ecole Superieure de Biotechnologie de 
Strasbourg, France. Spontaneously immortalized cell lines were derived from 
the primary MEFs to enable clonogenic survival assays to be performed. It was 
noted that the immortalized PARP-1+1+ MEFs expressed very high basal 
levels of p53 protein compared with the PARP-1-'- MEFs, and therefore, the 
p53 gene was sequenced. It was found that the PARP-1-- cells had a wt p53 
sequence, but the PARP-I+i+ had an Asp to Glu substitution at codon 278 in 
p53, within a conserved region of the DNA binding domain. This rendered the 
p53 unable to act as a transcriptional transactivator. 4 The significance of the 
difference in the functional status of p53, with respect to the results obtained, 
is explored in the "Discussion. " The Chinese hamster cell lines V3 (mutated in 
DNA-PKcs) and V3YAC [V3 transfected with a YAC carrying the comple- 
menting human DNA-PKcs gene] were kindly provided by Dr. Penny Jeggo, 
University of Sussex (34). 
All cell lines were cultured as monolayers in DMEM medium [supplement- 
ed with 10% (v/v) FCS, 100 units/ml penicillin, and 100 µg/ml streptomycin]. 
Glutamine was added at a final concentration of 2 mM. The V3YAC cell line 
was maintained under antibiotic selection with genticin (Life Technologies, 
Inc., Paisley, United Kingdom) at a final concentration of 500 tig/ml to ensure 
retention of the YAC. 
Purified Enzyme Assays. Mammalian DNA-PK (500 ng/µl) was isolated 
from HeLa cell nuclear extract after chromatography using Q-Sepharose, 
S-Sepharose, and Heparin agarose. DNA-PK (250 ng) activity was measured 
at 30°C, in a final volume of 40 µl, in buffer containing 25 mm HEPES (pH 
7.4), 12.5 mm MgCl2,50 mm KCI, 1 mm DTT, 10% v/v Glycerol, 0.1% w/v 
NP-40, and I mg of the substrate GST-p53N66 (the NHZ-terminal 66 amino 
acid residues of human wild-type p53 fused to glutathione S-transferase) in 
polypropylene 96-well plates. To the assay mix, varying concentrations of 
inhibitor (in DMSO at a final concentration of 1% v/v) were added. After 10 
min of incubation, ATP was added to give a final concentration of 50 µM, 
along with a 30-mer double-stranded DNA oligonucleotide (final concentra- 
tion of 0.5 ng/ml), to initiate the reaction. After Ih with shaking, 150 µl of 
PBS were added to the reaction, and 5 µl were then transferred to a 96-well 
opaque white plate containing 45 µl of PBS per well, where the GSTp53N66 
substrate was allowed to bind to the wells for 1 h. To detect the phosphoryl- 
ation event on the serine 15 residue of p53 elicited by DNA-PK, a p53 
phosphoserine-15 antibody (Cell Signaling Technology, Beverly, MA) was 
used in a basic ELISA procedure. An antirabbit horseradish peroxidase- 
conjugated secondary antibody (Pierce) was then used in the ELISA before the 
addition of chemiluminescence reagent (Renaissance, New England Nuclear) 
to detect the signal as measured by chemiluminescent counting via a TopCount 
NXT (Packard). 
The protocols used to detect ATM kinase and ATR kinase activities were 
performed essentially according to the methodologies described previously 
(35,36). ATM and ATR were immunoprecipitated using rabbit polyclonal 
antisera raised to the COOH-terminal 400 amino acids of ATM and antisera 
raised to amino acids 400-480 of ATR, respectively. The PI 3-kinase assay 
was performed essentially as described previously (37), using baculoviral 
derived recombinant pl 10a and p85a (a kind gift from Prof. Mike Waterfield, 
Ludwig Institute, London, United Kingdom). 
The ICs s for the compounds in all of the enzymes assays were derived from 
" P. A. Jowscy, unpublished results. 
sigmoidal plots using the graphic package Prism, in which the enzyme activity 
in the varying concentration of compounds was plotted against the concentra- 
tion of compound. 
Cytotoxicity Assays. Clonogenic assays were performed as described pre- 
viously (12). Briefly, exponentially growing cells (± AG14361 and/or 
NU7026) were exposed to IR. Drug(s) were added 60 min before irradiation 
followed by a 16-h postincubation at 37°C before harvesting and reseeding for 
colony formation in the absence of drugs. Data were normalized to untreated 
controls (1% v/v DMSO). PF90 values were calculated from the ratio of the 
individual LDO values, i. e., the LDv divided by LDp in the presence of 
inhibitor(s). 
PLDR. The effects of AG14361 and NU7026, alone or in combination, 
were investigated in growth arrested cells after approximately equitoxic doses 
of IR. Cells were grown to confluence to induce G, arrest (Go status) before 
irradiation and irradiated in conditioned medium obtained from plateau phase 
cells. Cell cycle distribution to confirm G, arrest in plateau phase cells was 
assessed by flow cytometric analysis (data not shown). Drug(s) were added in 
conditioned medium 60 min before irradiation. After exposure to IR, cells were 
trypsinized and reseeded for colony formation in the absence of drugs, either 
immediately after exposure to IR or after a 24-h postincubation (± AG 14361 
and/or NU7026) at 37°C. 
Western Blot Analysis of Protein Expression. Cell lysates were prepared 
from exponentially growing cells and loaded onto denaturing polyacrylamide 
gels using standard protocols. DNA-PKcs was resolved on 3-8% (w/v) Tris 
acetate gradient gels and all other proteins on 4-20% (w/v) Tris glycine 
gradient gels (Invitrogen Ltd., Paisley, United Kingdom). After electrophore- 
sis, proteins were electrotransferred onto nitrocellulose (Bio-Rad, Herts, 
United Kingdom) and probed for PARP-I (H-250 rabbit polyclonal; Santa 
Cruz Biotechnology, Santa Cruz, CA) and DNA-PKcs (Ab-4 cocktail mouse 
monoclonal; Stratech Scientific, Cambs, United Kingdom). As a loading 
control, an antiactin antibody (mouse clone AC-40; Sigma, Dorset, United 
Kingdom) was used. This was followed by binding of peroxidase-conjugated 
goat antimouse/rabbit antibody and detection of proteins by enhanced chemi- 
luminescence (DAKO, Ely, United Kingdom). 
Cell-based Enzyme Activity Assays. For comparison of enzyme activities 
in the cell lines, the following techniques were used: DNA-PK was assayed in 
nuclear extracts. Briefly, DNA was removed from the extracts using high salt 
elution (fast flow DEAE Sepharose; Amersham Pharmacia, Bucks, United 
Kingdom). Fifty microgram aliquots were assayed for DNA-PK activity using 
the SIGNATECT DNA-PK assay system (Promega, Hants, United Kingdom). 
PARP-l was assayed by measuring incorporation of radiolabel from ['ZP] 
NAD+ into acid precipitable counts in a permeabilized cell system (38). Cells 
were permeabilized using digitonin, and a 30-bp blunt-ended oligonucleotide 
was used in the assay to maximally activate PARP-1. 
DNA Strand-Break Assays. DNA DSB levels were measured by neutral 
filter elution (39). The radiolabelling, drug treatment, postincubation condi- 
tions, and sample preparation used in these experiments were exactly as 
described by Boulton et al. (11). In all experiments, cells were exposed to 75 
Gy IR. Cell cultures were preincubated ± AG14361 and/or NU7026 for 60 
min before exposure to IR, and the drugs remained in the culture medium 
during the postincubation periods. Regression analysis of each elution profile 
was performed to calculate the relative retention, i. e., the fraction of sample 
DNA retained on the filter when 50% of the internal standard has eluted (40). 
Values for cells treated with IR ± inhibitor(s) were expressed as a percentage 
of the values of unirradiated controls. 
RESULTS 
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Inhibitor Structures and Evaluation of Enzyme Inhibition. The 
structure of AG14361 (1-(4-dimethylaminomethyl-phenyl)-8,9-dihy- 
dro-7H-2,7,9a-benzo[cd]azulen-6-one) and NU7026 (2-(morpholin-4- 
yl)-benzo[h]chomen-4-one) is shown in Fig. 1. AG14361 is an ex- 
tremely potent competitive inhibitor of PARP-1 with a Ki value <5 
nm (16). In the permeabilized cell assay used here, the ICs0 for 
AG14361 in the V3YAC cells was 68.4 ± 3.5 nm and 56.3 ± 4.2 nm 
in the PARP-I"+ cells. 
Wortmannin is a noncompetitive, irreversible inhibitor of DNA-PK 
(10), whereas NU7026 is competitive with ATP. Shown in Table 1 is 
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I ig. 2B). I his may reflect ovcrexpression of the human DNA-Mc.,, by 
the YAC. As expected, DNA-PK activity was undetectable in the V3 
cells. PART'-I activity was similar in all of the cell lines, apart from 
the PART'-I cells, which retained 3.9 "- 0.51'', o residual activity 
compared with the PARP-I '' cells (Fig. 2C). This residual activity 
is likely to be attributable to PARP-2, which, together with PARP-I, 
has also been implicated in BER (16). 
Radiosensitization br AG14361 and N117026. The effects of 
A(i1436I and NU7(126 alone and on IR-induced cytotoxicity were 
investigated in exponentially growing cell fines. Both PARP-I- and 
DNA-PK-deficient cells were -4-told more sensitive to IR than their 
proficient counterparts (note the different IR dose ranges in Fig. 3, .f 
versus B and Fig. 3, C vei-sus l)). 
Neither AG14361 (-40 µst) nor NU7026 (-30 link), alone or in 
combination, reduced clonogenic survival (results not shown). The 
inhibitors were effective when added immediately before exposure to 
IR but for convenience were routinely added I It before irradiation. 
Both AGI436I and NU7026 potentiated IR in a concentration-depen- 
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AO 14301 (0.4 pm) completely inhibited purified PARP-I enzyme 
0 
activity while having no effect on DNA-PK activity, and similarly, 
NIJ7020 (I(1 µßt) completely inhibited purified DNA-PK activity, 
while hay ing no ellect on I'ARI'-I activity (results not shown). These 
inhibitor conceniral ons \serc used in all subsequent cell culture 
experiment, 
Characterization of ('ell Lines. Western blot analyses were car- 
ried out to asses PARI'-1 and DNA-PK protein levels in the paired 
cell lines. As e\pecled (fig. 2.1), the I': \RI'-I 
' cell line exhibited a 
band at At, 116,00( (PARP-I ), and this was completely absent in the 
PA RP- I cell line. I loss es er. both these cell lines showed hands for 
I)N. A\-I'Kcs and Ku 0( (results not shown). The V3 cell line lacked the 
l/, 47(1,1)0(1 DNA-PKcs hand, but this was restored in the V3YA(' cell 
line (fig. 2.1). Huth these cell lines showed the . 
11,116,001) PARP-I 
band (results not shown) DNA-PK and PARP-I assays were carried 
out to confirm that the lack of detectable protein in the V3 and 
PAR I'-I cells correlated with an absence of the corresponding 
enivme acti\ itics, to ensure that I)NA-PK activity was present in both 
the PARI'-1 '' and PAR)'-I cell Iities and to ensure that PARP-I 
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activity was present in both the V3 and V3YAC cell lilies (Fig. 
2, B Pig. 2. Characterization of I)NA-I'K and PARP-I lc%cl, and uctiýitae. a in the cell lines 
studied. A, Western blot analysis of PARP-I and t)NA-PK. Hlats neue probed using and i'). DNA-PK ; Icti%ltN' was slightly 
higher in the ß'31'A( f'i'll line 
(7ý() pmol A i'P mg. protein) Compared with the PARP-I and 
antibodies against PARP-I and DNA-PKcs, H, DNA-I'K acttvts, C PARI'-I activity. 
Results are the mean of three replicate samples each from three independent esperi- 
PARI'- I cell lines (SO) paid A-IThng protein for both cell lines; meats ± sl'-. 
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tion in the DNA-PK proficient cells (Fig. 3, A, C, and D; PF90 values 
1.1-1.7) but not in the DNA-PK-deficient cell (Fig. 3B). These data 
support the hypothesis that NU7026 and AG14361 mediate potenti- 
ation specifically by inhibition of their target enzymes, DNA-PK and 
PARP-1, respectively. 
Prevention of PLDR by AG14361 and NU7026. The effects of 
the inhibitors on PLDR were investigated. Cells were growth arrested 
by growing them to confluence. GO status was confirmed by flow 
cytometric analysis (results not shown). Cells were exposed to ap- 
proximately equitoxic doses of IR (see details in Fig. 4 legend), such 
that the survival of cells which were immediately replated was : 55%. 
After a 24-h delay in replating, which allows quiescent (GO) cells to 
repair PLD, the surviving fraction of V3YAC and PARP-1+1+ cells 
was increased 7-8-fold (Fig. 4, A and Q. This recovery was reduced 
by -70% by inclusion of AG14361 during the recovery period, 
whereas NU7026 alone completely abolished PLDR, and the combi- 
nation of NU7026 and AG14361 reduced survival even further (Fig. 
4, A and C). PLDR was reduced (2-3-fold) in both DNA-PK-deficient 
(V3) and PARP-deficient (PARP-1'1') cells, compared with their 
proficient counterparts, and this modest recovery was fully inhibited 
by AG 14361 or NU7026, respectively (Fig. 4, B and D). As expected, 
no inhibition of PLDR was obtained by the use of NU7026 in the V3 
cell line (Fig. 4B). However, when AG14361 was used in the PARP- 
I'ý' cell line (Fig. 4D), there was a small, but significant, inhibition 
of PLDR. A possible explanation is that AG 14361 may additionally 
inhibit PARP-2, which has also been implicated in BER (16). 
Inhibition of DNA DSB Repair by AG14361 and NU7026. The 
kinetics of DNA DSB repair after exposure to IR over a 60-min time 
period were investigated. In the DNA-PK-proficient (V3YAC) cells, 
DNA DSBs were rejoined rapidly with a80% rejoined by 60 min 
(Fig. 5A). Very similar results were obtained with the PARP-1+i+ 
cells (Fig. 5B). By contrast, in the V3 and PARP-1' cell lines, 
higher DNA DSB levels remained 60-min post-IR incubation with 
only -50% DNA DSB rejoined (5, A and B). 
To determine whether the inhibitors similarly modulated DNA 
DSB repair, DNA DSB levels were assessed in cells ± AG14361 
and/or NU7026 at 60-min post-IR. (Fig. 6, A-D). In the V3YAC and 
PARP-1+1+ cell lines, AG14361 and NU7026 inhibited DNA DSB 
repair, e. g., in the V3YAC cell line, AG14361 and NU7026 inhibited 
repair by 40 and 56%, respectively, compared with the drug-free 
control. When the inhibitors were used in combination in the enzyme- 
proficient cell lines, repair was reduced by z90% (Fig. 6, A and Q. 
In comparison, NU7026 or AG 14361 in the PARP-1-'- or V3 cells, 
respectively, only reduced repair by 70%, suggesting that inhibition of 
both enzymes has a more profound effect on repair than inhibition of 
one enzyme combined with lack of the other enzyme. Finally, as 
expected, NU7026 and AG14361 exerted no additional inhibitory 
effect on the reduced DNA DSB rejoining observed in the V3 or 
PARP-I cell lines, respectively (Fig. 6, B and D). 
Finally, the longer term effects of the inhibitors on DNA DSB 
repair were investigated by assessing DNA DSB levels in V3YAC 
and V3 cells 24-h postirradiation (Fig. 6, E and F). By this time, 
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Fig. 3. Effects of increasing doses of IR in the presence or absence of AG14361 and 
NU7026 on the survival of exponentially growing: A. V3YAC cells; B. V3 cells; C, 
PARP-l" cells; D. PARP-l-'- cells; ", IR alone; A, IR + AG14361; V, IR+ 
NU7026; 4, IR + AG14361 + NU7026. Cells were prcincubatcd with drug(s) for I It 
before exposure to IR, then incubated for l6-h post-treatment before reseeding for colony 
formation. Data are the mean of at least three independent experiments ± SE. 
dent manner, and maximum potentiation was achieved at 10 µM 
NU7026 and 0.4 µM AG14361 (results not shown). Therefore, these 
concentrations were used in all subsequent experiments. 
The inhibitors used alone, or in combination, potentiated the cyto- 
toxicity of IR in the enzyme proficient exponentially growing V3YAC 
and PARP-1 +1+ cells (Fig. 3, ,4 and Q. PF90 values were calculated 
to quantitate the potentiating effects of the inhibitors alone, and in 
combination, on IR-induced cytotoxicity, and the results are summa- 
rized in Table 2. Approximately additive effects were obtained when 
the inhibitors were used together (Fig. 3, A and C), e. g., the PF90 
values for AG14361 and NU7026 in the V3YAC cell line were 
1.4 ±0 and 1.51 ± 0.04, respectively; when used in combination, the 
PF90 value was 2.78 ± 0.04 (Table 2). Significant radiosensitization 
by AG14361 was observed in all of the cell lines with PARP-1 
activity (Fig. 3, A-C; PF90 values 1.3-1.4) but not in the PARP-1-'- 
cells (Fig. 3D). Similarly, NU7026 caused significant radiosensitiza- 
Table 2 Comparison of the PFvo values' derived from JR survival curves 
Cell lint/trcntmcnt V3YAC 
IR + AG14361 1.4 ± 0.00 
IR + NU7026 1.51 ± 0.04 
IR + AG14361 + NU7026 2.78 ± 0.04 
V3 PARP-1+i+ PARP-1-1- 
1.3 ± 0.01 1.37 ± 0.00 1.03±0.001" 
1.0±0.00" 1.69±0.03 1.12 ± 0.01 
1.3 ± 0.03 2.81 ± 0.19 1.13±0.00 
"All mean l'F90values (=SE) were calculated from the ratio of the individual LDyo values, f. e., LD, m divided by LDyo in the presence of inhibitor(s). The mean LD w values for IR + inhibitor(s)were all significantly different from the mean LD w values for IR alone in the same cell line (P 5 0.05, n- s3, two-tailed Student t test), excluding the LDvp values for IR + inhibitor in the cell line lacking its corresponding target enzyme (see below). 
b The bold FF, W values, which are not significantly different from unity, demonstrate the lack of potentiation by the inhibitor in the cell line which lacks its corresponding target 
enzyme. 
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Fig. 4, Effects of AG14361 and NU7026 on recovery 
from IR-induccd potentially lethal damage in growth- 
arrested cells. Cells were treated with approximately equi. 
toxic doses of IR; 6 Gy for V3YAC, 1.4 Gy for V3,5 Gy for 
PARP-1*'*, and 1.2 Gy for PARP-1''-. The cells were 
either replated immediately for colony formation (white 
bars) or after a 24-h postincubation to allow PLDR (black 
bars). A, V3YAC; B. V3; C. PARP-1*'*; D. PARP-t'' 
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96 ± 3% of DNA DSBs were rejoined in the control V3YAC cells, 
compared with 7± 2% and 60 ± 7% when treated with AG 14361 and 
NU7026, respectively (Fig. 6E). When AG 14361 and NU7026 were 
used in combination, only 10 ± 2% of the breaks had rejoined. The 
V3 cell line was only slightly less proficient than the V3YACs at 
rejoining DNA DSBs by 24 h (77 ± 3%), and this was further reduced 
by the inclusion of AG 14361, whereas NU7026 exerted no additional 
effect. 
DISCUSSION 
Here, we describe the effects on cellular responses to IR produced 
by novel specific inhibitors of the repair enzymes PARP-1 and DNA- 
PK. We demonstrate that these compounds radiosensitize both pro- 
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liferating and quiescent cells to IR and inhibit DNA DSB repair. 
Furthermore, when AG14361 and NU7026 are used in combination, 
their effects on all these biological endpoints are at least additive. In 
the survival experiments, cells were incubated for 16 h (approximately 
one cell cycle) after IR in the presence of the inhibitors before 
replating for colony formation. Additional experiments are required to 
determine the minimum exposure time to inhibitors necessary to 
obtain maximum potentiation. Use of the inhibitors in the paired cell 
lines, proficient or deficient for DNA-PK and PARP-l, has provided 
confirmation that the inhibitors mediate their effects on IR-induced 
cytotoxicity and DNA DSB repair specifically via inhibition of their 
target enzymes. Additionally, the radiosensitization and reduced DNA 
DSB repair observed in the deficient cell lines were mimicked by the 
use of the inhibitors in the proficient cell lines. The effect of enzyme 
inhibition or deficiency on cell survival closely paralleled the effects 
on DNA DSB repair, and hence, DNA DSB repair inhibition is a 
plausible mechanism for the radiosensitization observed. 
Ideally, paired cell lines should be isogenic, differing only in the 
gene of interest. However, this is rarely the case, and it was estab- 
lished during the course of this work that, in contrast to the PARP- 
I` MEFs, which had retained wild-type p53 after spontaneous 
immortalization, the PARP-1+"+ MEFs had acquired a p53 mutation 
in the DNA binding domain and did not induce mdm2 in response to 
IR. ` In consideration of the potential clinical use of DNA-PK and 
PARP-1 inhibitors, it is pertinent to point out that both inhibitors were 
able to cause radiosensitization in this cell line, despite the lack of a 
functional p53. This ability to radiopotentiate cells, regardless of their 
p53 status, increases the range of tumors for which the use of the 
inhibitors may be effective. 
The observation that both NU7026 and AG 14361 not only radio- 
sensitize proliferating cells but also prevent PLDR in quiescent cells 
is very important. PLDR is a significant factor in determining tumor 
responses to radiotherapy (reviewed in Ref. 41). Evidence for PLDR 
in the nonproliferating compartment of tumors is very sparse, but 
V 
25 50 75 0 25 60 75 
Time (minutes) Time (minutes) 
Fig. 5. Kinetics of DNA DSI3 repair after a fixed dose of IR. A.   V3YAC cells; 0 
V3 cells; B. " PARP"I"* cells; 0 PARP"1''' cells. Cells were exposed to 75 GY IR 
and postincubatcd for increasing amounts of time before being harvested for neutral 
elution. 
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Fig. 6. Effects of AG14361 and NU7026 on DNA DSB 
repair. A, V3YAC cells; B. V3 cells; C. PAPP-1''' cells; D, 
PARP-1'1' cells. Cells were prcincubatcd with inhibitor(s) for 
60 min, exposed to 75 GY IR, and postincubated for 60 min 
before harvesting for neutral elution (A-D) or exposed to 75 GY 
and postincuhated for 24 h. E. V3YAC cells; F. V3 cells. 
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experimental and clinical observations suggest that the rapid repopu- 
lation after IR-induced killing of the proliferating compartment of 
tumors results from recruitment of surviving Go cells into the prolif- 
erative cycle. 
Both inhibitors used alone substantially prevented PLDR. More 
dramatically, when used in combination, AG14361 and NU7026 not 
only completely abolished PLDR but reduced survival significantly 
below that obtained in cells exposed to IR alone and replated imme- 
diately (i. e., no 24-h recovery period), e. g., when quiescent V3YAC 
cells were irradiated, survival was reduced to 0.38% if the cells were 
replated immediately. Survival was increased to 3.3% by a 24-h delay 
in replating, but the presence of AG 14361 and NU7026 during the 
24-h delay reduced survival to 0.064%, even lower than the cells 
which were replated immediately post-IR. This extremely potent 
radiosensitization (-50-fold) of nonproliferating cells by the com- 
bined use of the NU7026 and AG14361 is one of the major aims of 
radiobiologists and radiotherapists alike. Current interest in clinical 
rediosensitization has focused on hypoxic radiosensitizers and chem- 
ical radiosensitizers, such as the halogenated pyrimidine analogues 
(42-44), whereas the potential of PLDR inhibitors has largely been 
ignored. These data point to inhibition of PLDR as a tool for clinical 
radiosensitization that merits further investigation. 
PARP-1 inhibition clearly results in higher levels of IR-induced 
DNA DSBs, but these data do not prove a direct role for PARP-1 in 
NHEJ. IR-induced clustered damage involves, e. g., near neighbor 
base oxidation and hydrolysis of the phosphodiester backbone on 
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opposite DNA strands (45). BER at these sites will generate DNA 
SSB intermediates. Absence or inhibition of PARP-1 by preventing 
BER-mediated strand rejoining by ligase IV (46,47) may result in the 
longer lived DNA SSBs converting to DNA DSBs, rather than by 
directly inhibiting NHEJ. 
A number of lines of evidence indicate that although DNA-PKcs 
highly stimulates the NHEJ pathway, in its absence, a slower repair 
pathway still operates (9,48). The slower component of repair is 
probably mediated by DNA-PKcs-independent NHEJ but may also 
involve HRR, which requires a complex of DNA repair proteins, 
including RAD51, BRCA1, BRCA2, XRCC2, and ATM (1). Both the 
slow component of NHEJ and HRR are considered to act independ- 
ently of DNA-PKcs and PARP-l. It was therefore a striking obser- 
vation that even 24-h postirradiation, the use of the inhibitors resulted 
in a reduction in the percentage of DNA DSBs rejoined. In particular, 
a profound effect on DNA DSB repair was observed in the V3YAC 
cells with the combined use of the inhibitors at 24 h, where only 
-10% of DNA DSBs had rejoined, compared with >95% of the 
control (Fig. 6A). DNA DSBs are considered to be the most cytotoxic 
lesion that cells encounter, and this almost complete and long-term 
abrogation of DNA DSB repair by the combined use of the inhibitors 
would easily explain their potent radiosensitizing effects in both 
proliferating and growth arrested cells. These data also indicate that 
the combined inhibition of PARP-1 and DNA-PK has downstream 
effects on the slow component of DNA DSB repair. One possible 
mechanism, which is suggested by the data, is that the inhibited 
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enzymes have more deleterious consequences for DNA DSB repair 
(and hence survival) than the lack of enzymes. DNA-PK and PARP-1 
bind avidly to DNA DSBs, and automodification by phosphorylation 
and poly(ADP-ribosylation), respectively, is essential for dissociation 
of these enzymes from the DNA (49,50). Furthermore, Wortmannin 
has been demonstrated to block DNA-PK at DNA ends and prevents 
their processing by either DNA polymerization, degradation, or liga- 
tion (51). Similarly, NU7026 and AG 14361, by inhibiting the auto- 
modification reactions of their target enzymes, are predicted to tether 
the enzymes irreversibly to the DNA ends. These protein-bound DNA 
termini could hinder assembly of the enzyme complexes required for 
the successful execution of NHEJ and HRR. 
A number of publications demonstrate interaction and/or coopera- 
tion between DNA-PK and PARP-1. Both enzymes have been shown 
to have high affinities for binding to DNA DSBs (52). Modulation of 
enzyme activity by poly(ADP-ribosylation) of DNA-PK by PARP-1 
and phosphorylation of PARP-1 by DNA-PK has also been demon- 
strated, suggesting reciprocal regulation of enzyme activity (53,54). 
Finally, an intimate association between PARP-1 and Ku has been 
demonstrated in coimmunoprecipitation studies (55). These observa- 
tions point to an, as yet, poorly understood functional association of 
the two enzymes in response to DNA damage. 
Increased DNA-PK activity has been widely demonstrated both in 
vitro and in vivo and correlates with the resistance of tumor cells to IR 
and bifunctional alkylating agents (56-59). Conversely, acquired 
resistance to chemotherapeutic agents has been shown to correlate 
with increased DNA-PK activity (60-62). Therefore, increased 
DNA-PK activity has been proposed as a novel cellular and tumor 
resistance mechanism. Such tumor-specific alterations are likely to be 
important in terms of therapeutic exploitation. Where DNA-PK is 
overexpressed, the use of a selective inhibitor is predicted to allow 
treatment of these tumors which would otherwise be radio and ehe- 
moresistant. The effects of NU7026 in model systems with increased 
DNA-PK activity merits further investigation. Whether there will be 
a therapeutic gain associated with the use of DNA-PK and PARP-1 
inhibitors remains to be established, and an in vivo evaluation using 
human tumor xenografts in nude mice is planned. 
In four recent reports, antisense oligonucleotides, small interfering 
RNAs, and a COOK-terminal peptide which targets Ku80 and pre- 
vents DNA-PKcs binding to Ku have been used to selectively deplete 
or inhibit DNA-PK function in human cell lines (63-66). Loss of 
DNA-PK activity correlated with radiosensitization, increased muta- 
tion, and inhibition of DNA damage repair. Our results, the first to use 
a selective small molecule inhibitor of DNA-PK, are consistent with 
these data which highlight the current high interest in this enzyme as 
a target for radio and chemotherapeutic modulation. A PARP-1 in- 
hibitor is currently entering Phase I clinical trials under the auspices 
of Cancer Research United Kingdom, and the evidence presented here 
indicates that the combination of this inhibitor with a DNA-PK 
inhibitor could prove a powerful chemotherapeutic strategy. 
In conclusion, the data presented here suggest that pharmacological 
inhibition of DNA-PK and PARP-1, both alone and in conjunction, 
represents a promising strategy for tumor radiosensitization. 
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APPENDIX 
General Reagents 
1x TE: 10 mM Tris base, 1mM EDTA, adjusted to pH.... with 
concentrated HCI. Filter sterilised and stored at room temperature. 
Tris-IICI (1M): 12.1 g of Tris base dissolved in 800 ml of distilled 
water. Adjusted to the desired pH value by adding concentrated HCl and made up to 
1 litre with distilled water. Stored at room temperature. 
Carnoys Methanol: Acetic acid 3: 1 
Western blotting Reagents 
SDS lysis Buffer: 100 mM Tris-Hcl pH 6.8,20 % v/v Glycerol, 4% w/v 
SDS. Stored in 10 ml aliquots at -20 °C 
Sample Buffer (4x): 0.0005 % w/v bromophenol blue solution (stored as 0.001 
% in water), 62.5 mM DTT (1 M stock solution in water stored at -20 °C). 
TBS 20 mM Tris, 140 mM NaCl adjusted to pH 7.6 
TBS-Tween: 1x TBS solution containing 0.1 % Tween-20 
Tris Glycine; 
lOx Running Buffer 250 mM Tris, 1.9 M Glycine, 0.1 % SDS. lx buffer 
adjusted to pH 8.3 
1x Transfer 25 mM Tris, 190 mM Glycine, 20 % v/v Methanol 
Tris Acetate 
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20 x Running Buffer 1M Tricine, 1M Tris Base, 2% SDS. 1x adjusted to pH 
8.25 
20 x Transfer: 500 mM Bicine, 500 mM Bistris, 20 mM EDTA. Adjusted 
to pH 7.2. 
DNA Strand Break Assay Reagents 
Lysis Buffer: 69 mM SDS, 25 mM EDTA, adjusted to pH 10 using 1M 
NaOH. Stored at room temperature 
Alkaline Elution Buffer: 2 mM EDTA-acid form, 5M tetrapropylammonium 
hydroxide adjusted to pH 12.2 with tetrapropylammonium hydroxide. Stored at 
room temperature. 
Neutral Elution Buffer: 0.05 M Tris, 0.05 M glycine, 0.025 M Na2EDTA, 2% w/v 
SDS. Adjusted to pH 9.6 and stored at room temperature. 
Enzyme assays : General Reagents 
Dithiothretol (DTT) : 100 mM in aqueous solution stored in 500 µl aliquots at - 
20°C 
Digitonin : 150 µg/ml in aqueous solution, stored at 4 °C 
Oligonucleotide(s) 
For PARP-1 activation, a 200 pg/ml stock solution (10 mM 
Tris-HCI, pH 7.8) of a palindromic sequence (CGGAATTCCG) was prepared from 
dry pellets synthesised by Dr J. Lunec (Cancer Research Unit, University of 
Newcastle, UK) on an Applied Biosystems 392 DNA/RNA synthesiser (PE Applied 
Biosystems, Warrington, Cheshire, UK). The pellets were dissolved in water and the 
UV absorbance at 260 nm measured in order to determine the concentration. Given 
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that 1 0.1) unit = 50µg, stock solutions of 200 µg/ml. The stock solution was stored 
in 20 µl aliquots at -20°C. 
For PARP-1 and DNA-PK activation, a 30bp double 
stranded oligonucleotide (5'-ACTTGATTAGTTACGTAACGTTATGATTGA-3') 
was purchased from Invitrogen (Paisley, UK). This was annealed to a reverse 
complementary oligonucleotide (5'- 
TCAACTATAACGTTACGTAACTAATCAAGT-3') ; Each oligonucleotide was 
resuspended in TE buffer at a final concentration of approximately 100 µM and 
vortexed for 15 seconds before mixing and heating to 65°C. The solution was then 
slowly cooled at a rate of approximately 1°C/min to allow them to accurately 
anneal. The final concentration was quantified by dilution in water and the UV 
absorbance read at 260 nm as described above. Stock solutions of 100 µg/ml and 200 
µg/ml were stored in 50 µl aliquots at -20°C. 
Permeabilised PARP Assay Reagents 
Ilypotonic Buffer :9 mM HEPES, 4.5 % Dextran, 4.5 mM MgC12, adjusted to 
pH 7.8 with NaOH/HCI. The buffer was filter sterilised and stored at 4°C. DTT was 
added to a final concentration of 5 mM using 100 mM stock solution prior to use. 
Isotonic buffer : 40 mM Hepes, 130 mM KCI, 4% Dextran, 2 mM EGTA, 
2.3 mM MgC12,225 mM sucrose, adjusted to pH7.8 with NaOH/HCI. The buffer 
was filter sterilised and stored at 4°C. DTT was added to a final concentration of 2.5 
mM using 100 mM stock solution prior to use. 
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Purified PARP Assay Reagents 
NAD+ buffer 110 mM Tris, 13.5 mM MgCIZ, adjusted to pH 8.0 with 
HCI. The buffer was filter sterilised and stored at 4°C 
PARP Buffer 30 mM Tris, 40 mM MgC12, adjusted to pH 8.0 with HCI. 
The buffer was filter sterilised and stored at 4°C. Just before use, stock 100 mM 
DTT was added to give a concentration of 400 µM in buffer. 
Ilistone solution I mg/ml histone Type IIS dissolved in water was stored in 
aliquots at -20°C 
Immunodotblot Reagents 
Permeabilisation Buffer 
10 mM Tris-HC1 pH 7.8,1 mM EDTA, 4 mM MgC12,30 
mM 2-mercaptoethanol, adjusted to pH 7.8. The buffer was filter sterilised and 
stored at 4 °C. (Supplemented with digitonin on the day of assay to a final 
concentration of 0.015 % using a 150 µg/ml stock). 
Reaction Buffer 100 mM Tris-HC1 pH7.8,1 mM NAD, 120 mM MgC12. 
The buffer was filter sterilised and stored at 4°C. (NAD+ added fresh on day of 
assay) 
Termination Buffer PARP-1 inhibitor, AG14361 10 mM'(100 % DMSO v/v) 
stock solution stored at -20°C 10 mM (diluted 1/8000 in PBS to give final 
concentration 1.25 µM on day of assay) 
PBS-Milk-Tween PBS, 0.05 % (v/v) Tween 20,5% Milk powder (w/v) 
Antibody 10H mouse monoclonal recognising p(ADPr) kindly 
provided by Alexander Burkle. Stored in stocks of 1.5 mg/ml at 4°C. 
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Purified DNA-PK Assay Reagents 
Peptide p53 peptide substrate (EPPLSQEAFADLKK) G. C. M 
Smith, KuDOS Pharmaceuticals, Cambridge, UK 
ATP Stock solution in sterile water of 500 µM. Aliquots of 500 
p1 were stored at -20°C. 
DNA-PK Buffer 50 mM KCI, 25 mM Hepes, pH7.6,12.5 mM MgC12,20 
% Glycerol, 0.1 % NP40. The buffer was filter sterilised and stored at 4°C. Just 
before use, DTT was added to a final concentration of I mM in buffer. 
Combined Assay Buffer 48 mM Tris HCI, 24 mM MgC12,0.2 mM DTT 
Purified Enzyme Assay Reagents for PIKK family enzymes 
Reaction Buffer 25 mM Hepes, pH 7.4,12.5 mM MgC12,50 mM KCI, 
1mM DTT, 10% v/v Glycerol, 0.1% w/v NP-40 
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